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This thesis focuses on priority setting in HIV/AIDS control in Indonesia and South Africa. As 
the majority of the research in this thesis is conducted in Indonesia, this chapter starts with a 
detailed description of the HIV/AIDS situation in Indonesia, followed by a shorter description 
of the South African setting. 
HIV/AIDS control in Indonesia
Indonesia’s HIV/AIDS epidemic 
Indonesia is among the few countries in the world not on track for controlling its HIV epidemic 
[1]. The country faces a concentrated epidemic (with exception of Papua) with an estimated 
640,0000 people living with HIV/AIDS (PLWHA) in 2013 [2]. This number will increase to 1.5 
million in 2020 unless the right actions are taken (Figure 1). The estimated HIV prevalence is 
high among people who inject drugs (PWID) (36.4%), female sex workers (FSW) (7.2%) and 
men having sex with men (MSM) (8.5%). In the general population the HIV prevalence remains 
low (0.3%) but is expected to increase coming years due to sexual transmission from clients of 
sex workers, PWID and MSM to their sexual partners and their children. Although in terms of 
absolute numbers the disease burden is relatively small compared to other affected countries 
in the world, HIV/AIDS is a pressing public health problem for Indonesia. 
Indonesia’s HIV/AIDS response
The HIV/AIDS response in Indonesia is coordinated by multi-sectorial AIDS commissions which 
are established at all (national, provincial and district) levels of the decentralized government 
system. The most recent national HIV/AIDs strategy (2015-2019) outlines four components: 1) 
HIV prevention 2) quality treatment care and support services 3) mitigation of the impact of 
the epidemic, and 4) creation of an enabling environment that promotes an effective response 
to HIV and AIDS at all levels, empowers civil society to have a meaningful role and reduces 
stigma and discrimination [3]. In addition, the strategy includes three programs that are in the 
course of implementation: 
  The Prevention of sexual transmission (PMTS) program, supported by the Global Fund, 
focuses on the prevention of sexual transmission. Since 2009, PMTS has mainly focussed on 
sex worker settings and was expanded in 2013 to high-risk men and MSM in high burden 
districts.
  The Strategic use of antiretrovirals for treatment and prevention (SUFA) program, promoted 
by the World Health Organization (WHO), aims to quickly accelerate HIV testing and antiret-
roviral treatment (ART) across the country and was an initiative by the Minister of Health 
after the release of the UNAIDS Global Report 2012 that warned Indonesia that it is not on 
track for controlling its HIV epidemic. Early 2013, Indonesia expanded its treatment guide-
lines to achieve early testing and treatment, which is strongly recommended by WHO with 
the knowledge that treatment works as prevention [4]. The new Indonesian guidelines 
advice to treat all people with CD4 cell counts of ≤350 cells/μL and all risk populations 
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Figure 1. Projection of the Indonesian HIV epidemic until 2025
Figure 2. Resource gaps for HIV control in Indonesia 2015-2019 [3]
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(MSM, PWID, FSWs, prisoners, pregnant women and TB/HIV patients and sero-discordant 
couples) regardless of their CD4 cell count. The scale up of the SUFA program is imple-
mented gradually with 13 selected priority districts in 2013 and 37 in 2014 and 76 in 2015. 
  The Continuum of care program (Layanan Komprehensif Berkesinambungan (LKB)), initiated 
by Ministry of Health, is a continuum of care program at district level that aims to integrate 
government institutions, health services and community organizations to cooperate in the 
delivery of HIV/AIDS care. In the selected LKB districts one district hospital is cooperating 
with five selected primary health clinics (i.e. Puskesmas) to deliver testing and treatment 
services close to the community. At this moment LKB is rolled out in 13 districts in 2013 and 
will be scaled up to 41 in 2014 and 75 in 2015. 
 
While in the past years Indonesia has successfully scaled-up interventions for PWID, resulting 
in a declining HIV/AIDS epidemic in this group (Figure 1), coverage remains low for interven-
tions like condom distribution, school-based education, mitigation and antiretroviral treat-
ment (ART). In 2013, 18% of those in need (29,960 out of 170,000 HIV infected people) were 
actually receiving ART and 8-23% of the HIV positive pregnant women received the WHO 
recommended regimen for prevention of mother to child transmission (PMTCT) [2]. Indo-
nesia is also not on track for 6 of the 10 UNGASS (The Global AIDS reporting response prog-
ress reporting) goals, including targets to eliminate stigma and discrimination against PLWHA 
through promotion of laws and policies and elimination of gender inequalities, gender based 
violence and increase capacity of women to protect themselves from HIV [5]. Especially stigma 
related to HIV/AIDS is prominent in Indonesia’s society and in particular among health care 
workers [6–8] and HIV-infected people [9,10].
Indonesia’s need for priority setting in HIV/AIDS control 
In this context Indonesia faces an urgent need to prioritize resources to control its epidemic. 
The total funding needed in 2013 was projected to be USD 107 million whereas only USD 84 
million was available. Resource gaps are expected to further expand (Figure 2) with accelera-
tion of the HIV/AIDS response according to the new National Strategy and Action Plan 2015-
2019 (assuming that prevention programs will cover 70% of the key populations and 70% of 
those eligible are on ART). Moreover, foreign donors (Global Fund and Australian, UK and US 
governments) still contribute for 43% of the funding and this is expected to decrease. As a 
response, Indonesia is now finding ways to increase resource allocation for HIV by district 
governments [3]. 
HIV/AIDS control in South Africa
South Africa is home to the largest HIV-infected population worldwide, with 6.3 million people 
living with HIV/AIDS in 2013 [11]. The country has a generalized epidemic, with an HIV/AIDS 
prevalence rate of 19.2% among adults 15-49 years. 
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The country also has the largest antiretroviral therapy (ART) program worldwide: with domestic 
investments amounting to US$1.9 billion in 2011 [12], it provided treatment to about 80% (2.0 
million people) of all eligible people in 2012 [11]. South Africa is quickly scaling up ART and 
with the guidelines state that all those with CD4 cell counts of ≤350 cells/µL, with a Tuber-
culosis (TB) co-infection, and HIV-infected pregnant women irrespective of CD4 are eligible 
[13]. Nevertheless, a significant treatment gap of about half a million people remains between 
those who receive treatment and those in need according to the eligibility criteria [11]. 
Despite these achievements, the present HIV programme is not optimal in three important 
areas. First, there are concerns about whether the current treatment strategy is most efficient. 
Research suggests that alternative policies such as universal testing and immediate treatment 
of all HIV-infected patients (UTT) [14] and targeting specific risk groups [15,16], would be more 
efficient than the present programme. Second, concerns exist regarding the equity of the 
distribution of ART across population groups – recent reviews show that e.g. men and chil-
dren have less access to treatment than women [17,18]. Third, there are concerns about the 
programme feasibility given the severely limited capacity of the health system. In 2011, 3.4 
million people were eligible for treatment in South Africa, and despite the achievement in 
scaling up the treatment programme, yet only 52% of them received it [8].
The “treatment gap” is related to funding constraints, but also due to staff shortages [19], and 
it will increase with more people surviving on treatment [19,20]. National health authorities 
acknowledge these concerns [21] but have not yet developed and implemented treatment 
guidelines that address these. This results in ad-hoc priority setting practices (where some 
clinicians treat patients on a first-come first-serve basis while others give preference to the 
most severely ill) and waiting lists in parts of the country [22].
Available methods to guide priority setting in health 
Over the years various methods have been developed to inform policy makers and thereby 
supporting priority setting of resources in many disease areas including HIV/AIDS. In the 1980’s, 
economists introduced the use of cost-effectiveness analysis (CEA) to prioritize between 
health interventions. Based on welfare theory, the underlying notion is that interventions 
should not only have established effectiveness, but should also be worth its costs [23]. For a 
certain budget, population health would then be maximized by choosing interventions that 
show best value for money (‘are most cost-effective’). The World Bank promoted the concept 
in low and middle income countries (LMICs) in 1993 [24] and the World Health Organization 
has followed up on this and made such information available at the regional level through the 
WHO-CHOICE project, for example for tuberculosis and HIV/AIDS control [25–27]. 
Yet, CEA falls short as clearly more criteria than cost-effectiveness play a role in decision 
making, like ethical (e.g. giving priority to the worst of populations in society) and feasibility 
(e.g. political acceptability and health care workers capacity) considerations [28–35]. This led 
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to the development of multi criteria decision analysis (MCDA), a method that advances from 
CEA by incorporating multiple criteria in priority setting [36] (Figure 3). Based on multi attri-
bute theory, MCDA refers to a set of approaches that provide a systematic process for incor-
porating multiple criteria in decision making and making transparent the impact (also called 
‘performance’) of interventions on these criteria [29,36–38]. Table 1 presents an example of the 
performance matrix used in MCDA to present the performance of different interventions on 
the criteria selected for priority setting. 
While some types of MCDA involve sophisticated algorithms to calculate the optimal choice 
and for example assign weights to criteria (to indicate its relative importance), others simply 
aim to provide some structure to the deliberative process of policy makers discussing priorities 
[29,39–54] In Ghana, MCDA guided the Ministry of Health in prioritizing national health care 
interventions and in Nepal it showed that a lung health program should be a priority, ranking 
13th out of 34 interventions [51,53]. In HIV/AIDS control, it is applied in Thailand to inform policy 
makers for the priority setting of HIV/AIDS interventions [42]. In these settings, MCDA success-
fully contributed to more transparent and accountable policy making and its application is 
expected to further expand in the coming years [29,55,56]. 
Only a few applications of MCDA have explicitly taken into account the view of stakeholders by 
asking them to indicate the relative importance of criteria or to respond to the performance matrix 
results during a deliberative process [42,57]. Decisions are often made without adequate involve-
ment of stakeholders and especially the public is often not engaged in the decision-making 
Table 1. Performance matrix used in multi criteria decision analysis [36]
OPTIONS COST-
EFFECTIVENESS
SEVERITY 
OF DISEASE
DISEASE
OF POOR
AGE
Antiretroviral treatment 
in HIV/AIDS
US$ 200 per DALY   15 years and older
Treatment of childhood 
pneumonia
US$ 20 per DALY   0-14 years
Inpatient care for acute 
schizophrenia
US$ 2000 per DALY  15 years and older 
Plastering for simple 
fractures
US$ 50 per DALY  all 
Note:  A tick indicates the presence of a feature. Severity of disease is shown of a four-scale, with more dots indicating a 
more severe disease  
DALY = disability adjusted life year
16
Figure 3. Multi criteria decision analysis to achieve rational priority setting [36]
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process [58,59]. However, inclusion of the views of relevant stakeholders is important to ensure 
fair priority setting processes [60] and to hold institutions accountable for their decisions [58,59]. 
The Accountability for Reasonableness (AFR) framework outlines four conditions (relevance, 
publicity, appeal and enforcement) for such a fair priority setting process [60]. It is a leading 
conceptual framework for the ethics of health care priority setting and based on justice theo-
ries of democratic deliberation it aims to strengthen the legitimacy of priority setting decisions 
[61–68]. The framework reasons that it is impossible to achieve consensus on the outcomes of 
a decision making process, but when the process is fair the outcomes (i.e. decisions) are legit-
imate and are more likely to be accepted by stakeholders. 
In HIV/AIDS control, there has been an increase in interest for the use of multiple criteria and 
fair processes for priority setting of interventions. In 2012, the World Health Organization devel-
oped guidelines for the strategic use of ART (SUFA) and recommended countries to consider 
the cost-effectiveness, equity and feasibility of ART program options [69]. These guidelines 
also recommend the application of MCDA and AFR frameworks for priority setting however 
the integrated approach has not yet been tested. Other available tools for HIV/AIDS control are 
less comprehensive and do not recommend to use of multiple criteria and fair processes for 
priority setting [70–75].
Without any guidance, priority setting processes tend to be not systematic and not evidence-in-
formed and without inclusion of all relevant stakeholders. This may lead to ad-hoc and histor-
ically based decisions [36,76–80]. Especially in LMICs priority setting is complex due to limited 
evidence available to inform decisions, fragile institutional capacity and the dominant influ-
ence of policy makers opinion’s and international donor agencies [64,81–83]. 
Rationale for this thesis 
The research community and WHO have called for the use of multiple criteria and fair processes 
in HIV/AIDS control [28,69], and we more specifically in the context of Indonesia and South 
Africa [84,85]. At this moment, it unclear how countries are currently setting priorities in HIV/
AIDS control, which criteria are considered important among stakeholders and how interven-
tions perform on various criteria for priority setting. Moreover, it is unknown how the use of 
multiple criteria and fair processes can be implemented in a countries’ health system. While 
the focus of this thesis is on Indonesia, we also conducted two studies on South Africa. 
18
Research questions 
The main research question of this thesis is:
How can priority setting in HIV/AIDS control in Indonesia and South Africa be improved with 
use of multiple criteria and fair processes?
The sub-questions of this thesis are: 
 Sub-question 1: 
 What is the current priority setting process in HIV/AIDS control in Indonesia? 
 Sub-question 2: 
 Which criteria are important for priority setting in HIV/AIDS control? 
 Sub-question 3: 
 What is the performance of HIV/AIDS interventions on criteria for priority setting? 
 Sub-question 4: 
 Can the integrated MCDA-AFR approach be used to support strategic planning processes 
in HIV/AIDS control? 
Study setting
This thesis mainly focuses on Indonesia, the largest archipelago in the world with an estimated 
13,466 islands and home to more than 250 million people [86]. While reading this thesis it is 
important to realize that this country is extremely diverse in its culture and development and 
it may be inappropriate to talk about one Indonesia. The country became independent in 
1945 after 300 years of colonization by the Dutch. Although Indonesia is now rapidly devel-
oping and is projected to be the seventh largest economy globally in 2030 the gap between 
the rich and poor is tremendous and still approximately 29 million people (11.4%) were living 
under the poverty line of one dollar a day in 2013 [87]. Indonesia is also home to the largest 
Muslim population worldwide – 87.2% of the people was following Islam, 9.9% Christianity, 
1.7% Hinduism, 0.7% Buddhism and 0.5% other religions in 2010 [88]. Democracy was intro-
duced two decades ago in 1998 after 40 years of dictatorship by president Suharto. Corruption 
is prominent in Indonesia indicated by a score of 32 out of 100 points for transparency (with 0 
meaning highly corrupt and 100 very clean) and a low rank on the world corruption list (114 out 
of 175) [89]. In July 2014, Joko Widodo was elected as the new president for Indonesia, with 53% 
of the votes while his opponent Prabowo received 48%. While Joko Widodo openly fights for 
increased transparency and accountability in Indonesia’s government system while Prabowo 
did not advocate for this in his presidential campaign [90–92]. 
Our research took place in West Java province, located at Indonesia’s most developed and 
densely populated island Java and is home to approximately 46 million people [93]. The prov-
ince has a concentrated epidemic comparable to the national picture and one of the highest 
HIV/AIDS burdens. West Java had an estimated 59,000 PLWHA in 2013 while only about 15,000 
were registered in the health care system based on the latest government reports in 2014 [94]. 
19
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Thesis outline 
This thesis is organized into four sections. Each section responds to one of the four sub-ques-
tions.
Table 2: Outline of the thesis
General introduction
Chapter 1
  Sub-question 1    Sub-question 2   Sub-question 3   Sub-question 4
What is the current 
priority setting 
process in HIV/AIDS 
control in Indonesia? 
Chapter 2
Which criteria are 
important for priority 
setting in HIV/AIDS 
control?
Chapters 3-4
What is the 
performance of HIV/
AIDS interventions 
on criteria for priority 
setting?   
Chapters 5-7
Can the integrated 
MCDA-AFR approach 
be used to support 
strategic planning 
processes in HIV/AIDS 
control? 
Chapters 8-9
General discussion 
Chapter 10
Current practices in priority setting in HIV/AIDS control 
In Chapter 2 we respond to the first sub-question and evaluate the current HIV/AIDS priority 
setting processes in Indonesia by assessing the development of the 5 year HIV/AIDS strategic 
plan for West Java province (2008-2013) and Bandung city (2007-2011) against the four condi-
tions of the AFR framework (relevance, publicity, appeal and enforcement). We reviewed docu-
ments and held qualitative interviews with key stakeholders. 
Criteria for HIV/AIDS priority setting
Chapter 3 and Chapter 4 respond to the second sub-question. In Chapter 3 we present a 
conceptual map of relevant criteria for priority setting of health interventions, based on liter-
ature reviews and categorized according to the World Health Organization’s Health Systems 
Performance and Health Systems Building Blocks frameworks. In Chapter 4 we analyze the 
importance of criteria for priority setting in HIV/AIDS control in Indonesia by surveying the 
opinion of four stakeholder groups: people living with HIV/AIDS, health care workers, the 
general population and policy makers. 
20
Performance of HIV/AIDS interventions
In Chapter 5-7 we respond to sub-question 3 and present studies that provide information on 
the performance of HIV/AIDS interventions on various criteria (unit cost, cost-effectiveness and 
equity). In Chapter 5 we evaluate the unit costs of hospital based ART provision for HIV/AIDS 
patients in Indonesia. The chapter outlines a cost profile differentiated by initiation of treatment 
at different CD4 cell count levels; time on treatment; cost components (e.g., drug and personnel 
costs) for HIV/AIDS care and opportunistic infections (OIs); and finally patient costs of seeking 
and undergoing care. In Chapter 6 we evaluate the cost-effectiveness of scaling up communi-
ty-based VCT up from 30% to 80% between 2010-2014. We use the Asian epidemic model (AEM) 
and resource needs model (RNM) to calculate the incremental costs per HIV infection averted 
and per disability-adjusted life years saved (DALYs). In Chapter 7 we evaluate the equity in utili-
zation of ART in South Africa for different equity criteria (i.e. sex, age, severity of disease, area 
of living, socio-economic status, marital status, ethnicity, religion and/or sexual orientation). We 
conduct a systematic review to determine the current quantitative evidence-base. 
Implementation of the use of multiple criteria and fair processes 
In Chapter 8 and Chapter 9 we respond to sub-question 4. In Chapter 8 we outline an alter-
native approach for HIV/AIDS priority setting by integration of multi criteria decision analysis 
(MCDA) and the Accountability for Reasonableness (AFR) framework. Chapter 9 presents the 
first implementation of the integrated MCDA-AFR approach during the development of the 5 
years (2014- 2018) strategic plan for HIV/AIDS control in West Java province in Indonesia. 
General discussion
Last, in Chapter 10 we discuss the findings for each sub-question and respond to the main 
research question on how priority setting in HIV/AIDS control can be improved by using 
multiple criteria and fair process. Furthermore, the limitations of this thesis and the need for 
future research will be addressed. 
21
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Abstract
Background: Indonesia has insufficient resources to adequately respond to the HIV/AIDS 
epidemic, and thus faces a great challenge in prioritizing interventions. In many coun-
tries, such priority setting processes are typically ad-hoc and not transparent leading 
to unfair decisions. Here we evaluated the priority setting process in HIV/AIDS control 
in West Java province against the four conditions of the Accountability for Reasonable-
ness (AFR) framework: relevance, publicity, appeals & revision, and enforcement. 
Methods: We reviewed government documents, and conducted semi-structured 
qualitative interviews based on the AFR framework with 22 participants of the 5-year 
HIV/AIDS strategy development for 2008–2013 (West Java province) and 2007–2011 
(Bandung). 
Results: We found that criteria for priority setting were used implicitly and that the 
strategies included a wide range of interventions. Many stakeholders were involved in 
the process but their contribution could be improved and particularly the public and 
people living with HIV/AIDS could be better engaged. The use of appeal and publicity 
mechanisms could be more transparent and formally stated. Public regulations are not 
yet installed to ensure fair priority setting. 
Conclusions: To increase fairness in HIV/AIDS priority setting, West Java should make 
improvements on all four conditions of the AFR framework.
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Background
In Indonesia, the available budget for HIV/AIDS control is far below the resources needed to 
control the epidemic; thus, priority setting is required. In 2010, only US$ 69 million was spent 
on HIV/AIDS control, while US$ 152 million was needed to effectively control the epidemic 
[1,2]. In 2012, an estimated 610,000 people in Indonesia were living with HIV/AIDS (PLWHA) 
(0.4% of the population age 15+), with the epidemic mostly concentrated in high-risk groups, 
i.e. people who inject drugs (PWID), female sex workers (FSW), and men having sex with men 
(MSM) — except in the Papua province where the epidemic is generalized [3]. Recently, the 
epidemic has started shifting further towards the general population, indicating that it is not 
yet controlled, and challenging the government to carefully deliberate over choosing the right 
HIV/AIDS interventions [3].
Priority setting in HIV/AIDS control in Indonesia has not been previously investigated. Indo-
nesia’s HIV/AIDS responses focus on a wide range of activities (e.g. harm reduction interven-
tions, voluntary counselling and testing, and antiretroviral treatment services) that are offered 
mainly for the most-at-risk populations, while mass media campaigns and out-of-school HIV 
education are introduced on a small scale for low-at-risk populations [1,2]. For most interven-
tions, coverage remains low—e.g. 18% for anti-retroviral treatment (ART) in 2012 [1]. Policy 
makers face difficult dilemmas and conflicting values in priority setting of all possible HIV/
AIDS interventions. For example, they must decide whether to prioritize interventions that are 
highly effective at reducing the spread of HIV, like distribution of clean needles and condoms 
for high-at-risk groups, knowing that these are less politically and culturally accepted. Alter-
natively, they can invest in prevention of mother-to-child transmission (PMTCT) interventions, 
which will lead to a smaller reduction of the spread of HIV/AIDS but will be politically more 
accepted because they prevent HIV infection among children.
Priority setting is also made difficult — particularly in less developed countries — by wide 
gaps between available and needed resources, insufficient data to inform decisions, and 
frequently weak decision bodies [4]. As a result, priority setting decisions are often histo-
ry-based and ad-hoc, and strongly influenced by policy makers’ opinions, preferences of 
international funding agencies, lobbying, and political pressure [5]. Generally, they are domi-
nated by concerns of effectiveness and efficiency at maximizing population health, while 
also involving other factors, like equity and feasibility of implementation are becoming more 
prominent [6,7]. Without consensus on which values should guide priority setting, the focus is 
placed on analysing the process of priority setting, assuming that the right process will produce 
fair and legitimate outcomes. 
The ethical framework “accountability for reasonableness” (AFR) was introduced to define a fair 
priority setting process; it is theoretically grounded in justice theories that emphasize demo-
cratic deliberation [8–11]. According to AFR, a fair priority setting process should meet four 
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conditions: relevance, publicity, appeals & revision, and enforcement (definitions are presented 
in Table 1). Since its introduction, AFR has been successfully used to evaluate priority setting 
processes in several countries [4,12–15]. However, it is not yet applied in Asia and differences 
in countries’ political system and cultures will likely effect priority setting processes and the 
outcomes of an AFR evaluation. The use of the framework seems appropriate for the Indo-
nesian setting as the country has a democratic political system and thereby aims to fulfil the 
underlying principles of AFR. More specifically, formal government regulations state that deci-
sion-making processes should incorporate the views of different stakeholders and be informed 
by scientific evidence [16,17]. As in the AFR framework the conditions are loosely defined (e.g. 
mechanisms for appeals & revision are not specifically outlined) it allows context specific inter-
pretations and makes it appropriate for use in various settings, also beyond Indonesia. 
Table 1. The four conditions of the AFR framework [8]
THE FOUR CONDITIONS OF THE AFR FRAMEWORK
Relevance The rationales for priority setting decisions must be based on reasons that 
stakeholders agree are relevant in the context.
Publicity Priority setting decisions and their rationales must be publicly accessible, and leaders 
must take action to ‘push’ the message out to all segments of the public. 
Appeals & revision There must be a mechanism for challenge, including the opportunity for revising 
decisions in light of considerations that stakeholders may raise. 
Enforcement There is voluntary or public regulation to ensure that the first three conditions are met.
The present study evaluates the HIV/AIDS priority setting process at the decentralized level in 
West Java province of Indonesia with regard to the four conditions of the AFR framework. For 
other low-income settings beyond Indonesia the results of this evaluation may give insights 
in whether their priority setting processes are fair and could provide lessons for improvement. 
Methods
The study setting
Our study area was West Java province, home to 40 million inhabitants, with an estimated 
58,834 PLWHA in 2013 [18]. Like elsewhere in Indonesia, the epidemic is concentrated in high-
risk groups (estimated HIV prevalence in 2013: PWID 23.2%; FSWs 6.4%; MSM 8.4%) but has 
started shifting towards the general population (estimated HIV prevalence in 2013: 0.18%) 
[18]. West Java has established a range of HIV/AIDS activities, including harm reduction inter-
ventions for PWID, methadone maintenance treatment clinics in six cities, voluntary counsel-
ling and testing and ART at hospital and community clinics, condom distribution and school-
based education interventions in Bandung city. However, coverage of these interventions 
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remains low according to the latest data available, at around 30% in 2009 [19]. With 3 million 
inhabitants, Bandung is West Java’s capital and is the centre for HIV/AIDS control. It houses 
West Java’s largest public referral and teaching hospital, Hasan Sadikin, and has HIV/AIDS in- 
and outpatient services.
The study design and data collection
We reviewed national and local AIDS strategies, guidance documents for strategic planning, 
UNGASS reports, and local monitoring and evaluation data [1,20–22]. We further conducted 
semi-structured qualitative interviews with twenty-two stakeholders involved in the five-year 
HIV/AIDS strategic planning at the West Java province level (2009–2013) and the Bandung 
city level (2007–2011). The respondents were selected from a list of participants by purposive 
sampling. For the province and city level we interviewed respectively three and two repre-
sentatives from the AIDS commission secretariat, three and four from the government health 
office, one and two from the local planning board, and five and two from non-governmental 
organizations (NGOs) and HIV clinics.
Interview questions were based on the four conditions of the AFR framework, and previous AFR 
studies were used for input [4,13]. For the relevance condition, we asked questions about the 
involvement and dominance of stakeholders, about which criteria and data were used for deci-
sions. For the publicity and appeals & revision conditions, we asked how consensus was reached 
among stakeholders, and which mechanisms were installed to ensure publicity of decisions 
and the ability to appeal decisions. For the enforcement condition, we asked about quality of 
leadership and whether decisions were implemented. Daniels defines enforcement as “there is 
voluntary or public regulation to ensure that the first three conditions are met”, and we further 
operationalize this condition by additionally asking questions about ‘leadership’ and ‘imple-
mentation of decisions’. Leadership is essential in facilitating explicit priority setting [23] and 
could be important to ensure that a priority setting process meets the first three conditions. 
Implementation of decisions is important as it indicates whether stakeholders indeed follow up 
on the outcomes of decisions making processes. Both items were also put forward as elements 
of fairness in other settings and it is recommended to use the AFR framework with flexibility [24]. 
All interviews lasted one to two hours and were carried out in April and May of 2011. We inter-
viewed respondents until saturation was reached, meaning that the respondents in successive 
interviews gave no new insights on for example criteria used for priority setting. 
Data analysis
Interviews were recorded and transcribed. One researcher (RP) coded the transcriptions on 
the basis of the interview questions, using Nvivo version 8.0. During the coding a wider list 
of codes was established to find more specific information, for example for type of appeals & 
revision mechanisms three codes were used: ‘formal mechanisms’ ‘informal mechanism’ ‘after 
decision taken mechanisms’. A second researcher (NT) went through all the coded transcrip-
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tions to check the coding and any disagreement between the two researchers was resolved 
through discussion until reaching consensus. Next, the two researchers summarized together 
the answers per respondent in a matrix. All findings were summarized in this paper. We then 
consulted the AIDS commissions to give feedback on our results, and minor adaptations were 
made based on their comments.
Ethical clearance
This research was approved by the Bandung citizens ethical committee and the Padjadajaran 
University Medical Faculty ethical committee. Respondents were sent an invitation letter, and 
all participants gave their consent. Respondents were told that our study aims to evaluate the 
decision making process in HIV/AIDS control in West Java and they could stop the interview 
at any time. The interviews were recorded with informal consent of the respondents, and a 
souvenir was given as a reward. Anonymity of the respondents was maintained during data 
coding and respondent categories (e.g. NGOs) were used during data analysis. In data storage 
anonymity was not maintained.
Results
Here we first describe HIV/AIDS priority setting in West Java province. Secondly, we evaluate 
this process against the four conditions of the AFR framework. All findings were similar for 
Bandung city and West Java province unless otherwise stated.
Priority setting process in West Java province
AIDS commissions 
Indonesia has established AIDS commissions on a national level, in all 33 provinces, and in 172 
out of 477 cities and districts. We found that these commissions had a multi-sectorial design, 
and the daily board comprised representatives of various government offices (e.g. health, 
education, social, tourism, law, and religious affairs), non-governmental organizations, and 
health care facilities (Figure 1). They primarily aimed to coordinate activities and provide tech-
nical support for all involved parties, but some also ran their own interventions, i.e. condom 
distribution and health promotion. In Indonesia’s decentralized system, the provincial health 
government offices were responsible for the infrastructure of HIV/AIDS clinics, and aimed to 
provide the district government offices with technical assistance and financial support for HIV/
AIDS services. The district level health government offices ran all HIV/AIDS services, apart from 
ART distribution, which was implemented by the provincial health office. 
Strategic planning 
The latest National AIDS commission strategy (2010–2014) aimed to guide strategic plan-
ning of the local AIDS commissions, and divided actions into four programs: prevention; care, 
support, and treatment; impact mitigation; and policy and program management and devel-
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* List of involved Ministries: Ministry of Law & Human Rights, Ministry of Cultural & Tourism, Ministry of Education, Ministry 
of Youth & Sport, Ministry of Reasearch & Technology, Ministry of Social Affairs, Ministry of Religion, Ministry of Communica-
tion & Infromatics, Ministry of Manpower & Transmigration, Ministry of Transportation, Ministry of Women Empowerment, 
Ministry of National Planning & Development; ** List of involved government offices: Health Office, Social Office, Manpower 
& Transmigration Office, Education Office, Law & Human Rights Office, Tourism Office, Communication & Informatics Office, 
Youth & Sport Office, Religion Office ; *** Consists of AIDS Commission members and other HIV/AIDS experts from govern-
ment institutions, universities, NGOs and most at risk populations
Figure 1. Organizational structure of national and local AIDS commissions 
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opment. The West Java and Bandung strategic plans contained a wide range of activities 
(including the AIDS commission’s coordination and technical assistance activities) without 
specific coverage targets. The West Java strategy presented in addition a task division of activ-
ities among implementing institutions. Afterwards, yearly plans were developed for HIV/AIDS 
control activities in West Java and Bandung, as well as for the AIDS commission’s technical 
assistance activities, both based on meetings with AIDS commission members from govern-
ment offices, NGOs and HIV clinics. 
The West Java provincial and district AIDS commissions received technical assistance for stra-
tegic planning from higher level that consisted of training in the Asian Epidemic Model and 
Resource Needs Model tools. The development of the five-year strategy was led by the staff 
of the AIDS commissions and the total process took two years in West Java province and eight 
months in Bandung city. 
Budget flows for HIV/AIDS control
In 2010, donors funded 59.8% of the HIV/AIDS programs in Indonesia [1]. The National AIDS 
commission received funding from the national budget (Anggaran Pendapatandan Belanja 
Nasional (ABPN)) and from international donors (e.g. Global Fund and AusAid) for their coor-
dination activities and to fund provincial AIDS commissions. The provincial and district AIDS 
commissions received funding for coordination activities and interventions from the local 
budget (Anggaran Pendapatan dan Belanja Daerah (APBD)), the national AIDS commission 
and from international donors; they also channelled funds to local governments and NGOs 
on the basis of received proposals. National and international donors funded NGOs and 
health care facilities. To receive funding directly from the local government budget for the 
activities in the yearly strategic plan, all government institutions had to write proposals each 
year in January for the year after. The funding, available one and a half year later, was influ-
enced by the local planning board (BAPPEDA), the mayor/governor, and the Musrenbang. The 
latter is an annual event where citizens meet government offices and the planning board to 
discuss issues faced by their communities. Together, they decided on the general priorities 
for improvement within government sectors and not on specific funding for certain HIV/AIDS 
interventions [25]. Figure 2 presents an overview of the different flows of funding for HIV/AIDS 
interventions in West Java. 
Evaluation against the AFR framework
Relevance condition
A wide range of stakeholders was involved in strategic meetings; however for all respon-
dents raised concerns about their HIV/AIDS expertise and contributions, due to frequent staff 
rotations, replacements, or low-attendance of meetings. Respondents recommended more 
involvement of religious leaders, the House of Representatives, and the governor. At the prov-
ince level, respondents from NGOs expressed concerns over not being invited to all meetings. 
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Figure 2. Funding flows for different HIV/AIDS interventions in West Java province
National Budget
Local Budget
International 
Donors
Corporate Social 
Responsibility
Ministries
National AIDS Commission
Government Offices
Healthcare
NGO
FSW, MSM, PWID, 
Transgender, Clients 
of sex workers
FUNDING COORDINATOR IMPLEMENTOR BENEFICIARIES
PLHIV in need of 
treatment
PLHIV eligible for 
microloans
PWID
School students
Province/City AIDS Commission
Antiretroviral & OI treatment
Sexual transmission 
prevention program
School-based education
Harm reduction program
Microfinance program 
The public was not explicitly involved in the priority setting process, but a respondent from the 
health government office at Bandung city level said that they were represented by the NGOs 
as they stand close to the community. A few PLWHA were involved directly as they represented 
NGOs that advocate for key affected populations like PWID or transgender. 
“The AIDS commission actually consists of all government offices, but not all come for the planning. 
In particular, the tourism government office rarely comes, is not really experienced, and doesn’t know 
what the role their office plays in HIV/AIDS control, and this creates confusion. However, tourism should 
be involved, because it regulates the places where the indirect female sex workers work, i.e. massage, 
karaoke, billiards, and sauna places.” – AIDS commission secretariat member
Most respondents were confident that their party (i.e. NGOs, governments, and health facilities) 
had the most influence in discussions during meetings. The government respondents said that 
they were most dominant in discussions because they run the health care system and coordi-
nate HIV/AIDS surveillance, while respondents from NGOs and health care providers said that 
FSW = female sex workers, MSM = men having sex with men, PWID = people who inject drugs, PLHIV = people living with 
HIV, NGO = non-governmental organization, OI = opportunistic infection
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they had more power due to their field experience with high-risk groups and HIV/AIDS patients.
The most frequently mentioned reasons for including a intervention in the strategic plan 
were 1) it being in line with the national strategy, 2) its impact on reducing the spread of the 
HIV epidemic, 3) its past effectiveness, and 4) cultural, political, and religious factors (Table 2). 
Participants advocated for their own interventions because they believed that these interven-
tions would work or would ensure receipt of funding from the local budget or international 
donors. At the city level, some interventions were prioritized for specific government offices 
(e.g tourism and religion office) to improve their capacity to contribute to HIV/AIDS control.
 
“In the past, we encouraged establishment of condom ATMs that provide free condoms in public places, 
but this did not go well because religious groups interpreted this differently. Therefore, we need to think of 
other ways to provide free condoms. The same also applies to clean needles for PWID. Maybe a condom 
ATM is possible in a different culture, but not here.“ – Staff member of government health office
Reasons for setting priorities were implicitly used during discussions and were not stated in the 
strategic plan. Data used included the number of HIV/AIDS cases per risk group as reported by 
the Ministry of Health, and the prevalence trends in these groups based on the Asian Epidemic 
Model projections. The budget impact of interventions was used to estimate the resources 
needed for HIV/AIDS control and not to prioritize interventions. In the discussions, participants 
were instructed to not be limited by budget limitations, but to propose all interventions that 
should be in the strategic plan. 
“We explain that the focus of programs is also shifting to the general population, by presenting data on 
the stabilizing HIV prevalence in PWID” – Provincial AIDS commissions secretariat member
Publicity condition
In Bandung, the five-year strategic document was well distributed among stakeholders. 
Although the document was not directly published to the public, socialization meetings were 
held that were mainly attended by AIDS commission members but also a few sub-district 
leaders and health care providers. In these meetings the process of strategic planning and the 
results were presented and division of tasks for implementation of interventions was discussed. 
Some respondents from NGOs stated that they were not aware of the yearly operational plans. 
At the province level, those involved in the meetings received the strategic document, but 
further dissemination to other stakeholders (e.g. local AIDS commissions) was limited. 
Publication of the document was postponed for one year due to a change in format required 
by the local planning board to implement interventions at different government offices. The 
government offices seemed to have more complete information on the plans than the NGOs, 
as some stated they were absent from follow-up meetings. At the province level, the stra-
tegic plan was published to the public through discussions on radio and television, and a 
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Table 2. Implicit criteria used for priority setting in HIV/AIDS control in West Java
CRITERIA EXAMPLE OF INTERVENTION/SITUATION
Bandung and West Java province level
1 Current HIV/AIDS epidemic HIV prevalence is stabilizing in PWID and rising in FSW and MSM
2 Guidelines from provincial and national 
AIDS commissions
Predetermined intervention focus on 4 areas: prevention; care, 
support, & treatment; impact mitigation; and policy and program 
management development
3 Previous experiences of interventions’ 
effectiveness
Proposal for new funding to upscale microcredit loans for PLHIV
4 Mix of local political, cultural, and religious 
values
Sensitivity of condom distribution interventions
West Java province
1 Feasibility related to current health care 
infrastructure
ART at community health centres is only partly established
2 Feasibility of reaching target groups Clients of FSW are more difficult to reach than FSW/PWID; 
interventions are started in families already familiar with HIV/AIDS
3 Likelihood of receiving local government
budget funding 
Preference for distribution of materials and products (e.g. 
condoms and ARVs) 
4 Current intervention coverage Children living with HIV/AIDS have low coverage
5 Interventions enacted in the past Socialization among policemen has been done and is no longer 
relevant
6 Focus on high risk groups Establishing PWID-friendly health services at public community 
health clinics (Puskesmas) 
7 Interventions applicable in all cities in 
province 
HIV-AIDS transmission through sexual transmission prevention 
program (PMTS) funded by the Global Fund through National AIDS 
commissions
8 Draft already made by AIDS commission Predetermined intervention focuses on 4 areas: prevention; care, 
support, & treatment; mitigation; and advocacy
9 Advocacy for own interventions The prison staff advocates for interventions in prison; NGOs for 
premarital counselling
Bandung level
1 Likelihood of donor funding ARV distribution is funded by Global Fund
2 Non-existent interventions Interventions to socialize the general population
3 Interventions for government offices with 
the least capacity for HIV/AIDS control 
Tourism office should be involved due to sex tourism but is not 
yet active in HIV/AIDS control and capacity should be improved
4 Urgent situations Rising number of HIV/AIDS orphans
PWID = people who inject drugs, FSW = female sex workers, MSM = men having sex with men, PLHIV, 
ART = antiretroviral treatment, ARV = antiretrovirals, NGOs = non governmental organizations
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press conference, but mostly examples of interventions were discussed and not the decision 
making process and rationales for decisions. The public could access the strategic plan docu-
ment by request at the AIDS commissions’ office. One expert was concerned about whether 
the public was indeed aware of the interventions and the reasons for prioritization. At both 
levels, the reasons for intervention prioritization were not published to stakeholders; however, 
some instances included underlying data to illustrate the reasons for setting priorities. Publicity 
was also influenced by the sensitivity of interventions due to local political, cultural, and social 
values. For example, the condom and MSM interventions are considered sensitive and a chal-
lenge to the AIDS commission regarding open implementation. 
“The strategic document is not open regarding the details; we have to be cautious.” – Staff member of 
government health office
Appeals & revision condition 
During strategic planning, there were no formal (i.e. registered) mechanisms to deal with 
disagreements related to priority-setting decisions. Participants at both city and province 
levels explained that there were enough opportunities to make appeals during meetings. 
Albeit, respondents from NGOs and health care institutions expressed concerns on whether 
appeals during meetings were taken into account, and stressed the importance of lobbying 
for interventions. Respondents from NGOs and HIV clinics were not involved in all meetings 
and described their desire for better opportunities to make appeal.
Respondents said that consensus was easily reached in meetings and voting was rarely used.
“Our complaint is that after the strategic planning meetings, our group was not invited again to see the 
new revised document and we didn’t get any information on the result of the meeting. So we do not 
know what is going on and can therefore not comment on activities and plans” – NGO worker
“In the meeting, there is some discussion but there is no conflict at all. It is very easy to reach consensus. It 
is usually difficult to reach a consensus with the religious office, for example about condom distribution, 
but in Bandung city they did not make any appeal. They didn’t say anything, the condom plan was there 
but they didn’t disapprove it.” – Bandung AIDS commission secretariat member
“The public can make an appeal to the government about HIV/AIDS activities, but it is a dream. If you 
have comments or suggestions, you can send them through the House of Representatives and then they 
will discuss it internally. And then they will invite the Ministry of Health. But it will take a lot of time, and 
there are a lot of delays. Another option is to have demonstrations.” – NGO worker
After the final document was signed by the mayor or governor a formal appeal mechanism 
through the House of Representatives could be used by all stakeholders (including the public), 
but the respondents considered this process to be time consuming. 
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Enforcement condition
There was no formal regulation to ensure that the first three AFR conditions were met. The 
national AIDS commission recommends to follow the national guideline for strategic plan-
ning in Indonesia, which recommends a participatory and bottom-up process. Respondents 
expressed concerns about leadership, as the AIDS commission had to coordinate all parties 
and as well run their own interventions. Respondents stated that the Bandung mayor was 
more committed to HIV/AIDS control than the governor from West Java, because the former 
allocated a substantial budget (1 billion IDR or US$ 104,177) to the Bandung AIDS commission 
for 2011. 
“The mayor of Bandung is the head of the AIDS commission and since he is very concerned with HIV/AIDS, 
he allocated one billion Indonesian Rupiah (US$ 100.000) to the Bandung AIDS commission in 2010. This 
money was used to improve the capacity of government offices to start creating HIV/AIDS programs.” – 
Bandung AIDS commission secretariat member
The secretariat of the AIDS commissions described coordination challenges due to the number 
of parties involved, their lack of commitment, and the inefficient annual funding procedure for 
interventions in the government offices. Figure 2 show the complexity of funding flows of 
different HIV interventions in West Java. The strategic plans, including task divisions, were only 
guidelines and government offices and NGOs were not obligated to implement the interven-
tions. Furthermore, it was expressed that additional priority setting processes were required, 
as the budget received by the government offices from the local budget was insufficient for all 
proposed activities. In 2012, a provincial local HIV/AIDS regulation was launched that enables 
enforcement of decisions made by provincial stakeholders in all districts [26] (Governor West 
Java 2012). For example, if the provincial health office aims to scale up testing services in the 
province, they can instruct the districts to install testing facilities in all community clinics. 
Discussion 
Here we evaluated the priority setting process for HIV/AIDS control at the decentralized level 
in West Java, using the AFR framework. Our results show that structures are in place for most 
AFR conditions, but improvements are needed to ensure fair priority setting. 
In evaluating relevance, we found that AIDS commissions in Indonesia involved multi-sec-
torial stakeholders. Indonesia performs better on this condition compared to other coun-
tries that have only limited stakeholder involvement in decision making [4,12–14]. However, 
governmental institutions might not be as legitimate as possible, as the quality of stakeholder 
involvement especially the public and PLWHA seems to be limited. At this moment the public’s 
values are not reflected and the views of PLWHA mainly through NGO representatives. For 
public involvement various methods exist although the effectiveness has hardly been eval-
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uated [27–29]. Therefor, we recommend investigating the appropriateness of public engage-
ment mechanisms in the context of Indonesia including the existing Musrenbang mech-
anism. Sometimes involved stakeholders (from governments, NGOs and HIV clinics) lacked 
commitment and HIV expertise, partly due to the frequent staff rotations in Indonesia, and the 
dominant role of donors in HIV/AIDS control [30]. Moreover, HIV/AIDS could be a low priority 
for policy makers due to the low burden compared to other diseases [31]. Also for PLWHA, 
although they seemed to be involved through the NGOs, the quality should be further inves-
tigated and ensured in planning processes as stakeholder understanding, acceptance, and 
satisfaction are important for successful priority setting [32]. Ideally, all relevant stakeholders 
should be involved in all steps of the process; however, this is challenging due to the high 
number of parties related to HIV/AIDS control and most efficient ways should be determined. 
Intervention inclusion in the strategic plan was based on many different reasons, which were 
not explicitly explained, reducing the transparency of strategic decisions. Daniels states that 
criteria that fair-minded people agree with are relevant for priority setting [8]. However, as 
this is difficult to operationalize we propose to use the WHO health systems framework as a 
conceptual underlying framework for selection of criteria for priority setting which was put 
forward by Tromp & Baltussen [33]. Based on the framework, the criteria ‘reducing the impact 
of the epidemic’, ‘past effectiveness’, and ‘cultural, political, and religious barriers’ used implic-
itly in West Java seem to be valid reasons for priority setting. It is debatable whether ‘align-
ment with national/provincial strategy’ should be used, as policy making should be context-
based and higher-level policies could be incompatible with the situation at the local level. 
However, in the context of Indonesia’s political system and culture, it might be inappropriate to 
ignore higher-level instructions and it would be not feasible on the short term to start provin-
cial programs instead of aligning with the national programs and related policies [34,35]. For all 
criteria, improved use of (scientific) evidence could help systematically compare interventions 
for priority setting, which should be guided by more evidence than only the HIV prevalence in 
risk groups. The strategic document scarcely prioritizes interventions, but primarily functions as 
a guideline presenting all possible activities. The Indonesian culture has a strong community 
system, and therefore it is an important norm to take care of everyone [35]. However, the small 
budget necessitates priority setting rather than trying to do everything for everybody [36]. 
In evaluating publicity, we found that despite dissemination meetings and media exposure, 
respondents were not aware of all decisions and the reasons. Explanation of strategic decisions 
is difficult and should be done using easily understandable language. In West Java, especially 
for the public, the current strategic plans seem difficult to understand as it contains technical 
HIV/AIDS and law terminology. Sparse publication of reasons is seen in all countries that have 
conducted AFR evaluations [4,12,13,15,37] and we recommend to develop a formal publicity 
plan in West Java to effectively inform all stakeholders. Finding more effective methods for 
communicating policy decisions for HIV/AIDS control in Indonesia to different types of stake-
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holders could help improve the transparency of the process. It should be evaluated whether 
the current publication mechanisms to the public through sub-district leaders (already 
involved in HIV interventions) is effective and potentially can be expended to all leaders. As 
social media is extensively used in Indonesia and is a low cost communication channel this 
might be an efficient way to inform the public and we recommend investigating its poten-
tial. The Citizens AIDS (Warga Peduli AIDS) intervention of the city AIDS commission estab-
lishes organizations comprised of local sub-district leaders, which could potentially inform the 
public about strategic decisions; however this may require substantial resources [38]. Lack of 
openness on sensitive issues, like condom distribution and MSM interventions, reduces policy 
making transparency; however, this is difficult to change due to Indonesia’s cultural values 
[35]. Still, options for improved transparency regarding sensitive interventions should be inves-
tigated. Furthermore, delays in strategy development should be prevented, as they prevent 
timely informing of stakeholders.
Our evaluation of appeals & revision revealed that, although no formal mechanisms are 
installed in the strategic planning, respondents feel that they can appeal and reach consensus 
through discussions during the process. This is in line with the five principles of Pancasila 
(Indonesia’s state principles introduced by president Sukarno in 1945) that name democracy 
as a core value, and state that disagreements should be resolved through discussions, with a 
voting procedure considered a last option [39]. The general formal process through the House 
of Representatives seems to be insufficient, as it is time-consuming and not specifically for HIV/
AIDS policies. Some respondents said that the dominant use of lobbying harms the transpar-
ency of the decisions. Therefore, the use of appeals & revision mechanisms should be more 
transparent and formally reported and we recommend holding a survey among stakeholders 
to propose the most appropriate mechanism in the context of Indonesia. Still it is difficult 
to judge whether selected mechanisms by stakeholders will also be the most appropriate 
ones to contribute to fair priority setting. Although stakeholders might perceive giving opin-
ions during meetings a proper mechanism, dominance in discussions is excessive in Indo-
nesia which affects opportunities for appeals and the fairness of the priority setting process. 
In countries that have undergone AFR evaluation, formal appeals & revisions mechanisms are 
seen in high-income countries (Norway, Canada) but not in low- and middle-income coun-
tries (Tanzania, Uganda, Thailand), with the exception of Israel, which also has no formal mech-
anism [4,12–15,37].
Our evaluation of enforcement revealed that, formal regulations for ensuring fairness of deci-
sion making were apparent, as observed in other AFR-evaluated countries [4,12–15,37]. There-
fore, we recommend that the National AIDS commission develops guidelines for HIV strategic 
planning in Indonesia that incorporate the four conditions of AFR and that the local AIDS 
commissions will be trained to use these. With regard to implementation, we found that the 
HIV/AIDS control funding system is fragmented and that the preference of individual institu-
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tions determines the intervention implementation and the actual priority setting. Ideally, all 
funding should be pooled and assigned by one decision body. However, this would require a 
total reorganization of Indonesia’s HIV/AIDS control, and necessitate the agreement of interna-
tional donors to not earmark funding for specific HIV/AIDS interventions. As an alternative, we 
recommend openness regarding the available local government budget for HIV/AIDS activities 
and the commitment of every local government department to execute activities. With regard 
to leadership, our investigation revealed more effective organization of HIV/AIDS control at the 
Bandung level than at the provincial level. This could be related to greater commitment and 
leadership of Bandung’s mayor compared to West Java’s governor. The importance of leader-
ship in priority setting has been proven in a hospital setting, but has not yet been investigated 
on provincial or national government levels [40]. 
To our knowledge, extensive evaluations of priority setting processes within and outside the 
HIV/AIDS field in settings outside of West Java province have not yet been done. The defi-
cits identified in the four AFR conditions are not limited to HIV/AIDS control but may repre-
sent a structural problem of accountability in government institutions in Indonesia [34]. Many 
districts have not yet developed the capacity to plan and manage their health budgets, to 
identify local health needs with use of available knowledge and to set targets and monitor 
progress [17]. 
Also for settings outside Indonesia implementation of the AFR framework will be instrumental 
to improve priority-setting processes. It will empower institutions to systematically and contin-
uously evaluate the quality of the process against the four AFR conditions. The framework will 
help to identify all relevant stakeholders and criteria for priority setting, to increase the uptake 
of evidence in decision-making and to identify and implement formal mechanisms for appeal 
and publicity. Implementation of the framework may also lead to better health outcomes as 
with better use of evidence the interventions with highest health impact might get priority. 
Although our findings of the Indonesian case should be generalised with caution, it provides 
lessons for the pitfalls that institutions in other settings may encounter and should overcome 
during implementation of the AFR framework. An essential component of any successful 
implementation of AFR is leadership and this should be ensured. Embedding of the priority 
setting process in a government regulation may improve commitment and participation 
of institutions. All relevant stakeholders should participate in the process and effective and 
context based mechanisms should be used to involve the public and PLWHA. Dominance in 
discussions should be solved with culturally accepted measures. To optimise the democratic 
learning process we recommend that the same person who represents an institution partici-
pates in all meetings.
We learned from the West Java case that formal appeal mechanisms should be installed that 
are considered effective by the stakeholders. Also, no technical terminology should be used 
so that the public and PLWHA have opportunity to appeal. Stakeholders should be involved 
 Evaluation of priority setting in HIV/AIDS control in Indonesia
43
 
2
that have power to allocate resources to the prioritized interventions. Ideally, resources 
should be pooled as a fragmented system increases the risk that high priority interventions 
are not funded. To improve understanding and acceptance of the framework local govern-
ment capacity should be established to facilitate priority setting processes. The government 
could be supported by local universities for education on the framework and facilitation of 
the process.
To further improve fairness and legitimacy in strategic planning, we recommend the use of an 
integrated multi-criteria decision analysis (MCDA) and AFR approach recently put forward by 
Baltussen et al. [41]. Both methods have been has been successfully applied in various coun-
tries but have potentially more impact in complementing each other settings [4,12–15,37,42–
44]. This method starts a (long term) democratic learning process and includes all rele-
vant stakeholders, identifies a comprehensive set of rational criteria for priority setting, uses 
evidence to compare the performance of all interventions on those criteria and lets the stake-
holders define appropriate mechanisms for publicity and appeals & revision. The method has 
not been tested in the context of Indonesia and this is a topic for further study. 
Study limitations
From our present study results, we can identify a few risks for biases. Our respondents were 
selected through purposive sampling, which might have caused recall bias. We also did not 
interview the public directly, which limited our ability to verify whether they think the strate-
gies are well published and whether they had adequate ability to appeal. Some respondents 
could have given politically correct answers; however, we received many critical opinions of 
the process, indicating that they felt free to respond honestly. The meetings took place a few 
years before the interviews, which could have caused recall bias. 
Conclusions
To increase the fairness and legitimacy of HIV/AIDS priority setting, West Java should make 
improvements on all conditions of the AFR framework. More specifically, explicit priorities 
should be made among HIV/AIDS interventions, with the use of explicit criteria that are trans-
parent for and agreed upon by all involved stakeholders. Although many stakeholders partic-
ipate in the priority setting process, the quality of their involvement should be ensured, espe-
cially regarding PLWHA and the public. An improved publication strategy should be developed 
and implemented to inform stakeholders about decisions. The use of appeals & revision mech-
anisms should be more transparent and formally stated. Finally, public regulations should be 
developed to ensure that fair priority setting processes in HIV control will be installed. 
  Sub-question 1
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 Subquestion 1
  What is the current priority setting process in 
  HIV/AIDS control in Indonesia?
 Sub-question 2
  Which criteria are important 
  for priority setting in
  HIV/AIDS control?
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Abstract
Background: In rationing decisions in health, many criteria like costs, effectiveness, 
equity and feasibility concerns play a role. These criteria stem from different disciplines 
that all aim to inform health care rationing decisions, but a single underlying concept 
that incorporates all criteria does not yet exist. Therefore, we aim to develop a concep-
tual mapping of criteria, based on the World Health Organization’s Health Systems 
Performance and Health Systems Building Blocks frameworks. This map can be an aid 
to decision makers to identify the relevant criteria for priority setting in their specific 
context.
Methods: We made an inventory of all possible criteria for priority setting on the basis 
of literature review. We categorized the criteria according to both health system frame-
works that spell out a country’s health system goals and input. We reason that the 
criteria that decision makers use in priority setting exercises are a direct manifestation 
of this.
Results: Our map includes thirty-one criteria that are distributed among five catego-
ries that reflect the goals of a health system (i.e. to improve level of health, fair distribu-
tion of health, responsiveness, social & financial risk protection and efficiency) and one 
category that reflects feasibility based on the health system building blocks (i.e. service 
delivery, health care workforce, information, medical products, vaccines & technolo-
gies, financing and leadership/governance).
Conclusions: This conceptual mapping of criteria, based on well-established health 
system frameworks, will further develop the field of priority setting by assisting deci-
sion makers in the identification of multiple criteria for selection of health interventions.
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Background
Concerns on the costs, effectiveness and cost-effectiveness of health interventions have 
dominated the debate on health rationing in a wide range of countries since long [1–3]. More 
recently, the explicit use of a number of equity-related criteria have been put forward, like 
severity of disease, socio-economic status, or gender, reflecting the increased attention for 
distribution of health in a population, as summarized by Johri and Norheim [4]. Still other 
criteria, like ease of implementation [5] or political acceptability [6] are presently finding their 
way in the prioritization of health interventions.
The recognition that not a single but multiple criteria should explicitly be considered has led 
to the development of multi criteria decision analysis (MCDA). This method sets programme 
priorities by referring to a comprehensive set of explicit criteria and guides decision makers 
in understanding the trade-offs between values that may be conflicting. For example while 
mobile clinics for HIV testing may be costly and therefore inefficient, they may deserve priority 
because they reach out to remote areas and therefore contribute to equity in service delivery. 
A core component in any MCDA is the identification of criteria that decision-makers consider 
important in their specific contexts. As a next step, MCDA scores the performance of health 
interventions on these criteria [7,8].
At the same time, surprisingly little work has been done to develop a meaningful conceptual 
mapping of criteria that can help to identify the relevant set of criteria. A recent report that 
advices the UK’s National Institute for Health and Clinical Excellence (NICE) for the use of MCDA 
reviewed the literature and one of the findings was that most applications have a fixed set of 
criteria and lack explanation of the rationale behind the selected criteria and the categories 
used. In addition, it was concluded that the applications give neither flexibility nor assistance 
to decision makers to select an unique set of criteria in their decision context [8]. More specif-
ically, in 1999, Musgrove presented the ‘nine criteria for public spending on health care’ in a 
spider-web like diagram, however, without classification of criteria [9]. Baltussen and Niessen 
presented in 2006 the ‘cloud of criteria’, suggesting that criteria cannot be systematically cate-
gorized [7]. Another framework, introduced by EVIDEM in 2010, does not explain an under-
lying rationale for the choice of categories that are used [10,11]. Furthermore, various reviews 
simply list priority setting criteria [4,8,11,12]. Only the list of criteria reported in the review of 
Golan et al., categorizes criteria according to the principles of allocative justice for rationing 
health care, i.e. need, maximizing and egalitarian principles, but is therefore limited in scope 
[13]. Our paper aims to develop a conceptual mapping of a comprehensive set of criteria, 
including efficiency, equity and feasibility concerns.
Categorization of criteria is important for two main reasons. Firstly, for decision makers, the 
grouping of a large and diffuse set of criteria into categories may ease their interpretation 
and facilitate decision-making. Second, such a categorization may be an aid to well-define 
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criteria, and to avoid overlap and double-counting of criteria. Criteria, especially those related 
to health distribution (i.e. equity) concerns are often difficult to define and a proper mapping 
sets boundaries to facilitate this.
Figure 1. The building blocks and goals of a health system [14-16]
The WHO Health System Framework
System Building Blocks Overall Goals / Outcomes
SERVICE DELIVERY
HEALHT WORKFORCE
INFORMATION
MEDICAL PRODUCTS,
VACCINES & TECHNOLOGIES
FINANCING
LEADERSHIP / GOVERNANCE
IMPROVED HEALTH 
(level and equity) 
RESPONSIVENESS
SOCIAL & FINANCIAL RISK 
PROTECTION
IMPROVED EFFICIENCY
Methods
Conceptual mapping of criteria
This paper introduces a conceptual mapping of criteria based on an integration of two well 
established health systems frameworks, i.e. the World Health Organization’s (WHO) Health 
Systems Performance framework [14] and Health Systems Building Blocks framework [15,16] 
(Figure 1). These frameworks spell out a country’s health system goals and input – we reason 
that the criteria that decision makers use in priority setting exercises are a direct manifestation 
of this. More specifically, the Health System Performance framework is a generally accepted 
concept to reflect the goals of a health system. Here, in our interpretation, the framework reflects 
criteria that indicate the goals of interventions in health, i.e. to improve the level and distribution 
of health, to improve responsiveness, to offer financial protection and to make efficient use of 
resources. This can be loosely defined as ‘what should a health system do’. The Health System 
Building Blocks framework is a generally accepted concept to reflect the required components 
(or inputs) for an effective health system. Here, in our interpretation, the framework reflects 
criteria that relate to the feasibility of interventions, or loosely defined as ‘what can a health 
system do’. These criteria relate to the building blocks: ‘service delivery’, ‘health workforce’, 
‘information’, ‘medical products, vaccines & technologies,’ ‘financing’, and ‘leadership/gover-
nance’. Together, the two frameworks offer a comprehensive framework for classifying priority 
setting criteria. We employ both WHO frameworks because they are worldwide used by deci-
sion makers at country level and are credible conceptualizations of health systems [15,17].
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Table 1.  Definitions of categories used in the criteria map
  (based on the health system goals and building blocks)
CATEGORY DEFINITION
Health system goals [14]
Health level To improve the total average level of health in the population
Health distribution To achieve absence of avoidable or remediable differences in 
health among groups of people, defined socially, economically, 
demographically, or geographically 
Responsiveness To use interventions that are responsive to people’s expectations in 
regard to non-health matters and reflect the importance of people’s 
dignity, autonomy and the confidentiality of information 
Social & financial risk 
protection
To provide financial protection against the costs of ill-health 
Improved efficiency To make the best and most efficient use of resources
Health system building blocks [15]
Service delivery Good health services are those which deliver effective, safe, quality 
personal and non-personal health interventions to those that need them, 
when and where needed, with minimum waste of resources.
Health workforce A well-performing health workforce is one that works in ways that 
are responsive, fair and efficient to achieve the best health outcomes 
possible, given available resources and circumstances (i.e. there is 
sufficient staff, fairly distributed; they are competent, responsive and 
productive).
Information A well-functioning health information system is one that ensures the 
production, analysis, dissemination and use of reliable and timely 
information on health determinants, health system performance and 
health status.
Medical products, 
vaccines
& technologies
A well-functioning health system ensures equitable access to essential 
medical products, vaccines and technologies of assured quality, safety, 
efficacy and cost-effectiveness, and their scientifically sound and cost-
effective use.
Financing A good health financing system raises adequate funds for health, in ways 
that ensure people can use needed services, and are protected from 
financial catastrophe or impoverishment associated with having to pay 
for them. It provides incentives for providers and users to be efficient.
Leadership/governance Leadership and governance involves ensuring strategic policy 
frameworks exist and are combined with effective oversight, coalition-
building, regulation, attention to system-design and accountability.
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We carried out two steps to develop our conceptual mapping of criteria. In a first step, we 
made an inventory of all possible criteria for priority setting on the basis of literature reviews 
[4,8,11–13]. In a second step, we categorized these criteria according to the health systems 
goals and building blocks, based on their definitions (Table 1). For example, following the 
health system performance framework, we distinguished the objective to improve health in 
two categories, i.e. to improve the ‘level of health’ and the ‘distribution of health’. We defined 
and classified criteria in these categories in order to avoid overlap between criteria.
Results
The conceptual mapping of criteria for priority setting is provided in Figure 2. The definitions 
of the categories are similar to those in the original WHO health system frameworks and are 
presented in Table 1. Our literature review resulted in the identification of a large set of criteria, 
which are often similar in concept but different in the ways they are described. In the appendix 
of this chapter we list all criteria we considered for inclusion in our framework, and present a 
rationale for their inclusion or exclusion. The included thirty-one criteria are all single not-over-
lapping arguments to prioritize health interventions and are defined in Table 2. Here, we will 
give the rationale used for a selection of the criteria considered.
On the right panel of the map we distinguish five categories of criteria related to intervention’s 
goals. The first category is ‘health level,’ and includes criteria ‘effectiveness on individual level,’ 
‘effectiveness on population level’ ‘patient reported health status’ and ‘safety’. Whereas reviews 
include ‘quality of evidence on effectiveness,’ we excluded this from our map, as we consider 
quality of evidence to be relevant to all criteria, e.g. how costly or complex an intervention is. 
Rather, we propose to capture quality of evidence in uncertainty analysis. The second category 
is ‘health distribution,’ and included criteria that relate to the core concept of ‘equal life time 
health,’ which means that all people independent of their background, their disease status or 
the availability of treatment should have a fair chance to live a full healthy life [18]. This concept 
encompasses both horizontal and vertical equity. We define horizontal equity as the provision 
of equal treatment for people with equal health needs. Horizontal equity is non-discriminative 
towards certain groups in society to give them equal access to care as other groups with the 
same needs. We define vertical equity as the provision of unequal but equitable treatment for 
people with unequal health needs – this implies giving priority to certain groups in society, 
on the basis of their background (‘socioeconomic status,’ ‘area of living,’ ‘sex and gender,’ ‘age,’ 
‘ethnicity,’ ‘sexual orientation’), disease status (‘severity of disease’) or the ‘availability of treat-
ment’ [19]. ‘Responsibility for health’ is included as interventions that focus on people that 
have bad luck may deserve more priority. The precise identification and definition of equity- 
related criteria is topic of a recent collaboration between different experts (ethicists, public 
health experts, economist, etc.) from academic institutes and the WHO [4,19]. Therefore we 
only provisionally list and define these criteria here.
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Figure 2. Mapping of priority setting criteria
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CATEGORY CRITERIA DEFINITION
Health level Individual 
effectiveness
Interventions that are effective in reduction of individual level 
morbidity and mortality may deserve priority
Patient reported 
health status
Interventions that have high impact on patient reported 
health status may deserve priority
Safety Interventions that do not harm in terms of morbidity and 
mortality may deserve priority
Health distribution Various criteria All criteria proposed in the map have the same underlying 
rationale: all people should have as much of a fair chance to 
live a healthy life, and therefore interventions focusing on 
certain social groups may deserve priority
Responsiveness Patient perceived 
quality of care
Interventions should be responsive to people’s expectations 
in regard to non-health matters and reflect the importance 
of people’s dignity, autonomy and the confidentiality of 
information
Burden of disease Interventions that focus on a high burden of disease in society 
may deserve priority
Social and financial 
protection
Catastrophic health 
expenditure
Health care related costs can push people into poverty. 
Interventions that protect people against catastrophic health 
expenditure may deserve priority
Economic 
productivity and 
care for others
People who are economically productive and/or take care of 
others and become ill, face income loss and health related 
costs, which could lead to poverty. Interventions that target 
those people may deserve priority
Rare diseases Interventions of rare diseases might be very costly (because 
of the small number patients) and could push people into 
poverty. Therefore, these interventions may deserve priority
Improved efficiency Size of target 
population
Interventions that show economies of scale because they 
target a high number of people may deserve priority
Feasibility Service 
delivery
Service 
requirements
Interventions that are easy to implement because of the 
current service capacity may have priority. E.g. availability 
of: service infrastructure, delivery models, safety & quality, 
management
Health care 
workforce
Health care 
workforce 
requirements
Interventions that are easy to implement because of the 
current health care workforce capacity may have priority. E.g. 
availability workforce and workforce policies, preferences of 
workforce for working conditions
Infor-
mation
Information 
requirements
Interventions that are easy to implement because of the 
current information system capacity may have priority. E.g. 
availability of surveillance systems
Table 2. Definition of categories and criteria for priority setting
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Table 2. Continued
The third category is ‘responsiveness’, and includes ‘patient perceived quality of care’. Interven-
tions should be responsive to people’s expectations in regard to non-health matters and reflect 
the importance of people’s dignity and autonomy, and the confidentiality of information.
Although this seems a general, and therefore system wide concern, some interventions do 
better than other interventions in satisfying perceived quality of care. We include ‘burden 
of disease’ to represent the wish of society to target high burden diseases. The fourth cate-
gory is ‘social and financial risk protection’ and includes ‘catastrophic health expenditure’, 
‘economic productivity and care for others’ and ‘rare diseases’. Regarding the latter, interven-
tions targeting rare diseases may deserve priority because they may be very costly (as inter-
vention (especially drug) development costs are only shared by a small number of patients) 
and could push people into poverty. The fifth category is ‘improved efficiency’ and reflects the 
economies of scale that can be obtained when reaching large number of people. Therefore 
we have included the criterion ‘size of target group’. We decided to exclude ‘cost-effectiveness’ 
as a criterion on itself, as theoretically costs (as a feasibility constraint) and effectiveness (as a 
goal) are both implicitly included in the mapping as individual criteria. However, regarding 
CATEGORY CRITERIA DEFINITION
Feasibility Medical 
product, 
vaccines & 
technology 
Medical product, 
vaccines & 
technology 
requirements
Interventions that are easy to implement because of the 
current medical products, vaccines & technology capacity may 
have priority. E.g. norms, standards and reliability procurement
Financing Budget impact Interventions that consume a small part of the budget may 
have priority
Unit costs Interventions that have small unit cost per patient may have 
priority
Financing party Interventions that receive sustainable financing may have 
priority
Gover-
nance & 
leadership
Congruency 
previous priority 
setting
Interventions that are in line with previous spending pattern 
may have priority
Cultural 
acceptability
Interventions that are cultural acceptable, because of the 
norms and values, may have priority
Political 
acceptability
Interventions that are political acceptable may have priority
Stakeholder 
acceptability
Interventions that are accepted by important stakeholder 
groups (e.g. patients groups, taxpayers, health care providers, 
donor agencies, voters) may have priority.
Legal barriers Interventions that face no legal barriers may have priority
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the importance of the criterion of cost-effectiveness in decision-making, decision makers may 
nevertheless consider it as a separate criterion.
On the left panel of the map we distinguish one category of criteria related to the feasibility 
of implementation of interventions. This category is divided in six subcategories, based on 
the building blocks, i.e. ‘service delivery’, ‘health workforce’, ‘information’, ‘medical products, 
vaccine and technologies,’ ‘financing,’ and ‘leadership/ governance’. In contrast to the criteria 
related to intervention goals (discussed above), little work has been done on these criteria 
(except on the criteria ‘cost’) and the criteria we put forward are first propositions. The first four 
subcategories relate to the current capacity of the health system and criteria reflect the require-
ments the for implementation of an intervention. The fifth subcategory on financing encom-
passes ‘unit costs’, ‘budget impact’ and ‘financing party’. The ‘unit costs’ are the total costs per 
patient from a health systems perspective whereas ‘budget impact’ incorporates the scale of 
an intervention. The ‘financing party’ criterion captures who is paying for a health intervention 
and reflects notions on its financial sustainability. The sixth subcategory represents the feasi-
bility in terms of leadership/governance and includes ‘congruency previous priority setting,’ 
‘cultural acceptability,’ ‘political acceptability,’ ‘stakeholder acceptability,’ and ‘legal barriers’.
Discussion
Our map should not be regarded as a top-down expert advice on a fixed set of criteria 
that should always be considered in all prioritization decisions, but rather as an aid to deci-
sion-makers in their selection of relevant criteria. We see two broad applications of priority 
setting, and therefore of our mapping of criteria. First, it can inform decision makers who work 
in a specific context, e.g. on the reimbursement decision of a single intervention. These deci-
sions are taken in the presence of a known budget and are likely limited by factors such as 
the currently available physical infrastructure, human resources or political consideration, at 
least in the short to medium term. This is labeled ‘context-specific priority setting’. The second 
application is to guide decisions on a wide range of interventions, to provide general informa-
tion on their relative rank order to arrive a more informed debate on resource allocation prior-
ities. Because priority setting in this application is not meant to provide a solution to a specific 
resource allocation question, it need not be highly contextualized in terms of e.g. physical 
infrastructure and/or human resources constraints. This is labeled ‘generalized priority setting’ 
[20]. The set of criteria for ‘context-specific priority setting’ is likely to be much more specific 
than those for ‘generalized priority setting’, but stem from the same conceptual mapping of 
criteria as presented above. That our mapping of criteria should not be considered as a fixed 
set of criteria is especially clear when setting priorities in a specific disease area. For example, 
an important criterion in HIV/AIDS health rationing decisions is whether the intervention 
reduces stigma. To include these disease-specific criteria in a generic list would increase its 
total number of criteria and make it unmanageable.
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As our mapping is based on the WHO health systems frameworks, it has a certain credibility 
among decision makers. However, the choice of a different underlying framework might lead 
to another mapping of criteria. 
In our framework, we included criteria related to the health system inputs and health system 
goals, but no criteria related to intermediate outcome measures as access and utilization. These 
measures are instrumental to reach health system goals, and are as such no goals in them-
selves. However, decision-makers can use them to monitor and evaluate progress towards the 
realization of the health system goals.
Another important step in MCDA is to define indicators to operationalize the criteria. For 
example, the severity of disease that an intervention targets can be measured in terms of 
health state valuations [21] and health gains in terms of disability adjusted life years averted. 
The operationalization of criteria would complement our mapping of criteria, and would allow 
the construction of a performance matrix that systematically demonstrates the performance 
of an intervention on all criteria [7,8]. Such a matrix can consequently be the basis for rationing 
decisions on (a set of) health interventions. Such decisions should eventually also account for 
non-quantifiable criteria related to e.g. complicated ethical judgments. These criteria are not 
reflected in our framework, and further research should be carried out on how these can best 
be accounted for, e.g. through a process of deliberation [8,20,22].
We consider the presented mapping of priority setting criteria as preliminary only and not as 
a final map. We welcome discussions to further develop it, to improve the use of MCDA for 
setting priorities in health.
Conclusions
This conceptual mapping of criteria, based on well-established health system frameworks, will 
further develop the field of priority setting by assisting decision makers in the identification of 
ltiple criteria for selection of health interventions. 
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Appendix
This appendix contains an overview of all criteria considered for inclusion in our map according 
to the consulted data sources. A rationale is given on why a criterion is excluded. For all the 
criteria that are included, we present the category and criteria it belongs to and for the related 
definitions we refer to table 1 and 2 of the chapter. 
Table A. Overview of criteria presented by review of Guindo et al. 2012 [11]
CRITERIA 
CATEGORY
CRITERIA EXCLUDED/ INCLUDED 
(CATEGORY/CRITERION)
RATIONALE FOR EXCLUSION
A
Health outcomes 
and benefits of 
intervention
A1: Health benefit Included (health level, 
effectiveness on individual level)
A2: Efficacy/
effectiveness
Included (health level, 
effectiveness on individual level 
and effectiveness on population 
level)
A3: Life saving Included (health level, 
effectiveness on individual level)
A4: Safety Included (health level, safety)
A5: PRO (patient 
reported 
outcomes) 
Included (health level, patient 
reported outcomes)
A6: Quality of care Included (responsiveness, patient 
reported quality of live)
B
Type of health 
benefit
B1: Population effect 
(prevention)
Included (health level, 
effectiveness on individual level 
and effectiveness on population 
level)
B2: Individual effect 
(medical service)
Included (health level, 
effectiveness on individual level)
C
Impact of the 
disease targeted
by intervention
C1: Disease severity Included (health distribution, 
disease severity)
C2: Disease 
determinants
Included (health distribution, all 
criteria)
C3: Disease burden Included (responsiveness, burden 
of disease)
C4: Epidemiology Included (responsiveness, burden 
of disease) 
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CATEGORY CRITERIA EXCLUDED/ INCLUDED RATIONALE FOR EXCLUSION
D
Therapeutic 
context of 
intervention
D1: Treatment 
alternatives
Included (health distribution, 
availability alternative treatment)
D2: Need Included (improved efficiency, 
size of target population)
D3: Clinical guidelines 
& Practices
Included (feasibility, service 
requirements)
D4: Pre-existing use Included (feasibility, congruency 
previous priority setting) 
E
Economic impact 
of intervention
E1: Cost Included (feasibility, unit costs)
E2: Budget 
impact
Included (feasibility, budget 
impact)
E3: Broad financial 
impact
Included (social & financial 
risk protection, economic 
productivity and care for others)
E4: Poverty 
reduction
Included (social & financial risk 
protection, catastrophic health 
expenditure) 
E5: Cost- 
effectiveness
Implicitly included (this criterion 
is a combination of unit costs 
(financing building block) and 
effectiveness on individual/
population level (health level goal))
E6: Value Included (health level, all criteria)
E7: Efficiency and 
opportunity costs
Efficiency is implicitly included 
(this criterion is a combination 
of unit costs (financing building 
block) and effectiveness on 
individual/population level 
(health level goal)), opportunity 
costs is included (feasibility, unit 
costs)
E8: Resources Included (feasibility, all criteria) 
E9: Insurance 
premiums
Excluded This criterion is conceptually not 
linked to building blocks or goals. 
Table A. Continued
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Table A. Continued
CATEGORY CRITERIA EXCLUDED/ INCLUDED RATIONALE FOR EXCLUSION
F
Quality and 
uncertainty of 
evidence
F1: Evidence  
available
Excluded The level of evidence can be cap-
tured in sensitivity analysis. 
F2: Strength of 
evidence
Excluded The strength of evidence can be 
captured in sensitivity analysis.
F3: Relevance of 
evidence
Excluded Any evidence used in deci-
sion-making should be relevant 
and this differentiates between 
interventions. 
F4: Evidence 
characteristics
Excluded All relevant evidence character-
istics should be included in de-
cision-making and this differenti-
ates between interventions. 
F5: Research ethics Excluded This criterion is conceptually not 
linked to building blocks or goals. 
F6: Evidence 
requirements
Excluded Evidence is required in decision 
making on all criteria.
G  
Implementation 
complexity of 
intervention
G1: Legislation Included (feasibility, legal barriers)
G2: Organizational 
requirements 
and capacity to 
implement
Included (feasibility, service 
and health care workforce 
requirements)
G3: Skills Included (feasibility, health care 
workforce requirements)
G4: Flexibility of 
implementation
Included (feasibility, service 
requirements) 
G5: Characteristics of 
intervention
Included (all criteria) 
G6: Appropriate use Included (health level, safety) 
G7: Barriers and 
acceptability
Included (feasibility, cultural, 
political and stakeholder 
acceptability) 
G8: Integration and 
system efficiencies
Included (feasibility, all criteria) 
G9: Sustainability Included (feasibility, financing 
party)
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CATEGORY CRITERIA EXCLUDED/ INCLUDED RATIONALE FOR EXCLUSION
H
Priorities fairness 
and ethics
H1 Population 
priorities
Included (health distribution, all 
criteria)
H2: Access Excluded This criterion is an intermediate 
outcome measure and is not di-
rectly related to the goals or build-
ing blocks. 
H3: Vulnerable and 
needy population
Included (health distribution, all 
criteria)
H4: Equity, fairness and 
justice
Included (health distribution, all 
criteria)
H5: Utility Included (all goals)  
H6: Solidarity Included (health distribution, all 
criteria)
H7: Ethics and moral 
aspects
Included (health distribution, all 
criteria)
I
Overall context
I1: Mission and man- 
date of health system
Included (all goals)
I2: Overall priorities Included (feasibility, political 
acceptability/ all goals)
I3: Financial constraints Included (feasibility, financing party)
I4: Incentives Included (feasibility, stakeholder 
acceptability)
I5: Political aspects: Included (feasibility, political 
acceptability) 
I6: Historical aspects Included (feasibility, congruency 
previous priority setting)
I7: Cultural aspects Included (feasibility, cultural 
acceptability)
I8: Innovation Included (medical products, 
vaccine and technology 
requirements)
I9: Partnership and 
leadership
Included (feasibility, political 
acceptability) 
I10: Citizen   
  involvement
Included (feasibility, stakeholder 
acceptability)
 
I11: Stakeholders  
  interests and   
  pressures
Included (feasibility, stakeholder 
acceptability) 
Table A. Continued
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CATEGORY SAMPLE CRITERIA INCLUSION / EXCLUSION / 
REPRESENTED BY OTHER 
CRITERIA
RATIONALE
FOR EXCLUSION
Disease-related 
criteria 
Disease severity Included (health distribution, 
disease severity) 
Poor capacity to benefit 
from treatment
Included (health distribution, 
disease severity) 
Rare diseases Included (social & financial risk 
protection, rare diseases)
Criteria related to 
characteristics of 
social groups
Equality among the 
members of distinct 
groups in relation to a 
normative standard of 
equal lifetime health.
Included (health distribution, all 
criteria)
Criteria related to 
protection against 
the financial and 
social effects of ill 
health
Economic productivity Included (social & financial risk 
protection, economic productivi-
ty and care for others) 
Catastrophic health 
expenditures
Included (social & financial risk 
protection, catastrophic health 
expenditures)
Impact on dependents Included (social & financial risk 
protection, economic productivity 
and care for others) 
Other Personal responsibility 
for health
Included (health distribution, 
responsibility for health)
Discounting Excluded This is presented in Johri 
& Norheim in reaction to 
cost-effectiveness analysis. 
This criterion is conceptu-
ally not linked to building 
blocks or goals.
Table B. Criteria included in EVIDEM framework (www.evidem.org)
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CATEGORIES CRITERIA 
(overlap with criteria from Guindo review presented in table 1)
MCDA model 
criteria 
(intrinsic criteria, 
universally 
operationalizable
Disease impact D1 - Disease severity  C1 in Table 1
D2 - Size of population  D4
Context of 
intervention
C1 - Clinical guidelines  D3
C2 - Comparative interventions limitations (unmet needs)  D2
Intervention 
outcomes
I1 - Improvement of efficacy/ effectiveness  A2
I2 - Improvement of safety & tolerability  A4
I3 - Improvement of patient reported outcomes  A5
Type of benefit T1 - Public health interest (e.g., prevention, risk reduction)  B1
T2 - Type of medical service (e.g., cure, symptom relief)  B2
Economics E1 - Budget impact on health plan (cost of intervention)  E2
E2 - Cost-effectiveness of intervention (optional)  E5
E3 - Impact on other spending (e.g., hospitalization, disability) 
E3
Quality of evidence Q1 - Adherence to requirements of decisionmaking body   F6
Q2 - Completeness and consistency of reporting evidence  F2
Q3 - Relevance and validity of evidence   F2
Contextual 
(extrinsic) criteria
Ethical framework Et1 - Utility - Goals of healthcare  H5 
Et2 - Efficiency - Opportunity costs   E7
Et3 – Fairness -  Population priority & access  H4
Contextual criteria O1 - System capacity & appropriate use of intervention  G2
O2 - Stakeholder pressures  I11
O3 - Political/historical context  I5/I6
 Note: In the last column we show the overlap between the criteria from evidem.org and Guindo et al (presented in table 1)
Table C. Criteria for equity presented by Johri & Norheim 2012 [4]
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PRINCIPLE OF 
ALLOCATIVE 
JUSTICE
CRITERIA INCLUSION / EXCLUSION /
REPRESENTED BY OTHER CRITERIA
RATIONALE FOR 
EXCLUSION
Need General Included (responsiveness, burden of 
disease)
Severity of the 
condition
Inclusion (health distribution, severity 
of disease)
Availability of 
alternatives
Inclusion (health distribution, 
availability alternative treatment)
Appropriateness Efficacy and safety Included (health level, effectiveness 
on individual level, effectiveness on 
population level, safety) 
Effectiveness Included (health level, effectiveness 
on individual level)
Clinical benefits General Included (health level, effectiveness 
on individual level)
Effect on mortality 
(life-saving)
Included (health level, effectiveness 
on individual level)
Effect on longevity Included (health level, effectiveness 
on individual level)
Effect on health-
related-quality-of-life
Included (health level, effectiveness 
on individual level)
Efficiency Cost-effectiveness/
benefit
Implicitly included (this criterion is a 
combination of unit costs (financing 
building block) and effectiveness on 
individual/population level (health 
level goal))
Budgetary impact Included (feasibility, budget impact)
Cost Included (feasibility, unit costs)
Equality General Included (health distribution, all 
criteria)
Accessibility to the 
service
Excluded This criterion is an 
intermediate outcome 
measure and therefor 
indirectly related to 
the goals and building 
blocks of our map.
Table D. Criteria presented by Golan et al 2010 [13]
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PRINCIPLE OF 
ALLOCATIVE 
JUSTICE
CRITERIA INCLUSION / EXCLUSION /
REPRESENTED BY OTHER CRITERIA
RATIONALE FOR 
EXCLUSION
Affordability to the 
individual
Included (health distribution, socio 
economic status/social and financial 
risk protection, catastrophic health 
expenditure) 
Solidarity -
Other ethical or 
social values
Autonomy Included (responsiveness, patient 
perceived quality of care)
Public health value Included (all goals)
Impact on future 
generations
Included (health level, effectiveness 
on population level) 
Quality of the 
clinical and 
economic 
evidence 
- Excluded The quality of the 
clinical and economic 
evidence can be 
captured in sensitivity 
analysis. 
Other 
considerations 
not elsewhere 
classified 
Strategic issues 
consistency with 
previous decisions and 
precedents
Inclusion (feasibility, congruency 
previous priority setting) 
Table D. Continued
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NICE (ENGLAND) – FACTORS TAKEN INTO ACCOUNT IN JUDGEMENTS ABOUT COST EFFECTIVENESS
Criteria Inclusion/exclusion/represented 
by other criteria
Rationale for exclusion
Severity of underlying illness Included (health distribution, severity of 
disease)
End of life treatments Included (health distribution, severity of 
disease)
Stakeholder persuasion Included (feasibility, stakeholder acceptability) 
Significant innovation Included (feasibility, medical products, 
vaccines and technology requirements) 
Disadvantaged populations Included (health distribution, all criteria)
Children Included (health distribution, age)
AGNSS 2010 (ADVISORY GROUP FOR NATIONAL SPECIALISED SERVICE, ENGLAND) 2010
Criteria Inclusion/exclusion/represented 
by other criteria
Rationale for exclusion
Health gain
Severity and ability of patients 
to benefit
Included 
(health distribution, severity of disease)
Clinical safety and risk Included (health level, safety)
Clinical effectiveness and
potential for improving health
Included (health level, effectiveness on 
individual level)
Societal value
Stimulating research and 
innovation
Included (feasibility, medical products, vac-
cines and technology requirements) 
Needs of patients and society Included (health distribution, severity of 
disease)
Reasonable cost
Average cost per client Included (feasibility, unit costs)
Overall cost impact and 
affordability including 
opportunity cost
Included (feasibility, budget impact / social & 
financial risk protection, catastrophic health 
expenditure) 
Value for money compared to 
alternatives
Implicitly included (this criterion is a combi-
nation of unit costs (financing building block) 
and effectiveness on individual/population 
level (health level goal))
Best practice
Best clinical practice in delivering 
the service
Included (health level, effectiveness on 
individual level)
Table E. Criteria presented by Devlin & Sussex 2010 [8] (additional to Golan et al. 2010 [13]) 
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AGNSS 2010 (ADVISORY GROUP FOR NATIONAL SPECIALISED SERVICE, ENGLAND) 2010
Criteria Inclusion/exclusion/represented 
by other criteria
Rationale for exclusion
Economic efficiency of provision Implicitly included (this criterion is a combi-
nation of unit costs (financing building block) 
and effectiveness on individual/population 
level (health level goal))
Continuity of provision Included (feasibility, financing party)
Accessibility and balanced 
geographic distribution
Accessibility is excluded, balanced geograph-
ic distribution is included (health distribution, 
area of living) 
HUNTINGDONSHIRE PRIMARY CARE TRUST (SUB-NATIONAL NHS COMMISSIONING, USED MCDA ON PRIORITIZATION 
OF THEIR SPENDING) (BOX 5.1)
Criteria Inclusion/exclusion/represented
by other criteria
Rationale for exclusion
Effectiveness (QALYs) Included (health level, effectiveness on 
individual level)
Burden of disease Included (responsiveness, burden of disease)
Equity/fairness between social 
groups
Included (health distribution, all criteria)
Deliverability and speed of 
implementation
Included (feasibility, all criteria)
Engagement of public and 
professionals in demand 
management
Included (feasibility, health care workforce 
requirements)
Acceptability to public and 
professions
Included (feasibility, cultural and stakeholder 
acceptability)
Certainty/quality of evidence Excluded The certainty/quality of evidence can 
be captured in sensitivity analysis. 
Fit with national standards/targets Included (feasibility, political acceptability)
ISLE OF WIGHT PRIMARY CARE TRUST (MCDA FOR COMMISSIONING STRATEGY 2008-2013) (BOX 5.2)
Criteria Inclusion/exclusion/represented 
by other criteria
Rationale for exclusion
Health benefit (= QALYs) Inclusion (health level, effectiveness on 
individual level)
Health inequalities between 
geographical areas, sexes, ‘special 
groups’ 
Inclusion (health distribution, all criteria)
Probability of success, comprising: 
ease of implementation, availability 
of workforce, acceptability to stake-
holders, process complexity (num-
ber of steps needed) 
Included (feasibility, all criteria)
Table E. Continued
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“HEALTH AUTHORITY D” PRIORITISING DEVELOPMENTS FOR USE OF ADDITIONAL FUNDING 
OVER THE NEXT FIVE YEARS USING SEVEN CRITERIA. (NHS SUB COMMISSION)
Criteria Inclusion/exclusion/represented 
by other criteria
Rationale for exclusion
Evidence of effectiveness Excluded The evidence of effectiveness may be 
used to conduct a sensitivity analysis. 
Value for money Implicitly included (this criterion is a combi-
nation of unit costs (financing building block) 
and effectiveness on individual/population 
level (health level goal))
Health gain or maintenance Included (health level, effectiveness on indi-
vidual level and effectiveness on population 
level) 
Equity Included (health distribution, all criteria)
Risk management Excluded This criterion is conceptually not 
linked to building blocks or goals. 
National or Board priority Included (health distribution, political 
acceptability)
Public preference Included (feasibility, stakeholder
acceptability)
ARGYLL AND CLYDE HEALTH BOARD IN SCOTLAND
Criteria Inclusion/exclusion/represented
by other criteria
Rationale for exclusion
Potential health gain Included (health level, effectiveness on indi-
vidual level/ effectiveness on population level)
Prevention of ill health Included (health level, effectiveness on indi-
vidual level/ effectiveness on population level)
Quality of life Included (health distribution, severity of 
disease)
Equity of access Included (health distribution, all criteria) 
Addressing health status 
inequalities at population level
Included (health distribution, all criteria) 
Expressed demand Included (feasibility, stakeholder
acceptability) 
Appropriateness Included (responsiveness, patient 
perceived quality of care)
Strength of evidence Excluded The strength of evidence can be 
captured in sensitivity analysis. 
Known priorities Included (feasibility, congruency 
previous priority setting)
Table E. Continued
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DEPARTMENT OF HEALTH - STRATEGIC OUTLINE CASE FOR EPSOM GENERAL HOSPITAL REDEVELOPMENT SCHEME 
(BOX 5.3)
Criteria Inclusion/exclusion/represented
by other criteria
Rationale for exclusion
Patient safety Included (health level, safety)
Meet quality standards Included (health level, safety)
Performance + outcomes Excluded This criterion is not related to one 
specific goal or building blocks. In a 
decision making process the perfor-
mance and outcomes on all relevant 
criteria should be taken into account. 
Long term clinical and financial 
stability
Included (feasibility, financing party) 
Productivity and efficiency of care 
services
Productivity is included (feasibility, service re-
quirements) and efficiency is implicitly includ-
ed (this criterion is a combination of unit costs 
(financing building block) and effectiveness on 
individual/population level (health level goal))
Patient focus Included (responsiveness, patient perceived 
quality of care)
Scope for modernization and 
innovation
Included (feasibility, medical products, vac-
cines and technology requirements)
Achievability Included (feasibility, all criteria)
Strategic fit Included (feasibility, political acceptability) 
Co-location of services Included (feasibility, service requirement)
Fits with “Centres of Clinical 
Excellence” 
Included (feasibility, leadership)
Fit with organizational cultures Included (feasibility, leadership)
Stakeholder’ expectations Included (feasibility, stakeholder acceptability)
Utilisation of estate Included (feasibility, legal barriers) 
DEPARTMENT OF HEALTH - OUTLINE BUSINESS CASE FOR THE ROYAL NATIONAL ORTHOPAEDIC HOSPITAL,  
STANMORE, REDEVELOPMENT SCHEME (BOX 5.4)
Criteria Inclusion/exclusion/represented 
by other criteria
Rationale for exclusion
Centre of excellence Included (feasibility, leadership)
Quality of clinical care Included (responsiveness, patients perceived 
quality of care)
Patient centered Included (responsiveness, patients perceived 
quality of care)
Table E. Continued
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DEPARTMENT OF HEALTH - OUTLINE BUSINESS CASE FOR THE ROYAL NATIONAL ORTHOPAEDIC HOSPITAL,  
STANMORE, REDEVELOPMENT SCHEME (BOX 5.4)
Criteria Inclusion/exclusion/represented 
by other criteria
Rationale for exclusion
Access Excluded This criterion is an intermediate out-
come measure and is not directly re-
lated to the goals or building blocks.
Elective capacity Included (feasibility, political acceptability)
Workforce recruitment and 
retention
Included (feasibility, health care workforce 
requirements)
Suitable for working with partners Included (feasibility, service requirements)
Deliverability/achievability Included (feasibility, all criteria)
Design, sustainability and quality 
of life 
Design is included (feasibility, all criteria), sus-
tainability is included (feasibility, financing 
party), quality of life is included (health distri-
bution, severity of disease) 
What impact does the patient’s 
condition have on their QoL
Included (health distribution, severity of 
disease)
To what extent is the patient’s 
condition able to be ameliorated 
by treatment?
Included (health level, effectiveness on 
individual level) 
ISRAEL’S HEALTH BASKET COMMITTEE: PILOT (BOX 5.8)
Criteria Inclusion/exclusion/represented
by other criteria
Rationale for exclusion
Indicators:
Lives saved, Life prolongation, 
Quality of life benefits
Included (health level, effectiveness on 
individual level)
Availability of alternative 
treatments
Included (health distribution, availability 
alternative treatment)
Other ethical/social benefits (e.g. 
reduces health gaps). 
Included (health distribution, all criteria) 
Criteria:
A. Benefits Included (all goals) 
B. Net costs Included (feasibility, unit costs)
C. Quality of Evidence Excluded The quality of evidence may be used 
to conduct a sensitivity analysis. 
D. Other considerations Included (all goals) 
Also presented on this case:
pClEff - Probability that the new 
technology is clinically effective
Excluded The probability that the new technol-
ogy is clinically effective may be used 
to conduct a sensitivity analysis. 
Table E. Continued
72
  Sub-question 2
ISRAEL’S HEALTH BASKET COMMITTEE: PILOT (BOX 5.8)
Criteria Inclusion/exclusion/represented
by other criteria
Rationale for exclusion
pCostEf 20k - Probability that the 
new technology is cost-effective 
relative to the comparator at a 
willingness to pay of < 20k per QALY 
gained
Excluded The probability that the new tech-
nology is cost-effective relative to the 
comparator at a willingness to pay of 
< 20k per QALY gained may be used 
to conduct a sensitivity analysis. 
Acceptability/Appropriateness/
Preferences (of public and patients)
Included (feasibility, stakeholders acceptabil-
ity)
Terminality - End of life use Included (health distribution, severity of 
disease) 
Orph/no alt/rescue - The new 
technology is an ‘orphan drug’ or 
it has no alternatives besides best 
supportive case, or it is used in a 
‘rule of rescue’ situation.  
Included (financial and social risk protection, 
rare diseases) 
OtherEq - Other equity 
considerations
Included (health distribution, all criteria)
DH priorities - Clinical priority areas 
as designed by Secretary of State 
for Health and Welsh Assembly 
Government
Included (feasibility, leadership)
Health System (HS) feasibility/
impact (no additional definition 
provided)
Included (feasibility, all criteria) 
Innovativeness - (no additional 
definition provided)
Included (feasibility, medical products, vac-
cines and technology requirements)
Wider Societal Considerations (no 
additional definition provided)
Included (social and financial risk protection/
economic productivity and care for others)
FIGURE 7.1 A TEMPLATE FOR EXPLICIT AND TRANSPARENT CONSIDERATION OF SOCIAL VALUE JUDGEMENTS 
IN NICE’S DELIBERATIVE PROCESS
Criteria Inclusion/exclusion/represented by other 
criteria
Rationale for exclusion
End of life Included (health distribution, severity of 
disease)
Severity Included (health distribution, severity of 
disease) 
Children Included (health distribution, age)
Social disadvantage Included (health distribution, all criteria)
Small patient numbers Included (social & financial risk protection, 
rare diseases) 
Table E. Continued
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FIGURE 7.1 A TEMPLATE FOR EXPLICIT AND TRANSPARENT CONSIDERATION OF SOCIAL VALUE JUDGEMENTS 
IN NICE’S DELIBERATIVE PROCESS
Criteria Inclusion/exclusion/represented
by other criteria
Rationale for exclusion
Lack of alternative treatments Included (health distribution, availability of 
alternative treatment) 
Aspects of innovation not taken 
into account the ICER
Innovation (feasibility, medical products, 
vaccines and technology requirements)
TABLE 7.2 ATTRIBUTES (CRITERIA) AND LEVELS (THE WAY THAT CRITERIA ARE MEASURED) INCLUDED IN A 
DISCRETE CHOICE EXPERIMENT WITH NICE APPRAISAL COMMITTEE MEMBER
Criteria Inclusion/exclusion/represented by other 
criteria
Rationale for exclusion
Incremental cost-effectiveness 
analysis
Implicitly included (this criterion is a combi-
nation of unit costs (financing building block) 
and effectiveness on individual/population 
level (health level goal))
Uncertainty Excluded The uncertainty of evidence can be 
captured in sensitivity analysis. 
Age Included (health distribution, age)
Baseline HR-QoL Included (health distribution, severity of 
disease)
Availability of other therapies Included (health distribution, availability 
alternative treatment)
Table E. Continued
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CRITERIA INCLUSION / EXCLUSION /
REPRESENTED BY OTHER CRITERIA
RATIONALE
FOR EXCLUSION
Claim based on need as illness Included (health distribution, all 
criteria) 
Claim based on need as capacity to benefit Included (health distribution, 
severity of disease) 
Claim based on morally arbitrary bad luck Included (health distribution, 
responsibility for health)
Claim based on deprivation or disadvantage Included (health distribution, all 
criteria) 
Claim based on extent to which someone is 
responsible for her HIV status
Included (health distribution, 
responsibility for health)
Claim based on the impact of treatment on 
social fabric 
Included (social & financial risk 
protection, economic productivity 
and care for others) 
Claim based on net impact on the health of 
society
Included (health level, effectiveness 
on population level)
Table F. Criteria (claims) presented by Cleary et al. 2010 [12] for considering to whom good 
  should be distributed
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 Subquestion 1
  What is the current priority setting process in 
  HIV/AIDS control in Indonesia?
 Sub-question 2
  Which criteria are important 
  for priority setting in
  HIV/AIDS control?
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Abstract
Background: Indonesia faces an urgent need to prioritized interventions for HIV/AIDS 
control as resources are far below needed to effectively respond to the epidemic. In 
priority setting processes many considerations (also called criteria), like an interven-
tion’s impact on health and equity and its feasibility, play a role. However, until now 
criteria have not been explicitly used for selection of HIV/AIDS interventions in Indo-
nesia. This study identifies the views of various stakeholders on the importance of 
different criteria for priority setting of HIV/AIDS interventions in Indonesia. 
Methods: Based on a literature search and a focus group discussion with stakeholders 
(n=6) a list was developed of 32 criteria that may play a role in priority setting in HIV/
AIDS control in West-Java province. Criteria were categorized according the World 
Health Organization’s health system goals and building block frameworks. People 
living with HIV/AIDS (PLWHA) (n=49), health care workers (HCW) (n=41), the general 
population (n=43) and policy makers (n=22) rated the importance of all 32 criteria for 
priority setting on a 5 point Likert-scale. Thereafter, respondents ranked the highest 
rated criteria to express more detailed preferences. 
Results: Based on the average ranking scores, all stakeholders perceived an interven-
tion’s impact on the epidemic as the most important criterion for priority setting. In 
addition, an intervention’s impact on stigma in society, its quality of care and its feasi-
bility related to the health system infrastructure (i.e. health care workers, service and 
information requirements) were considered highly important. Most criteria related to 
equity (i.e. prioritizing groups on the basis of their gender, SES and age) were consid-
ered least important. 
Conclusions: This study identified that an intervention’s impact on the epidemic, its 
impact on stigma in society, its quality of care and its requirements related the health 
system were perceived most important criteria among stakeholders for priority setting 
in HIV/AIDS control. This information may contribute to more transparent and system-
atic decision making in HIV/AIDS control in Indonesia. 
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Background
In Indonesia, priority-setting questions have arisen in the context of HIV/AIDS control as it faces 
one of Asia’s fastest growing HIV/AIDS epidemics and resources are scarce. In 2013, an esti-
mated 640 thousand people were living with HIV/AIDS (PLWHA) and this number will increase 
to 1,500,000 in 2020 if not the right actions are taken [1,2]. While the government seems to 
have the epidemic under control among people who inject drugs (PWID), the prevalence is 
increasing among female sex workers (FSW) and their clients, men having sex with men (MSM) 
and the general population. The budget for HIV/AIDS control is far from sufficient; in 2010 only 
US$ 69 million was spend on HIV/AIDS while US$ 152 million was estimated to be needed [3,4].
Both issues urge for a wisely choice between HIV/AIDS interventions. An evaluation at Bandung 
city and West-Java province level showed that priority setting in HIV/AIDS control in Indo-
nesia could be improved. At this moment the strategic plans developed by the AIDS commis-
sions include a long list interventions and although many stakeholders (e.g. government staff, 
communities and health care workers) are involved in the priority setting process their partic-
ipation could be improved. Various criteria played a role in the development of the HIV/AIDS 
strategic plans but they remained implicit. Systematic analysis of how important different 
stakeholders find various criteria could contribute to more systematic and transparent priority 
setting but has not yet been done. [5].
Most methods introduced to guide resource allocation decisions in health (i.e. evidence-based 
medicine, cost-effectiveness analysis, burden of disease and equity analysis [6,7], rely on one 
single criteria (mostly cost and cost-effectiveness), while in reality many criteria can play a role 
(e.g. feasibility, equity, cultural and political factors) [8–15]. Therefore, multi criteria decision 
analysis (MCDA) is put forward as one of the most important methods for priority setting and 
provides a systematic process for clarifying what is being taken into account (the ‘criteria’) and 
how much importance (‘weight’) to put on each [14]. It has been successful in various case 
studies, e.g. in Ghana MCDA guided the Ministry of Health in prioritizing national health care 
interventions, in Nepal it showed that a lung health intervention should be a priority (ranking 
13th out of 34 interventions), and in Thailand it guided decisions in HIV/AIDS control [16–31]. 
Multi criteria decision analysis contributed to transparent and accountable policy making and 
seems a step forward in rational decision-making. In HIV/AIDS field, the recognition of multiple 
criteria has risen and is reflected in the WHO programmatic guidance for ART that recom-
mends taking besides health impact also equity and feasibility criteria into consideration [32]. 
However, only a few studies have tried to measure explicitly the importance of multiple criteria 
for HIV/AIDS priority setting [33,34] and worldwide the main focus remains on how to reduce 
new infections and AIDS related death [35,36]. 
Recently, a few empirical priority setting studies have included the identification and 
weighting of the views of different stakeholders, such as patients and the general population 
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besides those of policy makers. [7,37,38] Inclusion of different perspectives in priority setting 
is important to enhance the legitimacy of the process, as has been acknowledged in the 
Accountability for Reasonableness framework [39]. 
This study aims to elicit the views of multiple Indonesian stakeholders on the importance of 
various criteria for priority setting in HIV/AIDS control. This information may be used to support 
Indonesian policy makers in resource allocation decisions related to HIV/AIDS control. 
Methods
Methods for MCDA - Identification of criteria
In MCDA, criteria can be identified by various approaches, e.g. a literature study, focus groups 
discussion with relevant stakeholders or using more structured approaches such as Q meth-
odology [40] that combines qualitative and quantitative analyses [14]. 
In our study, we started with a draft general list of criteria, that is based on the World Health 
Organization’s health system goals and building block frameworks and is published else-
where [41]. We argue that the reasons why stakeholders prioritize certain health interventions 
is reflected in these two frameworks and that it can be used to categorize criteria. The health 
system goals framework contains criteria related to five criteria categories: improvement of the 
level and distribution of health, responsiveness, social & financial risk protection and improved 
efficiency. The second framework, the health system building blocks, reflects criteria related to 
the feasibility of criteria and comprises of six categories, i.e. service delivery, health workforce, 
information, medical products vaccines & technology, financing and leadership/governance 
[42]. We adapted the draft general list of criteria of criteria to the West-Java HIV/AIDS context 
based on HIV/AIDS priority setting literature [8–12,14,15] and a focus group discussion with a lay 
person, public health expert, health care worker, economists, psychologist and anthropolo-
gist working in the HIV/AIDS field in Indonesia. Criteria definitions and overlap were discussed. 
In the end thirty-two criteria remained and their definitions and categorization are presented 
in Table 1. Among others, specific HIV/AIDS criteria that were added were ‘prevention versus 
treatment’, ‘HIV risk of target population’, ‘reduction of stigma in society’ and ‘marital status’ as 
unmarried people in Indonesia might be more vulnerable as they have less access to repro-
ductive health services. 
Methods for MCDA – Assessing the importance of criteria 
The importance (also called weights) of criteria can be identified by well-established economic 
methods like discrete choice experiments and conjoint analysis to uncover participants’ prefer-
ences about the importance of the various attributes (criteria) through their choices. Discrete 
choice experiments have been applied in several MCDA studies but have been criticized 
for being too technocratic and not being able to include more then six to eight criteria [43]. 
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Table 1. Selected criteria and their definitions for HIV/AIDS priority setting in Indonesia,
  categorized according to WHO health systems frameworks
CATEGORY CRITERIA DEFINITION
Health system goals
Health impact Individual effectiveness Interventions that have effect on a person’s individual health 
status, for example prevention of a person becoming HIV 
infected or the extension of life of HIV/AIDS patients, may 
deserve priority 
Safety Interventions that have no side effects in terms of health may 
deserve priority
Reducing spread of HIV Interventions that have high impact on de spread of the HIV 
epidemic may deserve priority 
Prevention or treatment Either interventions that prevent new HIV infections or focus on 
treatment of HIV/AIDS patients may deserve priority
Health 
distribution
Income class Interventions that target people with certain income classes 
may deserve priority 
Area of living Interventions that target people in certain areas of living may 
deserve priority (for example underserved areas where people 
have less access to care and education and live in poor living 
circumstances) 
Sex and gender Interventions that target people with certain sex or gender (i.e. 
men or women) may deserve priority  
Religion Interventions that target certain religious groups may deserve 
priority
Marital status Interventions that target people with certain marital status may 
deserve priority 
Age Interventions that target people with certain age may deserve 
priority 
Stigmatized groups Interventions that target people that are stigmatized may 
deserve priority 
Sexual orientation Interventions that target people with certain sexual orientation 
may deserve priority 
Responsible or bad luck Interventions that target people who have bad luck and may 
not be responsible for their HIV infection may deserve priority
Severity of disease Interventions that target people that are servely ill (e.g. AIDS 
patients) may deserve prioirty 
Level of at risk for HIV 
infection
Interventions that target people at high risk for HIV infection 
may deserve priority 
People who are  
easy to reach
Interventions that target people that are easy to reach (e.g. 
partners of HIV+ people, prisoners) may deserve priority 
Simpler and limited applied methods are rating and scaling of criteria and its feasibility for 
MCDA will therefore be explored in this study. 
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CATEGORY CRITERIA DEFINITION
Health system goals
Responsiveness Quality of care Interventions that provide good quality of care (are responsive 
to people’s expectations in regard to non-health matters and 
reflect the importance of people’s dignity, autonomy and the 
confidentiality of information) may deserve priority
Stigma reduction in society Interventions that reduce stigma in society may deserve priority 
Social & financial 
protection
Economic impact People who are economically productive and/or take care of 
others and become ill, face income loss and health related costs, 
which could lead to poverty. Interventions that target those 
people may deserve priority
Health system building blocks / Feasibility
Service delivery Service requirements Interventions that are easy to implement because of the current 
service capacity may have priority. E.g. availability of service 
infrastructure, delivery models, safety & quality, management. 
Health workforce Health care personnel 
requirements
Interventions that are easy to implement because of the current 
health care workforce capacity may have priority. E.g. availability 
workforce and workforce policies, preferences of workforce for 
working conditions
Information Information system 
requirements
Interventions that are easy to implement because of the current 
information system capacity may have priority. E.g. availability of 
surveillance systems
Medical products, 
vaccines & 
technologies
Medical products and 
technology requirements
Interventions that are easy to implement because of the current 
available medical products, vaccines & technology may have 
priority. E.g. norms, standards and reliability procurement
Financing In line with previous 
spending pattern
Interventions that received funding last year may have priority
Unit costs Interventions that have small unit cost per patient may have 
priority
Budget impact Interventions that consume a small part of the budget may have 
priority
Sustainability Interventions that receive sustainable financing may have 
priority
Leadership/ 
governance
Political acceptability Interventions that are political acceptable may have priority
Donor acceptability Interventions that are in line with requirements of donors may 
have priority  
Cultural acceptability Interventions that are cultural acceptable, because of the norms 
and values, may have priority
Religious acceptability Interventions that are accepted by certain religions may have 
priority
Legal regulations Interventions that face no legal barriers may have priority
Table 1. Continued
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Study setting
Our study was embedded in the IMPACT project, a five-year (2006-2011) EU funded project, 
that aimed to respond to the HIV/AIDS problems in Bandung city and West Java province. 
West Java province is one of the worse hit provinces in Indonesia with an estimated number 
of people living with HIV/AIDS of 59 thousand in 2013 [44]. The project has set up HIV/AIDS 
services in hospitals, community and society and conducts scientific clinical, epidemiology 
and economic research and has build up strong links with government institutes and civil 
society. Bandung is the centre for HIV/AIDS control as it houses West Java’s top governmental 
referral hospital (Rumah Sakit Hasan Sadikin) with a HIV/AIDS clinic (clinic Teratai) treating 
over 1000 patients per year. West-Java has established a range of HIV/AIDS activities, i.e. harm 
reduction interventions for PWID, including methadone maintenance treatment clinics in six 
cities, voluntary counselling and testing and ARV treatment at hospital and community clinics 
including outreach activities, and school-based education on sexual- and drug-related risk 
behaviour. The West Java AIDS commission consisting of representatives of various govern-
ment offices, NGOs and health care facilities, coordinates these activities. 
Data collection
Our questionnaire consisted of five parts. In part A we asked the general characteristics of the 
respondent, in part B we presented and explained all thirty-two criteria for HIV/AIDS priority 
setting and asked the respondent to compare them simultaneously and to rate the impor-
tance of each criteria on a five point Likert scale, where 1 = ‘not important at all’, 2 = ‘important’, 
3 = ‘indifferent’, 4 = ‘important’ and 5 = ‘very important’. For some criteria we asked an addi-
tional question to find out the preference for the level of a criteria, e.g. whether the respon-
dent has a preference for prevention over treatment, or men over women for the gender crite-
rion. In part C, the respondent was asked to rank the ten most important criteria, based on the 
highest scores on the Likert-scale. If less than ten criteria scored five on the Likert-scale, addi-
tional criteria were selected that scored four to include ten criteria for the ranking exercise. In 
part D, the respondents were asked to compare simultaneously eight interventions that each 
targets only one specific risk groups and to rate the importance on a five point Likert-scale 
(similar as the scale in Part B). In part E, the respondent could mention any additional criteria 
for HIV/AIDS priority setting that were missing in the questionnaire. At the start, the interviewer 
asked the respondent for informed consent and explained the topic of priority setting and 
handed over a souvenir afterwards. The questionnaire was translated in Indonesian language 
and Indonesian researchers (RP, AS) tested the face-validity. Four economic bachelor students 
who received an incentive per interview conducted the interviews and were trained in several 
sessions to make them familiar with the topic of priority setting and the questionnaire. There-
after, the questionnaire was piloted tested several times among fifteen respondents to find 
optimal phrasing of the questions. The duration of the interviews was on average thirty 
minutes. Data was collected during five months (12 May - 13 October 2011). 
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Table 2. General characteristics of respondents per stakeholder group
STAKEHOLDER GROUPS
Policy makers
(n=22)
People living with 
HIV/AIDS (n=49)
Health care
workers (n=41)
General 
population (n=43)
Age, mean years (SD) 38.5  (13.3) 31.6 (4.1) 37.3 (11.0) 26.5 (9.9) (9.9)
Gender
Male 14 (63.6%) 36 (73.5%) 14 (34.1%) 21 (48.8%) 
Female 8 (36.4%) 13 (26.5%) 27 (65.9%) 22 (51.2%)
Marital status
Not married 6 (27.3%) 22 (44.9%) 14 (34.1%) 31 (72.1%)
Married 15 (68.2%) 26 (53.1%) 27 (65.9%) 12 (27.9%)
Divorced 1 (4.5%) - - -
Widow - - - -
Education
No education - 1 (2,0%) - -
Elementary school - 2 (4,1%) - 3 (7,0%)
Junior high school 1 (4,5%) 2 (4,1%) - 3 (7,0%)
Senior high school 4 (18,2%) 24 (49,0%) 3 (7,3%) 24 (55,8%)
College 4 (18,2%) 8 (16,3%) 17 (41,5%) 1 (2,3%)
University 13 (59,1%) 12 (24,5%) 21 (51,2%) 12 (28,0%)
Religion
Islam 21 (95.5%) 45 (91.8%) 37 (90.2%) 39 (90.7%)
Christen 1 (4.5%) 4 (8.2%) 2 (4.9%) 3 (7.0%)
Catholic - - 2 (4.9%) -
Hindu - - - 1 (2.3%)
Buddhism - - - -
No religion - - - -
Occupation
Government officer 9 (40,9%) 3 (6.1%) - 5 (11.6%)
Private company employee - (9,1%) 9 (18,4%) - 11 (25.6%)
Health care worker
Doctor 2 (29.3%) - 12 (29.3%) -
Nurse - (43.9%) - 18 (43.9%) -
Case manager/admin - (7.3%) - 3 (7.3%) -
Pharmacist/analyst - (14.6%) - 6 (14.6%) -
Entrepreneur/freelancer 2 (9,1%) 18 (36,7%) - 2 (4.7%)
Student 2 (9,1%) 1 (2,0%) - 19 (44.2%)
Housewife - 6 (12,2%) - 4 (9.3%)
NGO/social worker 5 (22,7%) 8 (16,3%) 2 (4.9%) -
Other 1 (4,5%) - - -
Unemployed 1 (4,5%) 4 (8,2%) - 2 (4.7%)
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STAKEHOLDER GROUPS
Policy makers
(n=22)
People living with 
HIV/AIDS (n=49)
Health care
workers (n=41)
General 
population (n=43)
Income (monthly in million IDR (US$)§)
0-0.5 (0- 57.9) 2 (9,1%) 7 (14,3%) - 25 (58,1%)
0.5-1.0 (57.9-115.7) - 10 (20,4%) 2 (4,9%) 3 (7,0%)
1.0-2.0 (115.7-231.4) 2 (9,1%) 12 (24,5%) 9 (22,0%) 8 (18,6%)
2.0-3.0 (231.4-347.1) 4 (18,2%) 7 (14,3%) 6 (14,6%) 2 (4,7%)
3.0-4.0 (347.1-462.9) 2 (9,1%) 2 (4,1%) 12 (29,3%) 1 (2,3%)
4.0-5.0 (462.9-578.6) - 1 (2,0%) 5 (12,2%) 2 (4,7%)
5.0-7.0 (578.6-809.0) 6 (27,3%) 3 (6,1%) 3 (7,3%) 1 (2,3%)
> 7.0 (>809.0) 4 (18,2%) 3 (6,1%) 3 (7,3%) 1 (2,3%)
missing 2 (9,1%) 4 (8,2%) 1 (2,4%) -
§Average exchange rate period May-October 2011: 1US$ = 8642 Rp
Participants
We included four stakeholder groups in our study, i.e. policy makers, health care workers, 
people living with HIV/AIDS (PLWHA), and the general population, on the basis of the impor-
tance of their view in decision making. The policy makers (n = 22) were all involved in HIV/AIDS 
strategic planning and included representatives of the AIDS commissions, health office and 
government planning board (BAPPEDA), either at Bandung city or West-Java province level. 
The health care workers (n = 41) were all working with HIV/AIDS patients at in- and out-pa-
tients wards of Hasan Sadikin hospital in Bandung city (described above) and the PLWHA (n = 
49) were all visitors of the outpatient Teratai clinic. The sample for the general population (n = 
43) consisted of persons visiting the Sunday Market in Bandung city, a weekly market visited 
by diverse citizens of Bandung. General characteristics of each group are presented in table 2. 
Data analysis
All data was entered in Excel Microsoft Office 2010 and average Likert-scores and standard 
deviations were calculated in SPSS for the importance rating of 32 criteria (part B) and the 
importance of prioritizing certain risk groups (part D). For the analysis of the ranking exercises, 
a criterion received 10 points when ranked in first place, nine in second place, etcetera, and 
zero points when ranked below the 10th place. Average ranking scores and standard devia-
tions were calculated for each criterion. For part D, de reasons for prioritizing a risk group were 
entered in Excel and the frequency was counted accordingly. 
Table 2. Continued
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Results
Likert-scale scores
Table 3 (page 88) shows the importance of 32 criteria based on the mean Likert-scale scores 
per stakeholder group. Policy makers expressed a preference for interventions that are effec-
tive in improving health on individual level while health care workers, PLWHA and the general 
population valued reduction in spread of HIV in society as most important criterion. All stake-
holder groups valued feasibility criteria related to the current capacity of the health system 
(i.e. health care workers and service requirements) and stigma reduction in society as highly 
important and criteria related to health distribution (i.e. equity and prioritization for certain 
groups in society) as least important. In general the views of stakeholders overlapped as in the 
top ten criteria seven are similar.
Ranking scores
Table 4 (page 90) presents per stakeholder group the importance of 32 criteria based on the 
ranking scores. All stakeholders considered reduction of spread of HIV as the most important 
criteria to prioritize an intervention. While looking at the top 10 criteria all stakeholder groups 
perceived an intervention’s impact on stigma reduction in society, its quality of care and its 
additional requirements related to Indonesia’s health system capacity (i.e. service require-
ments, health care workers requirement and information requirements). In addition to these 
criteria, policy makers also perceived political and legal acceptability highly important and 
the individual effectiveness in terms of health gain of an intervention. While the availability 
of sustainable funding was considered highly important, the budget impact of an interven-
tion was the least important criteria for policy makers. People living with HIV/AIDS also consid-
ered the unit costs of intervention important and whether it was a prevention or treatment. 
The majority (40 out of 43 PLWHA that valued this criterion important) gave a preference for 
prevention over treatment interventions. The health care workers found it important that an 
intervention targets people at high risk of HIV infection and gave preference for prevention 
over treatment interventions. The general population also gave preference for prevention over 
treatment and considered an intervention’s individual effectiveness, its unit costs and the level 
of risk for HIV infection of the target important. All stakeholder groups gave least priority to 
the majority of equity criteria meaning that they find it less important that interventions give 
priority to certain groups on the basis of their gender, age or socio-economic status. 
Preferences for certain risk groups
Table 5 (page 92) hows the preference among stakeholders for a risk group that a HIV/AIDS 
intervention targets. Policy makers, PLWHA and health care workers find it most important 
to target injecting drug users while the general population gives most priority to female sex 
workers. Policy makers prefer to give least priority for transgender and the other three stake-
holders for people at low risk for HIV infection. The following five reasons were mostly given 
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for their choices: 1) level of at risk for HIV, 2) importance in spread of HIV epidemic, 3) size of 
population (infected), 4) equity considerations (a target group’s current access to HIV inter-
ventions, socio economic status and responsibility for HIV infection) and 5) experienced feasi-
bility/effectiveness of existing interventions, for example whether a group is already effectively 
targeted. An overview of the reasons given by the stakeholders to prioritize certain risk groups 
is given in Table 6 (page 92) . 
Additional criteria 
Twelve health care workers, eleven PLWHA and four persons from the general population 
mentioned additional criteria for HIV/AIDS priority setting. However, most were criteria already 
captured in our questionnaire, examples of interventions or irrational criteria for priority 
setting. One valid criterion mentioned was the human resources capacity within government 
institutions, and relates to the governance and leadership category of the feasibility criteria. 
Discussion 
This study has identified criteria for priority setting of HIV/AIDS interventions in Indonesia using 
perspectives of policy makers, PLWHA, health care workers and the general population. Overall 
all stakeholders found it most important that interventions have impact on the HIV epidemic, 
are feasible in terms of Indonesia’s health system capacity, provide good quality of care and 
reduce HIV related stigma in society. Most criteria related to equity (i.e. whether interventions 
give priority to groups on the basis of for example their gender, SES or age) were considered 
least important for choosing between HIV/AIDS interventions. 
The perceived importance of an intervention’s impact on the epidemic can be explained by 
Indonesia’s epidemic, which is still one of the fastest growing in Asia [45]. It is also in line with 
the worldwide preference to reduce new infections and AIDS related deaths, as is reflected 
in the UNAIDS goals for Asia (i.e. zero new infections, zero new death and zero discrimina-
tion). Indonesia’s National and West Java provincial HIV/AIDS strategies stress the importance 
of intervention’s impact on the epidemic, however it is not mentioned as an explicit crite-
rion for priority setting. [3,5] Similarly, our respondents rated injecting drug users as the most 
important target group for interventions with the reason that they are important in the spread 
of the HIV epidemic. At time of interview, most new infection were indeed seen among PWID, 
while now the epidemic has decreased in this population and MSM, low-at risk women and 
clients of sex workers are most at risk for HIV infection. 
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STAKEHOLDER GROUPS STAKEHOLDER GROUPS
Policy makers (n=22) People living with HIV/AIDS (n=49) Health care workers (n=41) General population (n=43) Overall (n=155)
 Criterion Mean (SD)  Criterion Mean (SD)  Criterion Mean (SD)  Criterion Mean (SD)  Criterion Mean (SD)
1 Individual effectiveness 4.64 (0.49) 1 Reduction spread HIV 4.67 (0.59) 1 Reduction spread HIV 4.76 (0.49) 1 Reduction spread HIV 4.65 (0.57) 1 Reduction spread HIV 4.66 (0.57)
2 Service requirements 4.64 (0.49) 2 Quality of care 4.67 (0.77) 2 Quality of care 4.54 (0.67) 2 Stigma reduction 4.63 (0.58) 2 Stigma reduction 4.55 (0.77)
3 HCWs a requirements 4.59 (0.50) 3 Individual effectiveness 4.59 (0.64) 3 Stigma reduction 4.49 (0.81) 3 Productsbrequirements 4.63 (0.85) 3 HCWs a requirements 4.52 (0.73)
4 Sustainable financing 4.55 (0.74) 4 HCWs a requirements 4.59 (0.67) 4 Sustainable financing 4.49 (0.81) 4 Sustainable financing 4.51 (0.77) 4 Quality of care 4.50 (0.78)
5 Reduction spread HIV 4.50 (0.60) 5 Stigma reduction 4.55 (0.94) 5 HCWs a requirements 4.41 (0.77) 5 HCWs a requirements 4.49 (0.86) 5 Productsbrequirements 4.48 (0.75)
6 Stigma reduction 4.50 (0.67) 6 Informationc requirements 4.53 (0.74) 6 Individual effectiveness 4.37 (0.54) 6 Service requirements 4.44 (0.77) 6 Individual effectiveness 4.47 (0.63)
7 Informationc requirements 4.41 (0.50) 7 Productsbrequirements 4.53 (0.62) 7 Informationc requirements 4.32 (0.72) 7 Unit cost 4.42 (0.70) 7 Sustainable financing 4.46 (0.85)
8 Productsbrequirements 4.41 (0.59) 8 Donors acceptability 4.53 (0.79) 8 Productsbrequirements 4.29 (0.84) 8 Donors acceptability 4.42 (0.85) 8 Service requirements 4.41 (0.73)
9 Quality of care 4.27 (0.94) 9 Service requirements 4.45 (0.65) 9 Legal rules acceptability 4.24 (0.66) 9 Quality of care 4.40 (0.79) 9 Informationc requirements 4.39 (0.72)
10 Legal rules acceptability 4.27 (0.70) 10 Sustainable financing 4.37 (1.01) 10 Service requirements 4.22 (0.85) 10 Individual effectiveness 4.35 (0.72) 10 Donors acceptability 4.24 (0.82)
11 Cultural acceptability 4.18 (0.66) 11 Side effects 4.27 (0.86) 11 Level at risk individual 4.20 (0.99) 11 Legal rules acceptability 4.33 (0.84) 11 Legal rules acceptability 4.22 (0.84)
12 Economic impact 4.14 (0.71) 12 Unit cost 4.27 (1.32) 12 Religious acceptability 4.17 (0.80) 12 Informationc requirements 4.28 (0.80) 12 Unit cost 4.10 (1.24)
13 Political acceptability 4.09 (1.02) 13 Legal rules acceptability 4.08 (1.02) 13 Cultural acceptability 4.00 (0.97) 13 Religious acceptability 4.21 (0.91) 13 Side effects 4.09 (0.80)
14 Religious acceptability 4.00 (1.02) 14 Cultural acceptability 4.00 (1.17) 14 Economic impact 3.98 (0.88) 14 Side effects 4.19 (0.63) 14 Religious acceptability 4.08 (1.03)
15 Side effects 3.86 (0.71) 15 Prevention or treatment 3.96 (1.32) 15 Donors acceptability 3.98 (0.79) 15 Cultural acceptability 4.19 (0.88) 15 Cultural acceptability 4.08 (0.98)
16 Unit cost 3.86 (1.32) 16 Religious acceptability 3.94 (1.28) 16 Prevention or treatment 3.93 (1.19) 16 Level at risk individual 4.12 (1.26) 16 Prevention or treatment 3.83 (1.31)
17 Donors acceptability 3.73 (0.83) 17 Economic impact 3.76 (1.53) 17 Side effects 3.90 (0.89) 17 Prevention or treatment 3.86 (1.36) 17 Economic impact 3.76 (1.29)
18 Severity of disease 3.55 (1.22) 18 Stigmatized groups 3.41 (1.55) 18 Unit cost 3.71 (1.36) 18 Political acceptability 3.60 (1.33) 18 Level at risk individual 3.72 (1.46)
19 Easy to target 3.36 (0.90) 19 Level at risk individual 3.31 (1.70) 19 Stigmatized groups 3.46 (1.57) 19 Economic impact 3.37 (1.48) 19 Political acceptability 3.41 (1.47)
20 Prevention or treatment 3.32 (1.39) 20 Severity of disease 3.22 (1.57) 20 Severity of disease 3.39 (1.43) 20 Severity of disease 3.35 (1.27) 20 Severity of disease 3.35 (1.46)
21 Level at risk individual 3.00 (1.51) 21 People easy to target 3.20 (1.40) 21 People easy to target 3.39 (1.16) 21 People easy to target 3.35 (1.51) 21 People easy to target 3.32 (1.23)
22 Age 2.91 (1.44) 22 Political acceptability 3.08 (1.66) 22 Age 3.34 (1.30) 22 Stigmatized groups 3.33 (1.55) 22 Stigmatized groups 3.30 (1.57)
23 Previous spendingd 2.91 (1.44) 23 Age 2.94 (1.75) 23 Political acceptability 3.24 (1.48) 23 Age 3.23 (1.65) 23 Age 3.12 (1.56)
24 Stigmatized groups 2.68 (1.62) 24 Previous spendingd 2.81 (1.57) 24 Area of living 3.20 (1.29) 24 Area of living 3.07 (1.70) 24 Previous spendingd 2.86 (1.45)
25 Area of living 2.45 (1.53) 25 Budget impact 2.52 (1.58) 25 Responsibility for health 3.05 (1.43) 25 Previous spendingd 2.86 (1.32) 25 Area of living 2.80 (1.56)
26 Income class 2.18 (1.50) 26 Area of living 2.39 (1.55) 26 Previous spendingd 2.90 (1.50) 26 Responsibility for health 2.74 (1.56) 26 Budget impact 2.44 (1.49)
27 Responsibility for health 2.14 (1.42) 27 Sexual orientation 2.33 (1.61) 27 Sexual orientation 2.76 (1.46) 27 Budget impact 2.56 (1.52) 27 Responsibility for health 2.43 (1.52)
28 Sexual orientation 1.86 (1.36) 28 Marital status 2.02 (1.51) 28 Marital status 2.73 (1.61) 28 Sexual orientation 2.51 (1.62) 28 Sexual orientation 2.43 (1.55)
29 Budget impact 1.68 (1.13) 29 Responsibility for health 1.78 (1.36) 29 Budget impact 2.61 (1.45) 29 Income class 2.44 (1.62) 29 Marital status 2.25 (1.56)
30 Marital status 1.59 (0.96) 30 Income class 1.61 (1.24) 30 Income class 2.44 (1.42) 30 Marital status 2.40 (1.69) 30 Income class 2.14 (1.47)
31 Gender 1.18 (0.66) 31 Gender 1.18 (0.81) 31 Gender 1.95 (1.34) 31 Gender 1.53 (1.24) 31 Gender 1.48 (1.12)
32 Religion 1.00 (0.00)  32 Religion 1.00 (0.00)  32 Religion 1.20 (0.60)  32 Religion 1.02 (0.15)  32 Religion 1.06 (0.33)
Table 3. Mean Likert scale scores and standard deviation per criterion and
  per stakeholder group
a HCW = health care workers, b products = medical products & technology requirements, c information =  information system requirements,
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STAKEHOLDER GROUPS STAKEHOLDER GROUPS
Policy makers (n=22) People living with HIV/AIDS (n=49) Health care workers (n=41) General population (n=43) Overall (n=155)
 Criterion Mean (SD)  Criterion Mean (SD)  Criterion Mean (SD)  Criterion Mean (SD)  Criterion Mean (SD)
1 Individual effectiveness 4.64 (0.49) 1 Reduction spread HIV 4.67 (0.59) 1 Reduction spread HIV 4.76 (0.49) 1 Reduction spread HIV 4.65 (0.57) 1 Reduction spread HIV 4.66 (0.57)
2 Service requirements 4.64 (0.49) 2 Quality of care 4.67 (0.77) 2 Quality of care 4.54 (0.67) 2 Stigma reduction 4.63 (0.58) 2 Stigma reduction 4.55 (0.77)
3 HCWs a requirements 4.59 (0.50) 3 Individual effectiveness 4.59 (0.64) 3 Stigma reduction 4.49 (0.81) 3 Productsbrequirements 4.63 (0.85) 3 HCWs a requirements 4.52 (0.73)
4 Sustainable financing 4.55 (0.74) 4 HCWs a requirements 4.59 (0.67) 4 Sustainable financing 4.49 (0.81) 4 Sustainable financing 4.51 (0.77) 4 Quality of care 4.50 (0.78)
5 Reduction spread HIV 4.50 (0.60) 5 Stigma reduction 4.55 (0.94) 5 HCWs a requirements 4.41 (0.77) 5 HCWs a requirements 4.49 (0.86) 5 Productsbrequirements 4.48 (0.75)
6 Stigma reduction 4.50 (0.67) 6 Informationc requirements 4.53 (0.74) 6 Individual effectiveness 4.37 (0.54) 6 Service requirements 4.44 (0.77) 6 Individual effectiveness 4.47 (0.63)
7 Informationc requirements 4.41 (0.50) 7 Productsbrequirements 4.53 (0.62) 7 Informationc requirements 4.32 (0.72) 7 Unit cost 4.42 (0.70) 7 Sustainable financing 4.46 (0.85)
8 Productsbrequirements 4.41 (0.59) 8 Donors acceptability 4.53 (0.79) 8 Productsbrequirements 4.29 (0.84) 8 Donors acceptability 4.42 (0.85) 8 Service requirements 4.41 (0.73)
9 Quality of care 4.27 (0.94) 9 Service requirements 4.45 (0.65) 9 Legal rules acceptability 4.24 (0.66) 9 Quality of care 4.40 (0.79) 9 Informationc requirements 4.39 (0.72)
10 Legal rules acceptability 4.27 (0.70) 10 Sustainable financing 4.37 (1.01) 10 Service requirements 4.22 (0.85) 10 Individual effectiveness 4.35 (0.72) 10 Donors acceptability 4.24 (0.82)
11 Cultural acceptability 4.18 (0.66) 11 Side effects 4.27 (0.86) 11 Level at risk individual 4.20 (0.99) 11 Legal rules acceptability 4.33 (0.84) 11 Legal rules acceptability 4.22 (0.84)
12 Economic impact 4.14 (0.71) 12 Unit cost 4.27 (1.32) 12 Religious acceptability 4.17 (0.80) 12 Informationc requirements 4.28 (0.80) 12 Unit cost 4.10 (1.24)
13 Political acceptability 4.09 (1.02) 13 Legal rules acceptability 4.08 (1.02) 13 Cultural acceptability 4.00 (0.97) 13 Religious acceptability 4.21 (0.91) 13 Side effects 4.09 (0.80)
14 Religious acceptability 4.00 (1.02) 14 Cultural acceptability 4.00 (1.17) 14 Economic impact 3.98 (0.88) 14 Side effects 4.19 (0.63) 14 Religious acceptability 4.08 (1.03)
15 Side effects 3.86 (0.71) 15 Prevention or treatment 3.96 (1.32) 15 Donors acceptability 3.98 (0.79) 15 Cultural acceptability 4.19 (0.88) 15 Cultural acceptability 4.08 (0.98)
16 Unit cost 3.86 (1.32) 16 Religious acceptability 3.94 (1.28) 16 Prevention or treatment 3.93 (1.19) 16 Level at risk individual 4.12 (1.26) 16 Prevention or treatment 3.83 (1.31)
17 Donors acceptability 3.73 (0.83) 17 Economic impact 3.76 (1.53) 17 Side effects 3.90 (0.89) 17 Prevention or treatment 3.86 (1.36) 17 Economic impact 3.76 (1.29)
18 Severity of disease 3.55 (1.22) 18 Stigmatized groups 3.41 (1.55) 18 Unit cost 3.71 (1.36) 18 Political acceptability 3.60 (1.33) 18 Level at risk individual 3.72 (1.46)
19 Easy to target 3.36 (0.90) 19 Level at risk individual 3.31 (1.70) 19 Stigmatized groups 3.46 (1.57) 19 Economic impact 3.37 (1.48) 19 Political acceptability 3.41 (1.47)
20 Prevention or treatment 3.32 (1.39) 20 Severity of disease 3.22 (1.57) 20 Severity of disease 3.39 (1.43) 20 Severity of disease 3.35 (1.27) 20 Severity of disease 3.35 (1.46)
21 Level at risk individual 3.00 (1.51) 21 People easy to target 3.20 (1.40) 21 People easy to target 3.39 (1.16) 21 People easy to target 3.35 (1.51) 21 People easy to target 3.32 (1.23)
22 Age 2.91 (1.44) 22 Political acceptability 3.08 (1.66) 22 Age 3.34 (1.30) 22 Stigmatized groups 3.33 (1.55) 22 Stigmatized groups 3.30 (1.57)
23 Previous spendingd 2.91 (1.44) 23 Age 2.94 (1.75) 23 Political acceptability 3.24 (1.48) 23 Age 3.23 (1.65) 23 Age 3.12 (1.56)
24 Stigmatized groups 2.68 (1.62) 24 Previous spendingd 2.81 (1.57) 24 Area of living 3.20 (1.29) 24 Area of living 3.07 (1.70) 24 Previous spendingd 2.86 (1.45)
25 Area of living 2.45 (1.53) 25 Budget impact 2.52 (1.58) 25 Responsibility for health 3.05 (1.43) 25 Previous spendingd 2.86 (1.32) 25 Area of living 2.80 (1.56)
26 Income class 2.18 (1.50) 26 Area of living 2.39 (1.55) 26 Previous spendingd 2.90 (1.50) 26 Responsibility for health 2.74 (1.56) 26 Budget impact 2.44 (1.49)
27 Responsibility for health 2.14 (1.42) 27 Sexual orientation 2.33 (1.61) 27 Sexual orientation 2.76 (1.46) 27 Budget impact 2.56 (1.52) 27 Responsibility for health 2.43 (1.52)
28 Sexual orientation 1.86 (1.36) 28 Marital status 2.02 (1.51) 28 Marital status 2.73 (1.61) 28 Sexual orientation 2.51 (1.62) 28 Sexual orientation 2.43 (1.55)
29 Budget impact 1.68 (1.13) 29 Responsibility for health 1.78 (1.36) 29 Budget impact 2.61 (1.45) 29 Income class 2.44 (1.62) 29 Marital status 2.25 (1.56)
30 Marital status 1.59 (0.96) 30 Income class 1.61 (1.24) 30 Income class 2.44 (1.42) 30 Marital status 2.40 (1.69) 30 Income class 2.14 (1.47)
31 Gender 1.18 (0.66) 31 Gender 1.18 (0.81) 31 Gender 1.95 (1.34) 31 Gender 1.53 (1.24) 31 Gender 1.48 (1.12)
32 Religion 1.00 (0.00)  32 Religion 1.00 (0.00)  32 Religion 1.20 (0.60)  32 Religion 1.02 (0.15)  32 Religion 1.06 (0.33)
 d previous spending = in line with previous spending patterns
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STAKEHOLDER GROUPS STAKEHOLDER GROUPS
Policy makers (n=22) People living with HIV/AIDS (n=49) Health care workers (n=41) General population (n=43) Overall (n=155)
 Criterion Mean (SD)  Criterion Mean (SD)  Criterion Mean (SD)  Criterion Mean (SD)  Criterion Mean (SD)
1 Reduction spread HIV 5.23 (4.29) 1 Reduction spread HIV 5.43 (4.04) 1 Reduction spread HIV 7.24 (3.95) 1 Reduction spread HIV 5.58 (4.34) 1 Reduction spread HIV 5.92 (4.17)
2 Service requirements 4.50 (3.54) 2 Quality of care 5.00 (3.22) 2 Quality of care 4.71 (3.76) 2 HCWsa requirements 3.95 (3.30) 2 Individual effectiveness 2.41 (3.17)
3 Sustainable financing 4.50 (3.76) 3 HCWsa requirements 4.47 (3.48) 3 Level at risk individual 3.85 (3.89) 3 Productsb requirements 3.77 (2.95) 3 Quality of care 4.34 (3.44)
4 Quality of care 4.27 (3.76) 4 Prevention or treatment 3.84 (4.40) 4 Stigma reduction 3.76 (3.53) 4 Stigma reduction 3.72 (3.77) 4 HCWsa requirements 4.05 (3.29)
5 Stigma reduction 4.23 (3.19) 5 Stigma reduction 3.80 (3.84) 5 Prevention or treatment 3.66 (4.14) 5 Prevention or treatment 3.26 (4.24) 5 Stigma reduction 3.83 (3.62)
6 HCWsa requirements 4.14 (3.11) 6 Unit cost 3.24 (3.56) 6 HCWsa requirements 3.61 (3.20) 6 Quality of care 3.26 (3.05) 6 Prevention or treatment 3.36 (4.18)
7 Individual effectiveness 3.68 (3.43) 7 Informationc requirements 3.22 (3.51) 7 Sustainable financing 3.22 (3.63) 7 Level at risk individual 2.98 (4.08) 7 Service requirements 3.06 (3.25)
8 Informationc requirements 2.45 (3.28) 8 Service requirements 2.98 (3.24) 8 Service requirements 3.05 (3.37) 8 Individual effectiveness 2.58 (3.54) 8 Productsb requirements 2.85 (2.90)
9 Political acceptability 2.45 (3.96) 9 Productsb requirements 2.82 (2.71) 9 Informationc requirements 2.59 (2.83) 9 Unit cost 2.44 (3.15) 9 Sustainable financing 2.72 (3.32)
10 Legal rules acceptability 2.36 (3.58) 10 Individual effectiveness 2.22 (2.92) 10 Productsb requirements 2.24 (2.89) 10 Service requirements 2.42 (2.86) 10 Informationc requirements 2.59 (3.21)
11 Productsb requirements 2.27 (2.95) 11 Donors acceptability 2.08 (3.22) 11 Individual effectiveness 1.78 (2.80) 11 Sustainable financing 2.19 (2.99) 11 Level at risk individual 2.51 (3.65)
12 Religious acceptability 2.18 (3.76) 12 Sustainable financing 1.98 (2.81) 12 Stigmatized groups 1.68 (2.48) 12 Informationc requirements 1.95 (3.15) 12 Unit cost 2.30 (3.15)
13 Prevention or treatment 1.95 (3.48) 13 Level at risk individual 1.65 (3.06) 13 Economic impact 1.59 (2.86) 13 Side effects 1.81 (3.06) 13 Religious acceptability 1.43 (2.81)
14 Economic impact 1.82 (2.48) 14 Side effects 1.37 (2.51) 14 Unit cost 1.41 (2.48) 14 Severity of disease 1.77 (3.31) 14 Economic impact 1.42 (2.60)
15 Cultural acceptability 1.73 (3.17) 15 Religious acceptability 1.37 (2.77) 15 Side effects 1.39 (2.75) 15 Legal rules acceptability 1.72 (2.76) 15 Side effects 1.41 (2.68)
16 Unit cost 1.55 (2.82) 16 Economic impact 1.35 (2.39) 16 Severity of disease 1.22 (2.29) 16 Religious acceptability 1.49 (2.88) 16 Donors acceptability 1.39 (2.63)
17 Level at risk individual 1.00 (2.43) 17 Stigmatized groups 1.20 (2.92) 17 Religious acceptability 1.02 (2.14) 17 Age 1.42 (2.78) 17 Legal rules acceptability 1.30 (2.64)
18 Severity of disease 0.77 (1.66) 18 Severity of disease 1.12 (2.65) 18 Donors acceptability 0.98 (2.33) 18 Donors acceptability 1.35 (2.36) 18 Severity of disease 1.28 (2.65)
19 Side effects 0.73 (2.10) 19 Political acceptability 1.06 (2.66) 19 Legal rules acceptability 0.88 (2.48) 19 Area of living 1.26 (2.83) 19 Stigmatized groups 1.14 (2.45)
20 Donors acceptability 0.73 (1.91) 20 Age 0.82 (2.21) 20 Age 0.76 (1.96) 20 Economic impact 1.14 (2.70) 20 Political acceptability 0.99 (2.49)
21 Stigmatized groups 0.55 (1.50) 21 Legal rules acceptability 0.82 (1.98) 21 Political acceptability 0.71 (1.90) 21 Stigmatized groups 0.86 (2.18) 21 Age 0.90 (2.24)
22 Previous spendingd 0.55 (1.87) 22 Cultural acceptability 0.76 (2.12) 22 Cultural acceptability 0.63 (1.53) 22 Cultural acceptability 0.77 (2.02) 22 Cultural acceptability 0.86 (2.15)
23 Income class 0.41 (1.22) 23 Budget impact 0.63 (2.05) 23 Sexual orientation 0.51 (1.86) 23 Marital status 0.60 (1.69) 23 Area of living 0.52 (1.83)
24 Age 0.36 (1.33) 24 Sexual orientation 0.39 (1.34) 24 Easy to target 0.46 (1.25) 24 Easy to target 0.56 (1.71) 24 Easy to target 0.43 (1.39)
25 Sexual orientation 0.18 (0.85) 25 Easy to target 0.39 (1.44) 25 Marital status 0.44 (1.29) 25 Responsibility for health 0.49 (1.65) 25 Sexual orientation 0.41 (1.56)
26 Easy to target 0.18 (0.66) 26 Marital status 0.27 (1.06) 26 Area of living 0.39 (1.41) 26 Sexual orientation 0.44 (1.78) 26 Marital status 0.37 (1.26)
27 Responsibility for health 0.14 (0.64) 27 Responsibility for health 0.18 (0.95) 27 Gender 0.39 (1.76) 27 Political acceptability 0.44 (1.33) 27 Budget impact 0.32 (1.46)
28 Area of living 0.09 (0.29) 28 Previous spendingd 0.18 (0.83) 28 Budget impact 0.37 (1.64) 28 Gender 0.33 (1.38) 28 Responsibility for health 0.25 (1.11)
29 Gender 0.00 (0.00) 29 Area of living 0.16 (1.14) 29 Income class 0.20 (1.10) 29 Income class 0.23 (1.15) 29 Gender 0.23 (1.19)
30 Religion 0.00 (0.00) 30 Income class 0.10 (0.51) 30 Responsibility for health 0.15 (0.69) 30 Previous spendingd 0.14 (0.91) 30 Income class 0.21 (0.98)
31 Marital status 0.00 (0.00) 31 Gender 0.10 (0.51) 31 Previous spendingd 0.12 (0.78) 31 Budget impact 0.07 (0.46) 31 Previous spendingd 0.21 (1.05)
32 Budget impact 0.00 (0.00)  32 Religion 0.00 (0.00)  32 Religion 0.00 (0.00)  32 Religion 0.00 (0.00)  32 Religion 0.00 (0.00)
Table 4 Mean ranking scores and standard deviation per criterion and per stakeholder 
  group
a HCWs = health care workers, b products = medical products & technology requirements, c information =  information system requirements, 
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STAKEHOLDER GROUPS STAKEHOLDER GROUPS
Policy makers (n=22) People living with HIV/AIDS (n=49) Health care workers (n=41) General population (n=43) Overall (n=155)
 Criterion Mean (SD)  Criterion Mean (SD)  Criterion Mean (SD)  Criterion Mean (SD)  Criterion Mean (SD)
1 Reduction spread HIV 5.23 (4.29) 1 Reduction spread HIV 5.43 (4.04) 1 Reduction spread HIV 7.24 (3.95) 1 Reduction spread HIV 5.58 (4.34) 1 Reduction spread HIV 5.92 (4.17)
2 Service requirements 4.50 (3.54) 2 Quality of care 5.00 (3.22) 2 Quality of care 4.71 (3.76) 2 HCWsa requirements 3.95 (3.30) 2 Individual effectiveness 2.41 (3.17)
3 Sustainable financing 4.50 (3.76) 3 HCWsa requirements 4.47 (3.48) 3 Level at risk individual 3.85 (3.89) 3 Productsb requirements 3.77 (2.95) 3 Quality of care 4.34 (3.44)
4 Quality of care 4.27 (3.76) 4 Prevention or treatment 3.84 (4.40) 4 Stigma reduction 3.76 (3.53) 4 Stigma reduction 3.72 (3.77) 4 HCWsa requirements 4.05 (3.29)
5 Stigma reduction 4.23 (3.19) 5 Stigma reduction 3.80 (3.84) 5 Prevention or treatment 3.66 (4.14) 5 Prevention or treatment 3.26 (4.24) 5 Stigma reduction 3.83 (3.62)
6 HCWsa requirements 4.14 (3.11) 6 Unit cost 3.24 (3.56) 6 HCWsa requirements 3.61 (3.20) 6 Quality of care 3.26 (3.05) 6 Prevention or treatment 3.36 (4.18)
7 Individual effectiveness 3.68 (3.43) 7 Informationc requirements 3.22 (3.51) 7 Sustainable financing 3.22 (3.63) 7 Level at risk individual 2.98 (4.08) 7 Service requirements 3.06 (3.25)
8 Informationc requirements 2.45 (3.28) 8 Service requirements 2.98 (3.24) 8 Service requirements 3.05 (3.37) 8 Individual effectiveness 2.58 (3.54) 8 Productsb requirements 2.85 (2.90)
9 Political acceptability 2.45 (3.96) 9 Productsb requirements 2.82 (2.71) 9 Informationc requirements 2.59 (2.83) 9 Unit cost 2.44 (3.15) 9 Sustainable financing 2.72 (3.32)
10 Legal rules acceptability 2.36 (3.58) 10 Individual effectiveness 2.22 (2.92) 10 Productsb requirements 2.24 (2.89) 10 Service requirements 2.42 (2.86) 10 Informationc requirements 2.59 (3.21)
11 Productsb requirements 2.27 (2.95) 11 Donors acceptability 2.08 (3.22) 11 Individual effectiveness 1.78 (2.80) 11 Sustainable financing 2.19 (2.99) 11 Level at risk individual 2.51 (3.65)
12 Religious acceptability 2.18 (3.76) 12 Sustainable financing 1.98 (2.81) 12 Stigmatized groups 1.68 (2.48) 12 Informationc requirements 1.95 (3.15) 12 Unit cost 2.30 (3.15)
13 Prevention or treatment 1.95 (3.48) 13 Level at risk individual 1.65 (3.06) 13 Economic impact 1.59 (2.86) 13 Side effects 1.81 (3.06) 13 Religious acceptability 1.43 (2.81)
14 Economic impact 1.82 (2.48) 14 Side effects 1.37 (2.51) 14 Unit cost 1.41 (2.48) 14 Severity of disease 1.77 (3.31) 14 Economic impact 1.42 (2.60)
15 Cultural acceptability 1.73 (3.17) 15 Religious acceptability 1.37 (2.77) 15 Side effects 1.39 (2.75) 15 Legal rules acceptability 1.72 (2.76) 15 Side effects 1.41 (2.68)
16 Unit cost 1.55 (2.82) 16 Economic impact 1.35 (2.39) 16 Severity of disease 1.22 (2.29) 16 Religious acceptability 1.49 (2.88) 16 Donors acceptability 1.39 (2.63)
17 Level at risk individual 1.00 (2.43) 17 Stigmatized groups 1.20 (2.92) 17 Religious acceptability 1.02 (2.14) 17 Age 1.42 (2.78) 17 Legal rules acceptability 1.30 (2.64)
18 Severity of disease 0.77 (1.66) 18 Severity of disease 1.12 (2.65) 18 Donors acceptability 0.98 (2.33) 18 Donors acceptability 1.35 (2.36) 18 Severity of disease 1.28 (2.65)
19 Side effects 0.73 (2.10) 19 Political acceptability 1.06 (2.66) 19 Legal rules acceptability 0.88 (2.48) 19 Area of living 1.26 (2.83) 19 Stigmatized groups 1.14 (2.45)
20 Donors acceptability 0.73 (1.91) 20 Age 0.82 (2.21) 20 Age 0.76 (1.96) 20 Economic impact 1.14 (2.70) 20 Political acceptability 0.99 (2.49)
21 Stigmatized groups 0.55 (1.50) 21 Legal rules acceptability 0.82 (1.98) 21 Political acceptability 0.71 (1.90) 21 Stigmatized groups 0.86 (2.18) 21 Age 0.90 (2.24)
22 Previous spendingd 0.55 (1.87) 22 Cultural acceptability 0.76 (2.12) 22 Cultural acceptability 0.63 (1.53) 22 Cultural acceptability 0.77 (2.02) 22 Cultural acceptability 0.86 (2.15)
23 Income class 0.41 (1.22) 23 Budget impact 0.63 (2.05) 23 Sexual orientation 0.51 (1.86) 23 Marital status 0.60 (1.69) 23 Area of living 0.52 (1.83)
24 Age 0.36 (1.33) 24 Sexual orientation 0.39 (1.34) 24 Easy to target 0.46 (1.25) 24 Easy to target 0.56 (1.71) 24 Easy to target 0.43 (1.39)
25 Sexual orientation 0.18 (0.85) 25 Easy to target 0.39 (1.44) 25 Marital status 0.44 (1.29) 25 Responsibility for health 0.49 (1.65) 25 Sexual orientation 0.41 (1.56)
26 Easy to target 0.18 (0.66) 26 Marital status 0.27 (1.06) 26 Area of living 0.39 (1.41) 26 Sexual orientation 0.44 (1.78) 26 Marital status 0.37 (1.26)
27 Responsibility for health 0.14 (0.64) 27 Responsibility for health 0.18 (0.95) 27 Gender 0.39 (1.76) 27 Political acceptability 0.44 (1.33) 27 Budget impact 0.32 (1.46)
28 Area of living 0.09 (0.29) 28 Previous spendingd 0.18 (0.83) 28 Budget impact 0.37 (1.64) 28 Gender 0.33 (1.38) 28 Responsibility for health 0.25 (1.11)
29 Gender 0.00 (0.00) 29 Area of living 0.16 (1.14) 29 Income class 0.20 (1.10) 29 Income class 0.23 (1.15) 29 Gender 0.23 (1.19)
30 Religion 0.00 (0.00) 30 Income class 0.10 (0.51) 30 Responsibility for health 0.15 (0.69) 30 Previous spendingd 0.14 (0.91) 30 Income class 0.21 (0.98)
31 Marital status 0.00 (0.00) 31 Gender 0.10 (0.51) 31 Previous spendingd 0.12 (0.78) 31 Budget impact 0.07 (0.46) 31 Previous spendingd 0.21 (1.05)
32 Budget impact 0.00 (0.00)  32 Religion 0.00 (0.00)  32 Religion 0.00 (0.00)  32 Religion 0.00 (0.00)  32 Religion 0.00 (0.00)
d previous spending = in line with previous spending patterns
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STAKEHOLDER GROUPS
Health care workers (n=41) People living with HIV/AIDS (n=49) Policy makers (n=22) General population (n=43)
Risk group Mean (SD) Risk group Mean (SD) Risk group Mean (SD) Risk group Mean (SD)
1 Injecting drug users 4.51 (0.68) 1 Injecting drug users 4.39 (0.61) 1 Injecting drug users 4.27 (0.63) 1 Female sex workers 4.19 (1.10)
2 Partners of HIV+ people 4.41 (0.63) 2 Female sex workers 4.20 (0.93) 2 Clients of FSW 4.27 (0.83) 2 Injecting drug users 3.95 (0.87)
3 Female sex workers 4.27 (0.59) 3 Clients of FSW 3.65 (1.16) 3 Partners of HIV+ people 4.14 (0.83) 3 Partners of HIV+ people 3.86 (0.89)
4 Clients of FSW 4.02 (1.01) 4 Men having sex with men 3.63 (1.24) 4 Female sex workers 4.09 (0.87) 4 Clients of FSW 3.53 (1.10)
5 Prisoners 4.00 (1.14) 5 Transgender 3.45 (0.96) 5 Prisoners 3.77 (1.31) 5 Prisoners 3.12 (1.14)
6 Transgender 3.85 (1.01) 6 Prisoners 3.55 (1.10) 6 Men having sex with men 3.41 (0.91) 6 Men having sex with men 3.09 (1.17)
7 Men having sex with men 3.71 (1.23) 7 Partners of HIV+ people 3.82 (1.03) 7 People at low risk 3.32 (1.36) 7 Transgender 3.05 (1.11)
8 People at low risk 2.51 (1.33) 8 People at low risk 2.94 (1.27) 8 Transgender 3.18 (0.73) 8 People at low risk 2.43 (1.15)
 FSW = female sex workers
Table 6. Reasons and frequency given by stakeholders to prioritize or not prioritize
  (Likert scale score 3-5) certain risk groups in HIV/AIDS control 
Table 5 Priority for targeting certain risk group, mean Likert scores and 
  standard deviation per stakeholder group Stakeholder groups
REASONS TO PRIORITIZE RISK GROUP (LIKERT SCORES 3-5) REASONS TO NOT PRIORITIZE GROUP (LIKERT SCORES 1-3)
Risk groups and  
stakeholders  
(# missing reasons)
At high  
HIV risk
Important 
in spread 
of HIV 
epidemic
Large 
number 
of people 
(infected)
Equity: 
less 
access to 
services, 
more 
vulner-
able
Feasibility: 
effective 
interventions 
are available/ 
easy group to 
reach
Feasibility: 
no effective 
interventions 
available/ 
difficult group 
to target Other
At low 
HIV 
risk
Not im-
portant 
in spread 
of HIV 
epidemic
Small 
number 
of people 
(infected)
Equity: group 
with relatively 
high socio 
economic status 
Equity: 
own re-
sponsibility 
Feasibility: 
effective 
interventions 
are available/ 
group is 
already 
targeted
Feasibility: 
no effective 
interventions 
available/ 
difficult group 
to target
No need for 
services (already 
show safe 
behaviour)
PWID
Policy makers (1) 3 10 5 1 3
Health care workers (1) 16 15 12 1 2
PLWHA (1) 20 9 4 4 4 1 1 1   
General population (0) 23 3 5 1 5 1 1 1 3
FSWs
Policy makers (1) 3 9 4 2 1 1 1
Health care workers (2) 15 15 1 2 9 2
PLWHA (3) 17 9 2 8 1 2 1
General population (1) 27 2 4 5 1 5
Clients of FSWs
Policy makers (1) 3 13 6 1
Health care workers (2) 9 15 4 5 1 1 1 2
PLWHA (4) 9 10 3 3 1 1 6
General population (1) 19 4 3 3 1 3 1 2 7
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STAKEHOLDER GROUPS
Health care workers (n=41) People living with HIV/AIDS (n=49) Policy makers (n=22) General population (n=43)
Risk group Mean (SD) Risk group Mean (SD) Risk group Mean (SD) Risk group Mean (SD)
1 Injecting drug users 4.51 (0.68) 1 Injecting drug users 4.39 (0.61) 1 Injecting drug users 4.27 (0.63) 1 Female sex workers 4.19 (1.10)
2 Partners of HIV+ people 4.41 (0.63) 2 Female sex workers 4.20 (0.93) 2 Clients of FSW 4.27 (0.83) 2 Injecting drug users 3.95 (0.87)
3 Female sex workers 4.27 (0.59) 3 Clients of FSW 3.65 (1.16) 3 Partners of HIV+ people 4.14 (0.83) 3 Partners of HIV+ people 3.86 (0.89)
4 Clients of FSW 4.02 (1.01) 4 Men having sex with men 3.63 (1.24) 4 Female sex workers 4.09 (0.87) 4 Clients of FSW 3.53 (1.10)
5 Prisoners 4.00 (1.14) 5 Transgender 3.45 (0.96) 5 Prisoners 3.77 (1.31) 5 Prisoners 3.12 (1.14)
6 Transgender 3.85 (1.01) 6 Prisoners 3.55 (1.10) 6 Men having sex with men 3.41 (0.91) 6 Men having sex with men 3.09 (1.17)
7 Men having sex with men 3.71 (1.23) 7 Partners of HIV+ people 3.82 (1.03) 7 People at low risk 3.32 (1.36) 7 Transgender 3.05 (1.11)
8 People at low risk 2.51 (1.33) 8 People at low risk 2.94 (1.27) 8 Transgender 3.18 (0.73) 8 People at low risk 2.43 (1.15)
 FSW = female sex workers
Table 6. Reasons and frequency given by stakeholders to prioritize or not prioritize
  (Likert scale score 3-5) certain risk groups in HIV/AIDS control 
REASONS TO PRIORITIZE RISK GROUP (LIKERT SCORES 3-5) REASONS TO NOT PRIORITIZE GROUP (LIKERT SCORES 1-3)
Risk groups and  
stakeholders  
(# missing reasons)
At high  
HIV risk
Important 
in spread 
of HIV 
epidemic
Large 
number 
of people 
(infected)
Equity: 
less 
access to 
services, 
more 
vulner-
able
Feasibility: 
effective 
interventions 
are available/ 
easy group to 
reach
Feasibility: 
no effective 
interventions 
available/ 
difficult group 
to target Other
At low 
HIV 
risk
Not im-
portant 
in spread 
of HIV 
epidemic
Small 
number 
of people 
(infected)
Equity: group 
with relatively 
high socio 
economic status 
Equity: 
own re-
sponsibility 
Feasibility: 
effective 
interventions 
are available/ 
group is 
already 
targeted
Feasibility: 
no effective 
interventions 
available/ 
difficult group 
to target
No need for 
services (already 
show safe 
behaviour)
PWID
Policy makers (1) 3 10 5 1 3
Health care workers (1) 16 15 12 1 2
PLWHA (1) 20 9 4 4 4 1 1 1   
General population (0) 23 3 5 1 5 1 1 1 3
FSWs
Policy makers (1) 3 9 4 2 1 1 1
Health care workers (2) 15 15 1 2 9 2
PLWHA (3) 17 9 2 8 1 2 1
General population (1) 27 2 4 5 1 5
Clients of FSWs
Policy makers (1) 3 13 6 1
Health care workers (2) 9 15 4 5 1 1 1 2
PLWHA (4) 9 10 3 3 1 1 6
General population (1) 19 4 3 3 1 3 1 2 7
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REASONS TO PRIORITIZE RISK GROUP (LIKERT SCORES 3-5) REASONS TO NOT PRIORITIZE GROUP (LIKERT SCORES 1-3)
Risk groups and  
stakeholders  
(# missing reasons)
At high  
HIV risk
Important 
in spread 
of HIV 
epidemic
Large 
number 
of people 
(infected)
Equity: 
less 
access to 
services, 
more 
vulner-
able
Feasibility: 
effective 
interventions 
are available/ 
easy group 
to reach
Feasibility: 
no effective 
interventions 
available/ 
difficult 
group to 
target Other
At low 
HIV 
risk
Not im-
portant 
in spread 
of HIV 
epidemic
Small 
number 
of people 
(infected)
Equity: group 
with relatively 
high socio 
economic status 
Equity: 
own re-
sponsibility 
Feasibility: 
effective 
interventions 
are available/ 
group is 
already 
targeted
Feasibility: 
no effective 
interventions 
available/ 
difficult group 
to target
No need for 
services (already 
show safe 
behaviour)
MSM
Policy makers (1) 5 1 1 2 5 1 1 2 2 2
Health care workers (4) 12 2 4 3 6 2 2 1 2 1 2
PLWHA (6) 13 4 1 5 1 1 1 1 7
General population (4) 11 1 1 2 4 11 1 2 3
Transgender
Policy makers (1) 4 3 3 5 2 1 1 1 1
Health care workers (7) 11 9 3 2 3 1 1 2 2
PLWHA (6) 14 3 6 4 1 3 2 3
General population (3) 12 2 7 2 3 1 8 1 2
Prisoners
Policy makers (2) 6 3 3 1 3 1 1 1
Health care workers (6) 22 11 1 2 1 1 1 1
PLWHA (4) 18 3 9 6 2 1 3 1 2
General population (3) 13 1 2 4 3 2 11 2
Partners of HIV+ people
Policy makers (1) 9 2 5 5
Health care workers (2) 25 3 7 2 1 3
PLWHA (5) 27 4 1 10 1 1 2 1
General population (1) 27 2 2 3 1 1 1 4
People at low risk
Policy makers (1) 9 1 2 3 3 1 1 1
Health care workers (7) 3 2 2 1 18 5
PLWHA (7) 3 1 1 12 20 1 2
General population (4) 3 3 5 15 1 5
Total 
Policy makers (9) 42 42 6 12 16 26 1 6 4 4 0 0 4 3 4
Health care workers (31) 110 70 23 21 4 27 3 24 2 3 1 0 15 4 4
PLWHA (35) 121 43 9 57 7 11 7 25 1 3 0 3 11 1 20
General 
population(17)
132 13 22 28 11 13 0 29 1 21 5 8 3 0 29
Overall 405 168 60 118 38 77 11 84 8 31 6 11 33 8 57
Table 6. Continued 
PWID = people who inject drugs, FSW = female sex workers, MSM = men having sex with men, PLWHA = people living with HIV/AIDS
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REASONS TO PRIORITIZE RISK GROUP (LIKERT SCORES 3-5) REASONS TO NOT PRIORITIZE GROUP (LIKERT SCORES 1-3)
Risk groups and  
stakeholders  
(# missing reasons)
At high  
HIV risk
Important 
in spread 
of HIV 
epidemic
Large 
number 
of people 
(infected)
Equity: 
less 
access to 
services, 
more 
vulner-
able
Feasibility: 
effective 
interventions 
are available/ 
easy group 
to reach
Feasibility: 
no effective 
interventions 
available/ 
difficult 
group to 
target Other
At low 
HIV 
risk
Not im-
portant 
in spread 
of HIV 
epidemic
Small 
number 
of people 
(infected)
Equity: group 
with relatively 
high socio 
economic status 
Equity: 
own re-
sponsibility 
Feasibility: 
effective 
interventions 
are available/ 
group is 
already 
targeted
Feasibility: 
no effective 
interventions 
available/ 
difficult group 
to target
No need for 
services (already 
show safe 
behaviour)
MSM
Policy makers (1) 5 1 1 2 5 1 1 2 2 2
Health care workers (4) 12 2 4 3 6 2 2 1 2 1 2
PLWHA (6) 13 4 1 5 1 1 1 1 7
General population (4) 11 1 1 2 4 11 1 2 3
Transgender
Policy makers (1) 4 3 3 5 2 1 1 1 1
Health care workers (7) 11 9 3 2 3 1 1 2 2
PLWHA (6) 14 3 6 4 1 3 2 3
General population (3) 12 2 7 2 3 1 8 1 2
Prisoners
Policy makers (2) 6 3 3 1 3 1 1 1
Health care workers (6) 22 11 1 2 1 1 1 1
PLWHA (4) 18 3 9 6 2 1 3 1 2
General population (3) 13 1 2 4 3 2 11 2
Partners of HIV+ people
Policy makers (1) 9 2 5 5
Health care workers (2) 25 3 7 2 1 3
PLWHA (5) 27 4 1 10 1 1 2 1
General population (1) 27 2 2 3 1 1 1 4
People at low risk
Policy makers (1) 9 1 2 3 3 1 1 1
Health care workers (7) 3 2 2 1 18 5
PLWHA (7) 3 1 1 12 20 1 2
General population (4) 3 3 5 15 1 5
Total 
Policy makers (9) 42 42 6 12 16 26 1 6 4 4 0 0 4 3 4
Health care workers (31) 110 70 23 21 4 27 3 24 2 3 1 0 15 4 4
PLWHA (35) 121 43 9 57 7 11 7 25 1 3 0 3 11 1 20
General 
population(17)
132 13 22 28 11 13 0 29 1 21 5 8 3 0 29
Overall 405 168 60 118 38 77 11 84 8 31 6 11 33 8 57
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The preference among all stakeholders for interventions that provide good quality of care 
and are feasible in terms of health care workers, service and information requirements can be 
explained by Indonesia poor quality of care and health system capacity that has not much 
improved after decentralization of services from national to district level in 2000 [46–48]. 
Currently, the coverage of most HIV/AIDS interventions is low (e.g. 18% coverage for ART [1]) 
and although scaling up at community level clinics (Puskesmas) is recommended [49] this is 
challenging regarding Indonesia’s current health system infrastructure for HIV/AIDS. Commu-
nity health care workers still have limited knowledge about HIV/AIDS, testing and treatment 
services are established at small scale at community level and monitoring and referral systems 
work suboptimal [50]. The preference among stakeholder for intervention’s that reduce stigma 
in society can be clarified by the high presence of HIV/AIDS related stigma in Indonesia among 
health care workers and in society [51–53]. Many risk groups and HIV/AIDS patients in Indonesia 
face stigma related barriers for accessing care [54,55]. However, little is known about which 
interventions are most effective in for the reduction of stigma [56,57]. 
Policy makers showed an additional preference for legal and political acceptability of inter-
ventions as these factors usually play a major role in HIV/AIDS resource allocation in Indonesia 
and other settings [5,58]. Their high concern for whether and intervention receives sustain-
able financing and less for its budget impact can be explained by the high amount of donor 
funding in Indonesia [4,50]. In addition, most policy makers in our study were implementing 
donor-funded interventions and had therefor no need to consider the budget impact of 
interventions. The perceived importance of PLWHA and the general population for unit costs 
can be explained by the high costs that people face when accessing HIV/AIDS care in Indo-
nesia [59,60]. The general population, HCWs and PLWHAs gave more preference for interven-
tions that prevent HIV infections compared to treating patients. However, with the knowl-
edge that treatment also works as prevention [61], the categories of this criterion should be 
adapted and treatment should be defined as ‘services for palliative patients and opportu-
nistic infections’.
 
All stakeholders valued equity criteria related to people’s social background characteristics as 
least important. This could be related to Indonesia’s strong community system in which persons 
are considered equal and may explain why our respondents do not prefer to prioritize people 
on the basis of income, gender and sexual orientation [62]. It could be that equity consider-
ations are more important in a generalized epidemic like in South Africa where resources are 
even tighter and questions on how to balance efficiency and equity considerations are more 
prominent [12]. In addition, as access to treatment is still low (i.e. 18%) in Indonesia it might not 
be a stakeholder’s first concern to consider inequities but how to provide access for as many 
people as possible. However, surveys show that inequities exist for other health services in 
Indonesia and may therefor also exist for HIV/AIDS related interventions [63,64]. Our respon-
dents did mention various equity related reasons for targeting a specific group. For example 
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they considered the socio-economic status and the vulnerability of the target group. This 
might indicate that our questionnaire did not measure the concept of equity properly. 
We observed several study limitations. Firstly, the questionnaire was challenging for the 
respondents, as they had to become familiar with 32 criteria and compare them simul-
taneously. However, inclusion of fewer criteria is a risk for leaving out criteria that might be 
perceived important by stakeholders. Compared to discrete choice experiments, it seems 
equally challenging as the method presents hypothetical choice sets to the respondents 
and there is limited space to explain the criteria. In a DCE approach, there is a risk to leave 
out important criteria and establishment of Likert-scale questionnaire is relatively simple. In 
addition, the results can be explained in the context of Indonesia and this may indicate that 
respondents had a good understanding of the topic. Secondly, the policy makers in our study 
were mainly implementing donor funded interventions and do not decide on allocation of 
budget for HIV/AIDS control. However, it is difficult to identify the persons within the local 
planning board and different government offices that actually decide on the budget alloca-
tion for HIV/AIDS control. In Indonesia the funding for HIV/AIDS control is fragmented and all 
government offices independently decide whether to follow recommendations of the AIDS 
commissions and usually set their own priorities [5]. Thirdly, due to our study design we were 
not able to check for consistency in the answers given by respondents. The ranking of criteria 
was an extension of the Likert-scale rating and not an independent exercise on itself. Fourthly, 
we used the WHO health systems frameworks as underlying concepts and another framework 
may have led to inclusion of a different set of criteria. Fifthly, we may have left out important 
criteria from the list of 32 criteria. For example, stakeholders also expressed the size of an inter-
vention’s target population as an important criterion for priority setting of target groups. This 
criterion fits into the responsiveness category as it reflects a society’s preference that health 
systems focuses on problems that affect a large number of people or that cause a high burden 
of disease. On the other hand, it could also be an efficiency reason as with a large target 
group an intervention can reach economies of scale and may therefor be more cost-effec-
tive. These two criteria are now included in the list (or map) of criteria for priority setting in 
health as proposed by [41], however they were not in the draft list that we used to develop to 
our questionnaire. In addition, ‘human resources capacity within government institutions’ was 
proposed as an additional criteria and fits into the ‘governance and leadership category’ of the 
feasibility criteria. This is indeed reported as an important barrier for effective HIV/AIDS control 
in Indonesia and should have been included as a criterion in our questionnaire [5].
Our study showed that multiple criteria play a role in priority setting of HIV/AIDS interventions. 
It also outlines a feasible approach for other settings that would like to elicit the importance 
of multiple criteria among different stakeholders groups for priority setting of interventions 
within or across disease areas. For Indonesia, this study is a first exploration of the impor-
tance of criteria in the context of HIV/AIDS control. The study results may be used as input for 
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a particular HIV/AIDS priority setting question, either on micro-level: e.g. how to prioritize risk 
groups for HIV testing and treatment, or macro-level: e.g. what interventions should be part 
of a 5 years HIV/AIDS strategy in West Java province. On the basis of our survey it would be 
important to identify which interventions have most impact on the epidemic, reduce stigma 
in society, provide good quality of care and are feasible in terms of health system require-
ments. Multi-criteria decision analysis (MCDA) may be used as a framework to guide such 
priority setting process. Besides the importance of criteria, interventions options should be 
defined and compared on all criteria using a performance matrix. The performance matrix can 
then be input for a deliberative process among various stakeholders to make a final decision 
on which interventions should be prioritized and implemented. 
Conclusions
This study has identified criteria for priority setting of HIV/AIDS interventions in Indonesia 
using perspectives of policy makers, PLWHA, health care workers and the general population. 
Overall all stakeholders found it most important that interventions have impact on the HIV 
epidemic, are feasible in terms of Indonesia’s health system capacity, reduce HIV/AIDS related 
stigma in society and provide good quality of care. Most criteria related to equity (i.e. priori-
tizing groups on the basis of their gender, SES and age) were considered least important for 
choosing between HIV/AIDS interventions. 
Our study design outlines an approach for other settings to identify which criteria are 
important for priority setting of health interventions within or across disease areas. For Indo-
nesia, these study results may be used in priority setting processes for HIV/AIDS control and 
may contribute to more transparent and systematic decision-making. 
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Abstract
Background: We report an economic analysis of HIV care and treatment in Indonesia 
to assess the options and limitations of increasing efficiency, improving access, and 
scaling up services. 
Methods: We calculated the cost of providing HIV care and treatment in a main referral 
hospital in West Java, Indonesia from 2008 to 2010, differentiated by initiation of treat-
ment at different CD4 cell count levels (0-50, 50-100, 100-150, 150-200, and >200 cells/
mm3); time of treatment; HIV care and opportunistic infections cost components; and 
costs of patients for seeking and undergoing care.
Results: Before antiretroviral treatment (ART) initiation costs were dominated by labora-
tory tests (>65%), and after initiation by antiretroviral drugs (≥60%). Average treatment 
costs per patient decreased with time on treatment. Higher CD4 cell counts at initia-
tion resulted in lower laboratory and opportunistic infection treatment costs. Transpor-
tation cost dominated the costs of patients for seeking and undergoing care (>40%).
Conclusions: Costs of providing ART are highest during the early phase of treatment. Effi-
ciency gains can likely be realized by early treatment initiation and applying alternative 
laboratory tests. Although scaling up ART at the community level may improve early 
uptake and adherence, its implementation requires further study given the current low 
HIV prevalence in the general population and required HIV expertise. 
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Background
The face of the HIV/AIDS epidemic in Indonesia is changing. While the epidemic started among 
injecting drug users, now it is shifting towards the general population. The percentage of HIV 
transmission through injecting drug use decreased from 53% in 2001-2005 to 34% in 2011, and 
heterosexual transmission increased from 37% to 71% during the same period [1].
Indonesia’s national response to the epidemic focuses on a wide range of programs, including 
continuing support for care and treatment programs [1].The need for antiretroviral therapy 
(ART) is expected to increase from approximately 30,000 patients in 2008 to almost 87,000 
patients in 2014 [2]. However, in 2013 only 18% of the HIV patients who were eligible for treat-
ment in Indonesia received ART which indicates the need for the government to increase ART 
service, and puts pressure on the already-constrained budget for HIV/AIDS control in Indo-
nesia [3].
There is an urgent need to address the following research questions. First, what are the present 
treatment unit costs by time of treatment and stage of disease, and is there any potential 
to increase efficiency? Although there is (limited) international evidence that initiating treat-
ment early is more efficient than late treatment [4], and that delivery of ART is less costly at the 
community level than the hospital level [5], these have not been substantiated for Indonesia, 
and have only limited studies in Asia [6,7]. There is also limited Indonesian data to suggest that 
the use of less intense diagnostic and treatment procedures might lead to cost savings [8–10]; 
however, this data has not been placed in the context of total treatment costs. 
Second, what are the costs of scaling up ART? International evidence suggests that cost 
increases stemming from increased patient numbers can partly be offset by reduced average 
treatment costs as patients are treated earlier [11]; however, there is no specific evidence for 
Indonesia to support this hypothesis.
Third, what is the financial burden of patients accessing care? Although international studies 
have shown that the financial burden on patients may constitute a barrier to treatment [12] 
and may affect adherence and retention to treatment [13,14], available evidence from Indo-
nesia stems from a single study only [15].
This paper presents an economic analysis of the provision of ART and care for HIV/AIDS 
patients. It presents a cost profile differentiated by initiation of treatment at different CD4 cell 
count levels; time on treatment; cost components (e.g., drug and personnel costs) for HIV care 
and opportunistic infections (OIs); and finally patient costs of seeking and undergoing care. 
We believe our approach is unique in the context of Indonesia and Asia and can be general-
ized to other settings with similar HIV/AIDS epidemics and health system profiles. 
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Methods
Study setting and study population
The study was conducted in Bandung, at an HIV/AIDS clinic in the largest public referral and 
teaching hospital (Hasan Sadikin) in West Java province (43 million inhabitants). The clinic is 
visited by highly at-risk groups and the general population, and delivers HIV-related services 
such as voluntary counseling and testing, ART, and sexually transmitted infections services. 
The clinic operates at full capacity because it is among the few clinics that deliver ART in 
Bandung. The clinic generates its own revenues through government, hospital, and private 
funding; ART-related services are free, excepting hospitalization and the registration fee.
The study included all records on inpatients and outpatients starting ART in the clinic between 
2008 and 2010. The study population was divided into five groups by CD4 cell count: 0–50, 
50–100, 100–150, 150–200, and >200 cells/mm3. The starting point of every patient initiating 
ART was uniformed as month 1, and patients were analyzed at 6, 12, 18, and 24 months of ART. 
We also observed the pre-ART period when patients received HIV care and treatment but had 
not yet initiated ART, which ranged from one week to 6 months before treatment initiation. 
Based on these starting points, each patient’s treatment pattern was tracked from available 
medical and financial records and all costs were calculated. Patients were required to visit the 
clinic monthly to take their antiretroviral drugs (ARVs), and undergo CD4 cell count, viral load, 
and routine laboratory tests approximately every 6 months.
Data collection and cost estimation
The cost estimation was divided into health care costs (costs related to the consumption of 
resources in the health care system) and non-health care costs (costs falling on the patient for 
seeking and undergoing care). Health care costs were divided into hospitalization, outpatient 
visits, OI treatment, and ARVs, as well as CD4 cell count, viral load, and routine laboratory test 
costs. The micro-costing approach [16] was used to calculate the unit cost of an outpatient 
visit and OI treatment. All resources consumed, prices, and salaries related to service utiliza-
tion were listed and estimated based on clinical records, pharmacy databases, staff interviews, 
government price standards, and hospital or market prices.
Outpatient costs were calculated based on the recurrent and capital costs of the clinic. Recur-
rent personnel costs were estimated based on actual wages or government salary scales [17]. 
Other recurrent costs (e.g., administration goods consumed during the observation period) 
were estimated using both actual and market prices. Capital costs included trainings and 
workshops attended by the clinic staff, and unit costs for organizing these activities were 
obtained from the actual budgetary or governmental records. Market prices were used to esti-
mate other capital costs, including equipment, furniture, and start-up costs (e.g., renovation 
costs, if applicable). Capital costs were subsequently annualized on the basis of the lifetime of 
the capital items, using a 3% discount rate [16]. We omitted the cost of utilities (i.e. water and 
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electricity). This result was then multiplied by the proportion of time allocated by the clinic to 
deliver ART, calculated through a separate time motion study in which we observed clinical 
activity and calculated the amount of time spent on ART-related duties per week by the clinic 
staff. The total outpatient visit cost was then divided by the number of total outpatient visits 
to obtain the unit cost per outpatient visit. Patients registered as outpatient were never also 
registered as inpatient in the same period. For example, a patient who is registered as inpatient 
in a certain month may be registered as outpatient in the next month, but never at the same 
month. The details of outpatient cost is presented in the Appendix (Table A). 
OI treatment cost was calculated based on the medical resources consumed by OI treatment 
(e.g. drugs and equipment), excluding hospitalization. Medical records and the physician’s 
patient database were used to estimate resource utilization, and the official hospital prices 
issued in 2011 were used to calculate the unit costs of drugs and equipment. We obtained 
the unit cost of OI treatment by dividing the total cost of OI treatment for each CD4 cell count 
group by its population. We were unable to retrieve data regarding the specific OIs that drugs 
and equipment were used to treat. The average unit cost of OI treatment is presented in the 
Appendix (Table B).
Because the data was limited, we did not perform micro-costing when calculating the costs of 
hospitalization, ARVs, or laboratory tests. We used the World Health Organization’s Choosing 
Interventions that are Cost Effective (WHO-CHOICE) estimates [18] to estimate the per day inpa-
tient hotel cost, which we then used to calculate the total hospitalization cost. The WHO-CHOICE 
estimates for inpatient cost include items such as personnel, capital, and food costs, and exclude 
drugs and diagnostic test costs. The prices of ARV drugs (except for Tenofovir) issued by Kimia 
Farma (a national pharmaceutical corporation) were used as the unit costs of ARVs, while the 
price of Tenofovir was based on Bender et al. (2010) [19]. The unit costs of laboratory tests (CD4 
cell count, viral load, and other laboratory tests) were derived from the 2011 official hospital 
price for each test. The summary of all unit costs used is presented in Appendix (Table C).
The non-health care costs comprised the patient costs, which were estimated by conducting a 
survey among 41 patients undergoing ART at the hospital. We collected information including 
(but not limited to) clinic service fee, travel costs, travelling time, the patient’s monthly income, 
the average number of daily working hours, and monthly expenditures. Next, we estimated 
patients’ monthly incomes based on their monthly expenditures. Patients did not have to pay 
for ARV, ARV monitoring, other lab tests, or OI medication/treatment. The patient cost estima-
tion does not, at any rate, collide with the calculation of provider cost as it is calculated sepa-
rately using different cost items specific to the patients. Therefore, there is no issue of double 
counting in this respect. 
All costs were measured in Rupiah, and converted to US$ using the 2010 exchange rate [20]. 
Both the utilization and cost data were analyzed using Microsoft Excel 2007. We report costs 
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from both the health care system and patient perspective. We did not approach an ethical 
committee or seek for ethical approval as our study mostly focus on costs and resources data 
spent for HIV treatment (mostly secondary data). Secondary data related to patients (e.g. ARV 
and OI drugs intake per patient) were taken from the clinic’s patients database (in a form of 
an Excel file). The database was anonymized after the data were received and prior to analysis 
(we utilize the patients hospital ID number during analysis), and none of the patients personal 
identity is published in any part of the study. On the event of non-health care costs (primary) 
data collection, all patients were asked to fill in written informed consent forms prior to partic-
ipating in the survey and the survey was anonymous (no patient names were collected). The 
survey was conducted by a group of enumerators and authors only receive the results. 
Results
Patient characteristics
Patient characteristics are presented in Table 1. The majority of patients with a CD4 cell count 
of 0–150 cells/mm3 are male, while females dominate the >150 cells/mm3 group. All patients 
are in their productive age and the majority are married, employed, and have experience with 
injecting drug use. The highest education level attained by patients was the secondary level 
(high school).
Resource utilization and costs of providing ART
Table 2 presents the resources used to provide ART. Hospitalization occurred only before ART 
and up to 6 months after treatment was initiated; the duration ranged from 3 to 20 days. The 
switch to second line ART occurred in 5% of patients with a CD4 cell count of 0−50 cells/mm3 
and 15% of those with 50−100 cells/mm3. Few patients with CD4 cell counts >200 cells/mm3 
were hospitalized and received OI treatment. Details regarding unit costs per item are summa-
rized in the appendix.
Table 3 details the costs associated with providing ART. Before ART initiation, costs were mainly 
dominated by laboratory tests (including the CD4, viral load, and routine laboratory tests). 
After the initiation of ART, costs were dominated by ARV, regardless of patients’ CD4 levels. 
Both total costs and per patient average costs decreased over time after ART initiation. The 
one anomaly was the OI drugs/treatment cost for patients with a CD4 level of 50−100 cells/
mm3, which increased from US$725 in 1-6 months to 2,099 in 7-12 months. A relatively high 
CD4 cell count at treatment initiation relates to relatively low costs of ARVs, laboratory tests, 
and OI drugs/treatment. Figure 1 shows the average costs per patient for different CD4 cell 
count levels and over time. The highest total costs for 24 months of ART per patient were for 
patients with a CD4 cell count <50 cells/mm3. The distribution of total costs for patients with 
different CD4 cell counts is provided in the Appendix (Figure A).
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CD4 CELL COUNT AT TIME OF STARTING ART
0-50      50-100 100-150 150-200 >200       Overall
No. of observation
at the start of ART
96 33 22 17 10 178
CD4 level at the start
of ART, mean (CI)*
19 
(16 – 22)
71 
(66 – 76)
124 
(118 – 130)
177  
(170-184)
275  
(252 – 298)
39 
(13-110)**
Sex (male) 80% 82% 59% 41% 40% 72%
Age, mean (CI*) 30 
(29 - 31)  
30 
(28-32)
29 
(28-30)
27 
(26-28)
27 
25 – 29)
30
(29-31)
History of injecting drug use 69% 70% 55% 41% 70% 65%
Marital status
Married 52% 58% 45% 35% 60% 51%
Not married 36% 24% 41% 29% 10% 33%
Widowed/ divorced 10% 15% 14% 29% 30% 15%
Occupation status
Employed 67% 82% 86% 82% 80% 74%
Student 2% - - 6% - 2%
Unemployed 30% 15% 14% 12% 20% 23%
Highest education
Primary 3% - - - - 2%
Secondary 58% 51% 59% 77% 80% 60%
Tertiary 36% 48% 41% 24% 20% 37%
 *CI = Confidence interval, 95%), ** Median (IQR)
Table 1. Characteristics of patients on ART
Non-health care costs per visit
Table 4 presents non-health care costs. The average patient’s non-health care costs per visit 
are US$10 and US$11, for patients with CD4 cell counts below and above 200 cells/mm3, 
respectively. Transportation cost and the clinic fee dominated the costs, while productivity 
loss accounted for less than 25% of the total cost per visit. Per visit, almost all patients spent 
US$2 for the registration fee and US$5 − US$6 for transportation. The mean time to reach the 
clinic was approximately 1 hour (most patients lived < 20 km away) and the average time 
spent in the clinic was approximately 100 min. There were no major differences in non-health 
care costs between patients with CD4 cell counts less than or greater than 200 cells/mm3 (we 
did not perform significance test for this due to our small sample size)
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CD4 CELL 
COUNT 
ITEM     PERIOD
Before 
ART
1 - 6
months
7 - 12 
months
13 - 18 
months
19 - 24 
months
0-50 Number of patients 96 96 95 84 61
%  hospitalized* 14% 22% - - -
Average days of hospitalization (CI**) 6 (4-8) 15 (10-20) - - -
Number of outpatient visit 95 47 75 63 41
% of patients treated for OI* 2% 63% 27% 18% 8%
 % switched to 2nd line ARV* - - 1% 2% 3%
Number of CD 4 tests 95 47 75 63 41
Number of viral load tests - 6 16 9 4
Number of routine lab tests 87 45 74 62 40
50-100 Number of patients 33 33 33 32 25
%  hospitalized* 3% 12% - - -
Average days of hospitalization (CI)** 3 6 (5-7) - - -
Number of outpatient visit 36 13 29 20 10
% of patients treated for OI* 3% 36% 21% 13% 4%
% switched to 2nd line ARV* - 3% 3% 6% 12%
Number of CD 4 tests 36 13 29 20 10
Number of viral load tests 0 5 6 4 0
Number of routine lab tests 30 14 28 20 9
100-150 Number of patients 22 22 22 18 13
%  hospitalized* - 14% - - -
Average days of hospitalization - 7 - - -
Number of outpatient visit 29 8 18 13 7
% of patients treated for OI* - 45% 18% 11% 15%
% switched to 2nd line ARV* - - - - -
Number of CD 4 tests 29 8 18 13 7
Number of viral load tests 1 1 4 3 -
Number of routine lab tests 21 8 17 13 7
150-200 Number of patients 16 16 13 13 11
%  hospitalized* 12% 6% - - -
Average days of hospitalization 5 3 - - -
Number of outpatient visit 26 9 9 11 7
% of patients treated for OI* - 47% 14% 21% -
% switched to 2nd line ARV* - - - - -
Number of CD 4 tests 26 9 9 11 7
Number of viral load tests 1 4 4 1 -
Number of routine lab tests 16 8 9 11 7
>200 Number of patients 10 10 10 7 4
%  hospitalized* - - - - -
Average days of hospitalization - - - - -
Number of outpatient visit 17 5 6 4 4
% of patients treated for OI* - 10% - - -
% switched to 2nd line ARV* - - - - -
Number of CD 4 tests 17 5 6 4 4
Number of viral load tests - - - - -
Number of routine lab tests 9 5 6 41 4
*for the whole sample within the indicated period, ** Confidence Interval, 95%
Table 2. Resource utilization of patients on ART by CD4 cell count at the start of ART,
  per specified period
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Table 3. Health care costs of patients on ART by CD4 cell count at the start of ART, 
  per specified period (US$*)
CD4 CELL 
COUNT
ITEM PERIOD
Before
ART
1 - 6
months
7 - 12
months
13 - 18 
months
19 - 24 
months
0-50 Number of patients 96 96 95 84 61
Hospitalization 1,483 (10%) 6,161 (9%) - - -
Outpatient visits 1,110 (8%) 6,707 (10%) 6,462 (12%) 5,247 (11%) 3,517 (11%)
OI treatment 86 (1%) 10,867 (16%) 2,163 (4%) 564 (1%) 1,538 (5%)
 ARV drugs - 40,012 (60%) 41,281 (78%) 37,724 (81%) 26,915 (81%)
CD 4 test 1,254 (9%) 620 (1%) 990 (2%) 832 (2%) 541 (2%)
Viral load test - 396 (1%) 1,056 (2%) 594 (1%) 264 (1%)
Routine lab test 10,452 (73%) 1,488 (2%) 1,289 (2%) 1,548 (3%) 363 (1%)
Total costs 14,377 (100%) 66,205 (100%) 53,196 (100%) 46,472 (100%) 33,115 (100%)
Average costs per patient (CI**)  150 (139 – 160) 690 (593-787) 560 (522-599) 554 (515-592) 543 (481-606)
50-100 Number of patients 33 33 33 32 25
Hospitalization 57 (1%) 418 (2%) - - -
Outpatient visits 421 (9%) 2,337 (12%) 2,232 (11%) 1,951 (11%) 1,110 (11%)
OI treatment 12 (0.3%) 725 (4%) 2,099 (10%) 13 (0.1%) 9 (0.1%)
ARV drugs - 14,694 (77%) 15,360 (73%) 14,763 (83%) 9,058 (87%)
CD 4 test 475 (10%) 172 (1%) 383 (2%) 264 (1%) 132 (1%)
Viral load test - 330 (2%) 396 (2%) 264 (1%) -
Routine lab test 3,608 (79%) 478 (2%) 494 (2%) 508 (3%) 104 (1%)
Total costs 4,570 (100%) 19,138 (100%) 20,947 (100%) 17,749 (100%) 10,405 (100%)
Average costs per patient (CI**)  139 (126-151)        580 (568-593)    635 (622-648)    555 (542-568)    417 (404-429)    
100-150 Number of patients 22 22 22 18 13
Hospitalization - 418 (4%) - - -
Outpatient visits 339 (10%) 1,566 (14%) 1,391 (13%) 1,157 (13%) 771 (14%)
OI treatment - 815 (7%) 77 (0.7%) 29 (0.3%) 2 (0.04%)
ARV drugs - 8,147 (72%) 8,587 (79%) 6,858 (79%) 4,661 (83%)
CD 4 test 383 (11%) 106 (1%) 238 (2%) 172 (2%) 92 (2%)
Viral load test 66 (2%) 66 (1%) 264 (2%) 198 (2%) -
Routine lab test 2,547 (76%) 222 (2%) 293 (3%) 317 (4%) 63 (1%)
Total costs 3,333 (100%) 11,329 (100%) 10,839 (100%) 8,722 (100%) 5,585 (100%)
Average costs per patient (CI**)  159 (144-173)        515 (501-530)      493 (479-508)    485 (470-500)   430 (415-445)    
150-200 Number of patients 17 17 14 14 11
Hospitalization 190 (7%) 57 (1%) - - -
Outpatient visits 304 (11%) 1,133 (14%) 982 (15%) 935 (14%) 654 (14%)
OI treatment - 66 (1%) 3 (0.05%) 5 (0.1%) - 
ARV drugs - 6,188 (77%) 4,865 (76%) 5,162 (77%) 3,717 (82%)
CD 4 test 343 (12%) 119 (1%) 119 (2%) 145 (2%) 92 (2%)
Viral load test 66 (2%) 264 (3%) 264 (4%) 66 (1%) -
Routine lab test 1,969 (69%) 200 (2%) 195 (3%) 362 (5%) 63 (1%)
Total costs 2,870 (100%) 8,020 (100%) 6,421 (100%) 6,670 (100%) 4,522 (100%)
Average costs per patient (CI**)  169 (136-202)        472 (440-505)    459 (427-492)      477 (444-509)  411 (379-444)    
>200 Number of patients 10 10 10 7 4
Hospitalization - - - - -
Outpatient visits 199 (13%) 701 (15%) 608 (13%) 363 (12%) 257 (20%)
OI treatment - 1 (0.02%) - - -
ARV drugs - 3,637 (79%) 3,797 (83%) 2,715 (84%) 938 (73%)
CD 4 test 224 (15%) 66 (1%) 79 (2%) 53 (2%) 53 (4%)
Viral load test - - - - -
Routine lab test 1,119 (73%) 223 (5%) 92 (2%) 68 (2%) 35 (3%)
Total costs 1,541 (100%) 4,623 (100%) 4,572 (100%) 3,218 (100%) 1,281 (100%)
Average costs per patient (CI**)  154 (114-195)        463 (422-503)    458 (417-498)      460 (420-501)    321 (280-361)    
*except for number of patients, **Confidence Interval, 95%
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Table 4. Patient costs of accessing ART (patient’s perspective) (US$)
CD4 LEVEL AT THE 
START OF ART
ESTIMATED AVERAGE PER VISIT ACCESS COSTS MONTHLY HOUSE-
HOLD INCOME*
Average trans-
portation cost
Average estimated 
productivity loss
Average fee 
for clinic
Average per 
visit total costs
0 – 200 (n=17) 6 (0-12)* 1 (0.5-2)* 2.4 (2-3)* 10 (3 – 16)** 71 (42 – 101)**
>200 (n=23) 5 (2-7)* 3 (2-5)* 2 11 (4 – 18)** 147 (72 – 221)**
*average, **Confidence Interval, 95%
Discussion
To our knowledge, this study is the first in Indonesia and among the few in Asia [21,22] to esti-
mate the cost of providing ART. The overall cost profile shows that the total costs and average 
costs per patient are reduced when patients’ CD4 levels are higher at the time of clinic enroll-
ment and ART initiation. In most instances, hospitalization, OI treatment, and ART average 
costs per patient decrease with longer use of ART. During the early phase of the treatment, 
the highest costs are the costs of hospitalization, OI treatment, and ART initiation; these costs 
decrease over time as a result of patients’ improved health. This trend is comparable with the 
results of a study conducted in Southern Africa [23].
These findings lead to several observations in response to the research questions. Regarding 
the cost of treatment and potential efficiency gain, the study confirms the hypothesis that the 
-
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following two measures have potential to improve efficiency in ART delivery.
First, early ART initiation. Most cost items are lower when patients’ CD4 cell counts are higher 
at ART initiation and especially the total cost share of hospitalization and OI treatment was 
reduced. CD4 cell counts can predict the likelihood of OIs; patients with CD4 cell counts >200 
cells/mm3appear to be at lower risk for the majority of OIs, compared with patients with <200 
cells/mm3 [24–27] and this explains our study results. Additionally, early treatment also reduces 
(1-year) mortality in Indonesia and its cost-effectiveness in resource-limited settings as well as 
its impact on the global epidemic have been proven [4,28]
Second, alternative diagnostics. Before ART initiation, costs are dominated by laboratory tests 
(CD4, viral load, and routine laboratory tests) followed by outpatient visits and hospitalization. 
After ART initiation, costs were dominated by ARV drugs followed by laboratory tests. Although 
efficiency gains in hospitalization and ARV use might be difficult, gains are possible for labo-
ratory test costs, as is found in the DART trial in four African countries [29], which showed that 
ART can be delivered safely without routine laboratory monitoring for toxicity. A recent study 
within the same hospital clinic with our study demonstrated that the total lymphocyte count 
(TLC) is a good alternative for CD4 testing as it is much cheaper and easier to implement in 
rural settings. Combining TLC test results with an algorithm of simple patient characteristics 
could save US$14 per patient compared with the current scenario [8]. Also, De Jong et al. (2012) 
[9] in Indonesia (study conducted at the same clinic as our study) and Kumarasamy et al. (2002) 
[30] in India found that TLC may reduce the need for routine CD4 measurements during ART 
(excepting the first year of treatment). In Indonesia, another method to reduce laboratory costs 
is proposed by Indrati et al. (2009) [10], who found that a dual-test or single rapid-test algo-
rithm (instead of a serial three-test algorithm) may be just as accurate and more cost-effective, 
although the single rapid-test should be interpreted carefully. Although these alternative labo-
ratory testing methods may lead to efficiency gains, additional study is needed to determine 
the cost savings.
Regarding our second research question about scaling up ART, the study indicates that 
although increased ART coverage may cause a large increase in health expenditure in the short 
run [22,31], it could also save costs in the long run. By reaching more people in need of ART, 
assuming that these are detected at earlier stages, costs related to opportunistic infections 
and hospitalization may be avoided as has been shown in our study. Importantly, providing 
ART can also act as HIV/AIDS prevention [32,33] because ART treatment reduces transmission 
rates. Universal voluntary HIV testing and early ART could therefore have a major effect on the 
HIV/AIDS epidemic and could be cost saving [4,34]. The costs of treatment of new HIV infec-
tions will be averted and may potentially free resources to prevent even more infections [11]. 
Considering these findings, we suggest further study regarding advantages (e.g., health bene-
fits of early treatment) and disadvantages (e.g., budget impact) of scaling up ART in Indonesia 
from both the short term and long term perspective.
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In terms of the location for scaling up ART, we cannot draw strong conclusions on the basis of 
the costing analysis in the hospital setting only. Yet, there seem to be advantages in scaling 
up ART at the community level as this may potentially increase early detection and reduce the 
burden in hospital clinics [35]. Also, the shorter waiting and travel time to the clinic may lead 
to lower patient’s costs and better uptake and adherence of ART [13,14,36]. In this scenario, 
the hospital and community health centres will have different roles (Table 5). The hospital will 
be a referral centre for complicated AIDS cases and treatment of OIs just as current practice 
[35,36]. Because patients become relatively stable over time (indicated by decrease in hospi-
talization and OI treatment over time) they could continue ART at community clinics, reducing 
the hospital burden. Patients that initiate ART at >200 cell/mm3 could also obtain ART at the 
community health care center, as our analysis suggests that hospitalization and OIs are rare 
in this population. In addition, patients mostly utilize first line ARV, and no patients with CD4 
cell counts >100 cells/mm3 switch to second line ARV (Table 2), indicating a low rate of treat-
ment failure within this group [37]. As such, the ARV distribution (in terms of medicine type) 
in community/primary health care centres for patients with CD4 cell counts >100 cells/mm3 
might not be too complex, as most patients are likely to require only first line ARV. Currently, 
there are only two primary health care centers in Bandung that provide ART, which presents 
considerable potential to increase the service to other community clinics. 
However, providing ART at all community health clinics in Indonesia at this stage seems ineffi-
cient due to the low HIV prevalence in the general population which will result in a low patient 
load per clinic for which all community staff will require training [38]. Therefore, providing HIV 
services through clinics in certain high prevalence settings such as prisons or cities may be 
preferable [39,40], although this strategy requires further study. 
Regarding our third research question about patients’ financial burden, the study shows that 
Table 5. Recommendation on role of clinics in delivering ART†
COSTS ITEMS TYPE OF CLINIC
Hospital Community/Primary Health Care Centre
Hospitalization + -
Outpatient visits +/- +
OI treatment +* +
ARV drugs +/- +
CD 4 test + -
Viral load test +** -
Routine lab test + +/-
†  ‘+’ and ‘-’ denote respectively a role of high and low importance for the clinic in the specified activities in HIV/AIDS control.
* for severe cases; ** if necessary, ART = antiretroviral treatment 
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patient’s non-health care costs per visit are US$10 and US$11, for patients with CD4 cell counts 
below and above 200 cells/mm3. This relates to approximately 14% and 7% of their monthly 
income, respectively. Especially for patients with CD4 cell counts <200 cells/mm3 these costs 
could be a barrier, as it exceeds 10% of their monthly income and can be considered to be 
catastrophic for a household economy [41].
Transportation comprises the highest proportion of costs: 62% and 43% for patients with 
CD4 cell counts below and above <200 cells/mm3, respectively, and this is comparable with 
the finding of Riyarto et al. [15] in Indonesia. A study by Haroen et al. [unpublished data] in 
Bandung, Indonesia, and international studies by Portelli et al. [13], Brinkhof et al. [14], and 
Posse et al. [12] have shown that transportation costs are a common reason why patients cease 
ARV. This information provides another reason to scale up ART at community level, as it likely 
reduces transportation costs for patients and may increase the uptake of ART, especially of 
patients with CD4 cell counts <200 cells/mm3.
Study limitations
Our results should be interpreted with some caution. First, this study has evaluated a contex-
tualized ART service delivery model, which may hamper the generalizability of its results. Cost 
structures and levels as well as patient populations are likely to vary between clinics, and specific 
costing studies for other settings (e.g., other hospitals, community/primary health centers, and 
prisons) should be considered. Regardless, we believe that our approach is of relevance also 
to other resource-limited settings. Second, we may have overestimated the total patient costs 
of seeking and undergoing care as this was based on assumptions regarding patients’ labour 
productivity losses, and not on empirical data collection on these losses per se. Third, although 
we have conducted a time motion study to control for inefficiency in ART delivery in the clinic 
(e.g., related to personnel and equipment), discrepancies may still exist, and we may have over- 
or undervalued the total costs. Fourth, we did not perform any comparison between WHO 
CHOICE estimates (that we used for calculating inpatient cost) and any local data. Although this 
is an important aspect, currently there is very limited local data available to do this comparison. 
Conclusions
Three main conclusions can be derived from our study. First, we show that the costs of providing 
ART are highest during the early phase of treatment, and will decrease and stabilize as treatment 
progresses. Second, our findings suggest that efficiency gains can be realized by early treatment 
initiation (which may reduce hospitalization, OI drug/treatment costs, and patient mortality) and 
by applying alternative laboratory tests. Third, scaling up ART at the community level has poten-
tial to save costs and improve uptake and adherence. However, provision of ART at all commu-
nity clinics seems inefficient due to the low prevalence in the general population and options to 
select certain clinics in high prevalence areas need further investigation. 
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Appendix 
Table A. Yearly Cost of ART outpatient service (US$)
TYPE OF COST US$ (2010) %
1.  CAPITAL COST (Annualized)
1.1 Personnel (trainings & workshops) 111.37 0.5
1.2 Building/Space 477.24 2.0
1.3 Equipments 510.72 2.1
Subtotal 1,099.33
2. RECURRENT COST
2.1 Personnel (number) 21,123.40 91.7
Medical doctor (4) 6,701.66
Nurse (2) 5.370.67
Laboratory (1) 1,196.22
Administration and cleaning service (6) 15,178.81
2.2 Supplies 895.13 3.7
Subtotal 23,018.54
Total 24,117.86
Unit cost per visit 11.69
Table B. Average unit costs of OI treatment by CD 4 cell count at the beginning of ART (US$)
CD 4 CELL COUNT PERIOD
Before
ART* 
1 - 6
months* 
7 - 12 
months* 
13 - 18 
months* 
19 - 24 
months* 
0-50 1 (0-2) 113 (48-179) 23 (3-42) 7 (0-16) 25 (0-60)
50-100 0.4 (0-1) 22 (1-43) 64 (0-170) 0.4 (0-1) 0.3 (0-1)
100-150 - 37 (0-94) 3 (0.1 – 7) 2 (0-3) 0.2 (0-0.4)
150-200 - 4 (0-9) 0.2 (0-1) 0.4 (0-1) -
>200 - 0.1 (0-0.3) - - -
*Confidence Interval 95%
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Table C. Unit Costs per Cost Item (US$)
COSTS ITEM UNIT COST SOURCE
Inpatient day 19.2 WHO CHOICE
Outpatient visit 11.7 Own calculation
Average unit costs of ARV drugs (min-max)
First line 28 (7-79) Kimia Farma
Second line 90 (56-117) Kimia Farma and Bender et al., 2010
CD 4 test 13.2 Hospital Decree
Viral load test 66 Hospital Decree
Average unit costs of laboratory t ests 
(confidence interval)
6 (4-8) Hospital Decree
Figure A. HIV treatment total costs per patient on ART, over 24 months
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  What is the current priority setting process in 
  HIV/AIDS control in Indonesia?
 Sub-question 3
  What is the performance of
  HIV/AIDS interventions on 
  criteria for priority setting?
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Abstract
Background: Voluntary counseling and testing (VCT) is a key component in combating 
Indonesia’s growing HIV epidemic, but coverage among most-at-risk populations is 
low, approximately 30%. Indonesia’s national HIV/AIDS strategy aims for coverage of 
80% through a community-based approach. Because information on costs and health 
effects is lacking, this study aims to evaluate the costs-effectiveness of scaling up 
community-based VCT in West-Java.
Methods: The Asian Epidemic Model (AEM) and Resource Needs Model (RNM) were 
used to calculate incremental costs per HIV infection averted and per disability-ad-
justed life years saved (DALYs). Locally monitored demographic, epidemiological 
behavior and cost data were used as model input. 
Results: Scaling up community-based VCT in West-Java will reduce the overall popula-
tion prevalence by 36% in 2030 and costs US$248 per HIV infection averted and US$9.17 
per DALY saved. Cost-effectiveness estimates were most sensitive to the impact of 
VCT on condom use and to the population size of clients of female sex workers (FSW), 
but were overall robust. The total costs for scaling up community-based VCT range 
between US$1.3 and US$3.8 million per year and require the number of VCT clinics inte-
grated at public community health centers to increase from 6 in 2010 to 594 in 2030. 
Conclusion: In our analysis, scaling up community-based VCT seems both an effec-
tive and cost-effective intervention. However, in order to prioritize VCT in HIV/AIDS 
control in West-Java, issues of budget availability and organizational capacity should 
be addressed. 
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Background
In most Asian countries national HIV epidemics are stabilizing, but Indonesia’s is growing [1]. 
The epidemic is concentrated among risk groups, such as people who inject drugs (PWID) and 
female sex workers (FSW), except in Papua province, where it is generalized [2]. In 2009, the 
prevalence of people living with HIV/AIDS (PLWHA) was estimated at 353,173 (0.3%) and long-
term projections vary between 500,000-1,000,000 in 2015. Importantly, these projections indi-
cate a shift of the epidemic towards the general population [3,4]. 
Indonesia’s national response focuses on a wide range of services, mainly for most-at-risk 
populations: e.g. harm reduction programs, condom distribution, and voluntary counseling 
and testing (VCT) [3]. Unfortunately, coverage of VCT remains low, approximately 30% among 
most-at-risk populations in 2009 [3]. As a result, HIV patients present themselves at hospitals 
at a very late stage, reflected in extremely low median CD4 cell counts (33/ml among PWID 
and 84/ml among non-PWID) [5]. VCT functions as an entry point for care and counselors 
aim to reduce the risk behavior of tested individuals by providing information about routes 
of HIV transmission and about prevention methods [6]. Because VCT is able to prevent the 
spread of HIV, it is a key component in Indonesia’s HIV/AIDS control. Based on WHO guidelines, 
VCT services in Indonesia consist of HIV rapid testing combined with pre- and post-test coun-
seling. In line with the WHO/UNAIDS goals for universal access to VCT in 2010, the National 
AIDS Commission (NAC) proposes in their National Strategy 2010-2014 to scale up VCT to 80% 
among most-at-risk groups in 2014 [3,7].
To date, VCT is mainly delivered at hospitals, but several researchers stress the need for a 
community-based approach to promote early detection and treatment and to reduce case 
loads at hospitals [8,9]. Moreover, Siregar et al. (2011) [8] showed that in Indonesia community 
health centers provide VCT at significantly lower costs than hospitals. However, the total costs 
and health effects of scaling up VCT at community level are not yet clear. The rise in costs 
caused by the increasing number of people covered might be largely offset by a decrease in 
unit costs of VCT. In addition, the cost-effectiveness of VCT is largely unknown. 
The Indonesian government substantially increased economic efforts to combat the HIV 
epidemic: the allocation from the national budget rose from US$11 to US$73 million between 
2006 and 2009 [3]. This is encouraging, but it will not be enough to implement every inter-
vention for every target group at full scale, emphasizing the urgent need for setting priorities 
for HIV/AIDS interventions [10]. Cost-effectiveness is proposed as a leading criterion in setting 
such priorities, but evidence on the cost-effectiveness of HIV/AIDS interventions is largely 
unavailable in Indonesia [10]. In addition, international literature is difficult to generalize and 
focuses mainly on Africa [11].
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Table 1. VCT coverage and population size covered per risk population for
  West-Java province, based on national strategy 2010-2014 [7]
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Note: population size increases over the years by overall West-Java population growth
PWID = people who inject drugs, FSW = female sex workers, MSM = men having sex with men, # VCT coverage data for 
West-Java province not available and therefore based on national data (outside Papua province), as reported in National 
Strategy 2010-2014 [7] 
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Against this background, our study aims to evaluate the costs, effects, and cost-effectiveness 
of scaling up community-based VCT in West-Java in order to support the national strategy as 
well as policy makers in setting priorities for HIV/AIDS interventions. Our study is an integrated 
component of a broader project on the economic analysis of HIV/AIDS control in Bandung, 
West-Java that also includes cost [12] and cost-effectiveness studies on methadone mainte-
nance treatment (MMT) [13].
Methods
Study Setting
Our area of analysis is West-Java province, with 40 million inhabitants and a high HIV prev-
alence in most-at-risk populations: 42.8% in PWID, 11.6% in direct FSW, and 3.3% in indirect 
FSW (direct FSW are those working in brothels and indirect FSW are those working in bars and 
hotels), and 2.0% in men having sex with men (MSM), according to most recent estimates in 
2007. In 2010, West-Java reported a prevalence of 2,168 HIV infections and 3,512 AIDS cases [14], 
although mathematical models (Asian Epidemic Model for West-Java) had projected 35,294 
and 3,856, respectively. To date in West-Java, 59 VCT clinics are integrated in hospitals, public 
and private community health centers, and prisons. Between April 2006 and November 2009 
these clinics provided VCT services to 27,007 people. However, in 2009 overall coverage was 
only 30% among the majority of most-at-risk populations and 2% among clients of FSW (Table 
1) [3,7]. Because many stakeholders agreed upon a strategy of scaling up community-based 
VCT services, advocacy and capacity building has recently begun to successfully integrate 
more VCT clinics in existing public community health centers (i.e. Puskesmas) [7]. So far, these 
clinics provide VCT services to 30 people per year, but have the capacity to test and counsel 
300 people per year, as estimated by the Ministry of Health (MoH) [15].
Scaling up community-based VCT versus current practice 
We compare the costs and effects of scaling up community-based VCT versus a base case 
of current practice, over the years 2010-2030, from a government perspective. We calculated 
incremental cost-effectiveness ratios (ICER) per HIV infection averted and disability adjusted 
live years (DALYs). The base case and scaling up strategy were defined as follows: 
Current practice (base case). In this situation, VCT services target only most-at-risk populations: 
indirect and direct FSW, PWID, higher risk MSM, transgenders, clients of FSW, prisoners, and 
partners of PWID. We assumed that VCT coverage among risk populations in 2009 remains 
stable until 2030 (Table 1) and that 60% of the people targeted receive VCT at hospitals, 20% 
at private community health centers, 10% at public community health centers, and 10% at 
prisons, reflecting current practice [16]. Unit costs of VCT per client depend on where the client 
is tested and counseled (i.e. health centers, hospitals, or prisons).
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Scaling up VCT at the community level. In this situation, VCT will be scaled up at public 
community health centers according to the National Strategy 2010-2014, as specific targets for 
West-Java province are not available [7,17]. “Community level” is defined as providing services 
at close distance to the living area of the target group, in public community health centers 
(i.e. Puskesmas) in both urban and rural areas. Coverage among most-at-risk populations will 
increase from approximately 30% in 2009 to 80% in 2014 and will remain stable until 2030 
(see Table 1). We assumed that hospitals will no longer offer VCT services, that the number of 
people tested and counseled at private community health centers and prisons remains stable, 
and that the additional people covered receive VCT at public community health centers. In 
this situation, 87% of the targeted people receive VCT at public community health centers, 9% 
at private community health centers, 4% at prisons and 0% at hospitals. The most-at-risk popu-
lations targeted, the VCT unit costs, and the capacity of public community health centers are 
similar as the defined base case. 
Study model
We projected costs and effects using a combined Asian Epidemic Model (AEM) [18,19] and 
Resource Needs Model (RNM) [20]. Both models are widely published and are the primary and 
only source of data on the HIV/AIDS epidemic for the Ministry of Health in Indonesia [4,7]. A 
detailed description of the models and the data sources used can be found in the Appendix. 
Because of model limitations we only modeled the impact of a reduction of condom use in 
contacts between direct and indirect FSW and their clients, PWID and FSW and their spouses 
or regular partners, and between MSM and their male partners. In our sensitivity analysis we 
anticipated the over- or underestimation of the effectiveness of VCT, as the impact matrix does 
not capture studies from Indonesia on the impact of VCT. However, in the literature we found 
one qualitative study on the impact of VCT on 40 PWID in Bali that reported that of those who 
tested positive, 50% reported decreased risky drug use and 37.5% decreased risky sex. The 
individuals with negative test results showed the same changes [21]. In addition, we assumed 
equal impact of VCT over risk groups, as we found no evidence for differences in the literature 
[22]. The costs of VCT coverage were included for all most-at-risk populations. 
Estimate of DALYs saved
AEM output (number of new HIV infections, AIDS cases, and deaths of men and women) was 
used to estimate DALYs for both the base case and the strategy of scaling up VCT, based on 
the following Global Burden of Disease formulas [23]:
  DALY = YLL + YLD
Years of Lives Lost (YLL) due to AIDS related death:
YLLs r K
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r
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where K =age weighting modulation factor; C= constant; r =discount rate; a =age of death; 
β=parameter from age weighting function; L =standard expectation of life at age a.
Years Lived in Disability (YLD) (separated for disease stages of HIV-infection and AIDS):
where K =age weighting modulation factor; C= constant; r =discount rate; a =age of onset of 
disability; β = parameter from age weighting function; L =duration of disability;a =age of onset 
of disability; D=disability weight. 
For men and women disability weights were 0.136 for HIV infection (0.123 until 15 years old) and 
0.505 for AIDS, the average duration in the HIV and AIDS states were 7.49 and 3.0 years respec-
tively [2,23], the discount rate was 0.03, and no age-weighting was applied. The average age 
of infection was estimated using the Asian Epidemic Model. The mortality and AIDS disability 
that will take place after 2030 (and relate to HIV infections that occurred between 2010-2030) 
were included in the DALY estimates. 
Estimate of costs
Siregar et al. (2011) estimated the costs of VCT in different delivery settings (public and private 
community health centers, hospitals, and prisons) in Bandung, West-Java (Table 2) [8]. Health 
care costs were estimated on the basis of data on service utilization retrieved from clinic records 
and unit costs, including all resources consumed and valued using a micro-costing approach. 
All costs were measured in Indonesian Rupiah, and converted to US$ using the 2008 exchange 
rate. Based on a MoH workshop with HIV/AIDS experts in West-Java, the health care costs for 
public community health centers were adjusted from 28 to 300 people per year to reflect 
normal capacity [15]. In all settings the VCT service is in line with the standard VCT delivery 
procedure instructed by the MoH: VCT includes a separate room for counseling and well-
trained counselors. Differences among clinics in capital personnel training and workshop costs 
are explained by differences in training quality and number of staff trained. Differences in recur-
rent personnel costs are caused by differences in number of admin staff, salary and time spend 
per VCT service. We assumed that only private community health centers have outreach teams. 
Additional costs for scaling up services were not included as the unit costs include capital costs 
reflecting costs for new buildings and training costs for new VCT counselors. 
YLDs r K D
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Table 2. Annual costs of delivering VCT service for different clinic settings
  (US$, 2008 exchange rate) [8]
ANNUAL COSTS OF DELIVERING VCT SERVICE
Type of cost / 
clinic setting
Public
community
health center†
Private  
community
health center
Hospital Prison
Capital costs (annualized)
Personnel training and workshops 207 (4.6§) 4,220 (10.0) 145 (0.5) 4,194 (32.4)
Building/space 181 (4.0) 266 (0.6) 657 (2.3) 1,624 (12.5)
Equipment 297 (6.6) 351 (0.8) 657 (2.3) 30 (0.2)
Subtotal 685 4,837 1,459 5,848 
Capital cost per VCT 2 6 3 10
Recurrent costs
Personnel 615 (13.8) 21,051 (50.0) 21,633 (74.9) 2,116 (16.4)
Supplies 2,297 (51.4) 10,007 (23.8) 2,591 (9.0) 539 (4.2)
Outreach team activities - 6,186 (14.7) - -
Laboratory 874 (19.5) - ¥ 3,255 (11.2) 4,439 (34.3)
Subtotal 3,787 37,244 27,479 7,093
Recurrent cost per VCT 12 48 65 12
Total annual cost 4,472 42,080 28,938 12,941
Clinic capacity 
(number of VCTs per year)
300 784 421 574
Unit cost per VCT 14.91 53.37 68.74 22.55
† Adapted to 300 patients per year 
§ Percentage of total costs  
¥ Not costed separately, but included in the capital and recurrent cost items 
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Sensitivity analyses
We examined the robustness of baseline incremental cost-effectiveness ratios to param-
eter variations in a one-way sensitivity analysis. For the impact of VCT on the reduction in 
non-condom use the uncertainty ranges as provided by the GOALS matrix were used. We 
varied coverage assumptions in the strategy of scaling up VCT and all costs components 
using a -/+ 25% approach. Other parameters, like AEM fitting variables, years of projection, 
clinic capacity, and most importantly epidemiological and behavioral variables were varied 
according to known uncertainty or a -/+25% approach. All uncertainty ranges are presented 
between brackets in an additional table in the Appendix. 
Results
Between 2010 and 2014, scaling up VCT will increase condom use for direct FSW from 62% to 
69%, for indirect FSW from 60% to 67%, for MSM from 45% to 55%, for sexual contact between 
PWID and FSW from 54% to 62%, and for sexual contact between PWID and spouses from 34% 
to 46%. Compared with the base case, scaling up VCT will decrease the overall HIV prevalence 
by 36%, from 0.44% to 0.28%, in West-Java in 2030. This reduction varies between most-at-risk 
populations: a decrease from 42.9% to 41.2% for PWID, 34.0% to 21.7% for FSW, and 15.7% to 
9.8% for MSM. Up to 2030, scaling up VCT will avert more than 94,000 HIV infections (Figure 
1), 41,000 AIDS cases and 26,000 deaths, and this corresponds to more than 2.5 million DALYs 
averted in West-Java. 
Unit costs of VCT delivery settings range between US$14.91 at public community health 
centers and $68.74 at hospitals (Table 2). Over the period 2010-2030, scaling up VCT at the 
community level will cost US$60 million, compared to US$37 million if current practice is main-
tained. Scaling up VCT will cost US$1.3 million in 2010, US$3.0 million in 2015, and US$3.8 million 
in 2030. The number of clinics integrated at public community health centers would need to 
increase from 6 in 2010 to 594 in 2030 in order to provide VCT services to more than 180,000 
people in West-Java in 2030. 
Scaling up VCT (compared to the base case) costs US$248 per HIV infection averted and 
US$9.17 per DALY averted. As presented in Figure 2, ICER estimates were most sensitive to the 
impact of VCT on condom use, population size of clients of FSW, HIV prevalence in the general 
population, population size of FSW, and condom use between FSW and clients. Costs per 
HIV infections averted range between US$104 and US$1,758 and cost per DALY saved range 
between US$5 and US$65. 
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Figure 1. Impact of scaling up VCT on cumulative and current number of HIV infection in 
  West Java
Figure 2. Results of one-way sensitivity analysis of incremental costs per DALY saved
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Discussion
Our estimates show that implementation of the national strategy of scaling up community-
based VCT to 80% of the most-at-risk populations in West-Java could reduce the overall 
population prevalence by 36% in 2030 (from 0.44% to 0.28%) and could avert a substantial 
amount of HIV-related morbidity and death. This strategy costs US$248 per HIV infection 
averted and US$9.17 per DALY saved. According to international thresholds put forward by 
WHO [24], this intervention seems very cost-effective as it falls within the one-time per capita 
gross domestic product (i.e. US$2,963 in 2010 [25]). Although our estimates are sensitive to 
parameter changes in the model, they do not exceed the threshold mentioned and therefore 
conclusions can be considered robust. Because the nature of the HIV epidemic is similar across 
Indonesia, with the exception of Papua province, study results can be generalized with caution.
Although scaling up community-based VCT is very effective and cost-effective it raises 
concerns. West-Java province will need between US$1.3 to US$3.8 million per year to spend 
on VCT while in 2010 the national HIV/AIDS expenditure for all 33 provinces together was only 
US$50.8 million and 61% was financed by international sources [3]. However, the prioritiza-
tion of VCT over other interventions could partially address this concern. Scaling up commu-
nity-based VCT requires a substantial rise in the number of public community health centers 
that deliver VCT (from 10 in 2010 to almost 600 in 2030) and it is not certain whether this is 
feasible, although first steps in this process have already been taken successfully.7 Because 
of these budget and organizational constraints, cost-effectiveness alone should not guide 
priority setting in HIV/AIDS control in West-Java [26].
Scaling up VCT is more cost-effective than MMT in West-Java. Wammes et al. (2012) estimated 
that scaling up MMT to 20% in West-Java costs $269 per DALY saved [13]. Unfortunately, we 
cannot compare these results to the cost-effectiveness of other HIV/AIDS interventions in 
Indonesia due to a lack of data. Compared to other countries our estimates are in the same 
order of magnitude. In India and Kenya, VCT costs, respectively, US$665 and US$249 per HIV 
infection averted. In Peru, VCT costs US$116 per DALY saved [27–29].
This study has a number of limitations. First, the AEM and RNM were not originally devel-
oped to conduct cost-effectiveness analysis and could not precisely reflect VCT in West-Java 
as some risk populations were not included. In addition, the effectiveness data in the impact 
matrix (i.e. the impact of VCT on condom use) was not based on Indonesian evidence and the 
exclusion of some populations caused an underestimation of the effectiveness. However, our 
effectiveness assumption was validated by the literature and sensitivity analysis showed that 
conclusions are robust. Second, VCT was evaluated as a single intervention and the impact 
of increased need for antiretroviral treatment (ART) on budget and health effects was not 
included. We excluded ART because its implementation is a separate decision for the govern-
ment; if we included it then the overall intervention would probably be even more cost- effec-
132
  Sub-question 3
tive, as ART can reduce HIV transmission and therefore has large population effects. In addi-
tion, we analyzed costs from a governmental perspective and did not include patient costs, 
although a recent study in three settings in Indonesia showed a substantial financial burden of 
HIV/AIDS care for patients [30]. Third, economies of scale, cost inflation, indirect costs (produc-
tivity loss due to disability and early death), and interactions between interventions were not 
taken into account, because accurate data was not available. Fourth, scaling up VCT could face 
feasibility constraints, e.g. a lack of VCT counselors and political and cultural support, but this 
can be partially resolved by training community workers and by advocacy for prioritizing HIV/
AIDS services. Fifth, we assume that high coverage of risk groups can be achieved although it 
is difficult to reach out to these populations. However, we see this assumption as a limitation 
of cost-effectiveness analysis in general. 
Conclusions
Scaling up community-based VCT seems an effective and cost-effective intervention. However, 
in order to prioritize VCT in HIV/AIDS control in West-Java, issues of budget availability and 
organizational capacity should be addressed. 
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Appendix
Description of the Asian Epidemic Model and Resource Needs Model
Asian Epidemic Model (AEM) 
The AEM is a dynamic, deterministic compartment model designed for macro simulation of 
populations and key processes driving HIV transmission; it is described in detail elsewhere 
[1,2]. The AEM considers HIV transmission within a population aged ≥ 15 years and divides the 
population in nine compartments: 1) clients of FSW; 2) males who are not clients of FSW; 3) 
lower risk, general population females; 4) direct FSW; 5) indirect FSW; 6) PWID in higher risk 
sharing networks; 7) PWID in a lower risk or not sharing network; 8) male sex workers; and 9) 
MSM who are not sex workers. Each compartment is divided into those infected with HIV and 
not infected. Movement between compartments is determined by the average duration of 
sex work, or death, or infection with HIV. The AEM includes data on factors such as demog-
raphy, population size, injecting, sexual behavior, and epidemiology for the years 1975-2030. 
The most important model output data are the number of new HIV infections, AIDS cases, 
deaths, and routes of transmission per year between 1975 and 2030. The number of new infec-
tions is calculated based on the prevalence in the partner population, the frequency of sex 
acts or injections, and the probability of HIV transmission. Corrections are made for increased 
HIV transmission due to the presence of other sexually transmitted infections (STIs) or the lack 
of male circumcision by adding co-factors that increase the effective transmission probability 
by a fixed amount. Finally, a correction is made for protective behaviors such as condom use. 
To fit the model, the AEM fitting parameters (e.g. probabilities of transmission, Table A) are 
adjusted in order to obtain a reasonable match between the prevalence reported and the 
prevalence calculated by the AEM. 
We used the West-Java baseline model as defined by local leading experts from AIDsina 
(Portal for Indonesia AIDS community) and the East-West Center (EWC), and as is compatible 
with data used by the MoH. This model is based on the National Indonesian AEM and adapted 
with local data for West-Java and assumptions made by ECW and AIDsina, who consulted 
experts in MoH and AIDS commissions. Data sources were retrieved to verify the data used in 
the model and only minor adaptations were made. Table A presents an overview of the model 
parameters, and their baseline values and references. The AEM uses these data to project HIV 
prevalence for most-at-risk-populations. We adjusted AEM fitting parameters so that projected 
HIV prevalence fits the observed HIV prevalence among PWID, FSW, and MSM from surveil-
lance studies in West-Java. HIV prevalence among the general population was not used for 
model fitting. Data on population sizes, and on epidemiological and behavior variables were 
sourced from government monitoring and evaluation systems and the International Biolog-
ical Behavior Surveillance System (IBBS); no change in behavior parameters was assumed after 
2007 (last year data of IBBS) [3]. The AEM was used, first, to reflect current practice of VCT 
delivery (base case) and second, to reflect the impact of increased condom use among most-
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at-risk populations caused by scaling up VCT. This increase in condom use was estimated by 
the RNM, described below, and altered in the AEM. As the AEM does not represent transgen-
ders, prisoners, and partners of PWID, these groups were excluded in our effectiveness anal-
ysis because we expected these groups to have minor impact on the spread of the epidemic.
Resource Needs Model 
The RNM [4] was used primarily to estimate the resources needed for both the base case and 
the strategy of scaling up VCT, by combining population sizes, coverage of VCT, and unit costs. 
The RNM also calculated the impact of VCT on risk behavior, based on the RNM impact matrix 
(originally part of GOALS model [5]). This matrix is based on a literature review of VCT effective-
ness on risk behavior [6] and differentiates the impact of VCT on the reduction in non-condom 
use for low-, middle-, and high-risk populations. We assumed that all populations targeted by 
VCT in the scaling up strategy are high-risk populations and used a baseline VCT impact value 
of 44% reduction in non-condom use. 
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Table A. Baseline values, sensitivity ranges and references of parameters used in Asian 
  Epidemic Model adapted for West-Java Province
PARAMETER BASELINE VALUE  (sensitivity range)
REFERENCE
AEM fitting parameters
Transmission probability
Male to female (Pm_f) 0.00125 (-/+ 25%) Fitting
Male to male (Pm_m) 0.01790 (-/+ 25%) Fitting
Needle stick 0.03 (-/+ 25%) Fitting
Ratio of male to female versus female to male transmission 3.80 (-/+ 25%) Fitting
PWID network parameter (%) 80.00 (-/+ 25%) Fitting
STI cofactor 
Female to male 16.00 (-/+ 25%) Fitting
Male to female 20.00 (- 25%) Fitting
Male to male 1.00 (+25%) Fitting
Circumcision factor 2.55 (1.91-3.19) Fitting
Epidemic start year 
PWID 2002 (1996-2004) Fitting
Heterosexual 1989 (1985-1993) Fitting
MSM 1992 (1988-1996) Fitting
Population sizes (2006)
FSW 37,422 (24,970-47,190) [7]
FSW who are direct FSW (%) 62.20 (-/+ 25%) [7]
PWID 9,596 (6,380-11,900) [7]
Higher risk MSM 15,117 (14,361-15,872) [7]
Lower risk MSM 133,220 [7]
Male sex workers 2,062 [7]
Prisoners 20,199 (15,149-25,249) [7]
Transgender 1,769 (1,568-1,733) [7]
Clients of FSW 204,200 (121,009 - 287,378) [7]
Partners of PWID 5,829 (5,537-6,120) [7]
Males age 15+ 14,596,400 [8]
Females age 15+ 14,152,600 [8]
HIV prevalence (% in 2007, used for fitting)
Direct FSW  11.60 (-/+25%) [3]
Indirect FSW 3.29 (-/+25%) [3]
PWID 42.80 (-/+25%) [3]
MSM 2.00 (-/+25%) [3]
General population 0.00 (0.00-3.00) [3]
Heterosexual behavior and STIs (2007)
Direct female sex workers
Direct to indirect FSW behavior movement each year (%) 1 Default value
Number of clients per day 1.7 [3]
Days worked per week 5.3 [3]
Condom use with clients (%) 62 (-/+25%) [3]
Average duration of sex work (years) 2.5 [3]
STI prevalence (% neisseria gonorrhea) 44 (-/+25%) [3]
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PARAMETER
BASELINE VALUE  
(SENSITIVITY RANGE)
REFERENCE
Heterosexual behavior and STIs (2007)
Indirect female sex workers
Number of clients per day 0.86 [3]
Days worked per week 5.5 [3]
Condom use with clients (%) 60 [3]
Average duration of sex work (years) 2.0 Local expert opinion¥
STI prevalence (% neisseria gonorrhea) 22 (-/+25%) Local expert opinion
Clients of sex workers
Males age 15-49 visiting sex workers (%) 1.7 [7]
Average duration of being a client (years) 11 Local expert opinion
Adult males circumcised (%) 87 (-/+25%) [9]
Male and female casual sex
Males having casual sex in last year (%) 0.3 Local expert opinion
Females having casual sex in last year (%) 0.1 Local expert opinion
Condom use in casual sex (%) 21 (-/+25%) [3]
Average number of casual contacts in last year (male) 1 Default value
Sex with spouses or regular partners 
Number of weekly sexual contacts with spouse/regular 
partner 
1.4 Local expert opinion
Condom use with spouses or regular partners (%) 10 Local expert opinion
Adult population with STI (%) 0.5 Local expert opinion
PWID injecting and sexual behavior (2007)
PWID mortality (% additional mortality per year) 1.0 Default value
PWID sharing (%) 32 (-/+25%) [3]
Injections shared, by those in sharing group (%) 70 (-/+25%) [3]
Number of injections each day 0.74 (-/+25%) [3]
Average duration of injecting (years) 8.0 (-/+25%) [3]
Sharing to non-sharing movement in a year (%) 20 (-/+25%) Local expert opinion
Visiting FSW (%) 41 (-/+25%) [3]
Condom use with direct FSW (%) 54 (-/+25%) [3]
Condom use with indirect FSW (%) 54 (-/+25%) [3]
Condom use with spouse or regular partner (%) 34 (-/+25%) [3]
Number of contacts with regular partners (per week) 1 (-/+25%) Default value
Injecting sex workers (ISW) (2007)Ω
Injecting behaviors - higher frequency injecting SWs
% of higher frequency sex workers who inject 0.1% [3]
% of higher frequency ISW in high risk networks 0% Default value
% of higher frequency ISW sharing 0% Default value
% of all injections shared (sharing higher frequency SW) 0% Default value
Number of daily injections for higher frequency ISW 0.7 [3]
Average duration of injecting for higher frequency ISW (years) 2.5 [3]
% condom use with clients (higher frequency ISWs) 62% [3]
Table A. Continued
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Table A. Continued
PARAMETER
BASELINE VALUE  
(SENSITIVITY RANGE)
REFERENCE
Injecting sex workers (ISW) (2007)Ω
Injecting behaviors - lower frequency injecting SWs
% of lower frequency sex workers who inject 0.1% [3]
% of lower frequency ISW in high risk networks 0% Default value
% of lower frequency ISW sharing 0% Default value
% of all injections shared (sharing low frequency SW) 0% Default value
Number of daily injections for lower frequency ISW 0.7% [3]
Average duration of injecting for lower frequency ISW (years)2.5 [3]
% condom use with clients (low frequency ISWs) 60% [3]
MSM sexual behavior (2007)§
Higher risk MSM (Hi MSM) sexual behavior
Reporting anal sex last year (%) 93 Local expert opinion
Number anal sex contacts last week 0.5 Local expert opinion
Average duration of same-sex behavior (years) 12.7 Local expert opinion
Shift from Hi MSM to Lo MSM 25% Default value
MSM having sex with other female partners (%) 34 [3]
Condom use in last anal sex (%) 45 (-/+25%) [3]
Prevalence Hi MSM with anal STI (%) 21 [3]
Lower risk MSM (Lo MSM) sexual behavior
% of Lo MSM reporting anal sex in last year 53% Local expert opinion
Number anal sex contacts last week (for MSM w/anal sex) 0.1 Local expert opinion
Average duration of same-sex behavior (years) 18.1 Local expert opinion
% of Lo MSM with other female partners 20% Local expert opinion
% condom use in anal sex with other Lo MSM 48% Local expert opinion
% Lo MSM with anal STI 5.4% Local expert opinion
MSM sexual behavior with commercial partners
% of Hi MSM visiting male sex workers 13% Local expert opinion
% of Lo MSM visiting male sex workers 2% Local expert opinion
Ratio of frequency of visiting MSW (Lo MSM/Hi MSM) 0.1 Default value
% of Hi MSM visiting female sex workers 6% Local expert opinion
% of Lo MSM visiting female sex workers 0% Local expert opinion
Condom use in anal sex with male sex worker (%) 50% Local expert opinion
Condom use direct FSW (%) 62% [3]
Condom use indirect FSW (%) 60% [3]
Male sex workers (MSW)
MSW size and duration
Average duration of male sex work (years) 6.3 Local expert opinion
Shifts from Hi MSM to MSW 1% Default value
Shifts from Lo MSM to MSW 1% Default value
Sexual behaviors and STI with clients
% of MSW reporting anal sex with clients in last year 93% Local expert opinion
Number anal sex contacts last week 1.0 Local expert opinion
% MSW with anal STI 23% Local expert opinion
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PARAMETER
BASELINE VALUE  
(SENSITIVITY RANGE)
REFERENCE
Male sex workers (MSW)
Female partners of MSW
% MSW visiting female sex workers in last year 9% Local expert opinion
% MSW with other female partners in last year 43% Local expert opinion
Intervention characteristics (2010 onwards)
Impact of VCT on reduction in non-condom use (%) 44 (6-93) [6]
Distribution delivery settings 
Current practice (base-case)
Hospitals (%) 60 (-/+25%) [10]
Community health centers (%) 10 (-/+25%) [10]
Private health centers (%) 20 (-/+25%) [10]
Prison (%) 10 (-/+25%) [10]
Scaling up VCT
Hospitals (%) 0 (-/+25%) Assumption
Community health centers (%) 87 (-/+25%) Assumption
Private health centers (%) 9 (-/+25%) Assumption
Prison (%) 4 (-/+25%) Assumption
Clinic capacity, number of VCT per year
Hospitals 421 (-/+25%) Current practice
Community health centers 300 (-/+25%) [11]
Private health centers 784 (-/+25%) Current practice
Prison 574 (-/+25%) Current practice
Projection period (years) 2010-2030 (2010-2020) Assumption
Disability adjusted life years
Discount rate 0.3 (0) Assumption
Age weighting 0 (1) Assumption
Note: order and categorization of parameters are in line with presentation in Asian Epidemic Model. 
PWID = injecting drug users, FSW = female sex workers, MSM = men having sex with men, STI = sexual transmitted infec-
tions: ¥ Local expert opinion was given by researchers from East West Center and AIDSIna; Ω The parameter values for 
injecting sex workers are copied from both FSW and PWID parameter values; § The IBBS 2007 report does not discriminate 
between higher risk MSM, lower risk MSM and MSW, but the raw IBBS data were used by local experts for parameter estimates. 
Table A. Continued
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  HIV/AIDS control in Indonesia?
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  What is the performance of
  HIV/AIDS interventions on 
  criteria for priority setting?
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Abstract
Background: About half a million people in South Africa are deprived of antiretro-
viral therapy (ART), and there is little systematic knowledge on who they are – e.g. by 
severity of disease, sex, or socio-economic status (SES). We performed a systematic 
review to determine the current quantitative evidence-base on equity in utilization of 
ART among HIV-infected people in South Africa. 
Methods: We conducted a literature search based on the Cochrane guidelines. A study 
was included if it compared for different groups of HIV infected people (by sex, age, 
severity of disease, area of living, SES, marital status, ethnicity, religion and/or sexual 
orientation (i.e. equity criteria)) the number initiating/adhering to ART with the number 
who did not. We considered ART utilization inequitable for a certain criterion (e.g. sex) if 
between groups (e.g. men versus women) significant differences were reported in ART 
initiation/adherence on that criterion.
 
Results: Twelve studies met the inclusion criteria. For sex, 2 out of 10 studies that inves-
tigated this criterion found that men are less likely than women to utilize ART, while the 
other 8 found no differences. For age, 4 out of 8 studies found inequities and reported 
less utilization for younger people. For area of living, 3 out of 4 studies showed that 
those living in rural areas or certain provinces have less access and 2 out of 6 studies 
looking at SES found that people with lower SES have less access. One study which 
looked at the marital status found that those who are married are less likely to utilize 
ART. For severity of disease, 5 out of 6 studies used more than one outcome measure 
for disease stage and reported within their study contradicting results. One of the 
studies reported inconclusive findings for ethnicity and no study had looked at reli-
gion and sexual orientation. 
Conclusions: It seems that men, young people, those living in certain provinces or rural 
areas, people who are unemployed or with a low educational level, and those being 
unmarried have less access to ART. As studies stem from different contexts and use 
different methods conclusions should be taken with caution. 
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Background
South Africa is home to the largest HIV-infected population worldwide, with 6.1 million people 
living with HIV/AIDS in 2012 [1]. The country also has the largest antiretroviral therapy (ART) 
program worldwide: with domestic investments amounting to US$1.9 billion in 2011 [2], it 
provided treatment to about 80% (2.0 million people) of all eligible people in 2012 [1]. Current 
South African guidelines state that all those with CD4 cell counts of ≤350 cells/µL are eligible [3].
Nevertheless, a significant treatment gap of about half a million people remains between 
those who receive treatment and those in need according to the eligibility criteria [1]. There 
is little knowledge on which people are deprived from treatment – e.g. by severity of disease, 
sex, age, socio-economic status (SES) and area of living [4], limiting the development of policy 
measures to specifically target and improve treatment coverage among these groups. This is 
illustrated in South Africa’s ‘National Strategic Plan on HIV, STIs and TB 2012-2016’ which flags 
the importance of inequalities in treatment utilization but is not specific on which marginal-
ized groups should be targeted [5].
It is clear that ART not only improves a patient’s health and survival [6,7], but also substan-
tially reduce their infectiousness [8,9]. As a result, ART can play an important role in controlling 
the epidemic in South Africa [10–12]. The World Health Organization (WHO) recently released 
new consolidated guidelines, taking both the prevention and treatment benefits of ART into 
account [13,14]. The new guidelines state that ART should be provided for HIV infected people 
with a CD4 cell count of ≤500 cells/µL, who are in a serodiscordant relationship, and/or preg-
nant [14]. In addition, the WHO also states that guidelines should be expanded when universal 
access for those with CD4 cell counts of ≤350 cells/µL has already been achieved [14]. As treat-
ment programs continue to expand, identifying and targeting hard-to-reach populations will 
be increasingly important. 
We determined the current quantitative evidence-base on equity in utilization of antiretro-
viral therapy (ART) among HIV-infected people in South Africa. This information may provide 
insight into the methods used for equity research and may help policy makers to identify and 
target hard-to-reach populations and reach universal ART coverage. 
Methods
We performed a systematic review on the basis of the Cochrane Handbook for Systematic 
Reviews of Interventions, Version 5.1.0.4 [15]. Our search strategy was performed on 18 February 
2013 using Pubmed, Embase, Central And Psychinfo database. Our search syntax consisted of 
search terms in four categories (ART, HIV, South Africa and Equity), that were combined using 
AND. The search strategy is presented in summary in Table 1 and in detail in Appendix A. 
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Table 1. Search strategy employed in systematic review of studies on equity in utilization of 
  ART in South Africa
CATEGORY SEARCH TERMS (IN PUBMED DATABASE)
ART antiretroviral therapy, highly active [MeSH Terms] OR ART [title/abstract] OR HAART [title/
abstract] OR AR V [title/abstract] OR ARVs [title/abstract] OR Anti-Retroviral Agents [Mesh] OR 
antiretroviral [title/abstract] OR anti retroviral [title/abstract] OR anti-retroviral [title/abstract] 
OR antiviral [title/abstract] OR therapy [title/abstract]
AND
HIV acquired immunodeficiency syndrome [MeSH Terms] OR acquired immunodeficiency 
syndrome [title/abstract] OR aids [title/abstract] OR hiv [MeSH Terms] OR hiv [title/abstract] OR 
human immunodeficiency virus [title/abstract] OR HIV infections [MeSH Terms]
AND
South Africa (South Africa [MeSH Terms] OR (South [title/abstract] AND Africa* [title/abstract]))
AND
Equity (equity [title/abstract] OR equities [title/abstract] OR inequity [title/abstract] OR inequities 
[title/abstract] OR equality [title/abstract] OR equalities [title/abstract] OR equal [title/
abstract] OR equitable [title/abstract] OR inequality [title/abstract] OR inequalities [title/
abstract] OR unequal [title/abstract] OR disparity [title/abstract] OR disparities [title/abstract] 
OR vulnerability [title/abstract] OR fairness [title/abstract] OR unfair [title/abstract] OR social 
justice [MeSH Terms] OR social justice [title/abstract] OR justice [title/abstract] OR barrier [title/
abstract] OR  coverage [title/abstract] OR barriers [title/abstract] OR healthcare disparities 
[MeSH Terms] OR health services accessibility [MeSH Terms] OR health services accessibility 
[title/abstract] OR access to health care[title/abstract]) 
Conceptual model 
Following the WHO’s guidance on monitoring equity in AIDS treatment programs [16], we 
distinguished five domains of coverage: 1) availability of resources; 2) physical and financial 
accessibility; 3) acceptability; 4) use of service; and 5) effective coverage (defined as the propor-
tion of the population in need of an intervention who fully comply with the recommended 
treatment program). This review focuses on the latter two domains as the other domains feed 
into these. We included studies on both ART initiation and adherence, together labeled as ‘ART 
utilization’. We acknowledge that an individual’s health care utilization can be explained by a 
function of predisposing factors (e.g. education, culture, health beliefs, age and sex), enabling 
factors (income, health insurance, waiting time, genetic factors) and need factors (perceived 
need to seek and adhere to care and professional’s judgment about people’s health status) 
[17]. We used the terms ‘equity’ and ‘inequity’ to reflect differences in utilization of ART by 
criteria such as severity of disease, age, or SES [18]. 
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Inclusion and exclusion criteria 
A study was included if it: 1) compared for different groups of HIV infected people (by sex, age, 
severity of disease, area of living, socio-economic status, marital status, ethnicity, religion and/
or sexual orientation (i.e. equity criteria [19,20]) the number initiating/adhering to ART with the 
number who are not); 2) was performed in South Africa; and 3) reported in English. Although 
some equity criteria are social determinants of health, severity of disease is not and therefore 
we preferred to use the term ‘equity criteria’ which was put forward by WHO [19] and Tromp 
et al [20]. A study was excluded if it: 1) focused on prevention of mother to child transmission 
(PMTCT), death during follow up, barriers for accessing care or tuberculosis (TB) services for 
HIV infected patients; 2) was a qualitative study, comment, editorial, economic evaluation or 
conference abstract; 3) was a duplicate reference from different databases; and 4) reported 
only differences in groups by a simple comparison with the gross number of people initi-
ating or adhering to ART. We only included studies that take into account the underlying need 
of a group for ART. For example, the mere fact that more women than men have access to 
ART does not necessarily indicate an inequity as more women than men may be infected in 
the country. There was no restriction for publication date for inclusion of studies. Following 
the Cochrane guidelines grey literature was excluded due to expected low methodological 
quality of studies [15]. 
Study selection, data extraction and quality evaluation
Two independent reviewers (CM and EM) assessed if the studies from the database search satis-
fied the inclusion criteria. First, all studies were screened on the basis of title and abstract, and 
subsequently on the basis of full-text. Reference lists of the retrieved articles were screened 
for additional studies (snowballing). The reviewers used a data collection form (Appendix B) to 
extract relevant information (study characteristics, results per equity criteria, and study limita-
tions) from the articles. Both reviewers evaluated the quality of studies using a quality-grading 
protocol (Appendix B) adapted from existing protocols [15,21,22]. The protocol covers 20 indi-
cators and for each item 0–2 points are given and added up to get an overall quality score 
(ranging from 0 to 40 points). Studies were categorized as low-quality (< 20 points), medi-
um-quality (20–29) or high-quality (≥ 30). During the study selection, data extraction and 
quality assessment, disagreements were resolved through discussion with a third researcher 
(NT) until consensus was reached. 
Data synthesis and analysis
A matrix was developed that containing the study results per investigated equity criterion. We 
established the following categories to summarize the results for each equity criteria investi-
gated in a study: 1) associated, differences reported in ART utilization between groups (e.g. 
men versus women for sex) were significant (p < 0.05, or when 1.0 does not fall in 95% confi-
dence interval (95%CI)); 2) not associated differences reported in ART utilization between 
groups were not significant (p value >0.05 or 1.0 falls in 95%CI; contradicting results, within 
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one study contradicting results were reported on differences in utilization between groups; 
and inconclusive results, differences in ART utilization between groups was investigated but 
the authors drew no conclusions due to small sample sizes. 
We adhered to the PRISMA guidelines for reporting of this systematic review [23]. 
Results 
Study inclusion
From the initial search (801 articles), 268 studies were duplicates, 483 studies were excluded on 
the basis of title/abstract and 39 on the basis of full-text screening. Screening of the references 
of the remaining 11 studies resulted in one extra article and added to a total of 12 studies that 
are included in this review (Figure 1, Table 2).
Characteristics of included studies
Seven studies assessed inequities in ART initiation (Table 3) and five studies in ART adher-
ence (Table 4). All studies were based on primary data analysis from observational surveys, 
except for one study using secondary data [24] and one review [25]. Studies defined ART initi-
ation differently, like ‘at least 14 days on ART’ [26] or ‘visited the ART clinic at least once after 
testing HIV positive’ [27]. Definitions of non-adherence also varied, and were measured in 
terms of patients’ absence at the clinic for more than one [28] three [29,30] or six [31] months, 
or in terms of the number of pills not taken and brought back to the clinic (clinic-based pill 
counts) [32]. The outcome measure used for equity criteria varied widely among studies. For 
severity of disease, some compared the differences in utilization of ART by WHO disease stages 
[27–30,32], while others used CD4 cell count levels [27–32] or viral load [29,32]. For age, many 
different age categories were used. Fatti et al [30] only included children in the study popula-
tion, and the oldest age group in that sample is younger than the youngest age group in for 
example Govindasamy et al [27] (who compared people below and above 30 years of age). Six 
studies, all using different databases, investigated urban and rural areas of the Western Cape 
province and two studies reported at the national level [24,25]. More than half of the articles 
(seven) [26–28,30–33] were of high-quality, three had medium-quality [29,34,35] and two were 
of low-quality [24,25]. Table 5 gives an overview of the quality scoring per study. 
Equity in utilization of ART 
For sex, two [25,28] out of ten studies [25–34] that reported on this equity criterion found an 
association between sex and utilization of ART. In both studies (high- and low-quality) men 
appear to have lower utilization of ART compared to women. The other eight studies (six high- 
and two medium-quality) found no association [26,27,29–34]. Four [31–34] (three high and 
one medium-quality) out of eight studies [27–34] reported that relatively young people have 
a lower utilization of ART. The other four studies (three high- and one medium-quality) that 
reported on age found no association [27–30].
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Figure 1. Flow diagram showing study selection for systematic review of studies on 
   access to antiretroviral therapy in South Africa
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  Sub-question 3
Table 2. Overview of reported findings per study on association between equity criteria 
  and ART initiation or adherence
REFERENCE EQUITY CRITERIA
Name, year Quality 
score
Sex Age Severity of disease Area of living Socio-economic status  
(including education and em-
ployment)
Marital status Ethnicity
ART initiation (lower < higher likelihood to initiate)
Cleary 2011  
[26] 
*** not associated
men = women
SES: not associated, SES distribu-
tion HIV+ in need = ART clinic 
patients
Inconclusive 
population size too small to 
draw conclusions
Cooke 2010 
[33] 
*** not associated  
men = women 
associated 
 younger (15-19 yrs)  
< older (>19 yrs)
not associated 
peri-urban = urban  
= rural 
SES: not associated, index profile 
1=2=3=4=5 (SES) 
education: not associated, years of 
education as continuous variable 
Govindasamy  
2011 
[27] 
*** not associated
men = women
not   
≤ 30 yrs = ≥ 30 yrs 
contradicting results, 
CD4 cell count: associated, 
CD4 >350 < ≤350,
WHO stages: not associated 
education: not associated, primary 
school completed = not com-
pleted
employment: not associated, 
employed<unemployed
Tsai 2009 
[34]
** not associated 
men = women
associated
 younger (18-30 yrs)  
< older (30-35 yrs)
education: associated, lower 
education (secondary) < higher 
education (matric/ tertiary)
employment: associated, non 
salaried employment < salaried 
employment, unemployed < 
employed
associated 
never married 
< married or 
cohabiting 
Adam 2009 
[35] 
** associated4 
unequal ART  coverage 
between 9 provinces
Muula 2007 
[25]
* associated4 
male < female
Nattrass 2006 
[24]
* associated4  
unequal ART  coverage 
between 9 provinces
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REFERENCE EQUITY CRITERIA
Name, year Quality 
score
Sex Age Severity of disease Area of living Socio-economic status  
(including education and em-
ployment)
Marital status Ethnicity
ART initiation (lower < higher likelihood to initiate)
Cleary 2011  
[26] 
*** not associated
men = women
SES: not associated, SES distribu-
tion HIV+ in need = ART clinic 
patients
Inconclusive 
population size too small to 
draw conclusions
Cooke 2010 
[33] 
*** not associated  
men = women 
associated 
 younger (15-19 yrs)  
< older (>19 yrs)
not associated 
peri-urban = urban  
= rural 
SES: not associated, index profile 
1=2=3=4=5 (SES) 
education: not associated, years of 
education as continuous variable 
Govindasamy  
2011 
[27] 
*** not associated
men = women
not   
≤ 30 yrs = ≥ 30 yrs 
contradicting results, 
CD4 cell count: associated, 
CD4 >350 < ≤350,
WHO stages: not associated 
education: not associated, primary 
school completed = not com-
pleted
employment: not associated, 
employed<unemployed
Tsai 2009 
[34]
** not associated 
men = women
associated
 younger (18-30 yrs)  
< older (30-35 yrs)
education: associated, lower 
education (secondary) < higher 
education (matric/ tertiary)
employment: associated, non 
salaried employment < salaried 
employment, unemployed < 
employed
associated 
never married 
< married or 
cohabiting 
Adam 2009 
[35] 
** associated4 
unequal ART  coverage 
between 9 provinces
Muula 2007 
[25]
* associated4 
male < female
Nattrass 2006 
[24]
* associated4  
unequal ART  coverage 
between 9 provinces
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  Sub-question 3
REFERENCE EQUITY CRITERIA
Name, year Quality 
score
Sex Age Severity of disease Area of living Socio-economic status  
(including education and em-
ployment)
Marital status Ethnicity
ART adherence (poorer < better adherence)
Boyles 2011 
[31] 
*** not associated
men = women
associated 
 younger (< 25 yrs) < older  
(25-50 yrs)
associated, CD4 cell count:  
CD4 ≥ 200 < <200 
Orrell 2003 
[32] 
*** not associated
 men = women
associated
younger < older, 
adherence group is older 
(34 yrs) than non- 
adhererce group (31 yrs)
contradicting results, CD4 cell count: 
associated, patients that not adhere had 
lower CD4 level 
Viral load: associated, patients that not 
adhere had higher VL 
WHO stage: not associated
SES: not associated, % low SES in 
patient group that continued  
ART = that not continued 
Kranzer 2010 
[28] 
*** associated 
 men < women
not associated  
 ≤ 30 yrs = > 30 yrs
contradicting results, CD4 cell count: 
associated,  
> 200 < ≤100
WHO stage: not associated 
Fatti 2010 
[30] 
*** not associated
 men = women
not associated
younger children (≤ 2 yrs)  
= older children (> 2 yrs) 
contradicting results, CD4 cell count 
(severe immunodeficiency1): not 
associated, WHO stage (severe clinical 
status2): associated
associated
rural/urban < urban/
urban  
< rural/rural3
Cornell 2009 
[29] 
** not associated 
men = women
not associated 
age as continuous 
variable 
contradicting results, CD4 cell count: 
contradicting results, CD4 < 50 < 50-150, 
but CD4 <50  = >150
WHO stage: not associated
Viral load: not associated
employment: associated, no 
income < income
ART = antiretroviral therapy, LTFU = lost to follow up, VL = viral load, WHO = world health organization 
1 defined according to WHO criteria, i.e. < 12 months old: CD4 percentage <25% or CD4 count <1500 cells/mm3; 12-35 months: 
<20% or CD4 count <750; 36-59 months: CD4 percentage <15% or CD4 count <350; 5 years and older: CD4 count <200
2  defined as a WAZ score of <-3 (severe underweight) or a WHO stage ≥3
3  rural/urban, urban/urban, rural/rural  = first term indicates place of residence and second the area of accessing ART clinic
4  no significance was reported and authors concluded that ART utilization was different among groups that were 
compared
Table 2. Continued
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REFERENCE EQUITY CRITERIA
Name, year Quality 
score
Sex Age Severity of disease Area of living Socio-economic status  
(including education and em-
ployment)
Marital status Ethnicity
ART adherence (poorer < better adherence)
Boyles 2011 
[31] 
*** not associated
men = women
associated 
 younger (< 25 yrs) < older  
(25-50 yrs)
associated, CD4 cell count:  
CD4 ≥ 200 < <200 
Orrell 2003 
[32] 
*** not associated
 men = women
associated
younger < older, 
adherence group is older 
(34 yrs) than non- 
adhererce group (31 yrs)
contradicting results, CD4 cell count: 
associated, patients that not adhere had 
lower CD4 level 
Viral load: associated, patients that not 
adhere had higher VL 
WHO stage: not associated
SES: not associated, % low SES in 
patient group that continued  
ART = that not continued 
Kranzer 2010 
[28] 
*** associated 
 men < women
not associated  
 ≤ 30 yrs = > 30 yrs
contradicting results, CD4 cell count: 
associated,  
> 200 < ≤100
WHO stage: not associated 
Fatti 2010 
[30] 
*** not associated
 men = women
not associated
younger children (≤ 2 yrs)  
= older children (> 2 yrs) 
contradicting results, CD4 cell count 
(severe immunodeficiency1): not 
associated, WHO stage (severe clinical 
status2): associated
associated
rural/urban < urban/
urban  
< rural/rural3
Cornell 2009 
[29] 
** not associated 
men = women
not associated 
age as continuous 
variable 
contradicting results, CD4 cell count: 
contradicting results, CD4 < 50 < 50-150, 
but CD4 <50  = >150
WHO stage: not associated
Viral load: not associated
employment: associated, no 
income < income
ART = antiretroviral therapy, LTFU = lost to follow up, VL = viral load, WHO = world health organization 
1 defined according to WHO criteria, i.e. < 12 months old: CD4 percentage <25% or CD4 count <1500 cells/mm3; 12-35 months: 
<20% or CD4 count <750; 36-59 months: CD4 percentage <15% or CD4 count <350; 5 years and older: CD4 count <200
2  defined as a WAZ score of <-3 (severe underweight) or a WHO stage ≥3
3  rural/urban, urban/urban, rural/rural  = first term indicates place of residence and second the area of accessing ART clinic
4  no significance was reported and authors concluded that ART utilization was different among groups that were 
compared
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  Sub-question 3
STUDY,  
QUALITY 
SCORE, STUDY 
TYPE 
STUDY OBJECTIVE STUDY AREA, TYPE OF CLINIC/
PROGRAM
YEAR OF DATA 
COLLECTION
STUDY DESIGN (COMPARISON 
BETWEEN POPULATION 
A AND B),  
population sizes, sampling method/
inclusion criteria
STATISTICAL 
ANALYSIS 
OUTCOME ON ASSOCIATION AS REPORTED PER EQUITY 
CRITERIA 
Cleary 2011 
***  
Observational 
[26]
To evaluate whether the dis-
tribution of ART services in 
the public system reflects the 
distribution of people in need 
among adults in the urban 
population
Urban area: poor communities in 
Mitchells Plain (Cape Town, West-
ern Cape province) and Soweto 
township (Johannesburg, Gauteng 
province), public clinics 
National survey: 
2008. Urban clinic 
data: unknown
a. Population in need for ART (n=742): 
national survey (2008, HIV+ resi-
dents), sampling unknown
b. ART patients in urban public clin-
ics (n=635): data from ART users 
(>18 yrs, >14 days on treatment) 
in three clinics in Mitchells Plain 
(selected proportional to the 
number of ART patients in facili-
ty) and three in Soweto (stratified 
random sampling)
Comparison 
distribution 
of equity 
criteria (i.e. 
patients char-
acteristics) 
Sex (not associated): percentage of HIV+ women in national 
survey is same as in ART users in urban clinic; 67.4% [95%CI: 
61.5-72.9] versus 65.7% [95%CI: 60.6-70.7], p >0.05. Socio-
economic status (not associated): no significant differences 
in SES distribution between HIV+ in need for ART and ART 
patients in urban clinics; independence partition Pearson’s 
chi-square test: 8 [p = 0.43] Race/ethnicity (inconclusive): per-
centage of non-African is 2,5% in population HIV+ in need 
versus 4.3% of ART users in urban clinics, authors state that 
sample size of non-African is too small to draw conclusions 
on equity 
Cooke 2010 
*** 
Observational 
[33]
To investigate factors asso-
ciated with uptake of ART 
through a primary health care 
system in rural South Africa
Rural, peri-urban and urban ar-
eas: Hlabisa sub-district, Umkha-
nyakude district, Northern Kwa-
Zulu-Natal province, public clinics 
supported by NGOs
Aug 2004 – Dec 
2008
a. HIV+ residents not on ART (n = 
1,003): population-based surveil-
lance in 6 catchment areas
b. HIV+ residents on ART (n = 1,251): 
population based 2008 cohort 
(HIV+, > 15 yrs, on ART) 
Multivariate 
logistic 
regression
Sex (not associated): no significant association between 
gender and receiving treatment: aOR men 0.875 [95%CI: 
0.708-1.081, p = 0.216] Age (associated, younger (15-19 yrs) < 
older (>19 yrs)): compared to age 15-19 (reference) all high-
er 5-year-age-groups [20-24, 25-29, 30-34, 35-40, 40-45, 45-
50, 50-54, 55-60, >60] have significant higher aOR [ranging 
between 4.9-14.0, p < 0.05] for receiving treatment Area of 
living (not associated): no significant differences in aORs be-
tween peri-urban [1.042, 95%CI: 0.699-1.554, p = 0.838], rural 
[0.941, 95%CI: 0.628-1.410, p = 0.768] and urban (reference) 
areas for receiving treatment Socioeconomic status (not as-
sociated): no significant differences in aORs between index 
profiles 1 (reference), 2 [0.932, 95%CI: 0.688-1.262, p = 0.649], 
3 [0.842, 95%CI: 0.624-1.135, p = 0.258], 4 [0.829, 95%CI: 0.607-
1.131, p = 0.237] and 5 [0.984, 95%CI: 0.702-1.379, p = 0.927] 
for receiving treatment Education (not associated): no signif-
icant association between years of education and receiv-
ing treatment; aOR years of education: 1.022 [95%CI: 0.995-
1.063, p = 0.128]
Table 3. Overview of finding per study reporting on equity in ART initiation 
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STUDY,  
QUALITY 
SCORE, STUDY 
TYPE 
STUDY OBJECTIVE STUDY AREA, TYPE OF CLINIC/
PROGRAM
YEAR OF DATA 
COLLECTION
STUDY DESIGN (COMPARISON 
BETWEEN POPULATION 
A AND B),  
population sizes, sampling method/
inclusion criteria
STATISTICAL 
ANALYSIS 
OUTCOME ON ASSOCIATION AS REPORTED PER EQUITY 
CRITERIA 
Cleary 2011 
***  
Observational 
[26]
To evaluate whether the dis-
tribution of ART services in 
the public system reflects the 
distribution of people in need 
among adults in the urban 
population
Urban area: poor communities in 
Mitchells Plain (Cape Town, West-
ern Cape province) and Soweto 
township (Johannesburg, Gauteng 
province), public clinics 
National survey: 
2008. Urban clinic 
data: unknown
a. Population in need for ART (n=742): 
national survey (2008, HIV+ resi-
dents), sampling unknown
b. ART patients in urban public clin-
ics (n=635): data from ART users 
(>18 yrs, >14 days on treatment) 
in three clinics in Mitchells Plain 
(selected proportional to the 
number of ART patients in facili-
ty) and three in Soweto (stratified 
random sampling)
Comparison 
distribution 
of equity 
criteria (i.e. 
patients char-
acteristics) 
Sex (not associated): percentage of HIV+ women in national 
survey is same as in ART users in urban clinic; 67.4% [95%CI: 
61.5-72.9] versus 65.7% [95%CI: 60.6-70.7], p >0.05. Socio-
economic status (not associated): no significant differences 
in SES distribution between HIV+ in need for ART and ART 
patients in urban clinics; independence partition Pearson’s 
chi-square test: 8 [p = 0.43] Race/ethnicity (inconclusive): per-
centage of non-African is 2,5% in population HIV+ in need 
versus 4.3% of ART users in urban clinics, authors state that 
sample size of non-African is too small to draw conclusions 
on equity 
Cooke 2010 
*** 
Observational 
[33]
To investigate factors asso-
ciated with uptake of ART 
through a primary health care 
system in rural South Africa
Rural, peri-urban and urban ar-
eas: Hlabisa sub-district, Umkha-
nyakude district, Northern Kwa-
Zulu-Natal province, public clinics 
supported by NGOs
Aug 2004 – Dec 
2008
a. HIV+ residents not on ART (n = 
1,003): population-based surveil-
lance in 6 catchment areas
b. HIV+ residents on ART (n = 1,251): 
population based 2008 cohort 
(HIV+, > 15 yrs, on ART) 
Multivariate 
logistic 
regression
Sex (not associated): no significant association between 
gender and receiving treatment: aOR men 0.875 [95%CI: 
0.708-1.081, p = 0.216] Age (associated, younger (15-19 yrs) < 
older (>19 yrs)): compared to age 15-19 (reference) all high-
er 5-year-age-groups [20-24, 25-29, 30-34, 35-40, 40-45, 45-
50, 50-54, 55-60, >60] have significant higher aOR [ranging 
between 4.9-14.0, p < 0.05] for receiving treatment Area of 
living (not associated): no significant differences in aORs be-
tween peri-urban [1.042, 95%CI: 0.699-1.554, p = 0.838], rural 
[0.941, 95%CI: 0.628-1.410, p = 0.768] and urban (reference) 
areas for receiving treatment Socioeconomic status (not as-
sociated): no significant differences in aORs between index 
profiles 1 (reference), 2 [0.932, 95%CI: 0.688-1.262, p = 0.649], 
3 [0.842, 95%CI: 0.624-1.135, p = 0.258], 4 [0.829, 95%CI: 0.607-
1.131, p = 0.237] and 5 [0.984, 95%CI: 0.702-1.379, p = 0.927] 
for receiving treatment Education (not associated): no signif-
icant association between years of education and receiv-
ing treatment; aOR years of education: 1.022 [95%CI: 0.995-
1.063, p = 0.128]
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STUDY,  
QUALITY 
SCORE, STUDY 
TYPE 
STUDY OBJECTIVE STUDY AREA, TYPE OF CLINIC/
PROGRAM
YEAR OF DATA 
COLLECTION
STUDY DESIGN (COMPARISON 
BETWEEN POPULATION 
A AND B),  
population sizes, sampling method/
inclusion criteria
STATISTICAL 
ANALYSIS 
OUTCOME ON ASSOCIATION AS REPORTED PER EQUITY 
CRITERIA 
Govindasamy
2011
*** 
Observational 
[27]
To assess the proportion and 
characteristics of individuals 
who accessed HIV care after 
testing HIV+ in a mobile 
testing unit
Rural area: Cape Metropolitan 
region, Western Cape province, 
type of clinic not clearly reported
Tested HIV+: 2008-
2009. Interviewed: 
Apr-Jun 2010.   
Patients tested HIV+ in mobile 
testing units that 
a. linked to ART care (i.e. receiving 
CD4 test result)  
b. not linked  
A random sample of patients 
tested HIV+ between August 
2008 – December 2009, ≥18 
yrs, CD4 <350, received CD4 
test results, available socio-
demographic variables was 
selected using mobile testing 
unit records (n=77)
Binomial 
univariate 
and bivariate 
regression 
analysis
Sex (not associated): same likelihood to link to care for 
female as male patients; **RR female: 1.18 [95%CI: 0.81-1.72, 
p = not reported, 1.0 falls within CI] Age (not associated): 
same likelihood to link to care for younger (≤30 years) as 
older patients  (≥30 years) to link to care; **RR ≥30 years: 
1.21 [95%CI: 0.83-1.77, p = not reported, 1.0 falls within 
CI] Severity of disease (contradicting results): significantly 
lower likelihood to link to care for patients with high (>350) 
compared to low (≤350) CD4 cell count;*RR CD4>350: 0.49 
[95%CI: 0.27-0.87, p = 0.014] / same likelihood to link to care 
for patients in WHO stage I  as WHO stage II, III or IV; **RR 
WHO clinical stage I: 0.88 [95%CI: 0.65-1.18, p = not reported, 
1.0 in CI] Education (not associated): same likelihood to link to 
care for patient completed primary school as patients that 
have not; **RR completed primary school: 1.17 [95%CI: 0.66-
2.08, p = not reported, 1.0 falls within CI] Employment (not 
associated, employed<unemployed): likely lower likelihood 
to link to care for employed compared to unemployed 
patients; **RR employed: 0.72 [95%CI: 0.51-1.01, p = 0.056].
 * = univariate ** = bivariate analysis
Tsai 2009
**  
Observational
[34]
To assess differences in 
socioeconomic profiles 
between those who access 
HIV-related clinical services 
and the HIV-infected 
individuals living in the wider 
community
Rural area: Limpopo province, 
public hospital
Community survey:  
2004-2005.  
Clinic survey: Jan 
2003 – Nov 2005
a. community sample, HIV+ not on 
ART (n =242):  household survey, 
random sampled from eight 
rural villages in the province (14-
35 yrs, HIV+)
b. clinical sample, HIV+ on ART (n 
= 534): convenience sample of 
patients (18-35 yrs) in primary 
HIV/AIDS provider hospital, 
referred by 45 primary health 
care clinics.  
Note: samples were not taken 
from identical sub-districts
Uni-variate 
comparison 
and multiple 
regression
Sex (not associated): no significant difference percentage 
women in the community vs. clinic sample: 79% vs. 79% 
[p = 0.78] Age (associated, younger (18-30 yrs) < older (30-
35 yrs)): significant difference in age distribution between 
community and clinic sample: 18-20 yrs: 13% vs 3.6%; 21-
25 yrs: 33% vs. 16%; 26-30 yrs: 36% vs 33%; 31-35 yrs: 18% 
vs. 47%; X2 = 85 [p<0.001*] Education (associated, higher 
education > lower education): significant difference in 
distribution educational attainment between community 
and clinic sample: in clinic less likely to completed secondary 
education [p<0.001], but more likely to completed matric or 
tertiary education [p = 0.04]  X2 42 [p<0.001*] Employment 
(associated, not having salaried employment < having 
salaried employment, unemployed < employed): significant 
difference percentage having salaried employment 
between community and clinic sample: 6.2% vs. 11%, X2 3.8 
[p = 0.05] and in percentage unemployed and able to work: 
57% vs. 37%; X2 26 [p < 0.001*] 
Table 3. Continued
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STUDY,  
QUALITY 
SCORE, STUDY 
TYPE 
STUDY OBJECTIVE STUDY AREA, TYPE OF CLINIC/
PROGRAM
YEAR OF DATA 
COLLECTION
STUDY DESIGN (COMPARISON 
BETWEEN POPULATION 
A AND B),  
population sizes, sampling method/
inclusion criteria
STATISTICAL 
ANALYSIS 
OUTCOME ON ASSOCIATION AS REPORTED PER EQUITY 
CRITERIA 
Govindasamy
2011
*** 
Observational 
[27]
To assess the proportion and 
characteristics of individuals 
who accessed HIV care after 
testing HIV+ in a mobile 
testing unit
Rural area: Cape Metropolitan 
region, Western Cape province, 
type of clinic not clearly reported
Tested HIV+: 2008-
2009. Interviewed: 
Apr-Jun 2010.   
Patients tested HIV+ in mobile 
testing units that 
a. linked to ART care (i.e. receiving 
CD4 test result)  
b. not linked  
A random sample of patients 
tested HIV+ between August 
2008 – December 2009, ≥18 
yrs, CD4 <350, received CD4 
test results, available socio-
demographic variables was 
selected using mobile testing 
unit records (n=77)
Binomial 
univariate 
and bivariate 
regression 
analysis
Sex (not associated): same likelihood to link to care for 
female as male patients; **RR female: 1.18 [95%CI: 0.81-1.72, 
p = not reported, 1.0 falls within CI] Age (not associated): 
same likelihood to link to care for younger (≤30 years) as 
older patients  (≥30 years) to link to care; **RR ≥30 years: 
1.21 [95%CI: 0.83-1.77, p = not reported, 1.0 falls within 
CI] Severity of disease (contradicting results): significantly 
lower likelihood to link to care for patients with high (>350) 
compared to low (≤350) CD4 cell count;*RR CD4>350: 0.49 
[95%CI: 0.27-0.87, p = 0.014] / same likelihood to link to care 
for patients in WHO stage I  as WHO stage II, III or IV; **RR 
WHO clinical stage I: 0.88 [95%CI: 0.65-1.18, p = not reported, 
1.0 in CI] Education (not associated): same likelihood to link to 
care for patient completed primary school as patients that 
have not; **RR completed primary school: 1.17 [95%CI: 0.66-
2.08, p = not reported, 1.0 falls within CI] Employment (not 
associated, employed<unemployed): likely lower likelihood 
to link to care for employed compared to unemployed 
patients; **RR employed: 0.72 [95%CI: 0.51-1.01, p = 0.056].
 * = univariate ** = bivariate analysis
Tsai 2009
**  
Observational
[34]
To assess differences in 
socioeconomic profiles 
between those who access 
HIV-related clinical services 
and the HIV-infected 
individuals living in the wider 
community
Rural area: Limpopo province, 
public hospital
Community survey:  
2004-2005.  
Clinic survey: Jan 
2003 – Nov 2005
a. community sample, HIV+ not on 
ART (n =242):  household survey, 
random sampled from eight 
rural villages in the province (14-
35 yrs, HIV+)
b. clinical sample, HIV+ on ART (n 
= 534): convenience sample of 
patients (18-35 yrs) in primary 
HIV/AIDS provider hospital, 
referred by 45 primary health 
care clinics.  
Note: samples were not taken 
from identical sub-districts
Uni-variate 
comparison 
and multiple 
regression
Sex (not associated): no significant difference percentage 
women in the community vs. clinic sample: 79% vs. 79% 
[p = 0.78] Age (associated, younger (18-30 yrs) < older (30-
35 yrs)): significant difference in age distribution between 
community and clinic sample: 18-20 yrs: 13% vs 3.6%; 21-
25 yrs: 33% vs. 16%; 26-30 yrs: 36% vs 33%; 31-35 yrs: 18% 
vs. 47%; X2 = 85 [p<0.001*] Education (associated, higher 
education > lower education): significant difference in 
distribution educational attainment between community 
and clinic sample: in clinic less likely to completed secondary 
education [p<0.001], but more likely to completed matric or 
tertiary education [p = 0.04]  X2 42 [p<0.001*] Employment 
(associated, not having salaried employment < having 
salaried employment, unemployed < employed): significant 
difference percentage having salaried employment 
between community and clinic sample: 6.2% vs. 11%, X2 3.8 
[p = 0.05] and in percentage unemployed and able to work: 
57% vs. 37%; X2 26 [p < 0.001*] 
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STUDY,  
QUALITY 
SCORE, STUDY 
TYPE 
STUDY OBJECTIVE STUDY AREA, TYPE OF CLINIC/
PROGRAM
YEAR OF DATA 
COLLECTION
STUDY DESIGN (COMPARISON 
BETWEEN POPULATION 
A AND B),  
population sizes, sampling method/
inclusion criteria
STATISTICAL 
ANALYSIS 
OUTCOME ON ASSOCIATION AS REPORTED PER EQUITY 
CRITERIA 
Tsai 2009
**  
Observational
[34]
Marital status (associated, never married < married or 
cohabiting): significant difference  distribution marital status 
between community and clinic sample: never married: 78% 
vs. 43%; married/ cohabiting: 16% vs. 30%; X2 83 [p < 0.001*] 
*also significant after multivariable regression
Adam 2009
**  
Observational 
[35]
To quantify the coverage in 
South Africa up to the middle 
of 2008, according to various 
definitions of antiretroviral 
treatment eligibility
Rural and urban:
National/ nine provinces,  
public clinics
2008 For nine provinces 
a. number of HIV+ in need for 
ART: Markov model on HIV 
progression using different CD4 
count compartments 
b. number of HIV+ on ART: 
estimates of patients starting 
ART in public health facilities 
using Department of Health 
unpublished internal report (7 
May 2009)
Comparison 
ART coverage 
data 
Area of living (associated, but significance not reported, 
unequal coverage among nine provinces): unequal ART 
coverage in 2008 among 9 provinces: Eastern Cape 32.4%, 
Free State 25.8%, Gauteng 43.5%, KwaZulu-Natal 39.4%, 
Limpopo 32.2%, Mpumalanga 31.2%, Northern Cape 61.1%, 
North West 35.4%, Western Cape 71.1%
Muula 2007 
*  
Systematic 
review [25]
To describe the gender 
distribution of patients 
accessing ART in Southern 
Africa
Rural and urban: National (1999-
2004), Khayelisha township in 
Capetown (2001-2), Eastern cape 
province 2001-4), Northern cape 
province (2001-5), public clinics 
2000 – 2006 a. National HIV+ prevalence female/
male ratio in 2005
b. access to ART female/male ratio 
Sampling methods not reported
Comparison 
female/male 
ratios
Sex (associated, but significance not reported, male < female): 
female have higher access than men to ART: HIV prevalence 
female/male ratio = 1.2, while 4 studies report access to ART 
female/male ratio of 1.9, 2.3, 1.8 and 1.5
Nattrass 2006
*  Critical 
assessment  
[24]
To compare ART roll-out 
in public sector between 
provinces in 2003-2005 
Rural and urban: National (nine 
provinces),  
public clinics 
2003 - 2005 For nine provinces
a. number of HIV+ in need for ART 
b. number of HIV+ on ART estimates 
of ART coverage based on 
ASSA2003 demographic model 
(includes public, NGOs and 
private sector providers) 
Comparison 
ART coverage 
data
Area of living (associated, but significance not reported, 
unequal coverage among 9 provinces): unequal ART 
coverage at the end of 2005 among 9 provinces: Eastern 
Cape 21.8%, Free State 21.0%, Gauteng 29.6%, KwaZulu-
Natal 20.0%, Limpopo 27.3%, Mpumalanga 20.9%, Northern 
Cape 32.3%, North West 24.5%, Western Cape 55.7%
CI = Confidence Interval, aOR = adjusted odds ratio, ART = antiretroviral therapy, WHO = world health organization
Table 3. Continued
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STUDY,  
QUALITY 
SCORE, STUDY 
TYPE 
STUDY OBJECTIVE STUDY AREA, TYPE OF CLINIC/
PROGRAM
YEAR OF DATA 
COLLECTION
STUDY DESIGN (COMPARISON 
BETWEEN POPULATION 
A AND B),  
population sizes, sampling method/
inclusion criteria
STATISTICAL 
ANALYSIS 
OUTCOME ON ASSOCIATION AS REPORTED PER EQUITY 
CRITERIA 
Tsai 2009
**  
Observational
[34]
Marital status (associated, never married < married or 
cohabiting): significant difference  distribution marital status 
between community and clinic sample: never married: 78% 
vs. 43%; married/ cohabiting: 16% vs. 30%; X2 83 [p < 0.001*] 
*also significant after multivariable regression
Adam 2009
**  
Observational 
[35]
To quantify the coverage in 
South Africa up to the middle 
of 2008, according to various 
definitions of antiretroviral 
treatment eligibility
Rural and urban:
National/ nine provinces,  
public clinics
2008 For nine provinces 
a. number of HIV+ in need for 
ART: Markov model on HIV 
progression using different CD4 
count compartments 
b. number of HIV+ on ART: 
estimates of patients starting 
ART in public health facilities 
using Department of Health 
unpublished internal report (7 
May 2009)
Comparison 
ART coverage 
data 
Area of living (associated, but significance not reported, 
unequal coverage among nine provinces): unequal ART 
coverage in 2008 among 9 provinces: Eastern Cape 32.4%, 
Free State 25.8%, Gauteng 43.5%, KwaZulu-Natal 39.4%, 
Limpopo 32.2%, Mpumalanga 31.2%, Northern Cape 61.1%, 
North West 35.4%, Western Cape 71.1%
Muula 2007 
*  
Systematic 
review [25]
To describe the gender 
distribution of patients 
accessing ART in Southern 
Africa
Rural and urban: National (1999-
2004), Khayelisha township in 
Capetown (2001-2), Eastern cape 
province 2001-4), Northern cape 
province (2001-5), public clinics 
2000 – 2006 a. National HIV+ prevalence female/
male ratio in 2005
b. access to ART female/male ratio 
Sampling methods not reported
Comparison 
female/male 
ratios
Sex (associated, but significance not reported, male < female): 
female have higher access than men to ART: HIV prevalence 
female/male ratio = 1.2, while 4 studies report access to ART 
female/male ratio of 1.9, 2.3, 1.8 and 1.5
Nattrass 2006
*  Critical 
assessment  
[24]
To compare ART roll-out 
in public sector between 
provinces in 2003-2005 
Rural and urban: National (nine 
provinces),  
public clinics 
2003 - 2005 For nine provinces
a. number of HIV+ in need for ART 
b. number of HIV+ on ART estimates 
of ART coverage based on 
ASSA2003 demographic model 
(includes public, NGOs and 
private sector providers) 
Comparison 
ART coverage 
data
Area of living (associated, but significance not reported, 
unequal coverage among 9 provinces): unequal ART 
coverage at the end of 2005 among 9 provinces: Eastern 
Cape 21.8%, Free State 21.0%, Gauteng 29.6%, KwaZulu-
Natal 20.0%, Limpopo 27.3%, Mpumalanga 20.9%, Northern 
Cape 32.3%, North West 24.5%, Western Cape 55.7%
CI = Confidence Interval, aOR = adjusted odds ratio, ART = antiretroviral therapy, WHO = world health organization
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STUDY,  
QUALITY 
SCORE, STUDY 
TYPE 
STUDY OBJECTIVE STUDY AREA, TYPE OF CLINIC/
PROGRAM
YEAR OF DATA 
COLLECTION
STUDY DESIGN (COMPARISON 
BETWEEN POPULATION A AND B)
Population sizes, sampling 
method and inclusion criteria
STATISTICAL 
ANALYSIS 
MAIN OUTCOME OF
 ANALYZED EQUITY CRITERIA 
Boyles 2011
***  
Observational 
[31]
To determine the factors 
predicting loss to follow-
up and mortality in a 
public-sector HIV and ART 
programme in rural South 
Africa
Rural area: Elliotdale/Xora 
area of Mbhashe sub-district 
in Eastern Cape province, 
combined public/donor program 
Jan 2005 –  
Sept 2009 
a. HIV+ patients that loss to follow 
up (n = 117 (6.5%))
b. HIV+ patients that do not loss to 
follow up (n = 1686)
Both groups are patients enrolled 
in clinics of Madwaleni HIV well-
ness and ART program including 
adherence counseling and home 
visits (i.e. Madwaleni Hospital, its 7 
primary healthcare feeder clinics 
and a community based outreach 
program): tested HIV+, ART naïve 
at time of study enrollment, >19 
years, initiated ART (CD4 < 200 
CD4), could be follow for at least 
3 months (n=1803)
Multiple Cox 
proportional 
hazard 
regression
Sex (not associated): females and males have same risk 
of being loss-to-follow-up: HR female: 1.42 [95%CI 0.90-
2.23, p = 0.134] Age (associated, younger (<25 yrs) < older 
(25-50 yrs)): younger people have significant higher risk 
to loss-to-follow-up: HR <25 yrs (compared to 25-50 
yrs): 1.87 [95%CI: 1.15-3.05, p = 0.012] Severity of disease 
(associated, ≥ 200 CD4 < <200 CD4): higher CD4 cell 
count significantly increases risk to loss-to-follow-up: 50-
199 CD4 (referent); HR 0-49 CD4: 1.00 [95%CI: 0.61-1.64, p 
= 0.019]; HR ≥ 200 CD4: 1.74 [95%CI 1.09-2.78, p = 0.019]
Orrell 2003
***  
Observational 
[32]
To determine adherence 
of an indigent African HIV-
infected cohort initiating 
ART to identify predictors 
of incomplete adherence 
and virologic failure 
Urban area: Cape Town, Western 
Cape province, university of 
Cape Town clinic 
Jan 1996 – May 2001 a.  Patients discontinued 48 weeks 
of ART (n=47)
b.  Patients that completed 48 
weeks of ART (n=242)
Both groups are from Cape Town 
AIDS Cohort (CTAC): HIV+ pa-
tients, presenting at University of 
Cape Town HIV clinics (referred by 
health care workers in the public 
sector of the wider Cape town 
area, mainly serving indigent 
populations), were ART naïve and 
eligible for adherence monitoring
T-test (age, 
VL, CD4 cell 
count), X2 test 
(gender, socio-
economic 
status)
Sex (not associated): no significant difference in per-
centage female between those discontinued (40.4%) 
and completed (43.4%) 48 weeks of ART [p = 0.7] Age 
(associated, younger < older): those discontinued ART 
before 48 weeks were significantly younger (31 yrs) than 
those completed (34.1 yrs) [p <0.005] Severity of disease 
(contradicting results): those discontinued ART before 48 
weeks had significantly lower mean CD4 cell count (197) 
than those completed (268) [p<0.01] / those discontin-
ued before 48 weeks ART had a significantly higher VL 
(5.71 log10) than those completed (5.49  log10) [p <0.05] 
/ no significant difference in percentage WHO stage 3 or 
4 between those discontinued (49.2%) and completed 
(38.2%) 48 weeks of ART [p = 0.2] Socio-economic status 
(not associated): no significant difference in the percent-
age of patients with low socio-economic status in the 
group that discontinued (36.2%) and completed (43.6%) 
48 weeks of ART [p = 0.4] 
Table 4. Overview of findings per study reporting on equity in ART adherence
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STUDY,  
QUALITY 
SCORE, STUDY 
TYPE 
STUDY OBJECTIVE STUDY AREA, TYPE OF CLINIC/
PROGRAM
YEAR OF DATA 
COLLECTION
STUDY DESIGN (COMPARISON 
BETWEEN POPULATION A AND B)
Population sizes, sampling 
method and inclusion criteria
STATISTICAL 
ANALYSIS 
MAIN OUTCOME OF
 ANALYZED EQUITY CRITERIA 
Boyles 2011
***  
Observational 
[31]
To determine the factors 
predicting loss to follow-
up and mortality in a 
public-sector HIV and ART 
programme in rural South 
Africa
Rural area: Elliotdale/Xora 
area of Mbhashe sub-district 
in Eastern Cape province, 
combined public/donor program 
Jan 2005 –  
Sept 2009 
a. HIV+ patients that loss to follow 
up (n = 117 (6.5%))
b. HIV+ patients that do not loss to 
follow up (n = 1686)
Both groups are patients enrolled 
in clinics of Madwaleni HIV well-
ness and ART program including 
adherence counseling and home 
visits (i.e. Madwaleni Hospital, its 7 
primary healthcare feeder clinics 
and a community based outreach 
program): tested HIV+, ART naïve 
at time of study enrollment, >19 
years, initiated ART (CD4 < 200 
CD4), could be follow for at least 
3 months (n=1803)
Multiple Cox 
proportional 
hazard 
regression
Sex (not associated): females and males have same risk 
of being loss-to-follow-up: HR female: 1.42 [95%CI 0.90-
2.23, p = 0.134] Age (associated, younger (<25 yrs) < older 
(25-50 yrs)): younger people have significant higher risk 
to loss-to-follow-up: HR <25 yrs (compared to 25-50 
yrs): 1.87 [95%CI: 1.15-3.05, p = 0.012] Severity of disease 
(associated, ≥ 200 CD4 < <200 CD4): higher CD4 cell 
count significantly increases risk to loss-to-follow-up: 50-
199 CD4 (referent); HR 0-49 CD4: 1.00 [95%CI: 0.61-1.64, p 
= 0.019]; HR ≥ 200 CD4: 1.74 [95%CI 1.09-2.78, p = 0.019]
Orrell 2003
***  
Observational 
[32]
To determine adherence 
of an indigent African HIV-
infected cohort initiating 
ART to identify predictors 
of incomplete adherence 
and virologic failure 
Urban area: Cape Town, Western 
Cape province, university of 
Cape Town clinic 
Jan 1996 – May 2001 a.  Patients discontinued 48 weeks 
of ART (n=47)
b.  Patients that completed 48 
weeks of ART (n=242)
Both groups are from Cape Town 
AIDS Cohort (CTAC): HIV+ pa-
tients, presenting at University of 
Cape Town HIV clinics (referred by 
health care workers in the public 
sector of the wider Cape town 
area, mainly serving indigent 
populations), were ART naïve and 
eligible for adherence monitoring
T-test (age, 
VL, CD4 cell 
count), X2 test 
(gender, socio-
economic 
status)
Sex (not associated): no significant difference in per-
centage female between those discontinued (40.4%) 
and completed (43.4%) 48 weeks of ART [p = 0.7] Age 
(associated, younger < older): those discontinued ART 
before 48 weeks were significantly younger (31 yrs) than 
those completed (34.1 yrs) [p <0.005] Severity of disease 
(contradicting results): those discontinued ART before 48 
weeks had significantly lower mean CD4 cell count (197) 
than those completed (268) [p<0.01] / those discontin-
ued before 48 weeks ART had a significantly higher VL 
(5.71 log10) than those completed (5.49  log10) [p <0.05] 
/ no significant difference in percentage WHO stage 3 or 
4 between those discontinued (49.2%) and completed 
(38.2%) 48 weeks of ART [p = 0.2] Socio-economic status 
(not associated): no significant difference in the percent-
age of patients with low socio-economic status in the 
group that discontinued (36.2%) and completed (43.6%) 
48 weeks of ART [p = 0.4] 
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STUDY,  
QUALITY 
SCORE, STUDY 
TYPE 
STUDY OBJECTIVE STUDY AREA, TYPE OF CLINIC/
PROGRAM
YEAR OF DATA 
COLLECTION
STUDY DESIGN (COMPARISON 
BETWEEN POPULATION A AND B)
Population sizes, sampling 
method and inclusion criteria
STATISTICAL 
ANALYSIS 
MAIN OUTCOME OF
 ANALYZED EQUITY CRITERIA 
Kranzer 2010 
***  
Observational 
[28]
To investigate the 
frequency and risk 
factors of defaulting 
treatment and identify 
factors associated with 
subsequent return to care 
in a long-term treatment 
cohort in South Africa
Peri-urban:  township in Cape 
Town, Western Cape province, 
public clinic
Mar 2004 - Dec 2009 a. HIV+ patients that defaulted 
ART (n = 291)
b. HIV+ patients that not defaulted 
ART (n = 863)
Both groups are from patients 
presenting at public-sector 
primary care clinic (single ART 
server in the area), >15 years, 
started ART (until 2007 < 350 CD4 
cells (NIH research study), after 
2007 <200 CD4 cells (provincial 
ART program) (n= 1154)
Multivariate 
Poisson 
regression 
Sex (associated, men < women): compared to women, 
men have a significant increased risk to default ART 
treatment, HR men: 1.51 [95%CI: 1.18-1.93, p < 0.01] Age 
(not associated): no significant association between 
age and defaulting treatment, compared to younger 
age (≤30 years), HR > 30 years: 0.90 [95%CI: 0.70-1.15, p 
= 0.40] Severity of disease (contradicting results): higher 
CD4 cell count increases significantly risk for defaulting 
treatment, ≤100 CD4 (referent); 101-200 CD4: HR 1.32 
[95%CI: 0.99-1.76, p = 0.06], CD4 >200 HR: 1.39 [95%CI 
1.02-1.91, p = 0.04]. No significant difference in the risk of 
defaulting treatment being in WHO stage 3/4 or 1/2, HR 
stage 3/4: 1.14 [95%CI: 0.85-1.53, p = 0.37]
Fatti 2010 
***  
Retrospective 
cohort study 
[30]
To compare clinical, 
immunological and 
virological outcomes 
between rural and urban 
children on ART in a large 
cohort from multiple 
public health facilities in 
four provinces of South 
Africa
Rural and urban: areas in 
Western Cape, KwaZulu-Natal, 
Eastern Cape and Mpumalanga 
province, public clinics 
supported by NGOs 
Nov 2003 – Mar 2008 a. Children on ART that loss to 
follow up (n = 179)
b. Children on ART that do not loss 
to follow up (n = 2153)
Both from retrospective cohort 
of children, (<16 yrs, ART naïve), 
enrolled in 44 routine public 
healthcare facilities (7 rural, 
33 urban/12 secondary level 
hospitals, 32 primary health care 
clinics) supported by a NGO, 
used electronic data collection 
systems for patient monitoring
Children were divided in 3 
groups a) urban residence and 
urban ART facility attended 
(urban group, n = 1727); rural 
residence and rural facility 
attended (rural group, n = 228); 
and rural residents attending 
urban facilities (rural/urban 
group, n = 377)
Multivariable 
Cox 
proportional 
hazards 
regression
Sex (not associated): gender is not associated with risk of 
LTFU: HR male: 1.1 [95%CI: 0.82-3.12, no p value reported, 
1.0 falls within CI] Age (not associated): younger children 
(<2yrs) are as likely to LTFU than older children (>2 
yrs): > 2yrs (referent); HR 1-2 yrs: 1.61 [95%CI: 0.96-2.68, 
no p value reported, 1.0 in CI]; HR < 1yr: [1.81, 95%CI: 
0.94-3.64, no p value reported, 1.0 in CI] Severity of 
disease (contradicting results): severe clinical status was 
associated with risk LTFU: HR severe clinical status: 1.47 
[95%CI: 1.03-2.12, no p value reported, 1.0 not in CI]/ 
severe immunodeficiency was not associated with 
risk LTFU: HR severe immunodeficiency: 0.81 [95%CI: 
0.52-1.24, p value not reported, 1.0 in CI] Area of living 
(associated, rural/urban < urban/urban < rural/rural): 
patient in rural areas visiting clinics in urban areas are 
more likely to LTFU than patients from rural areas visiting 
rural clinics and patients in urban areas visiting urban 
clinics: rural (referent); HR urban: 1.14 [95%CI: 0.57-2.24]; 
HR rural/urban 2.85 [95%CI, 1.41-5.79] [p = 0.004]
Table 4. Continued
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STUDY,  
QUALITY 
SCORE, STUDY 
TYPE 
STUDY OBJECTIVE STUDY AREA, TYPE OF CLINIC/
PROGRAM
YEAR OF DATA 
COLLECTION
STUDY DESIGN (COMPARISON 
BETWEEN POPULATION A AND B)
Population sizes, sampling 
method and inclusion criteria
STATISTICAL 
ANALYSIS 
MAIN OUTCOME OF
 ANALYZED EQUITY CRITERIA 
Kranzer 2010 
***  
Observational 
[28]
To investigate the 
frequency and risk 
factors of defaulting 
treatment and identify 
factors associated with 
subsequent return to care 
in a long-term treatment 
cohort in South Africa
Peri-urban:  township in Cape 
Town, Western Cape province, 
public clinic
Mar 2004 - Dec 2009 a. HIV+ patients that defaulted 
ART (n = 291)
b. HIV+ patients that not defaulted 
ART (n = 863)
Both groups are from patients 
presenting at public-sector 
primary care clinic (single ART 
server in the area), >15 years, 
started ART (until 2007 < 350 CD4 
cells (NIH research study), after 
2007 <200 CD4 cells (provincial 
ART program) (n= 1154)
Multivariate 
Poisson 
regression 
Sex (associated, men < women): compared to women, 
men have a significant increased risk to default ART 
treatment, HR men: 1.51 [95%CI: 1.18-1.93, p < 0.01] Age 
(not associated): no significant association between 
age and defaulting treatment, compared to younger 
age (≤30 years), HR > 30 years: 0.90 [95%CI: 0.70-1.15, p 
= 0.40] Severity of disease (contradicting results): higher 
CD4 cell count increases significantly risk for defaulting 
treatment, ≤100 CD4 (referent); 101-200 CD4: HR 1.32 
[95%CI: 0.99-1.76, p = 0.06], CD4 >200 HR: 1.39 [95%CI 
1.02-1.91, p = 0.04]. No significant difference in the risk of 
defaulting treatment being in WHO stage 3/4 or 1/2, HR 
stage 3/4: 1.14 [95%CI: 0.85-1.53, p = 0.37]
Fatti 2010 
***  
Retrospective 
cohort study 
[30]
To compare clinical, 
immunological and 
virological outcomes 
between rural and urban 
children on ART in a large 
cohort from multiple 
public health facilities in 
four provinces of South 
Africa
Rural and urban: areas in 
Western Cape, KwaZulu-Natal, 
Eastern Cape and Mpumalanga 
province, public clinics 
supported by NGOs 
Nov 2003 – Mar 2008 a. Children on ART that loss to 
follow up (n = 179)
b. Children on ART that do not loss 
to follow up (n = 2153)
Both from retrospective cohort 
of children, (<16 yrs, ART naïve), 
enrolled in 44 routine public 
healthcare facilities (7 rural, 
33 urban/12 secondary level 
hospitals, 32 primary health care 
clinics) supported by a NGO, 
used electronic data collection 
systems for patient monitoring
Children were divided in 3 
groups a) urban residence and 
urban ART facility attended 
(urban group, n = 1727); rural 
residence and rural facility 
attended (rural group, n = 228); 
and rural residents attending 
urban facilities (rural/urban 
group, n = 377)
Multivariable 
Cox 
proportional 
hazards 
regression
Sex (not associated): gender is not associated with risk of 
LTFU: HR male: 1.1 [95%CI: 0.82-3.12, no p value reported, 
1.0 falls within CI] Age (not associated): younger children 
(<2yrs) are as likely to LTFU than older children (>2 
yrs): > 2yrs (referent); HR 1-2 yrs: 1.61 [95%CI: 0.96-2.68, 
no p value reported, 1.0 in CI]; HR < 1yr: [1.81, 95%CI: 
0.94-3.64, no p value reported, 1.0 in CI] Severity of 
disease (contradicting results): severe clinical status was 
associated with risk LTFU: HR severe clinical status: 1.47 
[95%CI: 1.03-2.12, no p value reported, 1.0 not in CI]/ 
severe immunodeficiency was not associated with 
risk LTFU: HR severe immunodeficiency: 0.81 [95%CI: 
0.52-1.24, p value not reported, 1.0 in CI] Area of living 
(associated, rural/urban < urban/urban < rural/rural): 
patient in rural areas visiting clinics in urban areas are 
more likely to LTFU than patients from rural areas visiting 
rural clinics and patients in urban areas visiting urban 
clinics: rural (referent); HR urban: 1.14 [95%CI: 0.57-2.24]; 
HR rural/urban 2.85 [95%CI, 1.41-5.79] [p = 0.004]
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STUDY,  
QUALITY 
SCORE, STUDY 
TYPE 
STUDY OBJECTIVE STUDY AREA, TYPE OF CLINIC/
PROGRAM
YEAR OF DATA 
COLLECTION
STUDY DESIGN (COMPARISON 
BETWEEN POPULATION A AND B)
Population sizes, sampling 
method and inclusion criteria
STATISTICAL 
ANALYSIS 
MAIN OUTCOME OF
 ANALYZED EQUITY CRITERIA 
Cornell 2009
**  
Observational  
[29]
To investigate the impact 
of gender and income 
on survival and retention 
in a South African public 
sector ART programme
Urban: Nyanga township, 
outskirts of Cape Town, Western 
Cape province, public clinics 
supported by NGOs
Sept 2002 – Apr 2007 a. HIV+ patients that loss to follow 
up (n = 137)
b. HIV+ patients that do not loss to 
follow up (n = 2059)
Both groups from Gugulethu 
clinic patient cohort that receive 
adherence counseling including 
home visits, >15 years, ART naïve, 
WHO stage IV or CD4 <200 (n = 
2196) 
Proportional 
hazards 
regression 
models
Sex (not associated): gender is not associated with risk 
to LTFU: HR men: 1.38, [95%CI: 0.94-2.03, p = 0.100] Age 
(not associated): no significant difference between age 
and risk to LTFU: HR age: 0.98 [95%CI 0.96-1.00, p = 0.102] 
Severity of disease (contradicting results): patients with 
CD4 cell count <50 have higher risk to LTFU than CD4 
cell count 50-150, but a similar risk as CD4 >150: CD4 
<50 (referent); HR CD4 51-100: 0.62 [95%CI: 0.37-1.05, 
p = 0.077]; HR CD4 101-150 [0.57, 95%CI: 0.33-1.00, p = 
0.049]; HR CD4 > 150: 1.01 [95%CI: 0.64-1.59, p = 0.971]/ 
WHO stage has no association with risk to LTFU: WHO 
stage I & II (referent); HR stage III: 0.78 [95%CI: 0.50-1.21, 
p = 0.274] HR stage IV: 0.75 [95%CI 0.75 (0.44-1.28), p = 
0.294] /VL was not significantly associated with risk to 
LTFU: HR RNA level <5 log10 copies/ml (referent); >5 log: 
1.13 [95%CI: 0.78–1.64, p= 0.520] Employment (associated, 
no income < income): patient with no income have a 
increased risk to LTFU: HR with income: 0.53 [95%CI: 0.37-
0.77, p = 0.002] 
CI = confidence interval, HR = hazard ratio, ART = antiretroviral therapy, WHO = world health organization, LTFU = loss to 
follow up, VL = viral load
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Cornell 2009
**  
Observational  
[29]
To investigate the impact 
of gender and income 
on survival and retention 
in a South African public 
sector ART programme
Urban: Nyanga township, 
outskirts of Cape Town, Western 
Cape province, public clinics 
supported by NGOs
Sept 2002 – Apr 2007 a. HIV+ patients that loss to follow 
up (n = 137)
b. HIV+ patients that do not loss to 
follow up (n = 2059)
Both groups from Gugulethu 
clinic patient cohort that receive 
adherence counseling including 
home visits, >15 years, ART naïve, 
WHO stage IV or CD4 <200 (n = 
2196) 
Proportional 
hazards 
regression 
models
Sex (not associated): gender is not associated with risk 
to LTFU: HR men: 1.38, [95%CI: 0.94-2.03, p = 0.100] Age 
(not associated): no significant difference between age 
and risk to LTFU: HR age: 0.98 [95%CI 0.96-1.00, p = 0.102] 
Severity of disease (contradicting results): patients with 
CD4 cell count <50 have higher risk to LTFU than CD4 
cell count 50-150, but a similar risk as CD4 >150: CD4 
<50 (referent); HR CD4 51-100: 0.62 [95%CI: 0.37-1.05, 
p = 0.077]; HR CD4 101-150 [0.57, 95%CI: 0.33-1.00, p = 
0.049]; HR CD4 > 150: 1.01 [95%CI: 0.64-1.59, p = 0.971]/ 
WHO stage has no association with risk to LTFU: WHO 
stage I & II (referent); HR stage III: 0.78 [95%CI: 0.50-1.21, 
p = 0.274] HR stage IV: 0.75 [95%CI 0.75 (0.44-1.28), p = 
0.294] /VL was not significantly associated with risk to 
LTFU: HR RNA level <5 log10 copies/ml (referent); >5 log: 
1.13 [95%CI: 0.78–1.64, p= 0.520] Employment (associated, 
no income < income): patient with no income have a 
increased risk to LTFU: HR with income: 0.53 [95%CI: 0.37-
0.77, p = 0.002] 
CI = confidence interval, HR = hazard ratio, ART = antiretroviral therapy, WHO = world health organization, LTFU = loss to 
follow up, VL = viral load
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  TOTAL SCORE (out of 40 points) 37 34 34 33 32 31 30 26 26 26 19 12
1 Study design (peer reviewed = 2, other = 0) 2 2 2 2 2 2 2 2 2 2 2 2
2 Well-defined hypothesis/objective/research question?  (fully = 2, partial = 1, not at all = 0) 2 2 2 2 2 2 1 2 2 2 2 1
3 Clear motivation research question? (fully = 2, partial = 1, not at all = 0) 2 2 2 2 1 2 2 2 2 2 2 1
4 Concept clearly defined (e.g. access, equity) (fully = 2, partial = 1, not at all = 0) 2 1 1 2 2 1 2 0 1 2 0 0
5 Methods well described? (fully = 2, partial = 1, not at all = 0) 2 2 2 2 2 2 1 1 2 2 2 0
6 Main outcomes clearly described? (fully = 2, partial = 1, not at all = 0) 2 2 2 2 1 2 2 2 1 2 2 1
7 Potential sources of bias taken into account? (fully = 2, partial = 1, not at all = 0) 2 2 2 2 2 2 1 0 0 2 0 0
8 Population and sampling method clearly defined? (fully = 2, partial = 1, not at all = 0) 2 2 2 2 2 2 2 1 1 0 0 0
9 Type of information used (i.e sample size, time period) clearly described?  (fully = 2, partial = 1, not at all = 0) 2 2 2 2 1 2 2 1 2 1 1 1
10 Primary data used for key analyses? (yes = 2, no = 0) 2 0 2 2 2 0 2 2 0 0 0 0
11 Survey (household/provider level) data used? (yes = 2, partial = 1, no = 0) 2 2 2 2 2 1 2 2 0 2 0 0
12 Research/subquestion(s) answered? (fully = 2, partial = 1, not at all = 0) 1 2 2 1 2 2 1 1 2 2 2 1
13 Results based on evidence derived from the data analysis?  (fully = 2, partial = 1, not at all = 0) 2 2 2 2 2 1 2 2 2 0 0 1
14 Results credible given the methods, data, and analysis used?  (fully = 2, partial = 1, not at all = 0) 2 2 2 2 2 1 1 1 2 2 0 1
15 Robustness of findings and limitations of method discussed? (fully = 2, partial = 1, not at all = 0) 2 2 2 1 1 2 2 1 2 1 2 0
16 Findings discuss within context of existing evidence base?  (fully = 2, partial = 1, not at all = 0) 2 2 2 2 2 2 2 2 2 2 2 1
17 Missings clearly described?  (fully = 2, partial = 1,  not at all = 0) 2 2 1 0 2 1 1 2 0 0 0 0
18 Generalizable to rest of the country? (given sample size)  (fully = 2, partial = 1, not at all = 0) 2 1 2 1 1 0 0 0 1 2 2 2
19 Study subjects asked representative of entire population recruited from? (yes = 2, no = 0) 0 0 0 0 0 2 2 2 0 0 0 0
20 Study subjects prepared to participate representative of entire population recruited from?  
(yes = 2, partial = 1, no = 0)
2 2 0 2 1 2 0 0 2 0 0 0
‘For severity of disease, five [27–30,32] out of six studies [27–32] reported contradicting results. 
In four [27–29,32] out of these five studies an association was found between ART utilisation 
and a person’s CD4 cell level while no association was found with a patient’s WHO status. Of 
these studies, one ART initiation [27] and one on adherence [28] (both high quality) reported 
that higher CD4 cell counts are associated with lower utilization of ART. On the contrary, two 
other studies on adherence (one high- and one medium-quality) reported that lower CD4 cell 
count is associated with less utilization [29,32]. In one other study (high quality) that reported 
contradicting results for severity of disease among children, an association was found with 
Table 5. Overview of quality rating scoring per study 
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  TOTAL SCORE (out of 40 points) 37 34 34 33 32 31 30 26 26 26 19 12
1 Study design (peer reviewed = 2, other = 0) 2 2 2 2 2 2 2 2 2 2 2 2
2 Well-defined hypothesis/objective/research question?  (fully = 2, partial = 1, not at all = 0) 2 2 2 2 2 2 1 2 2 2 2 1
3 Clear motivation research question? (fully = 2, partial = 1, not at all = 0) 2 2 2 2 1 2 2 2 2 2 2 1
4 Concept clearly defined (e.g. access, equity) (fully = 2, partial = 1, not at all = 0) 2 1 1 2 2 1 2 0 1 2 0 0
5 Methods well described? (fully = 2, partial = 1, not at all = 0) 2 2 2 2 2 2 1 1 2 2 2 0
6 Main outcomes clearly described? (fully = 2, partial = 1, not at all = 0) 2 2 2 2 1 2 2 2 1 2 2 1
7 Potential sources of bias taken into account? (fully = 2, partial = 1, not at all = 0) 2 2 2 2 2 2 1 0 0 2 0 0
8 Population and sampling method clearly defined? (fully = 2, partial = 1, not at all = 0) 2 2 2 2 2 2 2 1 1 0 0 0
9 Type of information used (i.e sample size, time period) clearly described?  (fully = 2, partial = 1, not at all = 0) 2 2 2 2 1 2 2 1 2 1 1 1
10 Primary data used for key analyses? (yes = 2, no = 0) 2 0 2 2 2 0 2 2 0 0 0 0
11 Survey (household/provider level) data used? (yes = 2, partial = 1, no = 0) 2 2 2 2 2 1 2 2 0 2 0 0
12 Research/subquestion(s) answered? (fully = 2, partial = 1, not at all = 0) 1 2 2 1 2 2 1 1 2 2 2 1
13 Results based on evidence derived from the data analysis?  (fully = 2, partial = 1, not at all = 0) 2 2 2 2 2 1 2 2 2 0 0 1
14 Results credible given the methods, data, and analysis used?  (fully = 2, partial = 1, not at all = 0) 2 2 2 2 2 1 1 1 2 2 0 1
15 Robustness of findings and limitations of method discussed? (fully = 2, partial = 1, not at all = 0) 2 2 2 1 1 2 2 1 2 1 2 0
16 Findings discuss within context of existing evidence base?  (fully = 2, partial = 1, not at all = 0) 2 2 2 2 2 2 2 2 2 2 2 1
17 Missings clearly described?  (fully = 2, partial = 1,  not at all = 0) 2 2 1 0 2 1 1 2 0 0 0 0
18 Generalizable to rest of the country? (given sample size)  (fully = 2, partial = 1, not at all = 0) 2 1 2 1 1 0 0 0 1 2 2 2
19 Study subjects asked representative of entire population recruited from? (yes = 2, no = 0) 0 0 0 0 0 2 2 2 0 0 0 0
20 Study subjects prepared to participate representative of entire population recruited from?  
(yes = 2, partial = 1, no = 0)
2 2 0 2 1 2 0 0 2 0 0 0
‘For severity of disease, five [27–30,32] out of six studies [27–32] reported contradicting results. 
In four [27–29,32] out of these five studies an association was found between ART utilisation 
and a person’s CD4 cell level while no association was found with a patient’s WHO status. Of 
these studies, one ART initiation [27] and one on adherence [28] (both high quality) reported 
that higher CD4 cell counts are associated with lower utilization of ART. On the contrary, two 
other studies on adherence (one high- and one medium-quality) reported that lower CD4 cell 
count is associated with less utilization [29,32]. In one other study (high quality) that reported 
contradicting results for severity of disease among children, an association was found with 
WHO stage but not with CD4 cell count level [30]. The sixth study (high quality) reporting for 
severity of disease, only looked at CD4 cell count levels and found that patients with a higher 
CD4 cell count level adhered less to ART [31].
For area of living, three [24,30,35] out of the four studies [24,30,33,35] that reported on this 
criterion found an association between area of living and ART utilization. Two studies (high- 
and medium-quality) reported that people in certain provinces have lower utilization of ART 
(see Table 4) [24,35]. One of the studies (high-quality) reported that children living in rural areas 
168
  Sub-question 3
and who visit ART clinics in urban areas, have lower utilization than children that visit clinics in 
their own area of living (urban or rural area) [29]. The fourth study (high-quality) that reported 
on area of living found no association between ART utilization and area of living (peri-urban, 
urban or rural area) [33]. 
Socioeconomic status was found to be associated with ART utilization in two [29,34] (both 
medium-quality) out of the six studies [26,27,29,32–34] that reported on this criterion, which 
showed that those unemployed have lower utilization of ART. One of these studies also 
reported that those with lower education utilize less [34]. Of the four studies that found no 
association, one (high-quality) found no differences on the basis of employment and educa-
tion [27]. The other three (all high-quality) found no differences in ART utilization between 
those with differences in SES [26,32,33]. One of these also found no association between 
educational level and ART utilization [33]. 
For marital status only one study (medium-quality) was included in this review and reported 
that being unmarried is associated with lower ART utilization [34]. For ethnicity only one study 
(high-quality) was found, and it reported inconclusive results due to a small sample size [26]. 
None of the included studies had at the ART utilization by religion or sexual orientation. 
Discussion
This is the first systematic review that examines equity in utilization of ART in South Africa 
and identified 12 studies. It seems that men, young people, those living in certain provinces 
or rural areas, people who are unemployed or with low educational level, or those who are 
unmarried have less access to ART. For severity of disease, most studies used more than one 
outcome measure for disease stage and reported within their study contradicting results. No 
evidence of inequity in ART utilization by ethnicity, religion and sexual orientation was found. 
There were large heterogeneities in both context (study area, type of program, time period) 
and methodology of the studies in this review.
Only one high- and one low-quality study reported a significant difference in utilization of 
ART among men and women, and eight other studies found no differences. Although it is 
encouraging that access to ART seems mostly equal for both genders, the studies in our 
review failed to take the timing of ART initiation into account. Observational studies from 
South Africa recently showed that case-fatality rates among HIV-infected men were substan-
tially higher compared to women in South Africa, most likely related to late entry into care 
[36,37]. Late entry by men can be explained as ART is mainly provided through primary health 
care services, and its antenatal care services frequently serve as an entry-point for HIV treat-
ment for women. 
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The findings in some studies which showed that young age is associated with low utilization 
raises concerns. Young people may face more barriers to treatment (like lack of knowledge 
about treatment possibilities and benefits and fear for stigma and discrimination) [33]. Yet, this 
relationship may be confounded by eligibility, as older people are more likely to be eligible 
because of more advanced disease stages. In addition, many studies did not cover all ages. 
As the HIV epidemic in South Africa is ageing [38,39] it will become increasingly important 
to determine ART utilization among elderly, a group previously neglected in research on ART 
utilization.
Both area of living and SES did not seem to be associated with ART utilization. However, the 
studies looking at area of living were mostly of low-quality. The studies by Nattrass et al [24] 
and Adam et al [35] reported coverage levels for different provinces. However, these studies 
used a simple Markov-model to estimate the need for ART, and it is difficult to determine 
whether the model projections are valid. The study by Fatti et al [30] reports on children in 
four different areas. Lower utilization for children living in rural areas and accessing clinics in 
urban areas can be explained by financial and non-financial barriers such as the monetary 
cost of transportation or the opportunity cost of accessing health care services [34]. Neverthe-
less, more research is needed in order to generalize these findings to other areas and popu-
lation groups. Finally, Tanser et al [40] showed that self-reported visiting of health clinics in a 
rural South African area was significantly associated with the distance between the clinic and 
home, with greater distance resulting in lower utilization, yet we did not include this study 
because it didn’t specifically concern ART utilization. 
Studies on SES and area of living will likely measure the same inequities as people in deprived 
areas might have lower SES. However, Tsai et al [34] found significant evidence of socioeco-
nomic inequities in the uptake of ART services within a rural and deprived part of South Africa 
during the early years of the public sector scaling up of ART (2003–2005). Poorer households 
in South Africa and in sub-Saharan Africa generally have less access because they face various 
barriers like cost for transport to the clinic, knowledge of the benefit of ART treatment and a 
lower propensity to seek formal sector treatment for illness [41,42]. Cleary et al [26] reported no 
differences in SES distribution between those in need and those accessing ART in urban areas 
in 2008. This is in line with the ‘inverse equity hypothesis’ which predicts a paradoxical wors-
ening of health inequities as effective new public health interventions first diffuse among the 
well-to-do but later also among the poor. Last years ART has been scaled-up drastically (and 
now reaches about 80% of those in need) barriers to access might have been reduced and 
those least able to overcome those initial barriers are now able to use the services [26]. Yet, still 
about 20% lacks access to treatment and this group likely faces most barriers. In addition, if 
South Africa adopts the new WHO guidelines and further expands its ART program new ineq-
uities might appear. 
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We found contradicting results for severity of disease as within studies differences in ART utili-
zation were reported for HIV-infected people with different CD4 cell count levels but not for 
different WHO disease stages. Also some studies some studies reported lower utilization for 
healthier patients while other studies for the more severely ill. One of the studies by Govin-
dasamy et al [27] addressed ART initiation and concluded that those with a CD4 cell count 
of >350 are less likely linked to care after testing HIV positive than those ≤350. This can be 
explained by the fact that these patients were not yet eligible for ART and only needed to 
enrol in the clinic to monitor their CD4 level, or because they feel less need for care as they do 
not suffer from symptoms. The other five studies addressed ART adherence. Boyles et al [31] 
and Kranzer et al [28] both found that those with higher CD4 cell count (CD4 > 200) adhere less 
to ART and this may also be explained by the fact that individuals who default do so because 
they feel better on treatment [43,44]. In contrast, Fatti et al [30] and Orrell et al [32] found 
that most severely ill patients were more likely to lost of follow-up. One explanation could 
be that patients perceived a lack of effectiveness of treatment when ill or not being able to 
take the medicine because of symptoms [43]. However, the status of patients who are lost to 
follow-up is difficult to assess, and it is also likely that many of those are unregistered deaths, 
thus explaining the higher rates among those with advanced disease. 
Only one of the studies looked at marital status and reported less access for unmarried people. 
However, this study was of medium quality as it compared socio-economic characteristics of 
a community sample with a clinic sample which were taken from different areas. For ethnicity, 
religion and sexual orientation no evidence was available and more research is needed to 
determine inequities in ART utilization by these criteria. It is likely that inequities exist on the 
basis of ethnicity, as the history of apartheid caused differences in access between black and 
white South Africans [45]. Also, among black Africans differences in access between ethnic 
groups like Zulu-speakers, French speaking Cameroonians and Xhosa speakers likely exist, 
partly due to differences in language barriers that they may face when accessing care [46,47]. 
Although HIV-prevention services for men who have sex with men (MSM) are expanding across 
the country, there are still several gaps [48,49]. This group may face barriers in ART access due 
to fear of provider stigma and social isolation [50,51]. Low HIV testing rates are reported among 
Muslim people in predominantly Muslim residential areas in Cape Town [52] and different reli-
gions might face different levels of HIV-related stigma which might cause inequities in ART 
utilization [53]. 
After analyzing the findings of the included studies we found no patterns of equities or inequi-
ties that may be explained by differences in program design (e.g. NGO or university supported, 
public program, availability adherence counsellor), time period (e.g. before or after scale up 
of ART), target population (e.g. indigent populations, children) and study area (e.g. townships, 
rural areas). On the other hand, patterns might have been identified if the number of studies 
were higher. 
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We found only 12 studies which looked at equity criteria for ART utilization, and two of these 
were of low- quality. In addition, all studies differed in context (year of study, area, study popu-
lation), methodology, and outcome measured. Access to ART in South Africa has evolved 
quickly over the past decade [54] and inequities that were reported at the start of the ART 
scale-up might no longer be relevant now. Given the incomplete and mixed evidence base, 
we call for more rigorous analysis on equity of ART treatment in South Africa, and beyond. We 
flag three important domains. First, reviewed studies were based on different samples and 
this made any comparison or generalisation difficult to achieve. A national monitoring system 
on ART initiation and adherence, which also registers key criteria such as severity of disease, 
gender, age, SES and area of living could fill in this gap. To measure those in need for ART we 
recommend using the definition ‘eligible for ART on the basis of the country guidelines’ as 
not all HIV-infected people might be already eligible for ART. Yet, the challenge remains to 
identify HIV-infected patients who are in need of treatment but have not yet been linked to 
care. Second, most studies only assessed a few equity criteria. This could be explained by the 
emphasis in strategic ART plans worldwide to reduce gender, SES and area of living inequities 
[1]. In addition, the recent health equity monitor launched by the WHO uses a list of indica-
tors to present a country’s equity profile, but recommends to differentiate groups on the basis 
of SES, gender, area of living and education level only [55]. We therefore recommend getting 
similar insights in inequalities between groups that differ in age, severity of disease, marital 
status, ethnicity, sexual orientation and religion for ART utilization. Third, studies employed a 
variety of definitions of both ART initiation and adherence measures, but also of equity criteria 
measures, indicating the need to develop standardized measures in this area of study. 
Conclusions
On the basis of 12 studies identified in this review it seems that men, young people, those 
living in certain provinces or rural areas, those who are unemployed or with a low educa-
tional level, and those who are unmarried are disadvantaged from utilization of ART. For 
severity of disease, most studies used more than one outcome measure for disease stage and 
reported within their study contradicting results. For ethnicity, religion and sexual orientation 
there was no evidence available to draw conclusions. As studies stem from different contexts 
and use different methods, findings cannot be generalized and conclusions should be taken 
with caution. In order to better inform policy makers, we call for improved guidance in equity 
research on ART, addressing the need to develop national monitoring of inequity of utilization 
of ART and employing standardized measures of utilization and equity criteria. 
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Appendix A
Database search strategies for systematic review on equity in utilization of ART in South Africa
Table A. Pubmed database search on 18 February 2013
SEARCH 
CATEGORY
SYNTAX RESULTS
ART antiretroviral therapy, highly active[MeSH Terms] OR ART[title/abstract] OR
HAART[title/abstract] OR ARV[title/abstract] OR ARVs[title/abstract] OR
Anti-Retroviral Agents[Mesh] OR antiretroviral[title/abstract] OR anti
retroviral[title/abstract] OR anti-retroviral[title/abstract] OR
antiviral[title/abstract] OR therapy[title/abstract]
1.251.418
HIV acquired immunodeficiency syndrome[MeSH Terms] OR acquired 
immunodeficiency syndrome[title/abstract] OR aids[title/abstract] OR hiv[MeSH 
Terms] OR hiv[title/abstract] OR human immunodeficiency virus[title/abstract] 
OR hiv infections[MeSH Terms]
318.414 
South Africa (south africa[MeSH Terms] OR (south[title/abstract] AND africa*[title/abstract])) 41.343
Equity (equity[title/abstract] OR equities[title/abstract] OR inequity[title/abstract] OR 
inequities[title/abstract] OR equality[title/abstract] OR equalities[title/abstract] 
OR Equal[title/abstract] OR Equitable[title/abstract] OR inequality[title/abstract] 
OR inequalities[title/abstract] OR unequal[title/abstract] OR disparity[title/
abstract] OR disparities[title/abstract] OR vulnerability[title/abstract] OR 
fairness[title/abstract] OR unfair[title/abstract] OR social justice[MeSH Terms] 
OR social justice[title/abstract] OR justice[title/abstract] OR barrier[title/
abstract] OR  coverage[title/abstract] OR barriers[title/abstract] OR healthcare 
disparities[MeSH Terms] OR health services accessibility[MeSH Terms] OR health 
services accessibility[title/abstract] OR access to health care[title/abstract]) 
530.375
HIV AND ART 
AND Equity 
AND South 
Africa
Search: (equity[title/abstract] OR equities[title/abstract] OR inequity[title/
abstract] OR inequities[title/abstract] OR equality[title/abstract] OR 
equalities[title/abstract] OR Equal[title/abstract] OR Equitable[title/abstract] 
OR inequality[title/abstract] OR inequalities[title/abstract] OR unequal[title/
abstract] OR disparity[title/abstract] OR disparities[title/abstract] OR 
vulnerability[title/abstract] OR fairness[title/abstract] OR unfair[title/
abstract] OR social justice[MeSH Terms] OR social justice[title/abstract] OR 
justice[title/abstract] OR barrier[title/abstract] OR coverage[title/abstract] 
OR barriers[title/abstract] OR healthcare disparities[MeSH Terms] OR health 
services accessibility[MeSH Terms] OR health services accessibility[title/
abstract] OR access to health care[title/abstract]) AND (south africa[MeSH 
Terms] OR (south[title/abstract] AND africa*[title/abstract])) AND (acquired 
immunodeficiency syndrome[MeSH Terms] OR acquired immunodeficiency 
syndrome[title/abstract] OR aids[title/abstract] OR hiv[MeSH Terms] OR 
hiv[title/abstract] OR human immunodeficiency virus[title/abstract] OR hiv 
infections[MeSH Terms]) AND (antiretroviral therapy, highly active[MeSH 
Terms] OR ART[title/abstract] OR HAART[title/abstract] OR ARV[title/abstract] 
OR ARVs[title/abstract] OR Anti-Retroviral Agents[Mesh] OR antiretroviral[title/
abstract] OR anti retroviral[title/abstract] OR anti-retroviral[title/abstract] OR 
antiviral[title/abstract] OR therapy[title/abstract])
297
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SEARCH CATEGORY SYNTAX RESULTS
ART exp highly active antiretroviral therapy/ OR ART.ti,ab. OR HAART.
ti,ab. OR ARV.ti,ab. OR ARVs.ti,ab. OR exp antiretrovirus agent/ OR 
antiretroviral.ti,ab. OR anti retroviral.ti,ab. OR anti-retroviral.ti,ab. OR 
antiviral.ti,ab. OR therapy.ti,ab.
1.704.926 
HIV exp acquired immune deficiency syndrome/ OR "acquired 
immunodeficiency syndrome".ti,ab. OR aids*.ti,ab. OR exp Human 
immunodeficiency virus/ OR "hiv".ti,ab. OR "human immunodeficiency 
virus".ti,ab. OR exp Human immunodeficiency virus infection/
406.830 
South Africa Exp south africa/ OR (south.ti,ab. AND africa*.ti,ab.) 46.377
Equity equity.ti,ab. OR equities.ti,ab. OR inequity.ti,ab. OR inequities.ti,ab. 
OR equality.ti,ab. OR equalities.ti,ab. OR "inequality".ti,ab. OR Equal.
ti,ab. OR Equitable.ti,ab. OR "inequalities".ti,ab. OR "unequal".ti,ab. OR 
disparity.ti,ab. OR disparities.ti,ab. OR vulnerability.ti,ab. OR fairness.
ti,ab. OR unfair.ti,ab. OR "social justice".ti,ab. OR "justice".ti,ab. OR barrier.
ti,ab. OR barriers.ti,ab. OR "health services accessibility".ti,ab. OR "access 
to health care".ti,ab. OR "coverage".ti,ab. OR exp social justice/ OR exp 
health care disparity/ OR health care delivery/
620.062
HIV AND ART AND 
Equity AND South 
Africa
433 
Table C. CENTRAL database search on 18 February 2013
SEARCH CATEGORY SYNTAX RESULTS
ART
(Antiretroviral Therapy, Highly Active OR Anti-Retroviral Agents OR 
ART OR HAART OR ARV OR ARVs OR antiretroviral OR anti retroviral 
OR anti-retroviral OR antiviral OR therapy):ti,ab,kw
183.638
HIV (acquired immunodeficiency syndrome OR hiv OR hiv infections OR 
aids OR human immunodeficiency virus):ti,ab,kw 
14.559
South Africa
(South Africa OR South Africa*):ti,ab,kw 1.163
Equity
(equity OR equities OR inequity OR inequities OR equality OR 
equalities OR Equal OR Equitable OR inequality OR inequalities 
OR unequal OR disparity OR healthcare disparities OR disparities 
OR vulnerability OR fairness OR unfair OR social justice OR justice 
OR barrier OR barriers OR health services accessibility OR health 
services accessibility OR access to health care OR coverage):ti,ab,kw 
21.449
HIV AND ART AND Equity 
AND South Africa
13 
Table B. EMBASE database search on 18 February 2013
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Table D. PsycINFO database search on 18 February 2013
SEARCH CATEGORY SYNTAX RESULTS
ART highly active antiretroviral therapy.ti,ab. OR ART.ti,ab. OR HAART.
ti,ab. OR ARV.ti,ab. OR ARVs.ti,ab. OR antiretroviral.ti,ab. OR anti 
retroviral.ti,ab. OR anti-retroviral.ti,ab. OR antiviral.ti,ab. OR therapy.
ti,ab.
182.687
HIV Exp HIV/ OR hiv.ti,ab. OR human immunodeficiency virus.ti,ab. 
OR exp AIDS/ OR aids*.ti,ab. OR exp acquired immune deficiency 
syndrome/ OR acquired immunodeficiency syndrome.ti,ab. 
44.968
South Africa south africa or (south and africa*).ti,ab. 9.086
Equity equity.ti,ab. OR equities.ti,ab. OR inequity.ti,ab. OR inequities.ti,ab. 
OR equality.ti,ab. OR equalities.ti,ab. OR Equal.ti,ab. OR Equitable.
ti,ab.  OR inequality.ti,ab. OR inequalities.ti,ab. OR unequal.ti,ab. 
OR disparities.ti,ab. OR vulnerability.ti,ab. OR fairness.ti,ab. OR 
unfair.ti,ab. OR social justice.ti,ab. OR justice.ti,ab. OR barrier.ti,ab. 
OR barriers.ti,ab. OR health services accessibility.ti,ab. OR access 
to health care.ti,ab. OR "coverage".ti,ab. OR exp social justice/ OR 
exp health disparities/ OR health care delivery/ equity.ti,ab. OR 
equities.ti,ab. OR inequity.ti,ab. OR inequities.ti,ab. OR equality.ti,ab. 
OR equalities.ti,ab. OR Equal.ti,ab. OR Equitable.ti,ab.  OR inequality.
ti,ab. OR inequalities.ti,ab. OR unequal.ti,ab. OR disparities.ti,ab. OR 
vulnerability.ti,ab. OR fairness.ti,ab. OR unfair.ti,ab. OR social justice.
ti,ab. OR justice.ti,ab. OR barrier.ti,ab. OR barriers.ti,ab. OR health 
services accessibility.ti,ab. OR access to health care.ti,ab. OR exp 
social justice/ OR exp health disparities/ OR health care delivery/
166.097
HIV AND ART AND Equity 
AND South Africa
58
178
  Sub-question 3
Appendix B
Data extraction and quality assessment form for systematic review on equity in utilization of 
ART in South Africa
Table A. Data extraction sheet
SUBJECT QUESTION ANSWERS
General 
Information
Name of person performing data extraction 1. CM 2. EM
Date of data extraction
Author(s)
Title article 
Journal
Type of publication 1. Journal Article, 2. Dissertation,  
3. Other: …
Date/Year of publication
Geographical study area
Source of funding
Inclusion criteria study
Exclusion criteria study
Quality assessment score 
Study Character-
istics 
Research question / Objective of the study
Study design 1. Observational 2. Review, 3. Other:
Total duration of the study
Source of data and year of data collection? 1. Demographic health survey 2. Other: …
3. Unclear
Area of interest 1. Initiation of ART 2. Adherence to ART
3. Other: …
How were participants recruited?
Which sampling procedure was used to create 
a representative sample of the population?
Number of participants enrolled in the study 
(sample size)
In what manner was data collected? 1. Face-to-face interview, 2. Questionnaire, 
3. Other…
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SUBJECT QUESTION ANSWERS
Study Character-
istics
Compared groups / Number of participants 
allocated in each group
Where was the intervention implemented? 
(e.g. country level/ hospital/ community 
clinic/other)?
Type of data 1. Primary, 2. Secondary, 3. Not Clear
What statistical method(s) was used for analysis? 
Is informed consent correctly handled? 1. No, 2. Yes, 3. Not mentioned
Equity criteria Area living (location / setting / place of 
residency)
1. Not reported 2. Reported
Race/ethnicity 1. Not reported 2. Reported
Occupation 1. Not reported 2. Reported
Age 1. Not reported 2. Reported
Education 1. Not reported 2. Reported
Gender 1. Not reported 2. Reported
Socio economic status  (SES) 1. Not reported 2. Reported
Geographical region 1. Not reported 2. Reported
Religion 1. Not reported 2. Reported
Severity of disease (CD4 count / Viral load) 1. Not reported 2. Reported
Other equity criteria 1. Not reported 2. Reported
Description of equity criteria used
Intervention Initiation of ART 1. Not reported 2. Reported
Adherence to therapy 1. Not reported 2. Reported
Frequency in use ART 1. Not reported 2. Reported
Possible / potential care providers
By whom was the intervention implemented? 1. Primary care, 2. Secondary care, 3. 
Tertiary care
For who was the intervention aimed at? 1. Urban population
2. Rural population
3. Poor
4. Rich
5. General population
6. Sex workers
7. PWID
8. MSM
9. Other: …
10. No specific aim
Was the use of ART free? 1. Yes, 2. No, 3. Not mentioned
Equity criteria Equity criterion
Definition of criteria mentioned in the study 1. Not mentioned 2. Mentioned
Number of participants allocated to each 
group
Table A. Continued
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SUBJECT QUESTION ANSWERS
Summary data for each intervention group
Notes characteristics equity criterion
Miscellaneous Conclusion about access to ART
Comments on equity  e.g. comments on model of care or  
recommendations authors
Is the outcome generalizable/external 
vailidity? 
1. Not mentioned 2. Mentioned
Missing participant / Drop outs handled 
correctly? 
1. Not mentioned 2. Mentioned
Mentioned limitations of the study (like bias 
etc)
1. Not mentioned 2. Mentioned
References to other relevant studies
Miscellaneous comments by study authors
Comments on equity by reviewers (EM / CM)
Miscellaneous comments by review authors 
(EM / CM)
Table A. Continued
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Table B. Quality assessment form
SUBJECT QUESTIONS SCORE
Type of 
publication 
Type of  study design Peer-reviewed: 2 /Other: 0 
Research 
question 
Does the study have a clear and well-defined hypothesis/aim/
objective/research question?
Fully: 2, Partial: 1, Not at all: 0
Does the study motivate its research question? Fully: 2, Partial: 1, Not at all: 0
Concepts Does the study clearly define concepts including definitions like 
access, equity, ART and outcome measures?
Fully: 2, Partial: 1, Not at all: 0
Methods Does the study clearly describe the methods that are used to 
answer the analytical question(s)?
Fully: 2, Partial: 1, Not at all: 0
Are the main outcomes to be measured clearly described in the 
Introduction or Methods section?
Fully: 2, Partial: 1, Not at all: 0
Does the study take potential sources of bias into account? Fully: 2, Partial: 1, Not at all: 0
Does the study clearly define the population and sampling 
method used?
Fully: 2, Partial: 1, Not at all: 0
Is the type of information used in the study in terms of source, 
sample size, time period, levels etc. clearly described?
Fully: 2, Partial: 1, Not at all: 0
Does the study make use of primary (survey) data for its key 
analyses?
Yes: 2, Not at all: 0 
Does the study make use of survey (household/provider level) data? Yes: 2,  Partial:1, Not at all: 0 
Data Does the study answer (all of) the research (sub)question(s)? Fully: 2, Partial: 1, Not at all: 0
Are results based on evidence derived from the data analysis of 
the study?
Fully: 2, Partial: 1, Not at all: 0
Are the results credible given the methods, data, and analysis 
used?
Fully: 2, Partial: 1, Not at all: 0
Goal 
achievement 
Does the study critically discuss the robustness of findings, 
potential sources of bias, and possible limitations of the 
approaches of choice?
Fully: 2, Partial: 1, Not at all: 0
Findings Does the study discuss findings within the context of existing 
evidence base?
Fully: 2, Partial: 1, Not at all: 0
Are the missings / lost to follow up patients clearly described? Fully: 2, Partial: 1, Not at all: 0
Are the results generalizable* given size of the sample of study 
units? *Generalizability defined as generalizable to the rest of 
the country
Fully: 2, Partial: 1, Not at all: 0
Discussion / 
conclusion
Were the subjects asked to participate in the study 
representative of the entire population from which they were 
recruited?
Yes: 2, Not at all: 0 
Generalizability Were those subjects who were prepared to participate 
representative of the entire population from which they were 
recruited?
Yes: 2, Partial: 1, Not at all: 0 
Total points (max 40)
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  What is the current priority setting process in 
  HIV/AIDS control in Indonesia?
 Sub-question 4
  Can the integrated MCDA-AFR  
  approach be used to support 
  strategic planning processes in 
  HIV/AIDS control?
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Abstract
South Africa, the country with the largest HIV epidemic worldwide, has been scaling 
up treatment since 2003 and is rapidly expanding its eligibility criteria. The HIV treat-
ment programme has achieved significant results, and had 1.8 million people on treat-
ment per 2011. Despite these achievements, it is now facing major concerns regarding 
(i) efficiency: alternative treatment policies may save more lives for the same budget; 
(ii) equity: there are large inequalities in who receives treatment; (iii) feasibility: still only 
52% of the eligible population receives treatment.Hence, decisions on the design of the 
present HIV treatment programme in South Africa can be considered suboptimal. We 
argue there are two fundamental reasons to this. First, while there is a rapidly growing 
evidence-base to guide priority setting decisions on HIV treatment, its included studies 
typically consider only one criterion at a time and thus fail to capture the broad range 
of values that stakeholders have. Second, priority setting on HIV treatment is a highly 
political process but it seems no adequate participatory processes are in place to 
incorporate stakeholders’ views and evidences of all sorts. We propose an alternative 
approach that provides a better evidence base and outlines a fair policy process to 
improve priority setting in HIV treatment. The approach integrates two increasingly 
important frameworks on health care priority setting: accountability for reasonable-
ness (A4R) to foster procedural fairness, and multi-criteria decision analysis (MCDA) to 
construct an evidence-base on the feasibility, efficiency, and equity of programme 
options including trade-offs. The approach provides programmatic guidance on the 
choice of treatment strategies at various decisions levels based on a sound conceptual 
framework, and holds large potential to improve HIV priority setting in South Africa.
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Background
With 5.7 million HIV-positive people, South Africa is the country with the largest HIV epidemic 
worldwide [1]. In recent years, the country has gradually expanded its eligibility criteria for 
treatment initiation in line with the World Health Organization (WHO) guidelines [2–6]. It is 
now rapidly scaling up its treatment programme aiming to cover all HIV-infected people with 
a CD4 cell count of ≤350 μl patients with a TB co-infection, and HIV-infected pregnant women 
irrespective of CD4 cell count [4,7]. The treatment programme has achieved significant results: 
it is the largest programme of its kind in the world, with approximately 1.8 million people on 
HIV treatment [8]. Despite these achievements, the present HIV programme is not optimal in 
three important areas. First, there are concerns about whether the current treatment strategy is 
most efficient. Research suggests that alternative policies such as universal testing and imme-
diate treatment of all HIV-infected patients (UTT) [9] and targeting specific risk groups [10,11], 
would be more efficient than the present programme. Second, concerns exist regarding the 
equity of the distribution of ART across population groups – recent reviews show that e.g. 
men and children have less access to treatment than women [8,12]. Third, there are concerns 
about the programme feasibility given the severely limited capacity of the health system. In 
2011, 3.4 million people were eligible for treatment in South Africa, and despite the achieve-
ments in scaling up the treatment programme, yet only 52% of them received it [8]. This “treat-
ment gap” is related to funding constraints, but also due to staff shortages [13], and it will 
increase with more people surviving on treatment [13,14]. National health authorities acknowl-
edge these concerns [4] but have not yet developed and implemented treatment guidelines 
that address these. This results in ad-hoc priority setting practices (where some clinicians treat 
patients on a first-come first-serve basis while others give preference to the most severely ill) 
and waiting lists in parts of the country [15].
In this paper, we argue that the above observations are related to suboptimal decisions on 
the design of the present HIV treatment programme. We argue there are two fundamental 
reasons to this. First, while there is a rapidly growing evidence-base to guide priority setting 
decisions on HIV treatment, its included studies typically consider only one criterion at a time 
and thus fail to capture the broad range of values that stakeholders have. Second, priority 
setting on HIV treatment is a highly political process but it seems no adequate participatory 
processes are in place to incorporate stakeholders’ views and evidences of all sorts.
In the paper, we first outline the scientific evidence base on HIV treatment priority setting in 
South Africa, in terms of efficiency, equity and feasibility. We continue by proposing an alterna-
tive approach based on the combination of two innovative and increasingly important frame-
works for health care priority setting: accountability for reasonableness (A4R) to foster fair 
priority setting processes, and multi-criteria decision analysis (MCDA) to foster rational priority 
setting. The WHO has recently also recognised the need to trade-off the mentioned efficiency, 
equity and feasibility concerns [16], resulting in “Programmatic guidelines on HIV treatment” 
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issued in July 2013 [17]. This paper contributes to these guidelines by providing a practical lead 
way for making these difficult priority setting decisions at various decision levels, based on a 
firm conceptual framework. 
Present approaches to HIV treatment priority setting
Present studies on HIV treatment in South Africa priority setting typically focus on one of the 
following criteria.
Efficiency
Lately, a wide range of mathematical modelling studies have analysed the population health 
effects as well as costs and cost-effectiveness (or efficiency) of early versus late onset of treat-
ment, many incorporating the transmission benefits of ART [11,18–30]. Although models agree 
that HIV incidence can be substantially reduced through expanded access to ART, models 
differ substantially on predicted impact and cost-effectiveness of such an intervention [9,31]. 
In addition, there is a growing interest in tailoring HIV treatment guidelines to most efficiently 
target programmes [10,11].
Equity
Generally speaking, equity in health care pertains to judgements about distributive equality 
and the notion that every individual should have a “fair chance to live a full healthy life” [32]. 
Yet, with severely constrained resources as in HIV treatment in South Africa, difficult ethical 
choices need to be made on whom is prioritized for treatment. Only a few studies give norma-
tive guidance on this subject. More specifically, Cleary et al. use the concept of “communi-
tarian claims” in which an individual is viewed as having a claim on health care due to being 
a member of a community or society—and by extension, society has some obligation to 
provide the care [33]. Claim strength is said to be affected by the severity of disease (sicker 
patients would be prioritized for moral reasons) or the individual capacity to benefit patients 
with a better prognosis would be prioritized as this would lead to better clinical outcomes). 
Another claim stems from the impact of the programme on population health (patients 
would be prioritized whose treatment contributes most to reduction of the epidemic). Obvi-
ously, these above factors lead to conflicting recommendations on treatment initiation, partic-
ularly regarding whether this should be early or late in the course of disease. Other factors 
influencing claims include the “social context” of those in need. Kimmel et al., [15] showed 
that professionals in South Africa support prioritizing individual patients based on treatment 
adherence, pregnancy status, and severity of illness. Scholars take different positions when it 
comes to claim strength in the use of antiretrovirals for treatment or for prevention. Brock and 
Wikler argue that “the strongest moral imperative directs us to giving priority to saving the 
most lives (..) even if this means lowering the priority given to the goal of universal access to 
treatment, to provide maximum protection from HIV infection” [34]. In response, Macklin and 
Cowan reason that “it is unethical to deliberately watch patients with treatable
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 HIV/AIDS worsen and die (..) if medication for treatment are diverted to preexposure prophy-
laxis” [35]. Alternatively, Singh proposes that a state’s “minimum core obligation” be used as a 
guiding principle in HIV programmes. This would protect the interest of all people, and as a 
consequence, antiretrovirals should not be exclusively used for treatment but also for preven-
tion of HIV among, e.g. vulnerable young women [36].
Feasibility
Feasibility refers to constraints at the personal and health system level that may impede the 
implementation of HIV treatment programmes. A recent study in South Africa assessed the 
human and financial resources requirement for different HIV treatment strategies [14] but 
overall there is little systematic guidance on how these constraints can be considered.
Fundamental weaknesses of present approaches
The above overview shows a rapidly growing evidencebase on the efficiency, equity and feasi-
bility of HIV treatment in South Africa. Yet, we argue there are two fundamental weaknesses 
to the current approaches that hamper policy makers in their ability to guide priority setting 
decisions.
Firstly, the HIV treatment programme in South Africa is not fully rational, with rational refer-
ring to “evidencebased allocation decisions in health taking into account all relevant deci-
sion-making criteria” [37]. The current programme is largely based on international guidelines 
and does not adequately account for aspects of efficiency, equity, and feasibility – these are 
not well documented, difficult to trade-off and therefore typically considered one at a time. 
For example, cost-effectiveness analyses consistently show that UTT is a highly efficient inter-
vention but thereby ignore the severe health system capacity constraints of such a strategy, 
other than the budget [14]. As another example, the use of pre-exposure prophylaxis (PrEP) 
has shown to be effective and costeffective to prevent HIV acquisition, but the community 
may prioritise to treat those people who are in greatest need of ART for their own health (even 
when this is less cost-effective). It is obvious that studies that fail to simultaneously consider 
efficiency, equity and feasibility concerns also fail to fully inform priority setting decisions [37]. 
Underlying reason is that studies are typically not multidisciplinary (they stem from either clin-
ical medicine, epidemiology, health economics or ethics), nor interdisciplinary (little effort has 
been made to take into account community views) [37].
Second, HIV treatment priority setting is a highly political process but in the seemingly absence 
of fair participatory processes, stakeholders’ views are typically not incorporated. The legiti-
macy of decision-making in health refers to the use of “generally considered fair conditions 
for distributive decision-making in health” [38–40] corresponding to “the belief that author-
ities, institutions, and social arrangements are appropriate, proper, and just” [40]. Experience 
shows that there is often justifiable disagreement among stakeholders on which values to use 
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in priority setting decisions [41,42]. Ethicists have realized there are no absolute truths on prin-
ciples to guide priority setting decisions, and argue that decision-makers must rely instead on 
a fair process (i.e. procedural fairness) to establish fair decisions [43,44]. In contrast, the studies 
– as referred to above – typically rely on the assumption of ideal policy-makers, and that the 
mere provision of quantified evidence to policy makers leads to justified priority setting deci-
sions. The resulting picture is that of an ad-hoc priority setting process on HIV treatment 
(Figure 1, left panel).
An alternative approach
In this chapter we propose an alternative approach to provide a better evidence base and 
include a fairer policy process to improve HIV treatment rationing. It is based upon two inno-
vative and increasingly important frameworks to health care rationing: the ethical framework 
on accountability for reasonableness (AFR) that fosters fair rationing, and multi-criteria deci-
sion analysis (MCDA) that fosters rational rationing [37,45–56]. We believe that the integration 
of the two frameworks in a single approach holds large potential to improve fair and rational 
rationing [57]. Pilot studies show that decision makers in low-income countries support the 
principles of both frameworks [54,58]. 
Accountability for Reasonableness 
AFR is generally considered as a leading conceptual framework on the ethics of health 
care rationing. Based on justice theories of democratic deliberation, it aims to strengthen 
the fairness of rationing decisions [43,44]. Central to the framework is the acceptance that 
people may justifiably disagree on what reasons to consider when priorities are made. 
In order to narrow the scope of controversy, AFR relies on “fair deliberative procedures 
that yield a range of acceptable answers” [43]. Therefore, AFR provides structure for deci-
sion-makers to establish priorities for their specific contexts, while taking into account 
limited resources and regulatory conditions. Its central notion of democratic learning 
presumes that a continuous participatory process will lead to better knowledge and 
consensus building on criteria for decisions, and thus also strengthening agreement on - 
or at least acceptance of - decisions. AFR does not replace any other guideline, planning 
or decision making process, but adds procedural principles to support their implementa-
tion. The AFR framework consists of four conditions. 
  Relevance. Priority-setting decisions should be based on evidence, reasons and principles 
accepted by the stakeholders as relevant for meeting health needs fairly in their contexts. 
Closely linked to this condition is the inclusion of a broad range of stakeholders in the deci-
sion-making process. Having a wide range of stakeholders participating in the deliberation 
would help include the full range of relevant reasons and facilitate the implementation of 
the decisions made.
  Publicity. Decision makers should make the process of priority-setting transparent including 
the reasons behind the decisions. This gives the general public an opportunity to under-
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Figure 1 Ad-hoc versus rational and fair rationing (based on [37])
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stand the values of the choices involved and a possibility to assess whether the relevant 
procedures are being followed. Publicity is important because it facilitates comparison 
from case to case to ensure consistency; it invokes appeal and may improve trust.
  Appeals/Revision. The appeals condition is a mechanism that provides the public with an 
opportunity to dispute and challenge decisions. Thus, it also offers the decision makers 
an option to revise decisions in the light of further arguments. An appeals mechanism 
enriches decision-making process because initial agreement on reasons can be reassessed 
in light of new evidence. 
  Leadership/enforcement. There must be public or voluntary regulation of the deci-
sion-making process to ensure that relevance, publicity and appeals mechanisms are 
enforced and that decisions are considered as fair. Proper enforcement of fairness in 
decision making will ensure that decisions are acceptable and can be supported by all 
concerned. Activities based on such decisions are also likely to be more effective and 
sustainable. 
Many authors propose AFR as a guiding framework on the fairness of HIV treatment [33,35,41,42]. 
Yet, it has been criticised for being of limited practical use, i.e. for not detailing the ‘Relevance 
conditions’, and how to include relevant evidence in the deliberation process [57,59]. Given the 
importance of AFR as conceptual framework in health care rationing, there is an urgent need 
to put it into operation.
Multi-criteria decision analysis (MCDA)
MCDA is theoretically grounded in multi-attribute utility theory [60] and sets programme 
priorities by referring to a comprehensive set of explicit criteria and guides decision makers in 
understanding the trade-offs between values that may be conflicting [37]. As such, it could be 
used in studies on rationing of HIV treatment, to simultaneously consider feasibility, efficiency 
and equity concerns. 
MCDA is routinely used in other disciplines like agriculture [61,62], as a response to the 
observed inability of people to effectively analyze multiple streams of dissimilar information, 
but knows relatively few applications in health. An example of the use of MCDA, in HIV treat-
ment is a study by Cleary et al [41] in South Africa – who used mathematical programming 
techniques to trade-off equity and efficiency concerns. They estimated the health effects at 
different budget levels in the absence of any equity constraint (“health maximization”), and in 
the presence of two equity constraints: “equal treatment to all”, and “decent minimum”. The 
conclusion was that “health maximization” could achieve sizeable health gains but this would 
leave a quarter of those eligible for treatment without care. “Equal treatment” and a “decent 
minimum” would be more equitable but lead to less profound health gains. Another study 
has used MCDA to set priorities in HIV/AIDS control in Thailand [51,53] and Indonesia [63,64]. 
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A core component of any MCDA is the performance matrix which scores all programme 
options in terms of their performance on relevant criteria. Table 1 shows a hypothetical 
performance matrix for the evaluation of HIV treatment programmes. Each row describes a 
programme option (on how to deliver HIV treatment, when to initiate treatment, and who gets 
targeted for treatment) and each column describes the performance of the options against 
the criteria “feasibility”, “efficiency”, and “equity”. For example, mobile-clinic based treatment 
does not perform well on “efficiency” (as mobile clinics are relatively costly), but good on 
“equity” (as it is a way to reach remote areas and provide treatment to all). The matrix in Table 
1 is highly simplified — in reality, more criteria may be included which makes it adjustable to 
context. The matrix also quantifies the detailed performance on all criteria as well as trade-offs. 
For example, per programme option, the matrix may detail the number of life-years averted, 
among which population groups these occur, the expected costs, and required health system 
Table 1. Hypothetical and simplified MCDA for HIV treatment in South Africa
HIV TREATMENT
PROGRAMME OPTION
FEASIBILITY† EFFICIENCY† EQUITY† OTHER TOTAL‡
programme option Health system 
constraints
Acceptability Costs per 
health gain
Fair distribution 
of health gains
…..
How to deliver treatment
Hospital-based treatment •• •• •• •• ••
Facility-based treatment ••• ••• ••••• •••• ••••
Mobile clinic-based treatment • •••• •• ••••• •••
Transport subsidies •• •••• •• ••••• •••
When to initiate treatment
Treatment CD4 < 200 cells/μl ••••• ••• •• •••• •••
Treatment CD4 < 350 cells/μl ••• ••• •••• ••• •••
Universal test and treat • •• ••••• • ••
Who gets targeted for treatment
Discordant couples‡‡ ••• •• ••••• •• •••
Compliant patient groups‡‡ ••• •• ••••• • •••
Pregnant women‡‡ ••• •••• ••• ••• ••••
Productive adults ••• ••• ••• • ••
First-come first-serve ••• • •• • ••
Weights 20 20 30 30
 † The performance of interventions on feasibility, efficiency and equity is hypothetical and for iIIustrative purposes only. 
Criteria are example criteria only. The scoring ranges from • to ••••• respectively representing a very weak to very strong perfor-
mance of an intervention on a certain criteria.   ‡The total is calculated as the weighted scores on all criteria and rounded-off; 
‡‡ Irrespective of CD4 cell count. 
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capacity — this allows a quantification of the trade-offs. In addition, in a real life application, the 
programme options in the performance matrix include coverage levels and can be combined.
There are several ways to interpret the performance matrix. In a qualitative inspection, any 
decision maker simply makes implicit judgments on the weights of the various criteria. Alter-
natively, in a quantitative inspection, any decision maker weighs the different criteria on the 
basis of their relative importance, and multiplies the scores by the weights to obtain weighted 
averages for all programmes. Programmes can subsequently be rank-ordered according to 
these weighted averages, somehow representing social welfare [53]. Table 1 shows hypothet-
ical criteria weights at the bottom row, and weighted averages in the utter right column, to 
illustrate the latter; here facility-based treatment would be ranked first in the choice on ‘how 
to deliver treatment’ [37]. 
The contours of an alternative approach 
The integration of the two frameworks in a single approach (Figure 1) holds large potential 
to improve fair and rational rationing [57]. While important frameworks on themselves, AFR 
should be informed by better evidence, and MCDA could be very useful in this regard if imple-
mented in an accountable and transparent way. 
The contours of an alternative approach, including five steps, are shown in Figure 2. A first step 
involves the formation of a consultation panel consisting of all relevant stakeholders and this 
may include representatives from a broad range of parties, such as decision makers, commu-
nity representatives, people living with HIV/AIDS, health professionals, etc [48,53]. The forma-
tion of this panel can be a gradual process starting with the present decision-making body. 
In a second step, the panel identifies the decision-making criteria on the basis of local values. 
This involves a deliberative process in which panel members put forward relevant criteria 
(reasons) for rationing and discuss reasons, principles, and evidence that each view as relevant 
to making fair decisions about priorities. These criteria are discussed, and ultimately approved 
or rejected, by other panel members. The aim is to reach acceptance on a set of criteria that 
are considered reasonable by all panel members. Sometimes this will be through consensus or 
through democratic voting but other times through hierarchical decision making. Even these 
cases can be compatible with AFR when all values and criteria have been deliberated in a fair 
way, the rationales for the decisions are made available and appeals can be made when the 
rationing decision is implemented. 
This paper proposes the use of criteria under the general headings of “feasibility”, “efficiency” 
and “equity”, but these criteria are obviously not predetermined. Instead, these specific criteria 
should be defined by the consultation panel as an outcome of stakeholders’ discussions on 
which values they find most important for HIV priority setting. 
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A third step concerns the construction of the performance matrix, and this is the core 
component of any MCDA. In this step, all programme options are scored in terms of their 
performance on the selected criteria. In a fourth step, the panel interprets the performance 
matrix. This may or may not involve the weighing of the relevant criteria. The AFR framework 
stipulates that this step always includes a component of deliberation to discuss these weights, 
to identify any other criteria (that may have been ignored in the previous steps or that cannot 
be quantified), and to address the reasonability of the final ranking ordering. Step five is the 
phase of evaluating the rationing decision arrived at, and relates to the transparency, appeal 
and enforcement conditions of AFR (as described above). 
Health care rationing is a continuous process, where ethical dilemmas and programme priori-
ties may regularly need to be updated in the light of changes of available programme options, 
of programme characteristics in terms of efficiency, equity and feasibility, or of stakeholders’ 
preferences. Health care rationing is therefore represented here as a cyclical process. The cycle 
also reflects that health care rationing is a (democratic) interactive learning process, in which 
the consultation panel constantly refines the participatory process of identifying, elaborating 
and deciding on the inclusion of further relevant stakeholders, criteria and evidence. 
Figure 2. The health care rationing process of HIV treatment programmes -
    an alternative approach
1
Formation of
consultation panel
2
Denition of
relevant set of criteria
3
Assessment of 
performance of 
programmes
4
Arrangement of 
deliberative process 
on priorities
5
Implementing rationing
decision and evaluation
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Discussion
Balancing feasibility, efficiency and equity in HIV priority setting is a major challenge, and we 
have shown that present approaches fall short. We propose an alternative approach that inte-
grates two existing frameworks, and believe this provides a better evidence base and outlines 
a fairer policy process to improve HIV treatment rationing. 
This approach is innovative in a number of ways. Most importantly, the programme integrates 
separate disciplines of thought on health care rationing in a single framework. The scientific 
literature of health care rationing – whether it is in low-, middle- or high-income countries –
typically does not go beyond the boundaries of traditional disciplines like medicine, epide-
miology, health economics and ethics. Our suggested approach unites insights and methods 
from these disciplines, and merges disease modelling, cost-effectiveness analysis, equity anal-
ysis and procedural fairness in one single approach. The potential of merging approaches 
from different disciplines has been named before by Peacock et al, who proposed a novel 
interdisciplinary framework combining MCDA, AFR, Participatory Action Research (PAR) and 
Programme Budgeting and Marginal Analysis (PMBA) [59]. However, to the best of our knowl-
edge, this novel framework has not been explicitly put in practice. Yet, at the same time, PBMA 
is reported to routinely take care of many of the aspects raised above [65]. 
The approach can be implemented at different political levels including national, province, 
district and community level. Here it provides support for management and a strategy for 
quality improvement in regard to health care rationing, including a heretofore-missing 
evidence-base for these decisions. By combining the MCDA and AFR, the approach incorpo-
rates many elements that bring a large capacity for considerations. Its implementation results 
in policies that are grounded on evidence-based research and that encourage involvement 
from all stakeholders. More importantly it may lead to a greater understanding and accepta-
bility also from those directly affected by policy changes [57]. 
The use of our proposed approach in different decision-making contexts may lead to the 
inclusion of different stakeholders, identification of different criteria and ultimately to the 
selection of different interventions. While this may reflect the presence of different values in 
these different contexts, it may possibly also reflect differences in the rigor of implementa-
tion of the approach. The development of checklists on stakeholders and criteria (as proposed 
by [66] to consider may reduce these latter differences. The use of a standardized approach 
including a priori defined criteria (and possibly even criteria weights) would ignore differences 
in values in different contexts, and the importance of the deliberative process. 
The integration of AFR and MCDA also poses a number of challenges. First, whereas AFR can 
be considered as a continuous democratic governance approach based on reasons that any 
stakeholders brings into play, MCDA requires a higher level of competence for its interpreta-
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tion. This may run the risk of leaving out some stakeholders and limit the influence of others. 
Yet, first experiences on the use of MCDA did not identify this as a barrier in the process [48]. 
Second, the development of rigour evidence for health care rationing, through MCDA, requires 
innovative research. Quantitative measures of equity and feasibility need to be developed, and 
measures of impact and efficiency need refinement. Also, mathematical models need to be 
developed that reflect the performance of treatment programmes in terms of efficiency and 
equity - these models could include measures of feasibility (as e.g. health workers availability) 
as health system capacity constraints. Yet, if the latter would be necessary in any health care 
rationing process, MCDA runs the risk of needing a high level of expertise to provide credible 
evidence to the rationing process. One way of addressing this is to allow, at least in the begin-
ning of a process, more reliance on qualitative analysis within the consultation panel [67,68]. 
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Abstract
Various methods have been used to guide priority setting in health but have been crit-
icized for being rather technocratic, not sufficiently pragmatic and not process orien-
tated. Recently, an integrated approach was proposed that combines the Multi Criteria 
Decision Analysis (MCDA) and Accountability for Reasonableness (AFR) frameworks 
for priority setting of health interventions. We describe the first time implementation 
of the MCDA-AFR approach to develop the five-years (2014-2018) HIV/AIDS strategic 
plan for West Java province in Indonesia. A project team (n=5) was formed that imple-
mented the following steps between January and October 2013: 
1) formation of a stakeholders’ consultation panel, 2) definition of criteria for priority 
setting, 3) assessment of performance of interventions, 4) arrangement of a deliber-
ative process on priorities, 5) implementation of rationing decisions and evaluation. 
First, a consultation panel (n=23) was formed of policy-makers, West Java AIDS commis-
sion’s program managers, community organizations’ staff, health care workers and 
researchers. Second, the panel selected four criteria for priority setting: 
an intervention’s 1) impact on the epidemic, 2) impact on reducing stigma in society, 
3) cost-effectiveness, and 4) contribution to universal access. Third, the panel proposed 
50 interventions and data was collected on their performance on the four criteria. Fourth, 
after a deliberative process the panel agreed that HIV testing and treatment packages 
were the most attractive intervention to scale while mitigation activities were least 
attractive. Fifth, funding and implementation agencies were identified for the most 
attractive interventions. Compared to previous processes, this approach improved the 
transparency, the use of evidence and stakeholder engagement in priority setting in 
HIV/AIDS control. Main challenges were the availability of data and existing structures 
like the influence of donors and a missing direct link to funding of the prioritized inter-
ventions. To further improve the combined MCDA-AFR approach we propose to incor-
porate a situational analysis, to select context specific appeal and publicity mecha-
nisms and to develop better methodological guidelines for its application. 
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Background
Indonesia (243 million inhabitants) has one of Asia’s fastest growing HIV/AIDS epidemic with 
an estimated 610,000 people living with HIV/AIDS (PLWHA) in 2012 [1]. While at the start the 
epidemic was spread mainly through people who inject drugs (PWID), now sexual transmis-
sion causes most new HIV infections with increasing numbers among men having sex with 
men (MSM), female sex workers (FSWs) and their clients, and sero-discordant couples [1]. In a 
resource constrained environment, priority setting of HIV/AIDS interventions is crucial: in 2010 
only US$ 69 million was spent on HIV/AIDS control in Indonesia while an estimated US$ 152 
million was required to effectively control the epidemic [2,3].
While AIDS commissions in Indonesia are established at the national, provincial and district levels 
to coordinate the HIV/AIDS response, an evaluation by Tromp et al. [4] revealed weaknesses 
in strategic planning. Strategic plans typically contained a long list of activities and criteria to 
prioritize these were not stated explicitly and neither were they transparent for stakeholders. 
Although many stakeholders were involved in the development of the five year strategic plan for 
HIV/AIDS control their engagement could be improved. Furthermore, formal measures to give 
stakeholders an opportunity to appeal against decisions are not yet established. 
In both developed and developing countries processes of setting priority for public spending 
are challenging [5]. The limited use of systematic evidence often results in historical based 
and ad-hoc decisions [6]. Decisions are often made without public participation and hence 
are not always fully legitimate [7,8]. Particularly in low resource settings, contextual influences 
may be greater, information more scarce and capacity more limited [5]. However, in high-in-
come countries effective priority setting is becoming more important as well, now that popu-
lations live longer, expectations of good health raise and technical solutions to health prob-
lems expand, whilst resources become increasingly limited. Better priority setting processes 
would lead to better acceptance of policy decisions by the public, more rational funding deci-
sions and ultimately to improved health [5,9,10]. 
Various methods have been introduced to guide priority setting but there is little consensus 
on which is the most optimal one and until today no single method can be recommended 
[5]. Recently, Baltussen et al. [11] put forward an integrated approach that combines elements 
of the Multi Criteria Decision Analysis (MCDA) and Accountability for Reasonableness (AFR) 
frameworks for priority setting in health. The MCDA framework explicitly identifies criteria for 
priority setting and collects an evidence-base to guide decisions. Yet, it has been criticized 
for being too technocratic and not sufficiently focused on the decision making process [5,12]. 
The AFR framework outlines four conditions to ensure fair priority setting processes but these 
have been criticized for being conceptually abstract, difficult to implement and the framework 
lacks practical guidance for policy makers to set priorities [5,10,13–16]. An integration of both 
frameworks may therefore improve priority setting in health. 
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In this paper we describe the first time application of the integrated AFR-MCDA approach to 
develop the five-years (2014-2018) HIV/AIDS strategic plan for West Java province in Indonesia. 
In this article we describe the implementation steps, the results, the challenges and recom-
mendations for further development of the approach. 
Methods
Context of HIV/AIDS in Indonesia
West Java (43 million inhabitants) is among the provinces with the highest HIV/AIDS burden 
in Indonesia with an estimated 59 thousand PLWHA in 2013 [17]. The epidemic is concen-
trated in high-risk groups, with estimated HIV prevalence rates of 23.2% among people who 
inject drugs (PWID), 6.3% among female sex workers (FSWs) and 8.4% among men having 
sex with men (MSM) in 2013. However, it has started shifting towards the general popula-
tion with an estimated HIV prevalence of 0.18% in 2013. West Java has implemented a wide 
range of HIV/AIDS activities, including harm reduction programs for PWID, voluntary coun-
seling and testing and ART provision at hospital and community clinics, condom distribution 
and a school-based education program in Bandung city. However program coverage remains 
low, with 18% of those in need of treatment (CD4 cell count <350) actually receiving ART, 39% 
for needle exchange programs for PWID, and <1% for most mitigation programs like microfi-
nance programs for female sex workers [18]. 
Formation of the project team
In September 2012, the West Java provincial AIDS commission, Padjadjaran University Bandung 
Indonesia and Radboudumc The Netherlands established an agreement to implement the 
integrated MCDA-AFR approach for priority setting in the context of the development of the 
five-years (2014-2018) HIV/AIDS strategic plan for West Java. These parties formed a project 
team (n=5; NT, RP, RW, AL and RB) that coordinated the implementation. The West Java provin-
cial AIDS commission, which coordinates the development and implementation of the stra-
tegic plan, has a multi-sectorial design. The commission comprises representatives of various 
government offices (i.e. health, education, social tourism, law, and religious affairs), non-gov-
ernmental organizations (including community-based organizations) and health care facilities. 
The daily staff of the AIDS commission is responsible for the coordination of HIV activities in 
the province and provides support to the various government and non-government agencies 
that implement HIV/AIDS control activities [4]. In order to implement the integrated MCDA-AFR 
approach, the project team followed the five steps proposed by the Baltussen et al. [11]. Here-
after we will describe the implementation of each step (also presented in Figure 1). 
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The priority setting process: five steps
Step 1. Formation of a consultation panel
In step one, a consultation panel (n=23) was established that involved members from Tim Asis-
tensi (a working group of HIV/AIDS experts established at national and provincial AIDS commis-
sions in Indonesia), which consists of retired government staff (n=1), current government staff 
(n=3, health office, labour office and coordinating body for family planning) and a representative 
of a NGO on family planning (n=1). This team was complemented with government staff working 
on HIV/AIDS (health office, education office n=2), NGO staff (n=3) (representing PLWHA and high 
at risk groups), AIDS commission secretariat staff (n=2) program managers (n=5) and researchers 
(n=6) with backgrounds in economics and epidemiology from Padjadjaran university.
To stimulate participation, the consultation panel agreed that those not attending meetings 
could not influence the decisions that would be taken. An information bulletin was developed 
on request of the panel to keep all members and other relevant persons informed about the 
process and any decisions taken. The consultation panel agreed on a schedule of meetings 
(facilitated by the project team) for the development of the strategic plan. 
Step 2. Definition of relevant set of criteria
A focus group discussion (FGD) was held with the consultation panel (attendance rate: 43%) 
to select criteria for priority setting. Four different sources were used to guide the discussion: 
1) results of a survey on the importance of HIV criteria for priority setting rated by health care 
workers, policy makers, PLWHA and general population in West Java [19], 2) criteria implicitly 
Figure 1. The health care priority setting process based the integrated AFR and MCDA
   frame works as proposed by Baltussen et al. [11]
1
Formation of
consultation panel
2
Denition of
relevant set of criteria
3
Assessment of 
performance of 
programmes
4
Arrangement of 
deliberative process 
on priorities
5
Implementing rationing
decision and evaluation
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Table 1. Sources used during focus group discussion to define criteria for priority setting of 
  interventions in 5 years HIV/AIDS strategic plan for West Java province
SOURCE CRITERIA
Survey among health care workers, policy makers, 
people living with HIV/AIDS and general population 
in West Java (top 10 criteria of each stakeholder 
group was included) 
[19] 
Impact on HIV epidemic 
Stigma reduction 
Quality of care 
Individual effectiveness
Service requirement
Health care workers requirements
Information requirements
Political acceptabiltiy
Legal rules 
Sustainable financing 
Unit costs
Prevention versus treatment
Products requirements
Individual effectiveness
Level at risk individual
West Java planning process for 2009-2013 HIV/AIDS 
strategic plan (criteria implicitly used in discussions) [4]
Current HIV/AIDS epidemic
Guidelines from national AIDS commissions (four areas of intervention)
Previous experiences of programs effectiveness
Mix of local political, cultural, and religious values
Feasibility related to current health system infrastructure
Feasibility of reaching target groups
Likelihood of receiving local budget funding
Current program coverage
Programs enacted in the past (but no longer relevant)
Focus on high risk groups
Programs applicable in all cities in province
Indonesia’s national HIV/AIDS strategic plan 2010-
2014 (considerations stated in document) [2]
Impact on reducing spread of HIV epidemic
Cost-effectiveness
WHO’s programmatic guidance for ART [20] Cost-effectiveness
Equity
Feasibility
used during the development of the West Java HIV/AIDS strategic plan 2009-2013 [4] 3) consid-
erations stated in Indonesia’s national HIV/AIDS strategic plan 2010-2014 [2], and 4) criteria 
proposed by the World Health Organization (WHO) for programmatic guidance of ART [20]. 
An overview of the criteria is presented in Table 1. The criteria were separated into two catego-
ries, i.e. whether criteria are related to the WHO health systems’ goals or to the building blocks. 
During the focus group discussion the panel agreed to select four criteria related to the health 
system goals for inclusion of HIV/AIDS interventions in the strategic plan: 1) its impact on the 
epidemic (in terms of new HIV infections averted), 2) its impact on reducing in society, 3) its 
cost-effectiveness, and 4) its contribution to universal access. Together these criteria reflect 
stakeholders’ preferences for the health system goals that HIV/AIDS intervention would need 
to contribute to. In addition, four feasibility criteria were selected, related to some of the health 
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system building blocks: 1) health workforce capacity, 2) infrastructure capacity, 3) sustainability 
of funding, and 4) cultural, political and religious acceptability. Together, these criteria reflect 
stakeholders’ opinions on the most important barriers for implementation of HIV/AIDS inter-
ventions in West Java province. A survey was held among 19 out of the 26 members (response 
rate 73.1%) of the consultation panel to measure their perception on the relative importance 
(also called weights) of the goals criteria. The members were asked to divide 100 points among 
the four criteria to indicate its relative importance.
Step 3. Assessment of performance of interventions
The performance matrix is a key feature of MCDA and presents the scores obtained for each 
HIV/AIDS intervention on the selected criteria, which can then be systematically compared and 
ranked [6]. During the implementation process the project team decided to only include the 
criteria related to the health systems goals in the performance matrix as the feasibility criteria 
might only be relevant on the short term and should therefore not determine long term strat-
egies. Hereafter, the steps are described that were taken to establish the performance matrix. 
Identification of interventions 
The consultation panel established a wider list of 70 stakeholders (including West Java and 
national government institutions, NGOs and eight private sector parties) who proposed inter-
ventions for the strategic plan during six focus group discussions. The FDGs were categorized 
according to the working groups established in most AIDS commissions in Indonesia and the 
attendance rate differed per group: prevention sexual transmission 60% (6/10), care support 
treatment 2% (3/18); harm reduction 100% (11/11); mitigation 39% (7/19); media 67% (12/18) and 
workplace 41% (7/17). The proposed interventions were divided into core and support interven-
tions, with the latter referring to advocacy, policy and coordination activities. Only core interven-
tions were included in the performance matrix as the project team reasoned that supporting 
interventions could only be implemented for prioritized core interventions. For example, advo-
cacy activities to reduce cultural and religious barriers related to condom use to ensure effec-
tive implementation are required only if condom interventions are prioritized for the new five-
year plan. In addition, the project team added interventions that already existed in West Java 
province and intervention options related to international debates, for example alternative ART 
strategies. Some interventions were combined, for example a treatment package that included 
outreach, testing, treatment, adherence counseling and peer support. This was done in the 
understanding that it would be unrealistic to evaluate treatment interventions without taking 
into account the testing. In total 50 interventions were identified of which 10 were hypothet-
ical ones put forward by stakeholders and not yet established and implemented in West Java. 
Scoring of interventions 
To establish scores on the performance of interventions per criterion we first consulted a data-
base with Indonesian HIV/AIDS peer-reviewed literature up to June 2013 (described in detail 
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elsewhere [21]) and the Indonesian HIV/AIDS grey-literature inventory 1995-2009 (National 
AIDS commission 2009). From both sources two studies on cost-effectiveness of a Methadone 
Maintenance Treatment (MMT) [22] and Voluntary Counseling and Testing (VCT) program 
[23] could directly inform on the scores of interventions in the performance matrix. Due to 
the limited Indonesian evidence base, we performed an additional non-systematic search in 
Pubmed to find evidence on the cost-effectiveness and impact on stigma reduction of inter-
ventions. We identified no articles that could inform on the impact of stigma reduction of the 
included interventions, and one comprehensive review on the impact on the epidemic and 
cost-effectiveness on a wide range of HIV/AIDS interventions in Asia [24]. 
Due to scarce availability of literature the project team decided to consult Indonesian experts 
to score the performance of interventions. A relatively simple three level ‘low’, ‘moderate’ and 
‘high’ performance scoring system was used to make the performance matrix understandable 
for the consultation panel. 
For the criterion ‘impact on the epidemic’ a panel of three experts (a health economist, a 
public health expert and WHO country office staff member) scored all interventions on the 
basis of discussion. The panel was informed with the available literature on the effective-
ness and cost-effectiveness of HIV/AIDS interventions and the latest projections of the HIV/
AIDS epidemic with use of the Asian Epidemic Model version 3.2 (described in detail else-
where [17]. For the criterion ‘cost-effectiveness’, the project team calculated first the budget 
impact of each intervention using current coverage data, population size estimations from 
local monitoring data and local experts and the intervention unit cost estimations obtained 
from the national inventory of the National AIDS commission [25], scientific literature for Indo-
nesian setting [26], the Futures international literature database [27] and expert opinion of 
local program managers from the West Java AIDS commission, governments, and NGOs. For 
each intervention the budget impact was calculated for 5 years (2014-2018) assuming a scale 
up coverage of 50% among target population and 43% additional programs costs based on 
the latest NASA/UNGASS reporting in 2011 [3]. 
To score the cost-effectiveness of interventions the budget impact was then divided by the 
project team into four categories: low, middle, high and very high budget impact. The project 
team determined the overall cost-effectiveness scores by combining the impact on the 
epidemic and budget impact scores. The results are presented in Table 2. 
For the criterion ‘stigma reduction’, one anthropologist and one psychologist/HIV counselor 
formed an expert panel. The panel decided to rate first the impact of interventions on ‘self-en-
acted’ and ‘societal stigma’ and then agreed on an overall score. For the criterion ‘universal 
coverage’, the project team gave ‘moderate’ scores for all interventions because they reasoned 
that the coverage target set for 2018 and not the current coverage (in 2013) determines the 
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performance of an intervention. At this stage of the strategic planning process coverage 
targets for 2018 were not yet defined and therefore the performance of interventions on 
achieving universal coverage did not differ. 
Quality of evidence
To indicate the quality of evidence for the scores of interventions a three star rating system was 
used. Three stars indicated ‘high quality’ when based on scientific literature, two stars meaning 
‘moderate quality’ when based on experts opinion given for existing interventions and one star 
meaning ‘low quality’ when based on expert opinion given for hypothetical interventions. 
Step 4. Arrangement of deliberative process on priorities
The consultation panel participated during a full day meeting (participation rate 54% (13/24)) 
in an interactive exercise to critically assess and build consensus on the scores. For each inter-
vention an A1 size poster was developed that presented the intervention description, perfor-
mance scores and quality of evidence (Figure 2). All participants received 50 comment cards 
and were asked to walk around to look at the intervention performance and indicate on the 
comment card if they agreed or disagreed with the scores (Figure 3). In case of disagreement 
the participant was asked to provide an alternative score and related rationale. The comments 
were entered in a excel sheet on the spot and the consultation panel agreed to use a cut-off 
point of 19% disagreement (an average disagreement percentage for the four scores) in order 
to discuss the scores of a programs. In total all scores of 7 programs were discussed and 10 
scores were adapted (Table 3)
For each intervention a rank order was calculated by the sum of the weights times the scores 
per criterion. The performance matrix (Table 4, p212) was then presented to the consultation 
panel and they were given the opportunity to move interventions up or down in the rank 
order on the basis of additional reasons that were not captured by the four criteria for priority 
setting. Meeting participants proposed changes in the rank order of five interventions but the 
reasoning was not always rational (according the view of the project team) and only partly 
Table 2. Categories used to determine the cost-effectiveness of HIV/AIDS interventions
BUDGET IMPACT IMPACT ON THE EPIDEMIC COST-EFFECTIVENESS
very high moderate moderately cost-effective
moderate low not cost-effective
moderate moderate moderately cost-effective
low moderate cost-effective 
moderate low moderate cost-effective
moderate low low not cost-effective
very high high moderately cost-effective
very high low not cost-effective
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corrected by other members (Table 5). The consultation panel mainly commented on the low 
rank order of harm reduction and mitigation interventions and proposed to split up the inter-
ventions into the following categories: prevention, treatment and mitigation. 
Step 5. Implementation of rationing decision and evaluation
Because the reasoning during the deliberative process for changing the rank order was not 
always rational the project team decided to present the original rank order again to the 
consultation panel in a two-day meeting (70% participation rate at day one and 61% at day). 
This meeting was organized to discuss the draft document for the strategic plan and the 
implementation of interventions. After an extensive explanation by the project team on the 
development of the performance matrix, the consultation panel agreed on the rank order but 
proposed a division of interventions on the basis of the UNAIDS goals: 1) zero new infections, 
2) zero AIDS related death and 3) zero discrimination. 
Table 3. Overview of changes made in an intervention’s score on the criteria during the 
  deliberative process in step 4
INTERVENTION/CRITERIA CRITERIA SCORES
INTERVENTION  
TOTAL SCORE
INTERVENTION  
RANK ORDER
old new old new old new
Outreach stand alone
Impact on the epidemic 1 2 100 159 6 2
Stigma reduction 1 2
Post exposure prophylaxes 
Stigma reduction 1 0 48 23 12 13
Microloans
Impact on the epidemic 1 0 82 23 9 13
Stigma reduction 1 0
Transport subsidies for ART patients
Stigma reduction 1 0 48 23 12 13
World AIDS day
Impact on the epidemic 0 1 23 82 13 9
Stigma reduction 0 1
AIDS ambassador
Stigma reduction 0 1 23 48 13 12
IEC on televisions in minimarkets
Cost-effectiveness 1 0 100 82 6 9
ART = antiretroviral treatment, IEC = information, education and communication
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Figure 2. Example a scoring card that presents the performance of an intervention 
  (in this case school based education) on the four criteria 
Figure 3. Example of a comment card used by the consultation panel to comment on
  performance of and intervention (in this case school based education) 
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Table 4. Performance matrix used for priority setting of HIV/AIDS interventions for West 
  Java’s HIV/AIDS strategic plan 2014-2018
CRITERIA 
No. Category Intervention Im
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n
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-
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ni
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Co
ve
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ge
Total 
score Rank
 Weights 34 25 18 23   
1a-h Treatment Option A-H: HIV testing and 
treatment packagea
2b 2 2 1 177c 1
2 Prevention School Based Education 2 2 2 1 177 1
3 Prevention IEC during Moslem Friday Prayers 2 2 2 1 177 1
4 Prevention Websites and Social Media 2 2 2 1 177 1
5 Prevention Outreach Stand Alone 2 2 1 1 159 2
6 Prevention Citizen's AIDS Program 2 2 1 1 159 2
7 Prevention Work Place Programs 2 2 1 1 159 2
8 Prevention Condom Distribution and 
Promotion
2 0 2 1 127 3
9 Prevention Condom Sold with Energy Drinks in 
Hotspot
2 0 2 1 127 3
10 Prevention PMTCT – Component 1: IEC for 
Women in Reproductive Age
1 2 1 1 125 4
11 Prevention Radio - Talk shows 1 2 1 1 125 4
12 Prevention Television - Talk shows 1 2 1 1 125 4
13 Prevention Printed media - HIV columns 1 2 1 1 125 4
14 Prevention VCT stand alone 1 1 2 1 118 5
15 Prevention PMTCT – Component 2: Family and 
Reproductive Health Counseling for 
HIV-infected Women 
1 1 2 1 118 5
16 Prevention PMTCT – Component 3: PMTCT B+ 1 1 2 1 118 5
17 Mitigation Probation Program for Prisoners 1 1 2 1 118 5
18 Prevention PMTCT – Component 1: Opt-out 
Testing for Pregnant Women 
1 1 1 1 100 6
19 Prevention Universal Precautions 1 1 1 1 100 6
20 Prevention Training for Journalists 1 1 1 1 100 6
21 Prevention Printed IEC (Leaflets, Stickers, 
Posters)
1 1 1 1 100 6
22 Prevention Radio - adlibs 1 1 1 1 100 6
23 Prevention Radio – HIV Public Service 
Announcements
1 1 1 1 100 6
24 Prevention Blood Screening 1 0 2 1 93 7
25 Prevention STI Testing & Treatment 2 0 0 1 91 8
26 Mitigation Vocational Training 1 1 0 1 82 9
27 Prevention Television – HIV Public Service 
Announcements
1 1 0 1 82 9
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CRITERIA 
No. Category Intervention Im
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ra
ge
Total 
score Rank
28 Prevention World AIDS day 1 1 0 1 82 9
29 Prevention IEC on Televisions in Minimarkets 1 1 0 1 82 9
30 Mitigation Community-based Rehabilitation 0 2 0 1 73 10
31 Mitigation Stigma Reduction Training for Police 
Men & Law Enforcers
0 2 0 1 73 10
32 Mitigation Stigma Reduction Training for 
Health Care Workers
0 2 0 1 73 10
33 Prevention Needle Exchange and Medical 
Waste Management
1 0 0 1 57 11
34 Prevention Methadone + Peer support 1 0 0 1 57 11
35 Prevention VCT for pre marriage couples 0 1 0 1 48 12
36 Mitigation PMTCT – Component 4: Milk 
Program 
0 1 0 1 48 12
37 Prevention Functional Cure Experiments 0 1 0 1 48 12
38 Mitigation Education Scholarships for HIV-
infected People
0 1 0 1 48 12
39 Mitigation Support for Government Insurance 
Application (Jamkesmas)
0 1 0 1 48 12
40 Mitigation Psychological Counselling 0 1 0 1 48 12
41 Mitigation Legal support for stigmatized 
children in schools 
0 1 0 1 48 12
42 Prevention Edutainment Concerts 0 1 0 1 48 12
43 Prevention AIDS Ambassador 0 1 0 1 48 12
44 Prevention Post Exposure Profylaxes (PEP) 0 0 0 1 23 13
45 Treatment Opportunistic Infections (OI) 
Treatment
0 0 0 1 23 13
46 Mitigation Microloans 0 0 0 1 23 13
47 Mitigation Social Support for Widows (Group 
Discussion)
0 0 0 1 23 13
48 Mitigation Day Care for Children 0 0 0 1 23 13
49 Mitigation Transport Subsidies for ART patients 0 0 0 1 23 13
50 Mitigation In patient rehabilitation 0 0 0 1 23 13
Italics and bold = hypothetical intervention, does not yet exist in West Java
a The package consist of: outreach, voluntary counseling and testing, antiretroviral treatment, adherence counseling and 
peer support ; b The scores indicate the performance  of an intervention on the criteria: 2 = high, 1 = moderate, 0 = low. ; c 
The total score per intervention is calculated by the sum of the weights times the score per criterion, 2*34+2*25+2*18+2*23 = 
177; IEC = information, education and communication; PMTCT = prevention of mother to child transmission; VCT = volun-
tary counseling and testing, ART = antiretroviral treatment
Table 4. Continued
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Table 5. Overview of proposed changes in rank order of interventions in the performance 
  matrix and the rational given
OLD 
RANK 
PROPOSED 
RANK 
RATIONALE GIVEN BY MEETING PARTICIPANT 
Needle 
exchange 
and medical 
waste 
management
11 1 “The PWID epidemic might go up again, programs have been 
proven successfully in West Java to suppress the epidemic, this 
is the reason why the epidemic goes down’. This was challenged 
by another meeting participant who said: “But the National AIDS 
commission is not prioritizing on harm reduction programs 
anymore, because of the declining epidemic among PWID, they 
focus now more on sexual transmission of HIV”
STI testing 
and 
treatment 
8 1 “STI should have higher priority because it covers the low at risk 
groups, it therefor can have a wide coverage and great impact on 
the epidemic”
Blood 
screening
7 1 “This is like the same for the STI program, the blood screening 
program focuses on low at risk groups and therefor has a wide 
coverage and therefor great impact on the epidemic” 
IEC during 
Muslim Friday 
prayer’s 
1 1 “Those that are at high-risk and need information on HIV never 
attend Friday prayers.” Another participant challenged this and 
said: “The prevalence in low risk population (mainly women) is now 
increasing and that’s why National AIDS Commission focuses not 
anymore on PWID but also on general population, and therefor 
Friday prayers are useful.” 
IEC = information, education and communication, STI = sexual transmitted infections, PWID = people who inject drugs
Due to the proposed division of interventions into prevention, treatment and mitigation cate-
gories in step four, the project team prepared and held an exercise in which the consultation 
panel was split up in three groups on the basis of these categories to discuss coverage targets 
and funding and implementing parties for top interventions. For the treatment category the 
testing and treatment package was discussed and for prevention and mitigation the top five 
interventions with the highest rank order. 
During the meeting the consultation panel was also asked to comment on the draft document 
(written by the project team) but no major comments were made. In a follow up meeting with 
the consultation panel, no comments were made on the updated strategic document. There-
after, the West Java provincial planning board (BAPPEDA) invited representatives of different 
government offices to discuss the development of proposals for HIV/AIDS activities for submis-
sion to the Musrenbang. The Musrenbang is an annual event where government offices hand 
in proposals to the provincial planning board in order receive funding from the local govern-
ment budget (APBD). Then, the strategy was offered to the West Java governor for approval. 
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We compared the priority setting process on the basis of the AFR-MCDA approach with the 
previous strategic planning process in 2008 in West Java province (described by Tromp et al. 
[4] using the framework introduced by Sibbald et al. [28]. This framework outlines five process 
elements (stakeholder engagement, explicit process, clear and transparent information 
management, consideration of values and context, revision or appeal mechanism) and five 
outcome elements (stakeholder understanding, shifted resources, decision making quality, 
stakeholder acceptance & satisfaction, positive externalities) for successful priority setting. 
After reviewing various options for evaluation of priority setting processes, the framework by 
Sibbald et al seemed most comprehensive and has been successfully applied [29,30]. 
Results
Table 4 presents the performance matrix for West Java that shows for 50 selected HIV/AIDS 
interventions the scores per criterion, the overall score and rank order. The average criteria 
weights on a scale from 0 to 100 were: 34 for impact on the epidemic, 25 for stigma reduction, 
18 for cost-effectiveness and 23 for universal coverage. The performance scores were mainly 
based on expert opinion as scientific literature was scarce and the available Asian Epidemic 
Model version was not detailed enough to evaluate the impact on the epidemic and cost-ef-
fectiveness of most proposed interventions. Overall the consultation panel agreed that the 
Test and Treatment Package (including outreach, voluntary counseling and testing, partner 
notification, antiretroviral treatment and adherence counseling) is the most attractive inter-
vention to implement and scale up in West Java. These interventions are followed by preven-
tion interventions as School Based Education, HIV Information Education and Communication 
(IEC) during Moslem Friday Prayers, Websites and Social Media and the Citizens AIDS program. 
Mitigation and Harm Reduction interventions for PWID were considered to be relative unat-
tractive interventions as they performed less on the four criteria for priority setting. Harm 
reduction interventions were less effective as the Asian Epidemic Model projections showed 
a stabilization of the PWID epidemic and an increase of HIV incidence among MSM and low 
at risk women.
Process evaluation 
With regard to the process elements, the installment of the consultation panel may have 
improved stakeholder engagement, as compared in the previous development of the five-
year (2009-2013) strategic plan for HIV/AIDS control in West Java there was no explicit selec-
tion of stakeholders for participation. However, dominance was still observed by the project 
team in meetings and some stakeholders did not attend meetings. It may also require time 
and patience to set up democratic learning processes and before local stakeholders are 
committed to participate. The use of the MCDA-AFR approach and its five steps contributed 
to a more explicit process on which the consultation panel agreed and the development of 
the performance matrix contributed to more clear and transparent information management 
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by explicitly incorporating evidence into the priority setting process. Consideration of values 
and context is now taken into account with establishment of the consultation panel that iden-
tified explicit and context specific criteria and interventions and in the deliberative process 
opportunity was given to adapt the rank order with use of ethical and context specific values. 
However, considering the occasional non-rational reasoning that was observed by the project 
team during the deliberative process (Table 5), it is questionable whether stakeholders were 
able to express all values. Moreover, in the end the initial performance matrix determined the 
priorities in the strategic plan. As to Revision and appeals mechanisms, the process included a 
continuous involvement of the consultation panel that was given opportunity to appeal to the 
process and results at all times in meetings. More specifically, the interactive exercise as part 
of the deliberative process gave the opportunity to appeal on the scores of interventions and 
the rank order. However, it is unclear whether the exercise was accepted by the stakeholders 
and whether it was an effective mechanism for appeal [4]. 
Outcome evaluation
The outcome elements like Stakeholder understanding and Stakeholder acceptance and satis-
faction are difficult to evaluate at this moment, as this requires independent interviews with 
the participants of the consultation panel. The AFR and MCDA frameworks are conceptually 
difficult and may be difficult to understand which may affect stakeholder acceptance and 
satisfaction. The implementation of the MCDA-AFR approach was institutionalized in the West 
Java AIDS commission and improved their decision-making quality. In particular, the use avail-
able evidence is improved and the consistency of reasoning is enhanced compared to the 
previous process that used no explicit criteria for priority setting. At this moment, we cannot 
report on the shifted resources but the fragmented funding system on HIV/AIDS control, the 
missing direct link between the priorities set by the AIDS commission and the allocation of local 
government budget, and the high amount of donor funding for HIV/AIDS may hinder reallo-
cation of resources based on the priorities. Parallel to the implementation of the integrated 
MCDA-AFR approach, the West Java AIDS commission was asked by the provincial planning 
board (BAPPEDA) to give input on the priorities for HIV/AIDS control for the overall government 
plan for 2014-2018 for West Java province which may influence resource allocation. To respond 
to the request of the provincial planning board the project team informed the West Java AIDS 
commission with insights from the latest Asian Epidemic Model (AEM) projections of the HIV/
AIDS epidemic for West Java as at that time the performance matrix was not yet finalized. At 
the same time, the local planning board of West Java allocated funding to the provincial AIDS 
commission for the coordination of HIV/AIDS activities on the basis of the draft document of 
the strategic plan. The MCDA-AFR approach and outcomes were documented in the 5-years 
strategic document for HIV/AIDS control in West-Java that was approved by the governor. This 
official acknowledgement by the governor may also influence local funding streams for HIV/
AIDS control. A Positive externality noted by the project team was the strengthened collab-
oration between the local Padjadjaran University Bandung, embodying vast scientific knowl-
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edge on HIV/AIDS control, and the West Java AIDS commission. In addition, the National AIDS 
commission and UNAIDS Indonesia was informed about our project and showed interest to 
scale up the approach at district level to further improve decision-making in HIV/AIDS control. 
Discussion
The integrated MCDA-AFR approach for priority setting in health was implemented during 
the 5 year (2014-2018) HIV/AIDS strategic planning for West Java province. A consultation panel 
was established, criteria for priority setting were selected, a performance matrix was devel-
oped and in a deliberative process the stakeholders agreed that overall the test and treatment 
package is the most attractive intervention to implement and scale up in West Java, followed 
by prevention interventions as School Based Education, IEC during Moslem Friday Prayers, 
Websites and Social Media and the Citizens AIDS program. Mitigation and harm reduction 
interventions were considered less attractive interventions to scale up as they performed less 
on the four criteria used for priority setting. 
Challenges to using the integrated MCDA-AFR approach
On the basis of the above evaluation and our observations throughout the process we see 
various challenges within the application of the MCDA-AFR approach that need attention. 
First, for the assessment of the performance of interventions we relied mostly on expert opin-
ions, as the available local scientific evidence was scarce. This challenge may be overcome 
when an international repository is established on the impact of HIV/AIDS interventions on 
various criteria. Also, installment of mathematical models (like the AEM) at local level may be 
warranted, as those could predict the impact of interventions on the epidemic and inform on 
the related feasibility challenges (like an intervention’s budget impact and number of health 
care workers needed). In order to model the health impact of interventions studies on the 
individual effectiveness of HIV/AIDS interventions are key and need to be conducted at local 
level as at this moment there is little knowledge on this especially for behavioral interven-
tions [31]. For hypothetical interventions proposed by the stakeholders the uncertainty on its 
performance remains challenging. However, incorporating stakeholders’ ideas likely contrib-
utes to the acceptance of stakeholders on the process and its results and therefore hypo-
thetical interventions should always be incorporated with notice on the uncertainty of the 
performance [32]. A local monitoring database owned by the local AIDS commissions (respon-
sible for the coordination of activities) is needed to get insight in basic data like, population 
sizes, number of clinics and coverage of existing interventions. It is important that these moni-
toring systems incorporate formats and data requested by donors like Global Fund. In general, 
context specific research that is needed to inform HIV/AIDS control activities and can be stim-
ulated through a joint effort of the local universities and governments. 
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Second, we observed during meetings that the approach is conceptually challenging and 
labor intensive. The understanding of the MCDA and AFR frameworks and the facilitation of 
deliberative process may require a certain educational background and that may not always 
be present. Extensive training of local government staff and researchers on the approach may 
overcome this challenge. Also more research is needed on interactive methods to commu-
nicate evidence and priority setting results to stakeholders. With the interactive exercise we 
have only set a first step in this direction. For further capacity building, the establishment of 
an Health Technology Assessment institute in line with HITAP in Thailand and NICE in the 
UK is recommendable. Such organization could function as a center of excellence in which 
researchers, government staff and other important actors collaborate and could help to further 
develop and support national and local decision-making [9,33]. Our process was labor inten-
sive because eleven meetings were held, the performance of 50 interventions was evaluated 
and the entire process took almost one year. It is therefore necessary to see how this approach 
can be organized more efficiently without harming the democratic learning process.
Third, existing structures in the decision making context are a challenge. For example, we 
employed the Asian Epidemic Model following its frequent use by national and local health 
planners. However, the model has its limitations, as it is a deterministic model that could not 
yet evaluate the impact of ART and various prevention and mitigation interventions, and 
does not allow for context specific adaptations. A second challenge unique to Indonesia’s 
decision making context is the country’s dependence on donor funding. This was reflected 
in the stakeholder’s attitudes, which showed a preference on working on implementation 
of donor interventions instead of taking own initiatives. According to the Paris declaration 
donors should align their aid to the countries’ needs and the MCDA-AFR approach shows 
potential instigating a better dialogue between by including all relevant stakeholders into 
the process. A third challenge is the strong focus of donor and international organizations on 
health impact, and limited attention for other criteria like equity and feasibility constrains [34]. 
Hence, it is less common to consider and select multiple criteria for priority setting which may 
influence the acceptance of the MCDA-AFR approach [35]. A fourth challenging context factor 
is the missing direct link with local government funding and this stresses the need to inform 
and involve those in charge for resource allocation. Last, the high turnover of government staff 
in Indonesia also challenges proper engagement in the process and the effectiveness of the 
MCDA-AFR approach. 
Recommendations for future application of the integrated MCDA-AFR approach
To further develop the MCDA-AFR approach we propose the following changes.
First, the MCDA-AFR approach should incorporate a step to conduct an extensive situational 
analysis of the context of priority setting. This was also recently recommended in the roadmap 
for priority setting by [5] who concluded that context specific understanding is key. It is 
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important to get insight in the existing priority setting processes, funding mechanisms, key 
actors, disease area, existing interventions and health systems barriers like political and cultural 
constrains. Existing frameworks as the health systems building blocks and the ‘Know your 
epidemic, know your response’ frameworks for the HIV/AIDS field may be used as supporting 
frameworks to conduct a situational analysis [35,36]. In this phase of the priority setting 
process it is also important to define the goal of the priority setting process as this could be 
on a broad level (‘generalized priority setting’), like this study or at the margin on the reim-
bursement or implementation of a single intervention (‘context specific priority setting’) [12]. 
An extensive situational analysis is also important to decide on which interventions to include 
in the performance matrix as it predominately determines the priorities. In this study interven-
tions to decriminalize the use of drugs and homosexuality were not included in the perfor-
mance matrix, while this could be considered an important intervention to improve access to 
HIV testing and treatment for high at risk groups. It might be that we were not enough aware 
of the context of the HIV/AIDS field and missed these types of interventions. 
Second, improved guidance and training materials are needed to support local government 
staff and researchers on the implementation of the MCDA-AFR approach. At this moment the 
approach as proposed by Baltussen et al. [11] still allows for much freedom and gives limited 
practical guidance. More explicit guidelines need to be developed on how to facilitate meet-
ings, and respond to questions like which stakeholders to include, how to reduce dominance 
in discussions, how to guide a discussion for criteria selection, how to facilitate a deliberative 
process, and how to deal with irrational reasoning. In relation to this criteria need to be better 
operationalized. For example equity (i.e. universal coverage) and stigma reduction are hard 
to define measures. Although a map has been published that provides an overview of which 
criteria can be used in priority setting it does not yet provide indicators for operationalization
Third, the integrated approach does not yet explicitly pay attention to the most appro-
priate publicity and appeal mechanisms. We could reason that after implementation of the 
MCDA-AFR approach the transparency and opportunity for appeal automatically improves, 
however it is important to know whether stakeholders also consider this effective [4]. There-
fore, we propose to include a specific step in the process to ask stakeholders about their 
opinion on the best mechanisms for appeal and publicity and to implement these accordingly 
as part of the approach [37]. 
Conclusions
The MCDA-AFR approach supported priority setting of interventions for the 5-year (2014-
2018) strategic plan for HIV/AIDS control in West Java Indonesia. Overall the test and treatment 
package is the most attractive intervention to implement and scale up in West Java, followed 
by prevention interventions as School Based Education, IEC during Moslem Friday Prayers, 
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Websites and Social Media and the Citizens AIDS program. Mitigation interventions are overall 
least attractive to implement. Compared to previous strategic planning processes in West Java 
province, the integrated approach was able set priorities in a systematic and transparent way 
with use of criteria for priority setting and use of available (scientific) evidence. Stakeholder 
engagement seemed to be improved and the approach and its results were incorporated in 
the final strategic document signed by the governor. Main challenges of the approach were 
the scarce availability of local evidence to make a performance matrix, the conceptual under-
standing of the frameworks and the existing decision context with donor influence and a 
missing direct link between the priorities and local government funding. The following adap-
tations were proposed to further develop the approach: inclusion of situational analysis on 
the current priority setting process and actors involved, more explicit guidance for local deci-
sion makers on how to implement the approach and more explicit definition and implemen-
tation of appeal and publicity mechanisms. On the basis of its first application, the MCDA-AFR 
approach shows potential to improve priority-setting processes in health and we invite others 
to discuss on its further application. 
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This chapter responds to the main research question of this thesis:  
“How can priority setting in HIV/AIDS control in Indonesia and South Africa be improved with 
use of multiple criteria and fair processes?, and is organized alongside the four sub-questions. 
Furthermore, this chapter presents the limitations of this thesis and future research needs. 
 Sub-question 1:
 What is the current priority setting process in HIV/AIDS control in Indonesia? 
This thesis addresses the necessity to improve priority setting processes in HIV/AIDS control. 
Chapter 1 evaluated Indonesia’s situation and revealed that local HIV strategic plans do not 
explicitly prioritize activities, do not state criteria for selection of interventions and that the 
priority setting process is not fair due to poor stakeholder involvement and little transparency 
and opportunity for appeal. In addition, we learned from this evaluation that many stakeholders 
are involved in HIV/AIDS control in Indonesia, that funding for interventions is fragmented and 
that there is limited (inter-) national guidance for local priority setting processes. These lacunas 
and complex processes are also reported for HIV/AIDS control in other settings in Africa and Asia 
[1–5] where donors, political power and culture have a strong influence on HIV/AIDS resource 
allocation and there is lack of guidance for effective HIV/AIDS responses [4,5]. 
Challenges in improving priority setting in HIV/AIDS control 
This complex picture leads to a number of special challenges that need to be addressed to 
improve priority setting in HIV/AIDS control. These challenges call for an approach that goes 
beyond the use of standard cost-effectiveness analysis (CEA) for priority setting [6]. 
First, a high number of stakeholders are related to HIV/AIDS control, partly due to the encour-
agement internationally to set up multi-sectorial AIDS commissions [7]. It is a challenge to elicit 
the values of each of them. In addition, problems in HIV/AIDS control have a highly political 
and religious nature in Indonesia, adding to the number of different values that play a role in 
priority setting processes [8]. It is therefore of key importance to bring all relevant stakeholders 
together in participatory processes and to elicit all values that are at stake. 
Second, funding flows in HIV/AIDS control are often fragmented and decision spaces are 
unclear. Many donors (e.g. UNAIDS, World Health Organization (WHO), Worldbank, Pepfar, 
Global Fund) provide funding for HIV/AIDS interventions and allocate these at multiple levels 
of the health system. This results in highly complicated distribution processes especially at 
sub-national levels [1,7,9,10]. In Indonesia, funding for HIV/AIDS is extremely fragmented across 
a broad range of stakeholders especially because more than ten different government insti-
tutions are involved. At sub-national levels, these offices all have their own HIV/AIDS activities 
and each request separately for funding from the local planning board (BAPPEDA) (Chapter 
2). In such a situation, many stakeholders influence the funding and implementation of inter-
ventions and no single decision maker can be identified. To improve priority-setting processes 
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in real world setting it is therefor of key importance to understand the funding flows for HIV/
AIDS control to determine the “decision space”. A stakeholder analysis to identify and subse-
quently involve those that are in charge of funding allocation in the priority setting process is 
essential in that respect. 
Third, international guidelines for HIV/AIDS control provide little practical lead way for priority 
setting at sub-national levels [5]. In a situation were resources are scarce, broad guidelines 
without any guidance for priority setting likely results in ad-hoc practices that are not tailored 
to the local context [5]. Such ad hoc practices are reported in Indonesia’s Strategic use of 
anti-retrovirals (SUFA) program that promotes early testing and treatment. At this moment, no 
clear context specific targets are set per district while epidemics differ, e.g. in Cirebon district of 
West Java most HIV infections are seen among people who inject drugs (PWID) while in Indra-
mayu district mostly female sex workers are infected [11]. Scientists, community activist and 
government officials have articulated a variety of ethical and feasibility questions as a response 
to worldwide trend to rapidly scale-up treatment as prevention [12]. Concerns are raised about 
the effectiveness in specific contexts on how to balance individual and population demands 
and on power relations within clinical practice and competing resource demands at local 
levels. We argue that guidance for decentralized level priority setting is a crucial and a missing 
component in HIV/AIDS control and methods need to be developed to respond to this. 
 Sub-question 2: 
 Which criteria are important for priority setting in HIV/AIDS control? 
This thesis shows that in HIV/AIDS control in Indonesia the criteria ‘impact on the epidemic’, 
‘stigma reduction’ and ‘feasibility’ are considered most important. On the other hand, ‘equity’ 
criteria are considered least important. Hereafter, we will reflect on the use of these criteria for 
HIV/AIDS priority setting.
Impact on the epidemic 
An intervention’s ‘impact on the epidemic’ was used implicitly in the development of stra-
tegic plans for Bandung and West Java in 2008 and 2009 respectively, and was considered 
most important among all stakeholder groups surveyed in West Java (Chapter 4). It was also 
selected as most important criterion by the consultation panel during the development of 
West Java’s 5 years (2014-2018) strategic plan in 2013 (Chapter 9). The perceived importance of 
an intervention’s impact on the epidemic can be explained by the course of Indonesia’s HIV 
epidemic, which is still one of the fastest growing in Asia [13]. The importance of this criterion 
is also reflected in one of the three UNAIDS goals that aims for “zero new infections“ (with the 
other two aiming for “zero aids related death” and “zero discrimination”) [14]. Furthermore, 
across the world the criterion impact or effectiveness is also considered important. A survey 
among 140 decision makers from 23 countries from five continents showed that ‘clinical effi-
cacy/effectiveness’ was considered the most relevant criteria for healthcare decisions [15]. 
229
 General discussion
10
Stigma reduction
Stigma reduction was also considered highly important among stakeholders in Indonesia. 
This can be explained by the high prevalence of stigma in Indonesia’s society [16], among 
health care workers [17,18] and HIV infected people [19,20]. In the HIV/AIDS field there is strong 
emphasize on the reduction of stigma, for example by the decriminalization of people who 
use drugs, sex work and same-sex relations [21]. At the same time, there is little evidence on 
which interventions are most effective for the reduction of stigma [22]. 
Feasibility criteria 
Feasibility criteria were also considered important in HIV/AIDS control in Indonesia and we 
reason that these are key for priority setting of interventions in real world settings. The impor-
tance of feasibility concerns like political acceptability has been stressed by other researchers 
as well [8] and without inclusion of these considerations the interventions that have highest 
impact on the epidemic are not likely to be implemented. Some feasibility criteria overlap with 
the so-called critical enablers (e.g. political commitment) for an effective HIV/AIDS response 
and are put forward in the WHO and UNAIDS guidelines [23–25]. The WHO SUFA guidelines 
encourage to use feasibility criteria however it does not distinguish sub criteria and an under-
lying categorization like our map [26]. Our case study in West-Java province showed that 
feasibility criteria might only be relevant at district level or in specific contexts. Indonesia is 
now scaling up ART and the feasibility in terms of health care workers capacity and polit-
ical commitment likely differs among districts. While improving priority setting processes it is 
debatable whether some feasibility criteria as ‘religious and political acceptability’ should be 
used to prioritize interventions. These criteria can also be perceived as critical enablers and 
indicate that measures are needed to overcome feasibility barriers for successful implementa-
tion of interventions. 
Equity criteria 
Equity criteria were considered least important for HIV/AIDS control in Indonesia (Chapter 4). 
Yet, this thesis also shows that the understanding and use of equity criteria in HIV/AIDS control 
is underdeveloped (Chapter 4, Chapter 7). The criteria map contributes to the definition of a 
range of equity criteria however the criteria are not yet operationalized for priority setting of 
interventions. In West Java, stakeholders selected universal coverage as a criterion for priority 
setting, but as it was defined as 80% coverage it could not differentiate between interven-
tions. Recently, a more comprehensive and well-defined list of equity criteria (the GPS-health) 
is published and this could contribute to the improved use of equity criteria for priority setting 
in HIV/AIDS control [27].
In Chapter 4, stakeholders valued equity criteria least important and thereby did not prioritize 
certain populations in society on the basis of their social background characteristics. However, 
with the knowledge that some groups may be deprived from for example treatment, the 
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perception towards these criteria might differ. At this moment, it is unknown whether inequi-
ties in utilization of HIV/AIDS interventions actually exist in Indonesia. Yet, our cost analysis on 
ART (Chapter 5) shows that those patients that enter ART care late (with severe disease stage 
and therefor a bad prognosis) are relatively poorer and this may indicate that inequities in utili-
zation of ART exist in Indonesia. In West Java, men having sex with men (MSM) may also have 
less access to HIV/AIDS interventions as their sexual orientation is not accepted in Islam, the 
predominant religion in the province. In addition, the government considers MSM as a hidden 
population [28]. 
Challenges in the use of multiple criteria for priority setting 
The identification and selection of criteria for priority setting is challenging and also crucial for 
the choice of interventions. We observed several challenges in the use of multiple criteria and 
label these as areas for development. 
First, the criteria map presented in this thesis is a step forward in listing criteria but is based 
on an underlying framework that determined the choice for criteria. Another disease specific 
underlying framework like the HIV investment framework [23] might have resulted in another 
set and use of criteria. For example, stigma reduction is presented in this thesis as a goal crite-
rion in the category ‘health system’s responsiveness’ and was perceived highly important 
among stakeholders in Indonesia (Chapter 4, Chapter 9). However, in the HIV investment 
framework it is seen as a critical enabler for effective HIV/AIDS responses. While the investment 
framework seems to encourage countries to implement at all times interventions that reduce 
stigma in order to improve the effectiveness of the HIV/AIDS response, we have used this crite-
rion in West Java to differentiate between interventions. Those interventions that were not 
reducing stigma in society resulted with a lower ranking in the performance matrix and were 
perceived less attractive to implement and scale up in West Java province [23]. Therefor, we 
recommend using the criteria map only as a starting point for inclusion of multiple criteria in 
a priority setting process. 
Second, although the criteria map provides guidance for local decision makers, it does not yet 
inform on indicators for criteria and these should be developed. 
Third, while deliberative processes in MCDA provide room to incorporate ethical consider-
ations that cannot be captured in a performance matrix, this was challenging in West Java 
and in other settings [29]. In West Java, the consultation panel members did not express any 
of these ethical considerations, possibly because they struggled to understand and articu-
late them. For example, a consultation panel member proposed a higher ranking for the HIV 
blood screening intervention but he could not well-explain the underlying reason. His prefer-
ence might have been to ‘do no harm’ which implies that it is unacceptable that people might 
receive HIV contaminated donor blood. This could be a reason to prioritize the intervention for 
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HIV/AIDS control, although it was not prioritized based on the performance matrix. To improve 
the incorporation of these ethical considerations in deliberative processes we recommend 
to build capacity among the consultation panel members to understand and articulate their 
preferences.
 
Fourth, the consultation panel member proposed various changes for the rank order of inter-
ventions and some of their reasons might relate to criteria that could have been part of the 
performance matrix. For example, in the discussion stakeholders had a strong preference for a 
higher rank of mitigation interventions. Most of these interventions support vulnerable popu-
lations and focus on people affected by HIV/AIDS or the relatively poor (e.g. transport subsi-
dies for poor HIV-infected people to access ART). This proposed change may therefore relate 
to equity criteria like ‘severity of disease’ or ‘socio-economic status’ and this could have been 
captured in the performance matrix. Explicit guidelines on which criteria can be part of the 
performance matrix and which should be addressed in deliberative processes may respond 
to this challenge.
 
Fifth, the integrated MCDA-AFR approach provides no room to reflect on the criteria used 
for priority setting. To encounter this, we recommend to put more emphasize on the partic-
ipatory action research component of the AFR intervention as applied in the “Response 
to Accountable priority setting for trust” (REACT) for district level priority setting in Kenya, 
Tanzania and Zambia. In the REACT project a consultation panel was asked to continuously 
describe, evaluate and improve the priority setting process on the basis of the four condi-
tions of the AFR framework. This method may empower the consultation panel to reflect on 
the criteria selected for the priority setting of interventions and may provide space for mutual 
learning among stakeholders involved [30,31].
 Sub-question 3:
 What is the performance of HIV/AIDS interventions on criteria for priority setting?
This thesis presents various evaluations of the performance of HIV/AIDS interventions and 
there are a number of challenges in the use of such studies to fill out a performance matrix 
in MCDA. While focusing on a specific priority setting question, existing studies likely differ 
in terms of intervention design, time frame of evaluation and characteristics of HIV epidemic 
at time of study. For example, the cost estimations for ART (Chapter 5) were conducted in a 
hospital instead of community clinic setting where ART is being up scaled now in Indonesia. 
The cost-effectiveness study on VCT (Chapter 6) did not include an ART component (due to 
model limitations) and was conducted for a time period in the past (2010-2014). The equity 
review in Chapter 7 focused on South Africa that has a generalized epidemic and the situation 
likely differs from a country with a concentrated epidemic like Indonesia. 
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Methods to collect data on the performance of interventions
As evidence is not always available at local level and time and capacity is not sufficient to 
conducted scientific research we propose several options to better understand the perfor-
mance of HIV/AIDS interventions on multiple criteria. First, we propose to establish an inter-
national repository that includes evaluation studies on the performance of interventions for 
multiple criteria. Global evidence is considered to be a good starting point for judgments about 
effects, factors that modify these effects and insights into ways to approach and address prob-
lems [32]. Second, improved mathematical models can be used to evaluate the performance 
of interventions on multiple criteria, like impact on the epidemic but also feasibility criteria 
(e.g. number of health care workers needed) and equity criteria (e.g. intervention coverage 
of men as compared to women) [33,34]. For the development of mathematical models at 
decentralized level, data is required on the effectiveness of context specific interventions [34] 
and if scientific studies are not available experts could be consulted for such estimates. Third, 
when the repository and mathematical model estimates are insufficient we recommend using 
expert opinion for the scoring of the performance of interventions. To enhance the quality of 
such estimates, the experts should be carefully selected and may be informed with available 
data [35]. It remains challenging to evaluate the combination of various interventions as the 
(interaction) effects are largely unknown [36]. 
Knowledge translation 
Although good quality evidence may not always be available, the integrated MCDA-AFR 
approach seems to contribute to knowledge translation and has potential to improve 
evidence informed health policy making (EIHP). In our West Java application the performance 
matrix results were included in the new 5 years strategic document. In recent years, knowl-
edge translation has received much attention and various methods are available to commu-
nicate research findings [33,37]. Policies briefs are commonly used but exist in many forms, 
which leads to confusion and suboptimal use in policy making [38]. In general, the evidence 
base for effectiveness of methods to inform policy making is weak and current approaches 
need to be evaluated [39]. 
The MCDA-AFR approach fits in the category of exchange methods for knowledge translation, 
where relationships between researchers and policy makers are build [40,41]. Two other forms 
of knowledge translation are ‘push’ and ‘pull’ efforts, in the former the researchers undertake 
activities while in the latter the policy makers access and use research to inform decisions. 
The MCDA-AFR approach also has characteristics of knowledge translation platforms, which 
are partnerships between policymakers, stakeholders, and researchers are being established 
in LMICs to enhance EIHP. These networks contributed to increased awareness of the impor-
tance of EIHP and strengthened relationships among stakeholders [37]. 
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 Sub-question 4
 Can the integrated MCDA-AFR approach be used to support strategic planning 
 processes in HIV/AIDS control? 
In chapter 8 we outlined the theoretical foundation for the integrated MCDA-AFR approach 
and illustrated for the South African setting. In Chapter 9, we tested the approach in the context 
of strategic planning for HIV/AIDS control at provincial level in Indonesia. We concluded that 
approach was feasible and that the strategic planning process seemed to have improved 
compared to the previous one in 2008. Preliminary results of an independent evaluation 
through interviews with consultation panel members revealed that our approach was consid-
ered useful, that stakeholders felt they were better involved and that the plan was considered 
more scientifically based. Consultation panel members also expressed that it was easier to give 
comments (especially during the interactive exercise) and all had learned from the process. 
Concerns were raised on the duration of the process, interval between meetings and the high 
turnover and low attendance of members in meetings. A lack of understanding and commit-
ment to participate was also noticed and most members were concerned about the commit-
ment of West Java district governments to act for HIV/AIDS. The consultation panel members 
also had concerns on the use of the strategic document for budget allocation decisions at 
provincial and district levels [42]. 
Challenges in the use of the MCDA-AFR approach 
This thesis identified various challenges for using the MCDA-A4R approach to improve priority 
setting in HIV/AIDS control in Indonesia. Hereafter, we will discuss the main challenges together 
with possible remedies to overcome these. 
Stakeholder involvement 
During the implementation of the MCDA-AFR approach low attendance of meetings, replace-
ment and lack of commitment of consultation panel members was observed. The explicit set up 
of a consultation panel makes a start to continuously involve a group of stakeholders throughout 
a priority setting process, however some relevant stakeholders like religious leaders, donors and 
the public were not explicitly included. A stakeholder analysis of those that are relevant in the 
context and a predefined checklist of possible stakeholders to involve may overcome this. Partic-
ipation rates in meetings may be improved with government regulations for involvement in 
priority setting processes for HIV/AIDS control. Improved sensitization of the method may also 
contribute to commitment of consultation panel members as is reported in African settings [30]. 
Moreover, leadership for fair processes shown by for example the National AIDS commission, the 
new President Joko Widodo and local leaders like city majors may also contribute to commit-
ment and participation of stakeholders [8]. In the meetings dominance of stakeholders during 
discussions was observed and methods are needed to ensure that stakeholders can express 
their views. Working with anonymous comment cards like in the interactive excise and nominal 
group techniques may contribute to resolve dominance [43,44]. 
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Complexity of the approach
The integrated MCDA-AFR seems complex and this was also reported for the singular MCDA 
and AFR methods applied in other settings like Thailand [29] and Kenya, Tanzania and Malawi 
[30,45]. In the African settings, researchers encountered for the complexity by intensive and 
continuous training on the principles of the AFR method [30,45]. More emphasize in the inte-
grated MCDA-AFR approach on participatory action research may also contribute to the 
learning of stakeholders in this respect [30,42]. It may also require time and patience before 
stakeholders are familiar with concepts of fair processes and using multiple criteria, especially 
because in Indonesia democracy has been introduced only less than two decades ago.
Lack of available data 
A major challenge in the implementation of the integrated MCDA-AFR approach was the 
lack of data to fill out the performance matrix and this is also reported for the application of 
the singular MCDA method in Canada [35] and Thailand [29]. While more research is needed 
on the performance of interventions, on the short term this can be resolved by the use of 
global evidence, improved mathematical models and consultation of experts as is also noted 
above. For the application of the MCDA-AFR approach in even more constrained settings a 
predefined overview of the performance of HIV/AIDS interventions on multiple criteria can be 
outlined to support the priority setting process. 
Comparison with other methods for priority setting
Hipgrave et al compared various methods (including the AFR, MCDA and program budgeting 
and marginal analysis (PMBA) frameworks) to improve meso-level priority setting processes 
and concluded that no single approach can be recommended [10]. Based on this thesis, we 
see advantages of the integrated MCDA-AFR approach compared to the application of the 
singular MCDA, AFR and CEA methods for priority setting. Compared to the singular AFR 
method the integrated approach systematically compared different interventions options 
and made the existing evidence-base explicit. Compared to the MCDA and CEA methods the 
involvement of a consultation panel in the integrated approach likely improved the participa-
tion of stakeholders in the process and facilitated the uptake of priority setting results in West 
Java’s strategic document. 
Adaptations to the original MCDA-AFR approach 
On the basis of this thesis we propose three adaptations of the original MCDA-AFR approach 
to use multiple criteria and fair processes in priority setting in HIV/AIDS control. 
Situational analysis of the current priority setting context 
A situational analysis (as was done in Chapter 1) before the start of the implementation is 
necessary to get insight in the existing priority setting process, funding mechanisms, key 
stakeholders, existing interventions and health systems barriers like political and cultural 
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acceptability. The available WHO’s health systems building blocks and ‘Know your epidemic, 
know your response’ frameworks may be used to conduct such a situational analysis [46,47]. A 
revised version of the intergrated MCDA/AFR approach is presented in Figure 1.
Figure 1. The revised version of the integrated MCDA-AFR approach for priority setting
  in health
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5
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on priorities
6
Implementation of
rationing decision and
evaluation
Improved methodological guidance 
More explicit methodological guidance is needed for those implementing the integrated 
MCDA-AFR approach. Amongst others, identification of stakeholders, reduction of dominance 
in discussions, facilitation of deliberative processes and the participatory action research compo-
nent need to be addressed. This guidance could be provided as a checklist and is already avail-
able for research priority setting [48]. This checklist may be published by multilateral organizations 
(e.g. World Health Organization, UNAIDS) to ensure its credibility among involved stakeholders. 
Selection of context based publicity and appeal mechanisms
On the basis of the AFR framework a fair process should be transparent and provide oppor-
tunity for appeal [49]. As the effectiveness of mechanism for appeal and publicity are likely 
cultural determined and the priority setting processes needs to be accepted by stakeholders 
we recommend that the consultation panel members select these mechanisms. This is line 
with the participatory action approach in the REACT program in Africa. Such approach, seems 
feasible in Indonesia as the consultation panel requested to develop an information bulletin to 
inform stakeholders within and outside the consultation panel on the process. 
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Institutionalization of the use of multiple criteria and fair processes 
Learning from the example of West Java province, the Indonesian National AIDS commission 
is currently developing tools (with initial support of AusAID) to improve district level priority 
setting for HIV/AIDS control. The tool incorporates the MCDA and AFR frameworks for priority 
setting and also aims to increase domestic district funding for the HIV/AIDS response as donor 
money is phasing out [50]. Many initiatives to improve priority setting processes face diffi-
culties in being brought to scale within national health systems [30]. In Indonesia, one of the 
key challenges for the institutionalization of the approach at district level will be the local 
capacity to understand and facilitate the use of multiple criteria and fair processes for priority 
setting of HIV/AIDS interventions. On the short term, the tool could be simplified with the use 
of a preliminary set of criteria and interventions and data could be provided on the perfor-
mance of interventions on multiple criteria. Training of the consultation panel on the prin-
ciples of multiple criteria and fair processes for HIV/AIDS priority setting may also contribute 
to implementation of the approach at district level. On the long term, improved mathemat-
ical models are required to understand local epidemics and to provide better information on 
the performance on interventions. We also strongly recommend Indonesia to set up a Health 
Technology Assessment (HTA) institute, following the example of HITAP in Thailand to increase 
country expertise in evaluation of health interventions and to improve priority setting with use 
of multiple criteria and fair processes [51]. 
Limitations of this thesis
We see three important limitations of this thesis. First, the research was conducted in the West 
Java province and findings should be generalized with caution. For example, the organization 
of HIV/AIDS control and the acceptance and stakeholders’ understanding of the integrated 
MCDA-AFR approach may differ in other settings. Second, the researchers involved in the 
implementation of the MCDA-AFR approach may have influenced the findings in this thesis. 
As the approach allows for freedom, other researchers might have used different methods 
to facilitate discussions and to communicate the performance matrix results to the consulta-
tion panel. Some findings were based on observations during meetings and might have been 
different when other researchers were involved. The inclusion and categorization of criteria in 
the criteria map was also based on reasoning of the researchers. Third, although it was possible 
to implement the approach it could only be evaluated to a limited extend. We could mainly 
observe changes in the priority setting process while the long-term impact on for example 
funding streams could not yet be evaluated. In addition, the Sibbald framework [52] was used 
for evaluation of the priority setting process and this might not be applicable to Indonesia as it 
was developed based on interviews with stakeholders from high-income countries. 
237
 General discussion
10
Recommendations for further research 
In summary, we present three main research areas to further support the use of multiple 
criteria and fair processes to improve priority setting in HIV/AIDS control. 
Improved evidence base on performance of HIV/AIDS interventions
As outlined before we recommend improving the evidence base for performance of HIV/AIDS 
interventions on multiple criteria with use of international repository and improved mathe-
matical models. In addition, criteria should be operationalized and more knowledge is needed 
on equity in access to HIV/AIDS interventions in Indonesia. The later could be achieved with a 
national monitoring system and development of standard measures of equity criteria and utili-
zation of HIV/AIDS interventions. 
Evaluation of priority setting methods
Evidence on the effectiveness of methods to improve priority setting processes remains 
scarce. According to a World Bank report most participatory initiatives are still driven more 
by ideology than by systematic analysis to understand the particular challenges entailed in 
inducing participation or to learn from the failures of past programs [53]. A review of more 
than 500 studies on participatory development and decentralization found that often the 
most vulnerable populations are not included, that incentives for participatory approaches 
dissolve after projects are finished and that community engagement alone has little impact 
on health-related outcomes [53]. In addition, in various approaches to improve priority setting 
processes dominance of stakeholders is reported [30,45,54]. Also the costs of such approaches 
are largely unknown. Therefor, for the application of the integrated MCDA-AFR approach more 
knowledge is required on how to avoid dominance discussions, how to involve all relevant 
stakeholders including the public in the process, and how to communicate evidence such as 
in the performance matrix to stakeholders. 
In response to this, we will conduct between 2015-2018 in West Java province a randomized 
controlled trial to evaluate the effectiveness of the integrated MCDA-AFR method. In this trial, 
half of the districts will use the integrated approach for priority setting of HIV/AIDS interven-
tions while the other half remains current practice. Both groups will be compared in terms of 
process improvements, funding allocations patterns and ultimately the utilization of HIV/AIDS 
interventions and the impact on health. 
 
Implementation sciences 
This thesis outlines several challenges for the implementation of the MCDA-AFR integrated 
method to improve priority setting in HIV/AIDS control and remedies to overcome these. 
However, this is only a start and a more systematic analysis of the barriers and enablers for 
implementation of priority setting methods is needed. These barriers and enablers likely 
differ among settings across the world. For example, in some LMICs stakeholders might be 
less familiar with criteria for priority setting (e.g. cost-effectiveness) yet in high-income coun-
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tries this is more commonly used. While in some settings there is leadership for fair priority 
setting processes in others this might not be the case. As a next step, research is required 
on various implementation strategies that address these barriers and that can tailor priority 
setting methods to the local setting. Understanding of the barriers and enablers and develop-
ment of implementation strategies for the use of multiple criteria and fair processes will be key 
to improve priority setting and to make a difference in real world settings. 
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Summary
Although significant progress has been made in the HIV/AIDS response over the past years, 
worldwide, still 37 million people were living with HIV/AIDS and 2.0 million were newly infected 
in 2014. UNAIDS is aiming to end the HIV epidemic in 2030. In the short term, resources are 
scarce to implement all programs at full scale and therefore priority setting of the right inter-
ventions is crucial. To support policy makers, various methods have been developed to guide 
priority setting of interventions. Cost-effectiveness analysis (CEA) was introduced in the 1980’s 
by economics and aims at value for money. Yet, this approach falls short as clearly cost-ef-
fectiveness is not the only criterion involved in decision-making. Ethical criteria, like giving 
priority to the worst of populations and feasibility criteria, like an intervention’s political accept-
ability and its requirements in terms of health care workers’ capacity are also often consid-
ered by policy makers. This led to the development of multi criteria decision analysis (MCDA), 
a method that advances from CEA by incorporating multiple criteria in priority setting. Based 
on the multi attribute theory, MCDA refers to a set of approaches that provide a system-
atic process for incorporating multiple criteria in decision making and make transparent the 
impact (also called ‘performance’) of interventions on these criteria. While the use of MCDA 
has rapidly increased, it has also been criticized for being too technocratic and not adequately 
ensuring a fair priority setting process, which would require involvement of all stakeholders. 
The Accountability for Reasonableness (AFR) framework provides guidance for a fair priority 
setting process. It is based on justice theories of democratic deliberation and a leading concep-
tual framework for the inclusion of ethics. 
Rationale of this thesis
In the field of HIV/AIDS control, there is an increased interest for the use of multiple criteria 
and fair processes for priority setting of interventions. This has been outlined in the guide-
lines for the strategic use of antiretroviral treatment (SUFA) of the World Health Organization 
(WHO), which also recommends the use of the AFR framework and implicitly, the use of MCDA 
for priority setting of health interventions. In addition, the research community has called for 
the use of multiple criteria and fair processes in priority setting and we more specifically in 
the context of HIV/AIDS control in Indonesia and South Africa. However, at this moment, it 
is unclear in which way countries are currently setting priorities in HIV/AIDS control, which 
criteria are considered important among stakeholders, and how interventions perform on 
various criteria for priority setting. Moreover, it is unknown how the use of multiple criteria and 
fair processes can be implemented in a country’s health system. 
The main research question of this thesis is:
How can priority setting in HIV/AIDS control in Indonesia and South Africa be improved with 
use of multiple criteria and fair processes?
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The sub-questions of this thesis are: 
 Sub-question 1: 
 What is the current priority setting process in HIV/AIDS control in Indonesia? 
 (Chapter 2)
 Sub-question 2: 
 Which criteria are important for priority setting in HIV/AIDS control?  
 (Chapter 3,4)
 Sub-question 3: 
 What is the performance of HIV/AIDS interventions on criteria for priority setting? 
 (Chapter 5-7)
 Sub-question 4: 
 Can the integrated MCDA-AFR approach be used to support strategic planning processes 
in HIV/AIDS control? 
 (Chapter 8,9)
While the focus of this thesis is on Indonesia, we also conducted two studies on South Africa. 
Indonesia is among the few countries in the world not on track for controlling its HIV 
epidemic. The country faces a concentrated epidemic (with exception of Papua) with an esti-
mated 640,0000 people living with HIV/AIDS (PLWHA) in 2013. This number will increase to 1.5 
million in 2020 unless the right actions are taken. The estimated HIV prevalence is high among 
people who inject drugs (PWID) (36.4%), female sex workers (FSW) (7.2%), and men having sex 
with men (MSM) (8.5%) and remains low in the general population (0.3%). Coverage of some 
HIV/AIDS interventions is low. For example 18% of those eligible is receiving antiretroviral treat-
ment (ART). The research described in this thesis was conducted in West Java province (44 
million inhabitants) and has a comparable picture with the national epidemic. 
South Africa is home to the largest HIV-infected population worldwide with 6.3 million people 
living with HIV/AIDS in 2013. The country has a generalized epidemic, with an HIV/AIDS prev-
alence rate of 19.2% among adults between 15-49 years. The country also has the largest ART 
program worldwide. In 2011, it provided treatment to about 80% (2.0 million people) of all 
eligible people in 2012. Although South Africa is quickly scaling up ART a significant treatment 
gap of about half a million people remains.
Current practices in HIV/AIDS priority setting
Chapter 1 provides a general introduction to this thesis. In chapter 2, we evaluated the current 
priority setting process in HIV/AIDS control in Indonesia (Bandung city and West Java province) 
against the four conditions of the accountability for reasonableness framework. We found 
that although multiple criteria were used in priority setting, they were only used implicitly. 
Strategic documents contained a long list of interventions and no explicit priorities were set. 
Many stakeholders were invited to participate in the decision making process, however their 
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quality of involvement could be improved. The use of appeal and publicity mechanisms for 
decision making could be more transparent and formally stated. Public regulations were not 
yet installed to ensure fair priority setting processes. 
Criteria for priority setting of interventions 
In chapter 3, we mapped thirty-one criteria for priority setting of health interventions based 
on literature reviews and according to the health systems’ framework of the World Health 
Organization. Criteria were divided among five categories that reflect the goals of a health 
system (i.e. to improve level of health, fair distribution of health, responsiveness, social & finan-
cial risk protection, and efficiency) and one category that reflects feasibility of interventions 
based on the health system building blocks (i.e. service delivery, health care workforce, infor-
mation, medical products, vaccines & technologies, financing, and leadership/governance). 
This conceptual mapping of criteria may further assist decision makers in the identification 
of multiple criteria for selection of health interventions. In chapter 4, we surveyed the impor-
tance of criteria for HIV/AIDS priority setting among four stakeholder groups (policy makers, 
health care workers, general population, and people living with HIV/AIDS) in West Java prov-
ince in Indonesia. Stakeholders perceived an intervention’s impact on the HIV epidemic; its 
impact on HIV related stigma in society, its quality of care, and its feasibility related to the 
health system infrastructure (i.e. health care workers, service, and information requirements) 
as highly important. Most criteria related to equity (i.e. prioritizing groups on the basis of their 
gender or socio-economic status) were considered least important. There were no significant 
differences between stakeholder groups. 
Performance of HIV/AIDS interventions
In chapters 5-7, we analyzed the performance of interventions on various criteria, namely, 
unit costs, cost-effectiveness, and equity criteria. In chapter 5, we described a costing anal-
ysis of antiretroviral treatment (ART) in Indonesia. It shows that before ART initiation, costs 
were dominated by laboratory tests (>65%), and after initiation by antiretroviral drugs (≥60%). 
Average treatment costs per patient decreased with time on treatment. Higher CD4 cell counts 
at initiation resulted in lower laboratory and opportunistic infection treatment costs. Transpor-
tation cost dominated the costs of patients for seeking and undergoing care (>40%). Costs 
of providing ART are highest during the early phase of treatment. Efficiency gains can likely 
be realized by early treatment initiation and applying alternative laboratory tests. Chapter 6 
describes a cost-effectiveness analysis of scaling up community-based voluntary counseling 
and testing in West-Java province. Based on evaluation using the Asian Epidemic model, we 
found that scaling up voluntary counseling and testing (VCT) costs US$248 per HIV infection 
averted and US$9.17 per disability adjusted life years (DALY) saved. According to international 
thresholds put forward by WHO, this intervention seems very cost-effective as it falls within 
the one-time per capita gross domestic product (i.e. US$2,963 in 2010). However, in order to 
prioritize VCT in HIV/AIDS control in West Java, issues of budget availability and organizational 
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capacity should be addressed. Chapter 7 describes a systematic review of the literature on 
equity in utilization of ART in South Africa. Twelve studies met the inclusion criteria. It seems 
that men, young people, those living in certain provinces or rural areas, people who are unem-
ployed or with a low educational level, and those being unmarried have less access to ART. As 
studies stem from different contexts and use different methods conclusions should be taken 
with caution. 
Implementation of the use of multiple criteria and fair processes 
Chapter 8 describes the development of programmatic guidance for priority setting in HIV/
AIDS control in South Africa by integrating the MCDA and AFR frameworks. This approach 
outlines how to include a better evidence base on feasibility, efficiency, and equity criteria and 
how to ensure fair policy process in priority setting for HIV treatment. The approach consists of 
5 steps: 1) formation of a consultation panel involving all relevant stakeholders, 2) definition of 
a relevant set of criteria, 3) assessment of the performance of programmes, 4) arrangement of a 
deliberative process on priorities, 5) implementing rationing decisions and evaluation. Chapter 
9 describes the first time implementation of the integrated MCDA-AFR approach as proposed 
in chapter 8 in the context of the development of the 5 years (2014-2018) HIV/AIDS strategy for 
West Java province in Indonesia. The consultation panel agreed that HIV testing and treatment 
packages were the most attractive intervention to scale up while mitigation activities were least 
attractive. Preliminary results of an independent evaluation through interviews with consulta-
tion panel members revealed that the MCDA-AFR approach was considered useful, that stake-
holders felt they were better involved, and that the plan was considered more scientifically 
based. They also expressed that it was easier to give comments and all had learned from the 
process. Concerns were raised on the duration of the process, intervals between meetings, 
and the high turnover and low attendance of members in meetings. Most members were also 
concerned about the commitment of West Java district governments to act for HIV/AIDS and 
whether the strategic document would be used for budget allocation decisions. Main chal-
lenges reported by the researcher for the implementation were the availability of data and 
existing structures like the influence of donors and a missing direct link to funding of the prior-
itized interventions. To further improve the combined MCDA-AFR approach, we propose to 
incorporate a situational analysis, to select context specific appeal and publicity mechanisms, 
and to develop better methodological guidelines for its application. 
Limitations of this thesis and recommendations for further research
In Chapter 10 we discussed the limitations of this thesis and provide recommendation for 
further research. 
We see three important limitations of this thesis. First, the researchers may have influenced 
the findings of chapter 9, as they were strongly involved in the implementation of the MCDA/
AFR approach. The approach allows for much freedom and other researchers might have used 
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different methods to facilitate discussions among stakeholders and to communicate the perfor-
mance matrix results to the consultation panel. Second, most of the research was conducted 
in the West Java province in Indonesia and findings should be generalized with caution. The 
organization of HIV/AIDS control and the acceptance and understanding of stakeholders for the 
integrated MCDA-AFR approach may differ in other settings. Third, the implementation of the 
MCDA/AFR approach could only be partly evaluated through observations during the imple-
mentation and by interviews with the stakeholders afterwards. The long-term impact on for 
example funding streams and implementation of interventions remains unknown. 
This thesis outlines several topics for further research related to the use of multiple criteria and 
fair processes for priority setting in HIV/AIDS control. First, improved evidence is needed on 
the performance of HIV/AIDS interventions on multiple criteria. Second, knowledge is needed 
on how to operationalize multiple criteria for priority setting of HIV/AIDS interventions. Third, 
methodological guidelines need to be developed on the optimal implementation of the 
MCDA-AFR approach to support HIV/AIDS control. Fourth, evaluations need to be conducted 
on the impact of priority setting methods and on the barriers and enablers of the implemen-
tation of the integrated MCDA-AFR approach. And last, better understanding is warranted on 
how multiple criteria and fair processes can be introduced at larger scale and in various settings. 
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De hiv/aids-bestrijding heeft wereldwijd de laatste jaren grote vooruitgang geboekt. 
Desondanks werden er in 2014 twee miljoen mensen geïnfecteerd met het hiv-virus en 
leefden er in totaal 37 miljoen mensen met hiv/aids. UNAIDS heeft als doel gesteld om de 
hiv/aids-epidemie in 2030 wereldwijd te beëindigen. Er zijn op dit moment echter onvol-
doende financiële middelen beschikbaar om alle hiv/aids-interventies op grote schaal te 
implementeren. Het maken van keuzes en het daardoor stellen van prioriteiten in de hiv/
aids-bestrijding is daarom van essentieel belang. 
Er bestaan verschillende methoden om beleidsmakers te ondersteunen bij het maken van 
keuzes in de zorg. In de jaren tachtig introduceerden economen kosten-effectiviteitsanalyse 
om inzicht te krijgen in de kosten en de gezondheidswinst van interventies. Deze benadering 
schiet echter tekort omdat in beleidsprocesen ook vaak andere overwegingen (ook wel criteria 
genoemd) een rol spelen. Voorbeelden hiervan zijn ethische overwegingen en verwachte barri-
ères voor het implementeren van interventies. Vanwege rechtvaardigheidsprincipes kan men 
een voorkeur hebben voor interventies die de zorg voor kwetsbare groepen in een samenle-
ving verbeteren. Mogelijke barrières, zoals de politieke en maatschappelijk acceptatie van inter-
venties of het aantal benodigde gezondheidswerkers, spelen ook vaak een rol in beslissingen. 
Dit begrip leidde tot de ontwikkeling van de methode multi criteria decision analysis (MCDA). 
Deze methode is gebaseerd op de “multi-attribuut-utiliteitstheorie”. Het biedt hulp bij het in 
kaart brengen van de criteria en het systematisch vergelijken van interventies op basis van deze 
criteria en het bijbehorende wetenschappelijk bewijs. Op deze manier kunnen keuzes worden 
gemaakt op basis van multiple criteria. MCDA is al veelvuldig toegepast in de gezondheidszorg 
maar wordt ook bekritiseerd vanwege het technocratische karakter en het niet waarborgen 
van een fair besluitvormingsproces. De principes van Accountability for Reasonebleness (AFR), 
bieden kaders voor het vormgeven van een fair besluitvormingsproces. Het vereist dat alle rele-
vante partijen in het proces betrokken zijn en dat bezwaarprocedures voor beslissingen vast-
liggen. Het is gebaseerd op deliberatieve democratie en vormt een belangrijk theoretisch kader 
voor het opnemen van ethische overwegingen in de besluitvorming. 
De rationale van dit proefschrift kan als volgt samengevat worden. De interesse voor het 
gebruik van multiple criteria en principes van fairness bij het maken van keuzes in de hiv/
aids-bestrijding neemt toe. Dit wordt ondermeer duidelijk in de richtlijnen van de Wereldge-
zondheidsorganisatie voor het opschalen van antiretrovirale therapie (ART). Het gebruik van 
het AFR-raamwerk en multiple criteria wordt daarin aanbevolen voor het maken van keuzes. 
Ook wetenschappers hebben aanbevolen om het gebruik hiervan te onderzoeken en dan 
met name binnen de hiv/aids-bestrijding in Indonesië en Zuid-Afrika. Op dit moment is het 
echter nog onduidelijk hoe landen keuzes maken binnen de hiv/aids-bestrijding, welke criteria 
belangrijk worden gevonden door de verschillende betrokken partijen en wat het weten-
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schappelijk bewijs is voor verschillende interventies op basis van deze criteria. Bovenal is het 
onbekend hoe het gebruik van multiple criteria en principes van fairness past binnen het 
gezondheidszorgsysteem in een land. 
De hoofdvraag van dit proefschrift luidt als volgt: 
Hoe kunnen keuzes in de hiv/aids-bestrijding verbeterd worden in Indonesië en Zuid-
Afrika door het gebruik van multiple criteria en principes van fairness?
Deze hoofdvraag is opgesplitst in vier deelvragen:
	Deelvraag 1:
 Wat is het huidige besluitvormingsproces binnen de hiv/aids-bestrijding in Indonesië.   
(Hoofdstuk 2) 
 Deelvraag 2:
 Wat zijn belangrijke criteria voor het maken van keuzes in de hiv/aids-bestrijding?  
(Hoofdstuk 3,4)
 Deelvraag 3: 
 Wat is het wetenschappelijke bewijs van verschillende hiv/aids-interventies op deze criteria? 
 (Hoofdstuk 5-7)
 Deelvraag 4: 
 Kan een geïntegreerde benadering van multi criteria decision analysis en accountability for 
reasonableness gebruikt worden voor de ontwikkeling van strategische plannen binnen de 
hiv/aids-bestrijding?
 (Hoofdstuk 8, 9)
Dit proefschrift bevat voornamelijk studies uit Indonesië. Twee hoofdstukken gaan over Zuid-
Afrika. 
Indonesië is een van de weinige landen in de wereld die er niet in slaagt de hiv/aids-epidemie 
in te dammen. De epidemie is geconcentreerd (met uitgezondering van de provincie Papua) 
en in 2013 leefden ongeveer 640,000 mensen met hiv/aids. Als Indonesië niet de juiste maat-
regelen neemt zal dit stijgen tot 1,5 miljoen mensen in 2020. De hiv prevalentie is voorname-
lijk hoog in risico groepen zoals injecterende drugs gebruikers (36,4%), sekswerkers (7,2%) en 
mannen die seks hebben met mannen (8,5%). In de algehele populatie is de hiv-prevalentie 
slechts 0,3%. De toegang tot hiv/aids-interventies is gebrekkig. Op dit moment heeft bijvoor-
beeld maar 18% van de patiënten die in aanmerking komt toegang tot hiv-medicijnen.
In Zuid-Afrika leeft het grootst aantal mensen met hiv/aids ter wereld: in 2013 waren dat er 
6,3 miljoen. De epidemie is gegeneraliseerd en de hiv-prevalentie is 19.2% onder volwassen 
tussen de 15 en 49 jaar. Zuid-Afrika heeft wereldwijd het grootste programma voor antivirale 
therapie. In 2011 werd 80% (2 miljoen) van de patiënten die in aanmerking kwam voorzien van 
hiv-medicijnen. Hoewel Zuid-Afrika er in is geslaagd om antivirale therapie snel op te schalen, 
heeft nog altijd een half miljoen patiënten geen toegang tot deze zorg. 
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Huidige besluitvorming in de hiv/aids-bestrijding 
Hoofdstuk 1 beschrijft de algehele introductie van dit proefschrift. In hoofdstuk 2 evalueren 
we met behulp van het AFR-raamwerk het huidige proces van het maken van keuzes in de 
hiv/aids-bestrijding in Indonesië (met name in de stad Bandung en de provincie West-Java). Uit 
deze evaluatie blijkt dat meerdere criteria een rol spelen, maar dat ze alleen impliciet worden 
gebruikt. Er is een groot aantal partijen betrokken bij de besluitvorming, maar de kwaliteit 
van hun deelname kan worden verbeterd. Het blijkt dat de mogelijke bezwaarprocedures en 
maatregelen om transparantie van de besluitvormen te verbeteren niet formeelzijn vastge-
legd. Bovendien zijn er geen officiële richtlijnen voor het waarborgen van een fair besluitvor-
mingsproces. 
Criteria voor het maken van keuzes in de hiv/aids-bestrijding 
In hoofdstuk 3, hebben we op basis van de literatuur een overzicht gemaakt van 31 criteria 
die mogelijk een rol zouden kunnen spelen bij het maken van keuzes tussen de verschil-
lende gezondheidszorginterventies. De criteria zijn gecategoriseerd op basis van het gezond-
heidssysteem raamwerk van de Wereldgezondheidsorganisatie. In totaal zijn er vijf catego-
rieen die de doelen (hoog gezondheidsniveau en gelijke verdeling van gezondheid (equity), 
responsiviteit, sociale en financiële bescherming en efficiëntie) weergeven van een gezond-
heidszorgsysteem. Een categorie geeft de uitvoerbaarheid van een interventie aan en deze is 
onderverdeeld in de zes bouwstenen van een gezondheidszorgsysteem (i.e. service delivery, 
capaciteit van het gezondheidszorgpersoneel, informatievoorziening, medische producten/
vaccins/technologieën, financiering en leiderschap/governance). Deze conceptuele inde-
ling biedt mogelijk ondersteuning aan beleidsmakers bij het maken van keuzes in de zorg. 
In hoofdstuk 4 hebben we een survey-onderzoek uitgevoerd onder vier belanghebbende 
partijen in de hiv/aids-bestrijding in de provincie West-Java in Indonesië. Dit waren beleid-
smakers, gezondheidswerkers, de burgers en mensen die leven met hiv/aids. Uit deze survey 
blijkt dat deze partijen de impact op de hiv epidemie, de impact of stigma in de samenleving, 
de kwaliteit van zorg en de uitvoerbaarheid van een interventie (in termen van capaciteit van 
het gezondheidszorg personeel, service en informatievereisten) het belangrijkst vinden. De 
meeste criteria gerelateerd aan equity (zoals voorkeur geven aan interventies die zich richten 
op kwetsbare groepen in de samenleving) werd het minst belangrijk ondervonden. Er waren 
geen grote verschillen in de uitkomsten tussen de verschillende partijen. 
Wetenschappelijk bewijs voor hiv/aids-interventies
In hoofdstuk 5 tot en met 7 hebben we bekeken hoe hiv/aids-interventies scoren op verschil-
lende criteria, namelijk de kosten, kosteneffectiviteit en equity overwegingen. Hoofdstuk 5 
beschrijft een kostenanalyse van antivirale therapie. Het laat zien dat voor de start van een 
behandeling de kosten voornamelijk werden bepaald door laboratoriumtesten (>65%) en na 
de start van behandeling door de hiv-medicijnen (>60%). De gemiddelde kosten per patiënt 
namen af naarmate de tijd onder behandeling toenam. Hoge CD4-celwaarden bij de start van 
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een behandeling resulteerden in lage laboratoriumkosten en behandelkosten voor opportu-
nistische infecties. De kosten voor transport domineerde in de kosten die gemaakt werden 
door patiënten die antivirale therapie ondergingen (>40%). De kosten waren het hoogste tijdens 
de vroege fase van de hiv-behandeling. Kosten kunnen waarschijnlijk bespaard worden door 
vroege start van hiv-behandeling en alternatieve laboratoriumtesten. Hoofdstuk 6 beschrijft de 
analyse van de kosteneffectiviteit van het opschalen van het voorlichten en testen van mensen 
op hiv en dan specifiek op gemeenschapsniveau in de provincie West-Java. Op basis van een 
evaluatie met het Asian Epidemic Model vonden we dat de interventie US$248 dollar per voor-
komen hiv-infectie en US$ 9,17 per gewonnen “disability adjusted life year (DALY)” kost. Volgens 
de internationale richtlijnen van de Wereldgezondheidsorganisatie lijkt deze interventie zeer 
kosteneffectief omdat het binnen de marge van drie keer het bruto nationaal product van Indo-
nesië valt (US$ 2.963 in 2010). Bij het daadwerkelijk opschalen van het voorlichten en testen van 
mensen op hiv moet men echter wel rekening houden met het beschikbare budget en de orga-
nisatie van de zorg. Hoofdstuk 7 beschrijft een systematisch review van de literatuur naar gelijk-
heid in het gebruik van antivirale therapie in Zuid-Afrika. Twaalf studies voldeden aan de inclusie- 
criteria. Het lijkt erop dat mannen, jonge mensen, mensen die in bepaalde provincies of rurale 
gebieden leven, mensen die werkeloos zijn, een laag opleidingsniveau hebben en ongetrouwd 
zijn minder toegang hebben tot hiv-behandeling. Omdat de studies plaatsvonden in verschil-
lende settings en verschillende methodes gebruikten moeten de resultaten voorzichtig geïn-
terpreteerd worden. 
Implementatie van het gebruik van multiple criteria en principes van fairness 
Hoofdstuk 8 beschrijft de ontwikkeling van een theoretisch kader voor het maken van keuzes in 
the hiv/aids-bestrijding in Zuid-Afrika door het integreren van de MCDA- en AFR-raamwerken. 
Deze benadering laat zien hoe er beter gebruik kan worden gemaakt van wetenschappelijk 
bewijs op het gebied van uitvoerbaarheid, kosteneffectiviteit en equity en hoe fairness in een 
besluitvormingsproces gewaarborgd kan worden. De benadering bestaat uit 5 stappen: 1) het 
vormen van een ‘consultation panel’ met alle relevante partijen, 2) het selecteren van een rele-
vante set van criteria, 3) het verzamelen van wetenschappelijk bewijs en het analyseren van de 
performance van interventies, 4) het organiseren van een deliberatief proces over de keuzes, 
en 5) de implementatie van de gemaakte keuzes en evaluatie. Hoofdstuk 9 beschrijft de eerste 
implementatie van de geïntegreerde benadering (beschreven in hoofdstuk 8). Dit werd toege-
past tijdens de ontwikkeling van de 5-jaren strategie (2014-2018) voor de hiv/aids-bestrijding 
van de provincie West-Java in Indonesië. Het ‘consultation panel’ kwam uiteindelijk overeen 
dat het pakket van interventies rondom het hiv testen en behandelen het meest aantrekkelijk 
is en opgeschaald zou moeten worden in West-Java. De ‘mitigation’ interventies werden als 
minst aantrekkelijk bevonden en verdiende de laagste prioriteit. Voorlopige resultaten van een 
onafhankelijke evaluatie van de implementatie (door middel van interviews met deelnemers 
van het ‘consultation’ panel) laten zien dat de geïntegreerde benadering als waardevol werd 
beschouwd. De deelnemers gaven aan dat ze beter betrokken waren bij het beleid en dat het 
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plan beter gefundeerd was met wetenschappelijk bewijs. Ze gaven ook aan dat het makkelijk 
was om commentaar te geven binnen het besluitvormingsproces en dat ze er allemaal van 
geleerd hadden. Ze spraken hun zorgen uit over de lange duur van het proces, de lange tijd 
tussen de vergaderingen en de lage opkomst. De meesten deelden ook hun twijfels over de 
toewijding van de districten voor de hiv/aids problematiek en of het strategische plan finan-
cieringsstromen kon beïnvloeden. 
De grootste uitdagingen die de onderzoekers ondervonden waren de beschikbaarheid van 
data en huidige structuren zoals de invloed van donoren en een ontbrekende link tussen 
het proces en de financiering voor hiv/aids-interventies. Om de toepassing van de geïnte-
greerde benadering te verbeteren bevolen we het volgende aan: een “situational analysis”, het 
selecteren van context specifieke bezwaarprocedures en transparantie maatregelen en betere 
methodologische richtlijnen. 
Beperkingen van dit proefschrift en aanbevelingen voor toekomstig onderzoek
In hoofdstuk 10 bespreken we de tekortkomingen van dit proefschrift en aanbevelingen voor 
toekomstig onderzoek. We zien drie belangrijke beperkingen van dit proefschrift. 
Ten eerste hebben onderzoekers mogelijk een belangrijke rol gespeeld omdat ze de geïn-
tegreerde MCDA/AFR-benadering implementeerden. Andere onderzoekers zouden mogelijk 
andere keuzes gemaakt hebben wat betreft het faciliteren van discussies en het communi-
ceren van de bevindingen van het wetenschappelijk bewijs en de ‘performance matrix’ naar 
het ‘consultation panel’. Ten tweede voerden we het merendeel van het onderzoek uit in 
de provincie West-Java in Indonesië. Resultaten kunnen daarom maar tot op zekere hoogte 
gegeneraliseerd worden en vertaald worden naar andere settingen. De organisatie van de hiv/
aids-bestrijding en de acceptatie van de geintergreerde aanpak door belangrijke partijen kan 
verschillen in andere settingen. Ten derde kon de implementatie van de geïntegreerde MCDA/
AFR-benadering alleen beperkt geëvalueerd worden door middel van observaties tijdens de 
implementatie en interviews met het ‘consultation’ panel. De langetermijneffecten, bijvoor-
beeld op het gebied van financieringsstromen zijn op dit moment onbekend. 
Dit proefschrift geeft een aantal aanbevelingen voor verder onderzoek op het gebied van 
multiple criteria en fairness voor het maken van keuzes binnen de hiv/aids-bestrijding. Ten 
eerste onderzoek is nodig naar de operationalisering van criteria voor het maken van keuzes 
binnen de hiv/aids-bestrijding. Ten tweede is het essentieel om methodologische richtlijnen 
te ontwikkelen voor een optimale implementatie van de geïntegreerde MCDA/AFR-benade-
ring binnen de hiv/aids-bestrijding. Ten derde moet de impact van methodes voor het maken 
van keuzes in de zorg beter geëvalueerd worden. In het bijzonder moet er onderzocht worden 
wat de barrières en facilitators zijn van de implementatie van de geïntegreerde MCDA/AFR-be-
nadering. Tot slot is er behoefte naar meer kennis over hoe het gebruik van multiple criteria 
en principes van fairness plaats kan vinden op een grotere schaal (bijvoorbeeld in meerdere 
districten in Indonesië) en in andere settings. 
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